-DOCSTART- -X- O O

Effect NN N
of IN N
duloxetine NN I
on IN N
pain NN O
function NN O
and CC O
quality NN O
of IN O
life NN O
among IN N
patients NNS P
with IN P
chemotherapy-induced JJ P
painful JJ P
peripheral JJ P
neuropathy: FW P
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

IMPORTANCE NNP N
There EX N
are VBP N
no DT N
known JJ N
effective JJ N
treatments NNS N
for IN N
painful JJ P
chemotherapy-induced JJ P
peripheral JJ P
neuropathy NN P
. . P

OBJECTIVE UH N
To TO N
determine VB N
the DT N
effect NN N
of IN N
duloxetine NN I
60 CD N
mg JJ N
daily RB N
on IN N
average JJ O
pain NN O
severity NN O
. . O

DESIGN NNP N
SETTING NNP N
AND NNP N
PATIENTS NNP N
Randomized NNP N
double-blind JJ N
placebo-controlled JJ N
crossover NN N
trial NN N
at IN N
8 CD N
National NNP N
Cancer NNP N
Institute NNP N
(NCI)-funded JJ N
cooperative JJ N
research NN N
networks NNS N
that WDT N
enrolled VBD N
231 CD P
patients NNS P
who WP P
were VBD P
25 CD P
years NNS P
or CC P
older JJR P
being VBG P
treated VBN P
at IN P
community NN P
and CC P
academic JJ P
settings NNS P
between IN P
April NNP P
2008 CD P
and CC P
March NNP P
2011 CD P
. . P

Study NNP N
follow-up NN N
was VBD N
completed VBN N
July NNP N
2012 CD N
. . N

Stratified VBN N
by IN N
chemotherapeutic JJ N
drug NN N
and CC N
comorbid NN N
pain NN N
risk NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
duloxetine NN I
followed VBN N
by IN N
placebo NN I
or CC N
placebo NN I
followed VBN N
by IN N
duloxetine NN I
. . I

Eligibility NN P
required VBD P
that IN P
patients NNS P
have VBP P
grade VBN P
1 CD P
or CC P
higher JJR P
sensory NN P
neuropathy JJ P
according VBG P
to TO P
the DT P
NCI NNP P
Common NNP P
Terminology NNP P
Criteria NNP P
for IN P
Adverse NNP P
Events NNS P
and CC P
at IN P
least JJS P
4 CD P
on IN P
a DT P
scale NN P
of IN P
0 CD P
to TO P
10 CD P
representing VBG P
average JJ P
chemotherapy-induced JJ P
pain NN P
after IN P
paclitaxel NN P
other JJ P
taxane NN P
or CC P
oxaliplatin JJ P
treatment NN P
. . P

INTERVENTIONS VBZ N
The DT N
initial JJ N
treatment NN N
consisted VBN N
of IN N
taking VBG N
1 CD N
capsule JJ N
daily RB N
of IN N
either CC N
30 CD N
mg NN N
of IN N
duloxetine NN I
or CC N
placebo NN I
for IN N
the DT N
first JJ N
week NN N
and CC N
2 CD N
capsules NNS N
of IN N
either DT N
30 CD N
mg NN N
of IN N
duloxetine NN I
or CC N
placebo JJ I
daily JJ N
for IN N
4 CD N
additional JJ N
weeks NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT N
primary JJ N
hypothesis NN N
was VBD N
that IN N
duloxetine NN I
would MD N
be VB N
more RBR N
effective JJ O
than IN N
placebo NN I
in IN N
decreasing VBG N
chemotherapy-induced JJ P
peripheral JJ P
neuropathic JJ P
pain NN P
. . P

Pain NNP O
severity NN O
was VBD O
assessed VBN O
using VBG O
the DT O
Brief JJ O
Pain NNP O
Inventory-Short NNP O
Form NNP O
"average NN O
pain" NN O
item NN O
with IN O
0 CD O
representing VBG O
no DT O
pain NN O
and CC O
10 CD O
representing VBG O
as RB O
bad JJ O
as IN O
can MD O
be VB O
imagined VBN O
. . O

RESULTS JJ N
Individuals NNS N
receiving VBG N
duloxetine NN I
as IN N
their PRP$ N
initial JJ N
5-week JJ N
treatment NN N
reported VBD N
a DT N
mean JJ N
decrease NN N
in IN N
average JJ O
pain NN O
of IN N
1.06 CD N
(95% JJ N
CI NNP N
0.72-1.40) NNP N
vs NN N
0.34 CD N
(95% JJ N
CI NNP N
0.01-0.66) NN N
among IN N
those DT N
who WP N
received VBD N
placebo NN I
(P NNP N
= NNP N
.003; NNP N
effect NN N
size NN N
0.513) CD N
. . N

The DT N
observed JJ N
mean JJ N
difference NN N
in IN N
the DT N
average JJ O
pain NN O
score NN O
between IN N
duloxetine NN I
and CC N
placebo NN I
was VBD N
0.73 CD N
(95% JJ N
CI NNP N
0.26-1.20) NN N
. . N

Fifty-nine JJ N
percent NN N
of IN N
those DT N
initially RB N
receiving VBG N
duloxetine NN I
vs NN N
38% CD N
of IN N
those DT N
initially RB N
receiving VBG N
placebo NN I
reported VBD N
decreased JJ N
pain NN O
of IN N
any DT N
amount NN N
. . N

CONCLUSION NNP N
AND CC N
RELEVANCE NNP N
Among IN N
patients NNS P
with IN P
painful JJ P
chemotherapy-induced JJ P
peripheral JJ P
neuropathy IN P
the DT N
use NN N
of IN N
duloxetine NN I
compared VBN N
with IN N
placebo NN I
for IN N
5 CD N
weeks NNS N
resulted VBD N
in IN N
a DT N
greater JJR N
reduction NN O
in IN O
pain NN O
. . O

TRIAL NNP N
REGISTRATION NNP N
clinicaltrials.gov NN N
Identifier: NNP N
NCT00489411 NNP N
. . N

-DOCSTART- -X- O O

Additive JJ N
IOP-reducing JJ O
effect NN N
of IN N
latanoprost NN I
in IN N
patients NNS P
insufficiently RB P
controlled VBN P
on IN P
timolol NN P
. . P

PURPOSE NNP N
To TO N
evaluate VB N
the DT N
effect NN N
on IN N
intraocular JJ O
pressure NN O
(IOP) NN O
of IN N
switching VBG N
from IN N
timolol NN I
to TO N
latanoprost VB I
or CC N
adding VBG N
latanoprost NN I
to TO N
timolol VB I
in IN P
patients NNS P
with IN P
open JJ P
angle NN P
glaucoma NN P
or CC P
ocular JJ P
hypertension NN P
where WRB P
IOP NNP P
is VBZ P
not RB P
adequately RB P
controlled VBN P
with IN P
timolol NN P
. . P

METHODS NNP N
This DT N
was VBD N
a DT N
6-week JJ N
double-masked JJ N
randomised VBN N
multi-centre NN N
study NN N
. . N

53 CD P
patients NNS P
with IN P
primary JJ P
open JJ P
angle NN P
glaucoma NN P
capsular JJ P
glaucoma NN P
or CC P
ocular JJ P
hypertension NN P
with IN P
an DT P
IOP NNP P
of IN P
at IN P
least JJS P
21 CD P
mmHg NN P
on IN P
current JJ P
therapy NN P
were VBD P
recruited VBN P
. . P

After IN N
a DT N
run-in JJ N
period NN N
of IN N
at IN N
least JJS N
2 CD N
weeks NNS N
on IN N
timolol NN I
5 CD N
mg/ml NN N
twice RB N
daily JJ N
patients NNS N
were VBD N
randomised VBN N
to TO N
one CD N
of IN N
three CD N
groups NNS N
. . N

One CD N
group NN N
continued VBD N
on IN N
timolol NN I
one CD N
switched VBN N
from IN N
timolol NN I
to TO N
latanoprost VB I
50 CD N
microg/ml NNS N
once RB N
daily JJ N
and CC N
a DT N
third JJ N
group NN N
received VBD N
latanoprost RB I
in IN N
addition NN N
to TO N
timolol VB I
. . I

The DT N
efficacy NN O
was VBD N
evaluated VBN N
by IN N
comparing VBG N
IOP NNP O
at IN N
9 CD N
AM NNP N
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
IOP NNP O
at IN N
baseline NN N
and CC N
after IN N
6 CD N
weeks NNS N
of IN N
treatment NN N
(mean JJ N
+/- JJ N
SEM) NNP N
were VBD N
24.2 CD N
+/- JJ N
0.9 CD N
and CC N
23.8 CD N
+/- JJ N
1.0 CD N
mmHg NN N
(n NNP N
= VBZ N
16) CD N
for IN N
patients NNS N
continuing VBG N
on IN N
timolol JJ I
26.3 CD N
+/- JJ N
1.2 CD N
and CC N
19.6 CD N
+/- JJ N
1.1 CD N
mmHg NN N
(n NNP N
= VBZ N
17) CD N
for IN N
patients NNS N
switching VBG N
to TO N
latanoprost VB I
and CC N
23.2 CD N
+/- JJ N
1.0 CD N
and CC N
17.5 CD N
+/- JJ N
0.8 CD N
mmHg NN N
(n NNP N
= VBZ N
17) CD N
for IN N
patients NNS N
with IN N
combined JJ N
treatment NN N
. . N

Adding VBG N
latanoprost NN I
to TO N
timolol VB I
reduced VBN N
IOP NNP O
with IN N
5.9 CD N
+/- JJ N
0.9 CD N
mmHg NN N
(p NNP N
< VBZ N
0.001) CD N
and CC N
switching VBG N
from IN N
timolol NN I
to TO N
latanoprost VB I
reduced VBN N
IOP NNP O
with IN N
5.0 CD N
+/- JJ N
0.9 CD N
mmHg NN N
(p NNP N
< NNP N
0.001) CD N
which WDT N
caused VBD N
in IN N
each DT N
group NN N
a DT N
significant JJ N
IOP NNP O
reduction NN N
of IN N
about IN N
25% CD N
. . N

CONCLUSIONS VB N
The DT N
effect NN N
of IN N
latanoprost NN I
was VBD N
additive JJ N
to TO N
that DT N
of IN N
timolol NN I
and CC N
a DT N
good JJ N
effect NN N
on IN N
IOP NNP O
reduction NN N
was VBD N
also RB N
achieved VBN N
by IN N
switching VBG N
from IN N
timolol NN I
to TO N
latanoprost VB I
suggesting VBG N
that IN N
a DT N
switch NN N
in IN N
many JJ N
patients NNS N
is VBZ N
an DT N
effective JJ N
alternative NN N
to TO N
combination NN N
treatment NN N
. . N

-DOCSTART- -X- O O

Parent-implemented JJ N
enhanced VBD I
milieu NNS I
teaching VBG I
with IN N
preschool JJ P
children NNS P
who WP P
have VBP P
intellectual JJ P
disabilities NNS P
. . P

PURPOSE VB N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
effects NNS N
of IN N
enhanced JJ I
milieu NN I
teaching VBG I
(EMT) NNS I
implemented VBN N
by IN N
parents NNS N
and CC N
therapists NNS N
versus VBP N
therapists VBZ N
only RB N
on IN N
the DT N
language NN O
skills NNS O
of IN N
preschool NN P
children NNS P
with IN P
intellectual JJ P
disabilities NNS P
(IDs) VBP P
including VBG P
children NNS P
with IN P
Down NNP P
syndrome NN P
and CC P
children NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
. . P

METHOD NNP N
Seventy-seven JJ P
children NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
2 CD N
treatments NNS N
(parent JJ I
+ JJ I
therapist NN I
EMT NNP I
or CC N
therapist-only JJ I
EMT) NNP I
and CC N
received VBD N
36 CD N
intervention NN N
sessions NNS N
. . N

Children NNP P
were VBD N
assessed VBN N
before IN N
immediately RB N
after IN N
6 CD N
months NNS N
after IN N
and CC N
12 CD N
months NNS N
after IN N
intervention NN N
. . N

Separate JJ N
linear JJ N
regressions NNS N
were VBD N
conducted VBN N
for IN N
each DT N
standardized JJ O
and CC O
observational JJ O
measure NN O
at IN N
each DT N
time NN N
point NN N
. . N

RESULTS JJ N
Parents NNS N
in IN N
the DT N
parent NN N
+ NNP N
therapist NN N
group NN N
demonstrated VBD N
greater JJR N
use NN O
of IN O
EMT NNP I
strategies NNS O
at IN N
home NN N
than IN N
untrained JJ N
parents NNS N
in IN N
the DT N
therapist-only JJ N
group NN N
and CC N
these DT N
effects NNS N
maintained VBD N
over IN N
time NN N
. . N

Effect JJ N
sizes NN N
for IN N
observational JJ O
measures NNS O
ranged VBD N
from IN N
d NN N
= $ N
0.10 CD N
to TO N
d VB N
= JJ N
1.32 CD N
favoring VBG N
the DT N
parent NN N
+ NNP N
therapist NN N
group NN N
with IN N
the DT N
largest JJS N
effect NN N
sizes VBZ N
found VBD N
12 CD N
months NNS N
after IN N
intervention NN N
. . N

CONCLUSION NNP N
Findings NNS N
from IN N
this DT N
study NN N
indicate VBP N
generally RB N
that IN N
there EX N
are VBP N
benefits NNS N
to TO N
training VBG N
parents NNS N
to TO N
implement VB N
naturalistic JJ N
language NN N
intervention NN N
strategies NNS N
with IN N
preschool JJ P
children NNS P
who WP P
have VBP P
ID NNP P
and CC P
significant JJ P
language NN P
impairments NNS P
. . P

-DOCSTART- -X- O O

Sleep-anticipating JJ N
effects NNS O
of IN N
melatonin NN I
in IN N
the DT N
human JJ P
brain NN N
. . N

Melatonin NNP N
the DT N
hormone NN N
produced VBN N
nocturnally RB N
by IN N
the DT N
pineal NN N
gland NN N
is VBZ N
an DT N
endogenous JJ N
regulator NN N
of IN N
the DT N
sleep-wake JJ N
cycle NN N
. . N

The DT N
effects NNS N
of IN N
melatonin NN I
on IN N
brain NN O
activities NNS O
and CC N
their PRP$ N
relation NN N
to TO N
induction NN O
of IN O
sleepiness NN O
were VBD N
studied VBN N
in IN N
a DT N
randomized JJ N
double-blind NN N
placebo NN N
controlled VBD N
functional JJ N
magnetic JJ N
resonance NN N
imaging VBG N
(fMRI) NNP N
study NN N
. . N

Melatonin NNP I
but CC N
not RB N
placebo VB I
reduced VBN N
task-related JJ O
activity NN O
in IN N
the DT N
rostro-medial JJ N
aspect NN N
of IN N
the DT N
occipital JJ N
cortex NN N
during IN N
a DT N
visual-search JJ N
task NN N
and CC N
in IN N
the DT N
auditory JJ N
cortex NN N
during IN N
a DT N
music NN N
task NN N
. . N

These DT N
effects NNS N
correlated VBD N
with IN N
subjective JJ O
measurements NNS O
of IN O
fatigue NN O
. . O

In IN N
addition NN N
melatonin NN I
enhanced VBD N
the DT N
activation NN O
in IN O
the DT O
left NN O
parahippocampus NN O
in IN N
an DT N
autobiographic JJ N
memory NN N
task NN N
. . N

Results VB N
demonstrate NN N
that IN N
melatonin NN I
modulates NNS N
brain NN O
activity NN O
in IN N
a DT N
manner NN N
resembling VBG N
actual JJ N
sleep NN N
although IN N
subjects NNS N
are VBP N
fully RB N
awake RB N
. . N

Furthermore IN N
the DT N
fatigue NN O
inducing VBG N
effect NN O
of IN N
melatonin NN I
on IN N
brain NN O
activity NN O
is VBZ N
essentially RB N
different JJ N
from IN N
that DT N
of IN N
sleep JJ N
deprivation NN N
thus RB N
revealing VBG N
differences NNS N
between IN N
fatigues NNS N
related VBN N
to TO N
the DT N
circadian JJ N
sleep NN N
regulation NN N
as IN N
opposed VBN N
to TO N
increased VBN N
homeostatic JJ N
sleep NN N
need NN N
. . N

Our PRP$ N
findings NNS N
highlight VBD N
the DT N
role NN N
of IN N
melatonin NN I
in IN N
priming VBG N
sleep-associated JJ O
brain NN O
activation NN O
patterns NNS N
in IN N
anticipation NN N
of IN N
sleep NN N
. . N

-DOCSTART- -X- O O

An DT N
open-label JJ N
extension NN N
study NN N
of IN N
the DT N
safety NN O
and CC N
efficacy NN O
of IN N
risperidone NN I
in IN N
children NNS P
and CC P
adolescents NNS P
with IN P
autistic JJ P
disorder NN P
. . P

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
evaluate VB N
the DT N
long-term JJ O
safety NN O
and CC O
efficacy NN O
of IN N
risperidone NN I
in IN N
treating VBG N
irritability NN N
and CC N
related JJ N
behaviors NNS N
in IN N
children NNS P
and CC P
adolescents NNS P
with IN P
autistic JJ P
disorders NNS P
. . P

METHODS NNP N
In IN N
this DT N
6 CD N
month NN N
(26 JJ N
week) JJ N
open-label JJ N
extension NN N
(OLE) NNP N
study NN N
patients NNS P
(5-17 JJ P
years NNS P
of IN P
age NN P
who WP P
completed VBD P
the DT P
previous JJ P
fixed-dose JJ P
6 CD P
week NN P
double-blind JJ P
[DB] NN P
phase) NN P
were VBD N
flexibly RB N
dosed VBN N
with IN N
risperidone NN I
based VBN N
on IN N
body NN N
weight NN N
. . N

The DT N
maximum JJ N
allowed VBD N
dose NN N
was VBD N
1.25 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
20 CD N
to TO N
<45 VB N
kg NN N
and CC N
1.75 CD N
mg/day NN N
for IN N
those DT N
weighing VBG N
≥ JJ N
45 CD N
kg NN N
. . N

The DT N
study NN N
primarily RB N
assessed VBD I
risperidone's JJ I
safety; NN O
efficacy NN O
was VBD N
assessed VBN N
as IN N
a DT N
secondary JJ N
end-point NN N
. . N

RESULTS NNP P
Fifty-six NNP P
(71%) NNP P
out IN P
of IN P
79 CD P
enrolled JJ P
patients NNS P
completed VBD P
the DT P
OLE; NNP P
the DT N
most RBS N
common JJ N
discontinuations NNS N
were VBD N
for IN N
insufficient JJ N
response NN N
(7 NN N
[9%]) NN N
or CC O
adverse JJ O
events NNS O
(AE) VBP O
(5 JJ N
[6%]) NNP N
. . N

The DT N
most RBS N
common JJ N
(≥ NN N
5% CD N
frequency NN N
in IN N
the DT N
total JJ N
group) NN O
AEs NNP N
were VBD O
increased VBN O
appetite RB O
(11% JJ N
[n=9]); NN O
increased VBD O
weight NN O
and CC O
vomiting VBG O
(9% JJ N
[n=7] NNP N
each); NN O
sedation NN O
pyrexia NN O
and CC O
upper JJ O
respiratory NN O
tract JJ O
infection NN O
(8% NNP N
[n=6] NNP N
each); VBZ O
nasopharyngitis FW O
(6% NNP N
[n=5]); NNP N
and CC O
somnolence NN O
and CC O
fatigue NN O
(5% NNP N
[n=4] NNP N
each) NN O
. . O

Extrapyramidal NNP O
AEs NNP N
were VBD N
reported VBN N
in IN N
6 CD N
(8%) JJ N
patients NNS O
. . O

Increase NNP O
in IN O
mean JJ O
weight JJ O
(11-15%) NN N
and CC O
body NN O
mass NN O
index NN O
(5-10%) JJ N
occurred; IN N
one CD N
patient NN N
discontinued VBN N
because IN O
of IN O
weight JJ O
increase NN O
. . N

One CD N
potentially RB O
prolactin-related JJ O
AE NNP O
(irregular NNP O
menstruation) NN O
was VBD N
reported VBN N
. . N

The DT I
risperidone NN I
high-dose JJ N
group NN N
had VBD N
the DT N
greatest JJS O
mean JJ O
improvement NN O
in IN O
sleep JJ O
visual JJ O
analog NN O
scale NN O
(24.6) NNP N
. . N

All DT N
groups NNS N
showed VBD N
additional JJ N
improvement NN O
in IN O
efficacy NN O
scale JJ O
scores NNS O
during IN N
the DT N
OLE NNP N
. . N

CONCLUSIONS NNP N
During IN N
this DT N
OLE NNP O
safety NN O
findings NNS N
with IN I
risperidone NN I
treatment NN N
(maximum JJ N
weight-based JJ N
dose NN N
of IN N
1.25 CD N
mg/day NN N
or CC N
1.75 CD N
mg/day) NNS N
were VBD N
consistent JJ N
with IN N
those DT N
observed VBN N
in IN N
the DT N
DB NNP N
phase NN N
and CC N
with IN N
the DT N
current JJ O
safety NN O
information NN N
for IN I
risperidone NN P
in IN P
autistic JJ P
psychiatric NN N
and CC N
behavioral JJ N
disorders NNS N
. . N

Patients NNS N
experienced VBD N
some DT N
additional JJ N
improvement NN O
in IN O
irritability NN O
and CC O
related JJ O
behaviors NNS O
. . N

CLINICAL JJ N
TRIALS NNP N
REGISTRY NNP N
This DT N
phase-4 JJ N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
(NCT00576732) NNP N
. . N

-DOCSTART- -X- O O

Experimental JJ N
hyaline NN N
membrane NN N
disease NN N
in IN N
the DT P
premature NN P
monkey: JJ P
effects NNS N
of IN N
antenatal JJ N
dexamethasone NN I
. . I

A DT N
blind JJ N
randomized JJ N
trial NN N
of IN N
antenatal JJ N
glucocorticoid NN I
treatment NN N
was VBD N
conducted VBN N
using VBG N
the DT P
premature NN P
monkey NN P
(Macaca NNP P
nemestrina) JJ P
model NN P
of IN P
hyaline JJ P
membrane NN P
disease NN P
(HMD) NNP P
. . P

Twelve NNP P
dams VBZ P
received VBD N
dexamethasone NN I
(2 NNP N
mg/dose) VBD N
72 CD N
48 CD N
and CC N
24 CD N
h NN N
before IN N
abdominal JJ N
delivery NN N
at IN N
135 CD N
+/- JJ N
1 CD N
days NNS N
of IN N
gestation NN N
. . N

Twelve VB P
control NN P
animals NNS P
received VBD N
saline JJ I
. . I

Infants NNS N
of IN N
dexamethasone-treated JJ I
dams NNS N
had VBD N
significantly RB N
lower JJR N
incidence NN O
and CC O
severity NN O
of IN O
HMD NNP O
than IN N
did VBD N
infants NNS N
of IN N
control NN N
animals NNS N
(50 VBP N
versus IN N
92% CD N
p NN N
less JJR N
than IN N
0.05) CD N
. . N

Improvement NN N
with IN N
treatment NN N
was VBD N
markedly RB N
greater JJR N
for IN N
males NNS N
than IN N
for IN N
females NNS N
. . N

Differences NNS N
in IN N
volume-pressure JJ O
behavior NN O
of IN N
the DT N
excised JJ N
lungs NNS N
included VBD N
greater JJR N
distensibility NN O
in IN N
the DT N
infants NNS N
from IN N
dexamethasone-treated JJ I
dams NNS N
(20.6 VBP N
+/- JJ N
7.1 CD N
ml/g NN N
dry JJ N
lung NN N
versus IN N
14.7 CD N
+/- JJ N
6.1 CD N
p NN N
less JJR N
than IN N
0.05) CD N
and CC N
enhanced VBD N
deflation NN O
stability NN O
with IN N
treatment NN N
. . N

Accelerated JJ N
production NN O
of IN O
surface NN O
active JJ O
material NN O
(SAM) NN O
phospholipids NNS O
in IN N
infants NNS N
from IN N
dexamethasone-treated JJ I
dams NNS N
was VBD N
indicated VBN N
by IN N
increases NNS N
in IN N
total JJ O
lung NN O
phospholipid JJ O
(84.5 NNP N
+/- JJ N
8.1 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
75.1 CD N
+/- JJ N
9.9 CD N
p NN N
less JJR N
than IN N
0.025) CD N
alveolar JJ O
lavage NN O
fluid NN O
phospholipid JJ O
(5.65 NNP N
+/- JJ N
3.33 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
3.01 CD N
+/- JJ N
1.84 CD N
p NN N
less JJR N
than IN N
0.05) CD N
and CC N
alveolar JJ O
lavage NN O
fluid NN O
disaturated VBD O
phosphatidylcholine JJ O
(DPC) NNP N
(2.47 NNP N
+/- JJ N
1.84 CD N
mg/g NN N
dry JJ N
lung NN N
versus IN N
1.06 CD N
+/- JJ N
1.05 CD N
p NN N
less JJR N
than IN N
0.05) CD N
. . N

Incorporation NN N
of IN N
14C-palmitate JJ O
into IN N
lung NN O
lipid NN O
was VBD N
not RB N
influenced VBN N
by IN N
dexamethasone NN I
but CC N
a DT N
significantly RB N
greater JJR N
portion NN N
of IN N
the DT N
label NN N
appeared VBD N
in IN N
the DT N
DPC NNP O
fraction NN O
with IN N
treatment NN N
. . N

Antenatal NNP N
dexamethasone NN I
treatment NN N
was VBD N
successful JJ N
in IN N
reducing VBG N
the DT N
incidence NN O
and CC O
severity NN O
of IN O
experimental JJ O
HMD NNP O
in IN P
this DT P
animal JJ P
model; NN P
the DT N
beneficial JJ N
effects NNS O
of IN N
treatment NN N
were VBD N
associated VBN N
with IN N
accelerated JJ N
maturation NN N
of IN N
fetal JJ O
pulmonary JJ O
functions NNS O
including VBG N
but CC N
not RB N
limited JJ N
to TO N
synthetic JJ N
metabolism NN N
of IN N
SAM NNP N
phospholipid NN N
. . N

-DOCSTART- -X- O O

Paternal NNP O
RHD NNP O
zygosity NN O
determination NN N
in IN N
Tunisians: NNP P
evaluation NN N
of IN N
three CD N
molecular JJ N
tests NNS N
. . N

BACKGROUND IN N
The DT N
choice NN N
of IN N
a DT N
molecular JJ N
test NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ O
RHD NNP O
zygosity NN O
before IN N
entering VBG N
into IN N
invasive JJ N
diagnostics NNS N
is VBZ N
important JJ N
for IN N
the DT N
management NN N
of IN N
pregnancies NNS N
at IN N
risk NN N
of IN N
haemolytic JJ N
disease NN N
of IN N
the DT N
foetus NN N
and CC N
newborn RB N
related VBN N
to TO N
anti-RhD JJ N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
RHD NNP O
zygosity NN O
was VBD N
evaluated VBN N
in IN N
370 CD P
RH:1 NNP P
Tunisian JJ P
donors NNS P
by IN N
polymerase NN O
chain NN O
reaction NN O
- : O
sequence-specific JJ O
polymorphism NN O
(PCR-SSP) JJ O
analysis NN N
and CC N
polymerase NN O
chain NN O
reaction NN O
- : O
restriction NN O
fragment NN O
length NN O
polymorphism NN O
(PCR-RFLP) JJ O
amplification NN O
of IN O
hybrid JJ O
Rhesus NNP O
box NN O
and CC O
by IN O
real JJ O
time NN O
quantitative JJ O
polymerase NN O
chain NN O
reaction NN O
(RQ-PCR) JJ O
specific NN O
for IN O
RHD NNP O
exon VBD O
5 CD O
. . O

To TO N
evaluate VB N
the DT N
accuracy NN N
of IN N
molecular JJ N
tests NNS N
in IN N
the DT N
cases NNS N
of IN N
discordant JJ N
results NNS N
the DT N
ten JJ N
exons NNS N
of IN N
RHD NNP N
and CC N
Rhesus NNP N
boxes NNS N
were VBD N
amplified VBN N
by IN N
PCR NNP N
and CC N
sequenced VBN N
. . N

RESULTS NNP N
Molecular JJ N
investigations NNS N
revealed VBD N
that IN N
our PRP$ N
370 CD P
donors NNS P
comprise VBP N
193 CD N
dizygous JJ N
and CC N
145 CD N
hemizygous JJ N
individuals NNS N
and CC N
32 CD N
subjects NNS N
whose WP$ N
zygosity NN N
remains VBZ N
unknown JJ N
. . N

Positive JJ O
predictive JJ O
values NNS O
were VBD N
higher JJR N
than IN N
99% CD N
for IN N
all PDT N
the DT N
methods NNS N
reaching VBG N
100% CD N
for IN N
RQ-PCR NNP N
. . N

Negative NNP O
predictive JJ O
values NNS O
were VBD N
83.24% CD N
87.27% CD N
and CC N
98% CD N
for IN N
PCR-SSP NNP N
PCR-RFLP NNP N
and CC N
RQ-PCR NNP N
respectively RB N
. . N

This DT N
study NN N
also RB N
revealed VBD N
19 CD N
novel JJ N
Rhesus NNP O
box NN O
polymorphisms NN O
and CC N
three CD N
novel NN N
RHD NNP O
alleles: NN O
RHD(Trp185Stop) NNP N
RHD(Ala176Thr) NNP N
and CC N
RHD(Ile342Ile) NNP N
. . N

DISCUSSION NNP N
RQ-PCR NNP N
is VBZ N
the DT N
most RBS N
convenient JJ N
method NN N
for IN N
first JJ N
intention NN N
determination NN N
of IN N
paternal JJ O
RHD NNP O
zygosity NN O
in IN N
Tunisians NNPS P
. . P

However RB N
taking VBG N
into IN N
account NN N
positive JJ N
and CC N
negative JJ N
predictive JJ N
values NNS N
PCR-RFLP NNP O
could MD N
be VB N
an DT N
alternative JJ N
despite IN N
the DT N
heterogeneity NN N
of IN N
Rhesus NNP N
boxes NNS N
and CC N
the DT N
complexity NN N
of IN N
RHD NNP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
two CD N
types NNS N
of IN N
teacher NN P
training NN I
on IN N
implementation NN O
of IN O
Smart NNP O
Choices: NNP O
a DT N
tobacco NN N
prevention NN N
curriculum NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
implementation NN N
phase NN N
of IN N
a DT N
four-year JJ N
research NN N
project NN N
to TO N
test VB N
the DT N
effectiveness NN O
of IN N
strategies NNS N
to TO N
increase VB N
diffusion NN O
of IN O
Smart NNP O
Choices VBZ O
a DT N
school-based JJ N
tobacco NN N
prevention NN N
program NN N
. . N

The DT N
impact NN N
on IN N
curriculum JJ N
implementation NN N
of IN N
two CD N
approaches NNS N
to TO N
teacher VB P
training NN I
are VBP N
compared VBN N
. . N

School JJ P
districts NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
a DT N
live JJ I
workshop NN I
training NN I
or CC N
video NN I
training NN I
condition NN I
. . I

The DT N
outcome NN N
of IN N
the DT N
evaluation NN N
was VBD N
teachers' JJ O
implementation NN O
of IN O
Smart NNP O
Choices NNP O
. . O

Results NNP N
show VBP N
a DT N
lower JJR N
proportion NN N
of IN N
video-trained JJ I
teachers NNS P
implemented VBD N
the DT N
curriculum NN N
but CC N
overall JJ N
completeness NN N
and CC N
fidelity NN N
of IN N
implementation NN N
for IN N
those DT N
teachers NNS P
who WP N
did VBD N
teach VB N
the DT N
curriculum NN N
were VBD N
comparable JJ N
for IN N
the DT N
two CD N
groups NNS N
. . N

Video-trained JJ I
teachers NNS P
however RB N
were VBD N
less RBR N
likely JJ N
to TO N
use VB N
brainstorming NN N
and CC N
student NN N
presentations/role NN N
plays VBZ N
two CD N
of IN N
the DT N
methods NNS N
prescribed VBN N
by IN N
the DT N
curriculum NN N
. . N

Implications NNS N
of IN N
the DT N
results NNS N
for IN N
teacher JJ P
training NN I
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Chronic NNP N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN I
in IN N
congestive JJ P
heart NN P
failure NN P
. . P

This DT N
study NN N
was VBD N
conducted VBN N
to TO N
determine VB N
the DT N
long-term JJ O
effect NN O
of IN N
flosequinan NN I
a DT N
new JJ N
orally RB N
administered VBN N
arterial JJ N
and CC N
venous JJ N
dilator NN N
on IN N
the DT N
clinical JJ O
course NN O
of IN N
patients NNS P
with IN P
moderate JJ P
to TO P
severe VB P
congestive JJ P
heart NN P
failure NN P
. . P

Seventeen JJ P
patients NNS P
on IN P
chronic JJ P
digitalis NN P
and CC P
diuretic JJ P
therapy NN P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
flosequinan NN I
(n NNP N
= VBZ N
9) CD N
or CC N
placebo VB I
(n JJ N
= JJ N
8) CD N
in IN N
a DT N
double-blind JJ N
fashion NN N
. . N

Changes NNS O
in IN O
symptomatology NN O
exercise NN O
performance NN O
and CC O
left VBD O
ventricular JJ O
function NN O
were VBD N
assessed VBN N
serially RB N
during IN N
the DT N
two-month JJ N
treatment NN N
period NN N
. . N

During IN N
the DT N
course NN N
of IN N
therapy NN N
a DT N
modest JJ N
improvement NN N
in IN N
the DT N
symptom NN O
scores NNS O
and CC O
functional JJ O
classification NN O
of IN N
the DT N
flosequinan-treated JJ I
patients NNS N
was VBD N
observed VBN N
. . N

Flosequinan NNP I
evoked VBD N
a DT N
significant JJ N
increase NN N
in IN N
maximal JJ O
exercise NN O
capacity NN O
. . O

While IN N
long-term JJ N
flosequinan JJ I
administration NN N
also RB N
effected VBD N
a DT N
progressive JJ N
increase NN N
in IN N
resting VBG O
heart NN O
rate NN O
it PRP N
did VBD N
not RB N
consistently RB N
improve VB N
indices NNS N
of IN N
left JJ O
ventricular JJ O
systolic JJ O
function NN O
. . O

The DT N
addition NN N
of IN N
chronic JJ N
vasodilator NN N
therapy NN N
with IN N
flosequinan NN I
to TO N
standard VB N
digitalis-diuretic JJ N
regimens NNS N
is VBZ N
capable JJ N
of IN N
inducing VBG N
clinical JJ N
improvement NN N
in IN N
patients NNS P
with IN P
moderate JJ P
to TO P
severe VB P
chronic JJ P
heart NN P
failure NN P
. . P

Trials NNS N
involving VBG N
larger JJR N
patient JJ N
populations NNS N
will MD N
be VB N
necessary JJ N
to TO N
confirm VB N
the DT N
results NNS N
of IN N
this DT N
preliminary JJ N
study NN N
and CC N
to TO N
determine VB N
the DT N
extent NN N
of IN N
clinical JJ N
improvement NN N
subpopulations NNS N
benefited VBD N
role NN N
in IN N
heart NN N
failure NN N
therapeutics NNS N
and CC N
so RB N
forth JJ N
. . N

-DOCSTART- -X- O O

[Effect NN N
of IN N
branch NN I
chain NN I
amino NN I
acid NN I
enriched VBD I
formula NN I
on IN N
postoperative JJ O
fatigue NN O
and CC O
nutritional JJ O
status NN O
after IN P
digestive JJ P
surgery] NN P
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
effect NN N
of IN N
branch NN I
chain NN I
amino NN I
acid VBP I
(BCAA) NN I
enriched VBN I
formula NN I
on IN N
nutritional JJ O
status NN O
and CC N
postoperative JJ O
fatigue NN O
for IN N
digestive JJ P
surgery NN P
patients NNS P
. . P

METHODS NNP N
Forty NNP P
patients NNS P
who WP P
underwent VBP P
digestive JJ P
surgery NN P
were VBD N
randomly RB N
received VBN N
parenteral JJ N
nutrition NN N
with IN N
either DT N
BCAA NNP I
enriched VBD I
(study NNP N
group NN N
n=20) VBD N
or CC N
routine JJ I
amino NN I
acid NN I
(control NNP N
group NN N
n=20) NN N
for IN N
seven CD N
consecutive JJ N
days NNS N
. . N

Nitrogen NNP O
balance NN O
serum NN O
total JJ O
protein NN O
albumin IN O
prealbumin JJ O
transferrin NN O
retinol NN O
binding VBG O
protein NN O
and CC O
postoperative JJ O
fatigue NN O
score NN O
were VBD N
monitored VBN N
during IN N
the DT N
postoperative JJ N
period NN N
. . N

RESULTS VB N
The DT N
cumulative JJ O
postoperative JJ O
fatigue NN O
scores NNS O
were VBD N
lower JJR N
in IN N
BCAA NNP I
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
at IN N
the DT N
4th CD N
5th CD N
and CC N
7th CD N
day NN N
after IN N
operation NN N
(P< VBD N
0.05) CD N
. . N

Patients NNS N
achieved VBD N
positive JJ N
nitrogen NN O
balance NN O
2 CD N
days NNS N
earlier RBR N
in IN N
the DT N
study NN N
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
but CC N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
cumulative JJ O
nitrogen NN O
balance NN O
between IN N
the DT N
two CD N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
elevation NN N
of IN N
serum JJ O
total JJ O
protein NN O
albumin IN O
prealbumin JJ O
transferrin NN O
at IN N
the DT N
7th CD N
day NN N
after IN N
operation NN N
between IN N
the DT N
two CD N
groups NNS N
(P VBP N
> $ N
0.05) CD N
compared VBN N
with IN N
those DT N
at IN N
the DT N
first JJ N
day NN N
after IN N
operation NN N
. . N

The DT N
serum JJ O
level NN O
of IN O
retinol NN O
binding VBG O
protein NN O
was VBD N
higher JJR N
in IN N
BCAA-enriched NNP I
group NN N
than IN N
that DT N
in IN N
the DT N
control NN N
group NN N
(P=0.004) NNP N
. . N

CONCLUSION NNP N
TPN NNP N
with IN N
BCAA NNP I
enriched VBD I
formula NN I
can MD N
reduce VB N
postoperative JJ O
fatigue NN O
score NN O
and CC N
improve VB N
the DT N
nutritional JJ O
status NN O
for IN N
digestive JJ P
surgery NN P
patients NNS P
. . P

-DOCSTART- -X- O O

Role NNP N
of IN N
posterior JJ I
tibial JJ I
nerve NN I
stimulation NN I
in IN N
the DT N
treatment NN N
of IN N
refractory JJ P
monosymptomatic JJ P
nocturnal JJ P
enuresis: NN P
a DT N
pilot NN N
study NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
early JJ O
clinical JJ O
and CC O
urodynamic JJ O
results NNS O
of IN N
posterior JJ I
tibial JJ I
nerve NN I
stimulation NN I
in IN N
patients NNS P
with IN P
refractory JJ P
monosymptomatic JJ P
nocturnal JJ P
enuresis NN P
. . P

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
randomly VBP N
assigned VBD N
28 CD P
patients NNS P
with IN P
refractory JJ P
monosymptomatic JJ P
nocturnal JJ P
enuresis NN P
to TO N
2 CD N
equal JJ N
groups NNS N
. . N

Group NNP N
1 CD N
received VBD N
a DT N
weekly JJ N
session NN N
of IN N
posterior JJ I
tibial JJ I
nerve NN I
stimulation NN I
for IN N
12 CD N
weeks NNS N
and CC N
group NN N
2 CD N
was VBD N
the DT N
placebo NN I
group NN N
. . N

Evaluation NN N
was VBD N
performed VBN N
in IN N
each DT N
group NN N
at IN N
baseline NN N
and CC N
after IN N
posterior JJ I
tibial JJ I
nerve NN I
stimulation NN I
to TO N
compare VB N
clinical JJ O
and CC O
urodynamic JJ O
findings NNS O
. . O

Another DT N
clinical JJ N
assessment NN N
was VBD N
done VBN N
3 CD N
months NNS N
after IN N
the DT N
first JJ N
followup NN N
. . N

RESULTS VB N
The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
baseline JJ O
clinical JJ O
and CC O
urodynamic JJ O
data NNS O
. . O

Overall JJ N
13 CD N
patients NNS N
(46.4%) JJ N
had VBD N
detrusor VBN O
overactivity NN O
and CC N
14 CD N
(50%) NN N
had VBD N
decreased VBN N
bladder NN O
capacity NN O
. . O

After IN N
treatment NN N
11 CD N
group NN N
1 CD N
patients NNS N
(78.6%) JJ N
had VBD N
a DT N
partial JJ N
or CC N
full JJ N
response NN O
to TO O
posterior VB I
tibial JJ I
nerve NN I
stimulation NN I
but CC N
only RB N
2 CD N
(14.3%) NNS N
in IN N
group NN N
2 CD N
had VBD N
a DT N
partial JJ N
response NN O
(p NNP N
= VBZ N
0.002) CD N
. . N

Also RB N
the DT N
average JJ N
number NN O
of IN O
wet JJ O
nights NNS O
in IN N
group NN N
1 CD N
was VBD N
significantly RB N
lower JJR N
than IN N
at IN N
baseline NN N
(p NNP N
= VBZ N
0.002) CD N
. . N

All DT N
urodynamic JJ O
parameters NNS O
significantly RB N
improved VBN N
in IN N
group NN N
1 CD N
. . N

In IN N
contrast NN N
the DT N
number NN O
of IN O
wet JJ O
nights NNS O
and CC O
urodynamic JJ O
parameters NNS O
did VBD N
not RB N
change VB N
significantly RB N
in IN N
group NN N
2 CD N
. . N

At IN N
3-month JJ N
followup NN N
the DT N
number NN N
of IN N
patients NNS N
with IN N
a DT N
partial JJ N
or CC N
full JJ N
response NN O
in IN N
group NN N
1 CD N
had VBD N
decreased VBN N
from IN N
11 CD N
(78.6%) NNS N
to TO N
6 CD N
(42.9%) NNS N
. . N

No DT N
change NN N
was VBD N
evident JJ N
in IN N
group NN N
2 CD N
. . N

CONCLUSIONS NNP N
Posterior NNP I
tibial JJ I
nerve NN I
stimulation NN I
can MD N
be VB N
a DT N
viable JJ N
treatment NN N
option NN N
in IN N
some DT N
patients NNS P
with IN P
refractory JJ P
monosymptomatic JJ P
nocturnal JJ P
enuresis NN P
. . P

However RB N
deterioration NN N
in IN N
some DT N
responders NNS N
with IN N
time NN N
suggests VBZ N
the DT N
need NN N
for IN N
maintenance NN N
protocols NNS N
. . N

-DOCSTART- -X- O O

Sensory NNP I
Adapted NNP I
Dental NNP I
Environments NNP I
to TO N
Enhance VB N
Oral NNP N
Care NNP N
for IN N
Children NNP P
with IN P
Autism NNP P
Spectrum NNP P
Disorders: NNP P
A NNP N
Randomized NNP N
Controlled NNP N
Pilot NNP N
Study NNP N
. . N

This DT N
pilot NN N
and CC N
feasibility NN N
study NN N
examined VBD N
the DT N
impact NN N
of IN N
a DT N
sensory JJ I
adapted JJ I
dental JJ I
environment NN I
(SADE) NN I
to TO N
reduce VB N
distress JJ O
sensory JJ O
discomfort NN O
and CC O
perception NN O
of IN O
pain NN O
during IN N
oral JJ N
prophylaxis NN N
for IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNP P
. . P

Participants NNS P
were VBD P
44 CD P
children NNS P
ages VBZ P
6-12 JJ P
(n NNP P
= NNP P
22 CD P
typical JJ P
n NN P
= VBD P
22 CD P
ASD) NNP P
. . P

In IN N
an DT N
experimental JJ N
crossover NN N
design NN N
each DT N
participant JJ N
underwent JJ N
two CD N
professional JJ N
dental JJ N
cleanings NNS N
one CD N
in IN N
a DT N
regular JJ I
dental NN I
environment NN I
(RDE) NN I
and CC N
one CD N
in IN N
a DT N
SADE NNP I
administered VBN N
in IN N
a DT N
randomized JJ N
and CC N
counterbalanced JJ N
order NN N
3-4 JJ N
months NNS N
apart RB N
. . N

Outcomes NNP N
included VBD N
measures NNS N
of IN N
physiological JJ O
anxiety NN O
behavioral JJ O
distress NN O
pain NN O
intensity NN O
and CC O
sensory JJ O
discomfort NN O
. . O

Both DT N
groups NNS N
exhibited VBD N
decreased JJ N
physiological JJ O
anxiety NN O
and CC N
reported VBD N
lower JJR N
pain NN O
and CC O
sensory JJ O
discomfort NN O
in IN N
the DT N
SADE NNP I
condition NN N
compared VBN N
to TO N
RDE NNP I
indicating VBG N
a DT N
beneficial JJ N
effect NN N
of IN N
the DT N
SADE NNP I
. . I

-DOCSTART- -X- O O

A DT N
multi-component JJ I
social JJ I
skills NNS I
intervention NN I
for IN N
children NNS P
with IN P
Asperger NNP P
syndrome: VBP P
the DT N
Junior NNP I
Detective NNP I
Training NNP I
Program NNP I
. . I

BACKGROUND NNP N
The DT N
study NN N
aimed VBN N
to TO N
investigate VB N
the DT N
effectiveness NN O
of IN N
a DT N
new JJ N
multi-component JJ I
social JJ I
skills NNS I
intervention NN I
for IN N
children NNS P
with IN P
Asperger NNP P
syndrome VBP P
(AS): VBP P
The DT N
Junior NNP N
Detective NNP N
Training NNP N
Program NNP N
. . N

This DT N
7-week JJ N
program NN N
included VBD N
a DT N
computer NN N
game NN N
small JJ I
group NN I
sessions NNS I
parent VBP I
training VBG I
sessions NNS I
and CC N
teacher NN I
handouts NNS I
. . I

METHOD NNP N
Forty-nine JJ P
children NNS P
with IN P
AS NNP P
were VBD N
recruited VBN N
to TO N
participate VB N
and CC N
randomly VB N
assigned VBN N
to TO N
intervention VB N
(n NNP N
= NNP N
26) CD N
or CC N
wait-list JJ N
control NN N
(n NNP N
= NNP N
23) CD N
conditions NNS N
. . N

RESULTS NNP N
Relative NNP N
to TO N
children NNS N
in IN N
the DT N
wait-list JJ N
group NN N
program NN N
participants NNS N
showed VBD N
greater JJR N
improvements NNS O
in IN O
social JJ O
skills NNS O
over IN N
the DT N
course NN N
of IN N
the DT N
intervention NN N
as IN N
indicated VBN N
by IN N
parent-report JJ O
measures NNS O
. . O

Teacher-report NNP O
data NNS O
also RB N
confirmed VBD N
that IN N
children NNS N
receiving VBG N
the DT N
intervention NN N
made VBD N
significant JJ N
improvements NNS N
in IN N
social JJ O
functioning NN O
from IN N
pre- JJ N
to TO N
post-treatment JJ N
. . N

Treatment NNP N
group NN N
participants NNS N
were VBD N
better RBR N
able JJ N
to TO N
suggest VB N
appropriate JJ N
emotion-management JJ O
strategies NNS O
for IN N
story NN N
characters NNS N
at IN N
post-intervention NN N
than IN N
at IN N
pre-intervention JJ N
whereas NNS N
control NN N
participants NNS N
were VBD N
not RB N
. . N

However RB N
there EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
improvements NNS N
made VBN N
by IN N
children NNS N
in IN N
the DT N
intervention NN N
and CC N
control NN N
conditions NNS N
on IN N
facial JJ O
expression NN O
and CC O
body-posture NN O
recognition NN O
measures NNS O
. . O

Follow-up NNP N
data NN N
suggested VBD N
that IN N
treatment NN N
gains NNS N
were VBD N
maintained VBN N
by IN N
children NNS N
at IN N
5-months JJ N
post-intervention NN N
. . N

CONCLUSIONS VB N
The DT N
Junior NNP I
Detective NNP I
Training NNP I
Program NNP I
appeared VBD N
to TO N
be VB N
effective JJ O
in IN N
enhancing VBG N
the DT N
social JJ O
skills NNS O
and CC O
emotional JJ O
understanding NN O
of IN N
children NNS P
with IN P
AS NNP P
. . P

Limitations NNS N
and CC N
suggestions NNS N
for IN N
future JJ N
research NN N
are VBP N
discussed VBN N
. . N

-DOCSTART- -X- O O

Prevention NN N
of IN N
spinal JJ P
anesthesia-induced JJ P
hypotension NN N
in IN P
the DT P
elderly: NN P
comparison NN N
between IN N
preanesthetic JJ N
administration NN N
of IN N
crystalloids NNS I
colloids NNS I
and CC N
no DT I
prehydration NN I
. . I

The DT N
practice NN N
of IN N
routinely RB N
prehydrating VBG N
patients NNS N
by IN N
infusing VBG N
a DT N
crystalloid NN I
or CC N
colloid JJ I
solution NN I
(up NN N
to TO N
1.0 CD N
L/70 NNP N
kg) NN N
for IN N
prevention NN N
of IN N
spinal JJ N
anesthesia-induced JJ N
hypotension NN N
has VBZ N
been VBN N
challenged VBN N
recently RB N
after IN N
several JJ N
reports NNS N
of IN N
failure NN N
to TO N
demonstrate VB N
its PRP$ N
efficacy NN N
in IN N
young JJ N
women NNS N
. . N

We PRP N
compared VBN N
the DT N
incidence NN O
and CC O
frequency NN O
of IN O
hypotension NN O
and CC O
vasopressor NN O
therapy NN O
after IN N
spinal JJ P
anesthesia NN P
and CC N
no DT I
prehydration NN I
with IN N
crystalloid NN I
and CC N
colloid JJ I
prehydration NN I
in IN P
elderly JJ P
patients NNS P
. . P

Eighty-five JJ P
ASA NNP P
grade NN P
I PRP P
or CC P
II NNP P
patients NNS P
(aged VBD P
60-89 JJ P
yr) NN P
for IN P
elective JJ P
total JJ P
hip NN P
replacement NN P
were VBD N
randomized VBN N
to TO N
receive VB N
500 CD N
mL NN N
crystalloid JJ I
solution NN I
(Hartmanns NNP I
n VBZ N
= $ N
29) CD N
500 CD N
mL NN N
colloid NN I
(Haemaccel NNP I
n VBZ N
= $ N
28) CD N
or CC N
no DT I
prehydration NN I
(n VBZ N
= $ N
28) CD N
over IN N
10 CD N
min NNS N
prior RB N
to TO N
spinal JJ N
anesthesia NN N
. . N

Hypotension NNP O
was VBD N
defined VBN N
as IN N
a DT N
30% CD N
decrease NN N
from IN N
baseline JJ N
systolic JJ O
blood NN O
pressure NN O
(BP) NN O
or CC N
systolic JJ N
< $ N
90 CD N
mm NN N
Hg NNP N
and CC N
was VBD N
treated VBN N
with IN N
ephedrine JJ N
3-mg JJ N
boluses NNS N
. . N

Although IN N
absolute JJ O
systolic JJ O
BP NNP O
readings NNS O
were VBD N
significantly RB N
higher JJR N
in IN N
the DT N
colloid NN I
group NN N
between IN N
6 CD N
and CC N
30 CD N
min NN N
(P NNP N
< VBZ N
0.05) CD N
the DT N
incidence NN O
of IN O
hypotension NN O
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
the DT N
groups NNS N
. . N

The DT N
incidence NN O
of IN O
ephedrine NN I
use NN O
incidence NN O
of IN O
nausea/vomiting NN O
and CC O
median JJ O
total NN O
dose NN O
of IN O
ephedrine NN I
were VBD N
similar JJ N
in IN N
all DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that IN N
in IN N
elderly JJ P
patients NNS P
undergoing VBG P
elective JJ P
procedures NNS P
withholding VBG N
prehydration NN I
is VBZ N
not RB N
associated VBN N
with IN N
any DT N
greater JJR N
degree NN O
of IN O
hypotension NN O
or CC O
need NN O
for IN O
vasopressor NN O
therapy NN O
compared VBN N
with IN N
crystalloid NN I
or CC N
colloid JJ I
prehydration NN I
. . I

-DOCSTART- -X- O O

A DT N
randomized JJ N
comparison NN N
of IN N
alternative JJ N
techniques NNS N
to TO N
achieve VB N
coronary JJ P
sinus NN P
cannulation NN P
during IN P
biventricular JJ P
implantation NN P
procedures NNS P
. . P

INTRODUCTION NNP N
Biventricular NNP P
pacing VBG P
system NN P
implantation NN P
is VBZ N
a DT N
time-consuming JJ N
and CC N
challenging JJ N
procedure NN N
. . N

A DT N
critical JJ N
step NN N
in IN N
biventricular JJ P
pacemaker NN P
implantation NN P
is VBZ N
coronary JJ P
sinus NN P
(CS) NNP P
cannulation NN P
. . P

CS NNP P
cannulation NN P
can MD N
be VB N
achieved VBN N
either DT N
using VBG N
dedicated JJ N
guiding VBG N
catheters NNS I
(guiding VBG I
catheter NN I
alone RB I
positioning VBG N
strategy NN N
GCA) NNP N
or CC N
with IN N
the DT N
aid NN N
of IN N
an DT N
electrophysiology NN I
catheter NN I
advanced VBD I
inside IN N
the DT N
guiding NN N
catheter NN N
(electrophysiology NNP I
catheter NN I
aided VBD I
positioning VBG N
strategy NN N
EPA) NNP N
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
evaluate VB N
whether IN N
the DT N
EPA NNP I
technique NN N
is VBZ N
useful JJ N
for IN N
reducing VBG N
CS NNP O
cannulation NN O
time NN O
compared VBN N
to TO N
a DT N
conventional JJ N
GCA NNP I
technique NN N
. . N

METHODS NNP N
Thirty-four JJ P
consecutive JJ P
patients NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
GCA NNP I
(18 NNP N
patients) NN N
or CC N
EPA NNP I
(16 NNP N
patients) NN N
CS NNP N
cannulation NN N
strategy NN N
. . N

RESULTS JJ N
Time NNP O
to TO O
successful JJ O
catheterization NN P
of IN P
CS NNP P
was VBD N
5.0 CD N
+/- JJ N
2.4 CD N
min NN N
in IN N
the DT N
EPA NNP I
group NN N
versus VBD N
10.1 CD N
+/- JJ N
5.4 CD N
min NN N
in IN N
the DT N
GCA NNP I
group NN N
p VBD N
= RB N
0.004 CD N
. . N

Fluoroscopy NN O
time NN O
was VBD N
4.6 CD N
+/- JJ N
2.3 CD N
min NN N
in IN N
the DT N
EPA NNP I
group NN N
versus VBD N
9.2 CD N
+/- JJ N
4.9 CD N
min NN N
in IN N
the DT N
GCA NNP I
group NN N
p VBD N
= RB N
0.004 CD N
. . N

Total JJ N
contrast NN O
dye NN O
volume NN O
to TO N
search NN N
and CC N
engage VB N
the DT N
CS NNP N
ostium NN N
was VBD N
0.0 CD N
ml NN N
in IN N
the DT N
EPA NNP I
group NN N
versus VBD N
14.3 CD N
+/- JJ N
3.4 CD N
ml NN N
in IN N
the DT N
GCA NNP I
group NN N
p VBD N
< RB N
0.001 CD N
. . N

CONCLUSIONS NNP N
Cannulation NNP P
of IN P
CS NNP P
with IN N
the DT N
adjunct NN N
of IN N
an DT N
electrophysiology NN N
catheter NN N
to TO N
dedicated VBN N
delivery NN N
systems NNS N
significantly RB N
reduces VBZ N
procedural JJ O
time NN O
fluoroscopy JJ O
time NN O
and CC O
contrast NN O
dye NN O
volume NN O
compared VBN N
to TO N
a DT N
conventional JJ N
strategy NN N
. . N

-DOCSTART- -X- O O

Teacher DT N
and CC N
child JJ N
predictors NNS N
of IN N
achieving VBG N
IEP NNP N
goals NNS N
of IN N
children NNS P
with IN P
autism NN P
. . P

It PRP N
is VBZ N
encouraging VBG N
that IN N
children NNS P
with IN P
autism NN P
show VBP N
a DT N
strong JJ N
response NN N
to TO N
early JJ N
intervention NN N
yet RB N
more RBR N
research NN N
is VBZ N
needed VBN N
for IN N
understanding VBG N
the DT N
variability NN N
in IN N
responsiveness NN N
to TO N
specialized JJ N
programs NNS N
. . N

Treatment NNP O
predictor NN O
variables NNS O
from IN N
47 CD P
teachers NNS P
and CC P
children NNS P
who WP N
were VBD N
randomized VBN N
to TO N
receive VB N
the DT N
COMPASS NNP I
intervention NN I
(Ruble JJ N
et NN N
al NN N
. . N

in IN N
The DT I
collaborative JJ I
model NN I
for IN I
promoting VBG I
competence NN I
and CC I
success NN I
for IN N
students NNS N
with IN N
ASD NNP N
. . N

Springer NNP N
New NNP N
York NNP N
2012a) CD N
were VBD N
analyzed VBN N
. . N

Predictors NNS O
evaluated VBD N
against IN N
child NN N
IEP NNP N
goal NN N
attainment NN N
included VBD N
child NN O
teacher NN O
intervention NN O
practice NN O
and CC O
implementation NN O
practice NN O
variables NNS O
based VBN O
on IN O
an DT O
implementation NN O
science NN O
framework NN O
(Dunst NN N
and CC N
Trivette NNP N
in IN N
J NNP N
Soc NNP N
Sci NNP N
8:143-148 JJ N
2012) CD N
. . N

Findings NNS N
revealed VBD N
one CD N
child NN N
(engagement) VBZ N
one CD N
teacher NN N
(exhaustion) NN N
two CD N
intervention NN O
quality NN O
(IEP NNP O
quality NN O
for IN O
targeted VBN O
and CC O
not RB O
targeted VBN O
elements) NN O
and CC N
no DT N
implementation NN O
quality NN O
variables NNS O
accounted VBD N
for IN N
variance NN N
in IN N
child NN N
outcomes NNS N
when WRB N
analyzed VBN N
separately RB N
. . N

When WRB N
the DT N
four CD N
significant JJ N
variables NNS N
were VBD N
compared VBN N
against IN N
each DT N
other JJ N
in IN N
a DT N
single JJ N
regression NN N
analysis NN N
IEP NNP N
quality NN N
accounted VBD N
for IN N
one CD N
quarter NN N
of IN N
the DT N
variance NN N
in IN N
child NN N
outcomes NNS N
. . N

-DOCSTART- -X- O O

Recurrent JJ P
epithelial JJ P
ovarian JJ P
carcinoma: NN P
a DT N
randomized JJ N
phase NN N
III NNP N
study NN N
of IN N
pegylated VBN I
liposomal JJ I
doxorubicin NN I
versus NN N
topotecan JJ I
. . I

PURPOSE NNP N
To TO N
compare VB N
the DT N
efficacy NN O
and CC N
safety NN O
of IN N
pegylated JJ I
liposomal JJ I
doxorubicin NN I
(PLD) NN I
and CC N
topotecan JJ I
in IN N
patients NNS P
with IN P
epithelial JJ P
ovarian JJ P
carcinoma NN P
that WDT P
recurred VBD P
after IN P
or CC P
didn't VB P
respond NN P
to TO P
first-line JJ P
platinum-based JJ P
chemotherapy NN P
. . P

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS P
with IN P
measurable JJ P
and CC P
assessable JJ P
disease NN P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
PLD NNP I
50 CD N
mg/m(2) NN N
as IN N
a DT N
1-hour JJ N
infusion NN N
every DT N
4 CD N
weeks NNS N
or CC N
topotecan JJ I
1.5 CD N
mg/m(2)/d NN N
for IN N
5 CD N
consecutive JJ N
days NNS N
every DT N
3 CD N
weeks NNS N
. . N

Patients NNS N
were VBD N
stratified VBN N
prospectively RB N
for IN N
platinum NN N
sensitivity NN N
and CC N
for IN N
the DT N
presence NN N
or CC N
absence NN N
of IN N
bulky JJ N
disease NN N
. . N

RESULTS VB N
A DT P
total NN P
of IN P
474 CD P
patients NNS P
were VBD P
treated VBN P
(239 JJ N
PLD NNP I
and CC N
235 CD N
topotecan) NN I
. . N

They PRP N
comprised VBD N
the DT N
intent-to-treat JJ N
population NN N
. . N

The DT N
overall JJ O
progression-free JJ O
survival NN O
rates NNS O
were VBD N
similar JJ N
between IN N
the DT N
two CD N
arms NNS N
(P JJ N
=.095) NN N
. . N

The DT N
overall JJ O
response NN O
rates NNS O
for IN N
PLD NNP I
and CC N
topotecan JJ I
were VBD N
19.7% CD N
and CC N
17.0% CD N
respectively RB N
(P JJ N
=.390) NNP N
. . N

Median JJ O
overall JJ O
survival NN O
times NNS O
were VBD N
60 CD N
weeks NNS N
for IN N
PLD NNP I
and CC N
56.7 CD N
weeks NNS N
for IN N
topotecan JJ I
. . I

Data NNP N
analyzed VBD N
in IN N
platinum-sensitive JJ N
patients NNS N
demonstrated VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
PLD NNP I
for IN N
progression-free JJ N
survival NN N
(P NNP N
=.037) NN N
with IN N
medians NNS N
of IN N
28.9 CD N
for IN N
PLD NNP I
versus FW N
23.3 CD N
weeks NNS N
for IN N
topotecan JJ I
. . I

For IN N
overall JJ O
survival NN O
PLD NNP I
was VBD N
significantly RB N
superior JJ N
to TO N
topotecan JJ I
(P NNP N
=.008) NN N
with IN N
a DT N
median NN N
of IN N
108 CD N
weeks NNS N
versus RB N
71.1 CD N
weeks NNS N
. . N

The DT N
platinum-refractory JJ N
subgroup NN N
demonstrated VBD N
a DT N
nonstatistically RB N
significant JJ N
survival JJ O
trend NN N
in IN N
favor NN N
of IN N
topotecan JJ I
(P NNP N
=.455) NNP N
. . N

Severe NNP O
hematologic JJ O
toxicity NN O
was VBD N
more RBR N
common JJ N
with IN N
topotecan JJ I
and CC N
was VBD N
more RBR N
likely JJ N
to TO N
be VB N
associated VBN N
with IN N
dosage NN N
modification NN N
or CC N
growth NN N
factor NN N
or CC N
blood NN N
product NN N
utilization NN N
. . N

CONCLUSION VB N
The DT N
comparable JJ N
efficacy NN O
favorable JJ O
safety NN O
profile NN O
and CC N
convenient NN O
dosing VBG O
support NN N
the DT N
role NN N
of IN N
PLD NNP I
as IN N
a DT N
valuable JJ N
treatment NN N
option NN N
in IN N
this DT N
patient JJ N
population NN N
. . N

-DOCSTART- -X- O O

Rapid JJ N
tightening NN N
of IN N
blood NN O
glucose NN O
control NN N
leads VBZ N
to TO N
transient VB O
deterioration NN O
of IN O
retinopathy NN O
in IN N
insulin NN P
dependent NN P
diabetes VBZ P
mellitus: VBP P
the DT N
Oslo NNP N
study NN N
. . N

In IN N
a DT N
study NN N
of IN N
retinopathy NN N
during IN N
one CD N
year NN N
of IN N
tight JJ N
blood NN O
glucose VB O
control NN N
45 CD P
type NN P
I PRP P
(insulin VBP P
dependent) JJ P
diabetics NNS P
without IN P
proliferative JJ P
retinopathy NN P
were VBD N
randomised VBN N
to TO N
receive VB N
either RB N
continuous JJ N
subcutaneous JJ N
insulin NN I
infusion NN I
multiple JJ N
insulin NN I
injections NNS I
or CC N
conventional JJ N
insulin NN I
treatment NN I
(controls) NNP N
. . N

Near IN N
normoglycaemia NN N
was VBD N
achieved VBN N
with IN N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
but CC N
not RB N
with IN N
conventional JJ N
treatment NN N
. . N

Blind NNP N
evaluation NN N
of IN N
fluorescein JJ O
angiograms NNS O
performed VBD N
three CD N
monthly JJ N
showed VBD N
progression NN O
of IN O
retinopathy NN O
in IN N
the DT N
control NN N
group NN N
transient JJ N
deterioration NN N
in IN N
the DT N
continuous JJ N
infusion NN N
group NN N
and CC N
no DT N
change NN N
in IN N
the DT N
multiple JJ N
injection NN N
group NN N
. . N

Half PDT N
the DT N
patients NNS N
receiving VBG N
continuous JJ N
infusion NN N
and CC N
multiple JJ N
injections NNS N
developed VBD N
retinal JJ N
cotton NN N
wool NN N
spots NNS N
after IN N
three CD N
to TO N
six CD N
months NNS N
. . N

These DT N
changes NNS N
regressed VBD N
in IN N
all DT N
but CC N
four CD N
patients NNS N
after IN N
12 CD N
months NNS N
. . N

Control NNP N
patients NNS N
did VBD N
not RB N
develop VB N
cotton NN O
wool NN O
spots NNS O
. . O

Patients NNS N
who WP N
developed VBD N
cotton NN N
wool NN N
spots NNS N
are VBP N
characterised VBN N
by IN N
a DT N
larger JJR N
decrement NN N
in IN N
glycosylated JJ O
haemoglobin NN O
and CC O
blood NN O
glucose NN O
values NNS O
more RBR N
frequent JJ O
episodes NNS O
of IN O
hypoglycaemia NN O
a DT N
longer JJR N
duration NN O
of IN O
diabetes NNS O
and CC N
more JJR N
severe JJ N
retinopathy NN O
at IN O
onset NN O
. . O

A DT N
large JJ N
and CC N
rapid JJ N
fall NN N
in IN N
blood NN O
glucose JJ O
concentration NN O
may MD N
promote VB N
transient JJ N
deterioration NN N
of IN N
diabetic JJ N
retinopathy NN O
. . O

-DOCSTART- -X- O O

Double-blind NNP N
comparison NN N
of IN N
doxepin NN I
versus NN N
bupropion NN I
in IN N
outpatients NNS P
with IN P
a DT P
major JJ P
depressive JJ P
disorder NN P
. . P

A DT N
double-blind NN N
controlled VBN N
study NN N
comparing VBG N
the DT N
effects NNS N
of IN N
bupropion NN I
to TO N
doxepin VB I
in IN N
outpatients NNS P
with IN P
primary JJ P
depression NN P
was VBD N
conducted VBN N
to TO N
evaluate VB N
efficacy NN O
and CC N
safety NN O
differences NNS O
between IN N
the DT N
two CD N
drugs NNS N
. . N

Following VBG N
a DT N
7-day JJ N
placebo NN I
washout IN N
period NN N
patients NNS N
could MD N
be VB N
treated VBN N
for IN N
up RB N
to TO N
13 CD N
weeks NNS N
on IN N
either DT N
treatment NN N
. . N

Antidepressant JJ O
response NN O
was VBD N
assessed VBN N
by IN N
the DT N
Hamilton NNP O
Depression NNP O
and CC O
Anxiety NNP O
Scales NNP O
Clinical NNP O
Global NNP O
Severity NNP O
and CC O
Improvement NNP O
Ratings NNP O
and CC O
the DT O
Zung NNP O
Self-Rating NNP O
Depression NNP O
Scale NNP O
. . O

Comparable JJ N
efficacy NN O
between IN N
the DT N
compounds NNS N
was VBD N
found VBN N
across IN N
the DT N
13-week JJ N
study NN N
. . N

Doxepin NNP I
differed VBD N
from IN N
bupropion NN I
mainly RB N
on IN N
the DT N
sleep JJ O
factor NN N
of IN N
the DT N
Hamilton NNP O
Depression NNP O
Scale NNP O
with IN N
doxepin NN I
improving VBG N
sleep NN O
to TO N
a DT N
greater JJR N
extent NN N
than IN N
bupropion NN I
. . I

Doxepin NNP I
produced VBD N
a DT N
greater JJR N
incidence NN N
of IN N
anticholinergic JJ O
side NN O
effects NNS O
including VBG N
dry JJ O
mouth NN O
constipation NN O
sleepiness NN O
and CC O
tiredness NN O
in IN N
comparison NN N
to TO N
bupropion NN I
. . I

Also RB N
increased VBD O
appetite RB O
and CC O
weight JJ O
gain NN O
were VBD N
consistent JJ N
side NN O
effects NNS O
of IN N
doxepin NN I
relative NN N
to TO N
bupropion NN I
. . I

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN I
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN I
infusion NN N
on IN N
postoperative JJ O
morphine NN O
requirement NN O
in IN N
patients NNS P
undergoing VBG P
laparatomy NN P
. . P

OBJECTIVES NNP N
To TO N
evaluate VB N
and CC N
compare VB N
the DT N
effects NNS N
of IN N
preoperative JJ N
oral JJ N
pregabalin NN I
and CC N
perioperative JJ N
intravenous JJ N
lidocaine NN I
infusion NN N
on IN N
postoperative JJ O
morphine NN O
requirement NN O
adverse JJ O
effects NNS O
patients' JJ O
satisfaction NN O
mobilization NN O
time NN O
to TO O
first JJ O
defecation NN O
and CC O
time NN O
to TO O
discharge VB O
in IN N
patients NNS P
undergoing VBG P
laparotomy NN P
. . P

METHODS NNP N
Eighty NNP P
patients NNS P
(18 VBP P
to TO P
65 CD P
years NNS P
of IN P
age) NN P
undergoing VBG P
elective JJ P
laparotomy NN P
were VBD N
randomly RB N
divided VBN N
into IN N
four CD N
groups NNS N
(n=20 VBP N
in IN N
each DT N
group): NN N
group NN N
C NNP N
placebo NN I
capsules NNS N
and CC N
normal JJ I
saline JJ I
infusion NN I
perioperatively RB N
(control); NNP N
group NN N
L NNP N
placebo NN I
capsules NNS N
and CC N
lidocaine JJ I
1 CD N
mg⁄kg RB N
intravenous JJ N
bolus NN N
dose NN N
followed VBN N
by IN N
2 CD N
mg⁄kg⁄h JJ N
infusion NN N
until IN N
skin JJ N
closure; NN N
group NN N
P NNP N
150 CD N
mg NN I
oral JJ I
pregabalin NN I
and CC I
normal JJ I
saline JJ I
infusion NN I
perioperatively; NN N
and CC N
group NN N
PL NNP N
150&nbsp;mg CD I
oral JJ I
pregabalin NN I
and CC I
lidocaine NN I
2 CD N
mg⁄kg⁄h NN N
infusion NN N
until IN N
skin JJ O
closure NN O
. . O

Hemodynamic NNP O
parameters NNS O
visual JJ O
analogue JJ O
scale NN O
(VAS) NN O
scores NNS O
analgesic JJ O
consumption NN O
side NN O
effects NNS O
time NN O
to TO O
mobilization NN O
time NN O
to TO O
first VB O
defecation NN O
time NN O
to TO O
discharge VB O
and CC O
patients' VB O
satisfaction NN O
were VBD N
recorded VBN O
. . O

RESULTS NNP O
VAS NNP O
scores NNS N
of IN N
group NN N
L NNP N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
were VBD N
lower JJR N
than IN N
group NN N
C NNP N
(P<0.05) NNP O
. . O

Morphine NNP O
consumption NN O
of IN N
group NN N
P NNP N
and CC N
group NN N
PL NNP N
was VBD N
lower JJR N
than IN N
group NN N
C NNP N
(P<0.05) NNP O
. . O

Incidence NN O
of IN N
nausea NN N
in IN N
group NN N
C NNP N
was VBD N
higher JJR N
than IN N
group NN N
L NNP N
and CC N
group NN O
PL NNP O
. . O

Time NNP O
to TO O
first VB O
defecation NN O
and CC O
mobilization NN O
were VBD N
shorter JJR N
in IN N
group NN N
L NNP N
and CC N
group NN N
PL NNP N
compared VBN N
with IN N
group NN N
C NNP N
(P<0.05) NNP N
. . N

CONCLUSION NNP N
Preoperative NNP I
oral JJ I
pregabalin NN I
and CC N
perioperative JJ N
intravenous JJ I
lidocaine NN N
infusion NN N
decreased VBD O
postoperative JJ O
VAS NNP O
scores NNS N
. . N

Preoperative JJ I
oral JJ I
pregabalin NN I
decreased VBD O
morphine JJ O
requirement NN O
and CC N
perioperative JJ N
intravenous JJ I
lidocaine NN N
infusion NN N
hastened VBD N
gastrointestinal JJ N
motility NN N
and CC N
mobilization NN N
and CC N
decreased VBD O
the DT O
incidence NN O
of IN N
nausea NN P
in IN P
patients NNS P
undergoing VBG P
laparotomy NN P
. . N

Therefore RB N
preoperative JJ I
pregabalin NN I
with IN N
or CC I
without IN I
lidocaine JJ N
provides VBZ O
superior JJ O
pain NN O
relief NN P
in IN P
patients NNS P
undergoing VBG P
laparatomy NN P
. . N

-DOCSTART- -X- O O

A DT N
novel JJ N
approach NN N
to TO N
the DT N
use NN N
of IN N
subgingival JJ N
controlled-release JJ N
chlorhexidine NN I
delivery NN N
in IN N
chronic JJ P
periodontitis: NN P
a DT N
randomized JJ N
clinical JJ N
trial NN N
. . N

BACKGROUND IN N
We PRP N
aimed VBD N
to TO N
analyze VB N
clinical JJ O
microbiologic NN O
and CC O
serologic JJ O
effects NNS O
of IN N
chlorhexidine NN I
(CHX) NNP I
chips NNS N
used VBD N
as IN N
a DT N
subgingival JJ N
controlled-release JJ N
delivery NN N
device NN N
before IN N
and CC N
immediately RB N
after IN N
scaling VBG N
and CC N
root NN N
planing NN N
(SRP) NN N
. . N

METHODS NNP N
Twenty-four JJ P
patients NNS P
presenting VBG P
with IN P
≥12 NNP P
teeth NNS P
with IN P
probing VBG P
depth NN P
(PD) NNP P
≥5 NNP P
mm NN P
and CC P
bleeding NN P
on IN P
probing VBG P
were VBD N
assigned VBN N
in IN N
test NN N
or CC N
control NN N
groups NNS N
. . N

After IN N
prophylaxis JJ I
CHX NNP I
chips NNS I
(test) VBD I
or CC I
placebo JJ I
chips NNS N
(control) WDT N
were VBD N
placed VBN N
in IN N
pockets NNS N
with IN N
PD NNP N
≥5 NNP N
mm NN N
. . N

Ten CD N
days NNS N
later RB N
SRP NNP N
was VBD N
performed VBN N
in IN N
all DT N
teeth NNS N
with IN N
PD NNP N
≥4 NNP N
mm NN N
in IN N
a DT N
single JJ N
appointment NN N
. . N

Immediately RB N
after IN N
SRP NNP N
new JJ N
chips NNS N
were VBD N
inserted VBN N
in IN N
all DT N
pockets NNS N
with IN N
PD NNP O
≥5 NNP O
mm NN O
. . O

Parameters NNS O
were VBD N
assessed VBN N
at IN N
baseline; NN N
beginning NN N
of IN N
SRP; NNP N
and CC N
1 CD N
3 CD N
and CC N
6 CD N
months NNS N
after IN N
treatment NN O
. . O

Subgingival JJ O
samples NNS N
were VBD N
obtained VBN N
at IN N
baseline; JJ N
beginning NN N
of IN N
SRP; NNP N
and CC N
at IN N
1 CD N
month NN N
after IN N
treatment NN O
. . O

Periodontal JJ O
pathogens NNS O
Aggregatibacter NNP O
actinomycetemcomitans NNS O
Porphyromonas NNP O
gingivalis NN O
Prevotella NNP O
intermedia NN O
Tannerella NNP O
forsythia NN O
and CC O
Treponema NNP O
denticola NN N
were VBD N
analyzed VBN O
. . O

Serum NNP O
levels NNS O
of IN O
high JJ O
sensitive JJ O
C-reactive JJ O
and CC O
lipopolysaccharide-binding JJ O
proteins NNS N
were VBD N
measured VBN N
. . N

The DT N
changes NNS O
of IN O
the DT O
parameters NNS O
between IN N
and CC N
within IN N
the DT N
groups NNS N
were VBD N
tested VBN O
by IN O
Mann-Whitney NNP O
U NNP N
test NN N
(P NN N
<0.05) NNP N
. . N

RESULTS NNP O
All NNP O
clinical JJ O
and CC O
serologic JJ O
parameters NNS O
improved VBN N
in IN N
both DT N
groups NNS N
over IN N
time NN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
difference NN O
in IN O
clinical JJ O
attachment NN O
level NN O
(CAL) VBP N
gain NN N
from IN N
baseline NN N
to TO N
6 CD N
months NNS N
between IN N
groups NNS N
(1.17 NNP N
mm NN N
in IN N
the DT N
test NN N
group NN N
versus VBD N
0.79 CD N
mm NN N
in IN N
the DT N
placebo NN N
group) NN N
(P NNP N
<0.05) NNP N
. . N

The DT N
treatment NN I
with IN I
CHX NNP N
chips NNS N
showed VBD N
a DT O
greater JJR O
reduction NN O
of IN O
the DT O
microorganisms NN O
of IN O
the DT O
"red NNP O
complex" NN N
after IN N
1 CD N
month NN N
(P NNP N
= VBD N
0.02) CD N
. . N

CONCLUSION VB N
The DT I
use NN I
of IN I
CHX NNP N
chips NNS N
before IN N
and CC N
immediately RB N
after IN N
SRP NNP O
improved VBD O
CAL NNP N
and CC N
reduced VBD O
the DT O
subgingival JJ O
microorganisms NN O
of IN O
the DT O
red JJ O
complex NN N
in IN N
the DT N
treatment NN P
of IN P
chronic JJ P
periodontitis NN P
. . N

-DOCSTART- -X- O O

Raising VBG N
high-density NN O
lipoprotein NN O
in IN N
humans NNS N
through IN N
inhibition NN N
of IN N
cholesteryl NN N
ester NN N
transfer NN N
protein: VBZ N
an DT N
initial JJ N
multidose NN N
study NN N
of IN N
torcetrapib NN I
. . I

OBJECTIVE CC N
The DT N
ability NN N
of IN N
the DT N
potent NN N
cholesteryl NN I
ester NN I
transfer NN I
protein NN I
(CETP) NNP I
inhibitor NN I
torcetrapib VBD I
(CP-529 JJ I
414) CD I
to TO N
raise VB N
high-density NN O
lipoprotein JJ O
cholesterol NN O
(HDL-C) JJ O
levels NNS O
in IN N
healthy JJ P
young JJ P
subjects NNS P
was VBD N
tested VBN N
in IN N
this DT N
initial JJ N
phase NN N
1 CD N
multidose NN N
study NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
Five NNP P
groups NNS P
of IN P
8 CD P
subjects NNS P
each DT P
were VBD N
randomized VBN N
to TO N
placebo VB I
(n=2) NNP N
or CC N
torcetrapib VB I
(n=6) NN N
at IN N
10 CD N
30 CD N
60 CD N
and CC N
120 CD N
mg NNS N
daily RB N
and CC N
120 CD N
mg NN N
twice RB N
daily RB N
for IN N
14 CD N
days NNS N
. . N

Torcetrapib NN I
was VBD N
well RB N
tolerated VBN N
with IN N
all DT N
treated JJ N
subjects NNS N
completing VBG N
the DT N
study NN N
. . N

The DT N
correlation NN N
of IN N
plasma JJ O
drug NN O
levels NNS O
with IN N
inhibition NN N
(EC50=43 FW N
nM) NN N
was VBD N
as IN N
expected VBN N
based VBN N
on IN N
in IN N
vitro JJ N
potency NN N
(IC50 NNP N
approximately RB N
50 CD N
nM) NNS N
and CC N
increases NNS N
in IN N
CETP NNP N
mass NN N
were VBD N
consistent JJ N
with IN N
the DT N
proposed VBN N
mechanism NN N
of IN N
inhibition NN N
. . N

CETP NNP N
inhibition NN N
increased VBD N
with IN N
escalating VBG N
dose JJ N
leading VBG N
to TO N
elevations NNS N
of IN N
HDL-C NNP O
of IN N
16% CD N
to TO N
91% CD N
. . N

Total JJ O
plasma JJ O
cholesterol NN O
did VBD N
not RB N
change VB N
significantly RB N
because IN N
of IN N
a DT N
reduction NN N
in IN N
nonHDL-C JJ O
including VBG N
a DT N
21% CD N
to TO N
42% CD N
lowering NN N
of IN N
low-density NN O
lipoprotein NN O
cholesterol NN O
at IN N
the DT N
higher JJR N
doses NNS N
. . N

Apolipoprotein NNP O
A-I NNP O
and CC O
E NNP O
were VBD N
elevated VBN N
27% CD N
and CC N
66% CD N
respectively RB N
and CC N
apoB NN O
was VBD N
reduced VBN N
26% CD N
with IN N
120 CD N
mg NNS N
twice RB N
daily RB N
. . N

Cholesteryl NNP O
ester NN O
content NN O
decreased VBN N
and CC N
triglyceride VB O
increased VBN N
in IN N
the DT N
nonHDL JJ O
plasma NN N
fraction NN N
with IN N
contrasting VBG N
changes NNS N
occurring VBG N
in IN N
HDL NNP O
. . O

CONCLUSIONS NNP N
These DT N
effects NNS N
of IN N
CETP NNP N
inhibition NN N
resemble VBP N
those DT N
observed VBN N
in IN N
partial JJ N
CETP NNP N
deficiency NN N
. . N

This DT N
work NN N
serves VBZ N
as IN N
a DT N
prelude NN N
to TO N
further JJ N
studies NNS N
in IN N
subjects NNS N
with IN N
low JJ N
HDL NNP N
or CC N
combinations NNS N
of IN N
dyslipidemia NN N
in IN N
assessing VBG N
the DT N
role NN N
of IN N
CETP NNP N
in IN N
atherosclerosis NN N
. . N

-DOCSTART- -X- O O

Levobunolol NNP I
compared VBN N
with IN N
timolol: NN I
a DT N
four-year JJ N
study NN N
. . N

Fifty-one CD P
patients NNS P
with IN P
raised VBN P
intraocular JJ P
pressure NN P
(IOP) NN P
were VBD N
treated VBN N
for IN N
up IN N
to TO N
four CD N
years NNS N
with IN N
one CD N
of IN N
three CD N
ophthalmic JJ N
solutions: NN N
0.5% CD N
levobunolol NN I
1% CD N
levobunolol NN I
or CC N
0.5% CD N
timolol NN I
. . I

The DT N
study NN N
was VBD N
conducted VBN N
as IN N
a DT N
double-masked JJ N
randomised JJ N
trial NN N
in IN N
which WDT N
medications NNS N
were VBD N
administered VBN N
twice RB N
daily RB N
to TO N
both DT N
eyes NNS N
. . N

Levobunolol NNP I
and CC N
timolol NN I
were VBD N
equally RB N
effective JJ O
in IN N
reducing VBG N
overall JJ O
mean JJ O
IOP; NNP O
reductions NNS N
were VBD N
greater JJR N
than IN N
8.8 CD N
mmHg NNS N
in IN N
all DT N
three CD N
treatment NN N
groups NNS N
. . N

The DT N
study NN N
showed VBD N
levobunolol NNS I
to TO N
be VB N
as IN N
safe JJ N
and CC N
effective JJ O
as IN N
timolol NN I
in IN N
the DT N
long-term JJ N
control NN N
of IN N
raised VBN N
IOP NNP N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
multicenter NN N
study NN N
to TO N
assess VB N
the DT N
safety NN O
and CC N
cardiovascular JJ O
effects NNS O
of IN N
skeletal JJ I
myoblast NN I
implantation NN I
by IN N
catheter NN N
delivery NN N
in IN N
patients NNS P
with IN P
chronic JJ P
heart NN P
failure NN P
after IN P
myocardial JJ P
infarction NN P
. . P

BACKGROUND NNP N
We PRP N
sought VBD N
to TO N
determine VB N
the DT N
safety NN O
and CC N
preliminary JJ O
efficacy NN O
of IN N
transcatheter NN N
intramyocardial JJ N
administration NN N
of IN N
myoblasts NNS I
in IN N
patients NNS P
with IN P
heart NN P
failure NN P
(HF) NNP P
. . P

METHODS NNP N
MARVEL NNP N
is VBZ N
a DT N
randomized JJ N
placebo-controlled JJ N
trial NN N
of IN N
image-guided JJ N
catheter-based JJ N
intramyocardial JJ N
injection NN N
of IN N
placebo NN I
or CC N
myoblasts NNS I
(400 VBP N
or CC N
800 CD N
million) NNS N
in IN N
patients NNS P
with IN P
class NN P
II NNP P
to TO P
IV NNP P
HF NNP P
and CC P
ejection NN P
fraction NN P
<35% NNP P
. . P

Primary JJ N
end NN N
points NNS N
were VBD N
frequency NN O
of IN O
serious JJ O
adverse JJ O
events NNS O
(safety) FW O
and CC O
changes NNS O
in IN O
6-minute JJ O
walk NN O
test NN O
and CC O
Minnesota NNP O
Living NNP O
With IN O
HF NNP O
score NN O
(efficacy) NNP O
. . O

Of IN P
330 CD P
patients NNS P
intended VBN P
for IN P
enrollment NN P
23 CD P
were VBD P
randomized VBN P
(MARVEL-1) JJ P
before IN P
stopping VBG P
the DT P
study NN P
for IN P
financial JJ P
reasons NNS P
. . P

RESULTS NNP N
At IN N
6 CD N
months NNS N
similar JJ N
numbers NNS N
of IN N
events NNS N
occurred VBN N
in IN N
each DT N
group: NN N
8 CD N
(placebo) NN I
7 CD N
(low JJ N
dose) NN N
and CC N
8 CD N
(high JJ N
dose) NN N
without IN N
deaths NNS N
. . N

Ventricular JJ O
tachycardia NN O
responsive NN O
to TO N
amiodarone VB N
was VBD N
more RBR N
frequent JJ N
in IN N
myoblast-treated JJ I
patients: NN N
1 CD N
(placebo) NN I
3 CD N
(low JJ N
dose) NN N
and CC N
4 CD N
(high JJ N
dose) NN N
. . N

A DT N
trend NN N
toward IN N
improvement NN N
in IN N
functional JJ O
capacity NN O
was VBD N
noted VBN N
in IN N
myoblast-treated JJ I
groups NNS N
(Δ6-minute JJ N
walk JJ N
test NN N
of IN N
-3.6 NNP N
vs FW N
+95.6 NNP N
vs FW N
+85.5 NNP N
m FW N
[placebo NNP N
vs FW N
low JJ N
dose NN N
vs NN N
high JJ N
dose; NN N
P NNP N
= NNP N
.50]) NNP N
without IN N
significant JJ N
changes NNS N
in IN O
Minnesota NNP O
Living NNP O
With IN O
HF NNP O
scores NNS O
. . N

CONCLUSIONS NNP N
In IN P
HF NNP P
patients NNS P
with IN P
chronic JJ P
postinfarction NN P
cardiomyopathy NN P
transcatheter NN N
administration NN N
of IN I
myoblasts NNS I
in IN N
doses NNS N
of IN N
400 CD N
to TO N
800 CD N
million CD N
cells NNS N
is VBZ N
feasible JJ N
and CC N
may MD N
lead VB N
to TO N
important JJ N
clinical JJ N
benefits NNS N
. . N

Ventricular JJ N
tachycardia NN N
may MD N
be VB N
provoked VBN N
by IN I
myoblast JJ I
injection NN N
but CC N
appears VBZ N
to TO N
be VB N
a DT N
transient NN N
and CC N
treatable JJ N
problem NN N
. . N

A DT N
large-scale JJ N
outcome JJ N
trial NN N
of IN I
myoblast JJ I
administration NN N
in IN P
HF NNP P
patients NNS P
with IN P
postinfarction NN P
cardiomyopathy NN P
is VBZ N
feasible JJ N
and CC N
warranted VBD N
. . N

-DOCSTART- -X- O O

A DT N
selective JJ N
angiotensin NN N
receptor NN N
antagonist NN N
Valsartan NNP I
produced VBD N
regression NN O
of IN O
left JJ P
ventricular JJ P
hypertrophy NN P
associated VBN N
with IN N
a DT N
reduction NN N
of IN N
arterial JJ O
stiffness NN O
. . O

We PRP N
investigated VBD N
whether IN N
a DT N
selective JJ I
angiotensin NN I
II NNP I
receptor NN I
blocker NN I
(ARB) NNP I
would MD N
have VB N
a DT N
regressive JJ O
effect NN O
on IN O
left NN P
ventricular JJ P
hypertrophy NN P
(LVH) NN P
in IN P
patients NNS P
on IN P
continuous JJ P
ambulatory JJ P
peritoneal JJ P
dialysis NN P
(CAPD) NN P
. . P

In IN N
a DT N
double-blind NN N
study NN N
24 CD P
CAPD NNP P
patients NNS P
with IN P
LVH NNP P
[left NNP P
ventricular JJ P
mass NN P
index NN P
(LVMi) NNP P
> VBZ P
110 CD P
g/m2 NN P
for IN P
women NNS P
and CC P
LVMi NNP P
> NNP P
137 CD P
g/m2 NN P
for IN P
men] NN P
were VBD N
randomized VBN N
to TO N
12 CD N
months' JJ N
administration NN N
of IN N
either CC N
the DT N
ARB NNP I
valsartan NN I
(n NNP N
= VBZ N
14) CD N
or CC N
a DT N
placebo NN I
(n NNP N
= VBZ N
10) CD N
. . N

The DT N
target NN O
blood NN O
pressure NN O
(BP) NNP O
was VBD N
140/90 CD N
mmHg NN N
or CC N
lower JJR N
in IN N
both DT N
groups NNS N
. . N

The DT N
following JJ N
parameters NNS N
were VBD N
measured VBN N
before RB N
and CC N
at IN N
the DT N
end NN N
of IN N
the DT N
study: NN N
aortic JJ O
and CC O
large-artery JJ O
compliance NN O
and CC O
arterial JJ O
wave NN O
reflections NNS O
[pulse VBP O
wave VBP O
velocity NN O
(PWV) NN O
and CC O
augmentation NN O
index NN O
(AI) NNP O
application NN O
tonometry] NN O
and CC O
cardiac JJ O
echocardiography NN O
. . O

Periodically RB N
recorded VBN N
were VBD N
body JJ O
weight JJ O
BP NNP O
(mercury NNP O
sphygmomanometer) VBD O
serum JJ O
creatinine NN O
electrolytes VBZ O
complete JJ O
blood NN O
cell NN O
counts VBZ O
urine JJ O
volume NN O
drainage NN O
volume NN O
and CC O
weekly JJ O
creatinine NN O
clearance NN O
. . O

Two-way JJ N
analysis NN N
of IN N
variance NN N
for IN N
repeated JJ N
measurements NNS N
was VBD N
used VBN N
for IN N
statistical JJ N
analysis NN N
. . N

Systolic NNP O
and CC O
diastolic JJ O
BP NNP O
were VBD N
both DT N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP I
. . I

The DT N
LVMi NNP O
was VBD N
significantly RB N
reduced VBN N
in IN N
patients NNS N
treated VBN N
with IN N
ARB NNP I
(to $ N
121 CD N
+/- JJ N
4 CD N
from IN N
145 CD N
+/- JJ N
5) CD N
but CC N
not RB N
in IN N
those DT N
receiving VBG N
placebo NN I
(to $ N
137 CD N
+/- JJ N
3 CD N
from IN N
152 CD N
+/- JJ N
3 CD N
p NN N
< VBD N
0.05) CD N
. . N

The DT N
decrease NN N
in IN N
LVMi NNP O
was VBD N
associated VBN N
with IN N
a DT N
reduction NN N
in IN N
PWV NNP O
and CC N
AI NNP O
. . O

In IN N
CAPD NNP P
patients NNS P
with IN P
LVH NNP P
ARB NNP I
reduced VBD N
LVMi NNP O
in IN N
association NN N
with IN N
alterations NNS N
in IN N
arterial JJ O
hemodynamics NNS O
. . O

-DOCSTART- -X- O O

The DT N
effects NNS N
of IN N
sevoflurane NN I
and CC N
isoflurane NN I
on IN N
recovery NN N
from IN N
outpatient JJ P
surgery NN P
. . P

This DT N
randomized VBD N
open-label NN N
study NN N
compared VBN N
the DT N
investigational JJ N
inhalational JJ N
anesthetic JJ N
sevoflurane NN I
with IN N
isoflurane NN I
in IN N
47 CD P
healthy JJ P
women NNS P
undergoing VBG P
elective JJ P
ambulatory NN P
surgery NN P
. . P

The DT N
women NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
sevoflurane NN I
or CC N
isoflurane NN I
in IN N
60% CD N
nitrous JJ N
oxide-oxygen NN N
. . N

Induction NN N
with IN N
thiopental JJ I
3-6 JJ N
mg/kg NN N
was VBD N
followed VBN N
by IN N
vecuronium NN I
0.1 CD N
mg/kg NN N
and CC N
fentanyl JJ I
0-200 JJ N
micrograms NNS N
. . N

Duration NN O
of IN O
anesthesia JJ O
time NN O
to TO O
emergence VB O
orientation NN O
length NN O
of IN O
stay NN O
in IN O
the DT O
surgical JJ O
unit NN O
and CC O
hospital JJ O
discharge NN O
were VBD N
recorded VBN N
. . N

The DT N
emergence NN O
length NN O
of IN O
stay NN O
and CC O
discharge NN O
times NNS O
after IN O
discontinuation NN O
of IN N
sevoflurane NN I
were VBD N
9.7 CD N
+/- JJ N
0.7 CD N
120.6 CD N
+/- JJ N
8.0 CD N
and CC N
244 CD N
+/- JJ N
15 CD N
minutes NNS N
respectively RB N
and CC N
for IN N
isoflurane NN I
were VBD N
11.9 CD N
+/- JJ N
1.4 CD N
106.8 CD N
+/- JJ N
7.1 CD N
and CC N
282 CD N
+/- JJ N
24 CD N
minutes NNS N
respectively RB N
(NS) VBP N
. . N

The DT N
isoflurane NN I
group NN N
had VBD N
a DT N
higher JJR N
frequency NN N
of IN N
postoperative JJ O
cough NN O
. . O

At IN N
the DT N
end NN N
of IN N
surgery NN N
the DT N
sevoflurane NN I
group NN N
received VBD N
a DT N
deeper JJR N
level NN O
of IN O
anesthesia JJ O
(minimum JJ N
alveolar JJ N
concentration NN N
1.5 CD N
vs NN N
1.3) CD N
however RB N
these DT N
patients NNS N
were VBD N
oriented VBN N
earlier RBR N
(13.6 JJ N
+/- JJ N
1.1 CD N
min NN N
vs NN N
17.0 CD N
+/- JJ N
1.5 CD N
min NN N
isoflurane; NN I
p NN N
= VBD N
0.02) CD N
after IN N
discontinuation NN N
of IN N
anesthesia NN N
although IN N
this DT N
difference NN N
is VBZ N
of IN N
little JJ N
clinical JJ N
significance NN N
. . N

-DOCSTART- -X- O O

Cryoprobe NNP I
biopsy NN I
increases VBZ N
the DT N
diagnostic JJ O
yield NN O
in IN N
endobronchial JJ P
tumor NN P
lesions NNS P
. . P

OBJECTIVE NNP N
Forceps NNP N
biopsy NN N
is VBZ N
the DT N
standard JJ N
method NN N
to TO N
obtain VB N
specimens NNS N
in IN N
endoscopically RB P
visible JJ P
lesions NNS P
. . P

It PRP N
is VBZ N
common JJ N
to TO N
combine VB N
forceps NNS N
biopsy VB N
with IN N
cytology NN N
methods NNS N
to TO N
increase VB N
the DT N
diagnostic JJ O
yield NN O
. . O

Although IN N
the DT N
flexible JJ N
cryoprobe NN I
has VBZ N
been VBN N
established VBN N
for IN N
bronchoscopic NN N
interventions NNS N
in IN N
malignant JJ N
stenosis NN N
the DT N
obtained VBN N
biopsies NNS N
called VBN N
"cryobiopsies NNS I
" NNS N
have VBP N
not RB N
been VBN N
investigated VBN N
in IN N
a DT N
large JJ N
cohort NN N
of IN N
patients NNS N
. . N

The DT N
aim NN N
of IN N
this DT N
feasibility NN N
study NN N
was VBD N
to TO N
prospectively RB N
evaluate VB N
the DT N
diagnostic JJ O
yield NN O
and CC N
safety NN O
of IN N
cryobiopsy NN I
and CC N
forceps JJ I
biopsy NN I
. . I

METHODS NNP N
During IN N
a DT N
6-year JJ N
period NN N
296 CD P
patients NNS P
with IN P
visible JJ P
endoluminal JJ P
tumor NN P
lesions NNS P
were VBD P
included VBN P
in IN N
the DT N
study NN N
at IN N
the DT N
bronchoscopy NN P
unit NN P
of IN P
a DT P
university NN P
hospital NN P
. . P

In IN N
the DT N
first JJ N
consecutively RB N
conducted VBN N
55 CD N
cases NNS N
both DT N
techniques NNS N
forceps VBP I
biopsy NN I
and CC I
cryobiopsy NN I
were VBD N
applied VBN N
simultaneously RB N
. . N

Pathologic NNP O
and CC O
quantitative JJ O
image NN O
analyses NNS O
were VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
size NN O
and CC O
quality NN O
of IN O
the DT O
obtained VBN O
specimens NNS O
. . O

We PRP N
evaluated VBD N
the DT N
safety NN O
and CC N
diagnostic JJ O
yield NN O
to TO N
describe VB N
the DT N
feasibility NN O
of IN N
cryobiopsy NN I
. . I

RESULTS NNP N
Comparative JJ N
analysis NN N
of IN N
the DT N
first JJ N
conducted VBN N
and CC N
randomly RB N
assigned VBD N
55 CD N
cases NNS N
revealed VBD N
a DT N
significantly RB N
higher RBR N
diagnostic JJ O
yield NN O
for IN N
cryobiopsy NN I
compared VBN N
with IN N
forceps NNS I
biopsy VBP I
(89.1% JJ N
vs NN N
65.5% CD N
P NNP N
< NNP N
.05) NNP N
. . N

In IN N
this DT N
cohort NN N
quantitative JJ O
image NN O
analysis NN O
showed VBD N
significantly RB N
larger JJR N
biopsies NNS N
regarding VBG N
size NN O
and CC N
artifact-free JJ N
tissue NN N
sections NNS N
for IN N
cryobiopsy NN I
compared VBN N
with IN N
forceps NNS I
biopsy VBP I
(P JJ N
< NNP N
.0001) NNP N
. . N

The DT N
overall JJ O
diagnostic JJ O
yield NN O
of IN N
cryobiopsy NN I
was VBD N
89.5% CD N
. . N

Mild NNP N
bleeding VBG O
occurred VBD N
in IN N
11 CD N
cases NNS N
(3.7%) JJ N
moderate JJ N
bleeding NN O
occurred VBD N
in IN N
3 CD N
cases NNS N
(1.0%) CD N
and CC N
severe JJ N
bleeding NN O
occurred VBD N
in IN N
1 CD N
case NN N
(0.3%) NNP N
. . N

CONCLUSION NNP N
Cryobiopsy NNP I
is VBZ N
safe JJ O
and CC N
increases VBZ N
the DT N
diagnostic JJ O
yield NN O
in IN N
endobronchial JJ P
tumor NN P
lesions NNS P
. . P

The DT N
method NN N
also RB N
is VBZ N
feasible JJ O
under IN N
routine JJ N
conditions NNS N
. . N

-DOCSTART- -X- O O

Antioxidant JJ I
supplementation NN I
and CC N
exercise-induced JJ O
oxidative JJ O
stress NN O
in IN N
the DT P
60-year-old JJ P
as IN N
measured VBN N
by IN N
antipyrine NN I
hydroxylates NNS I
. . I

The DT N
effects NNS N
of IN N
12 CD N
weeks NNS N
of IN N
antioxidant JJ I
supplementation NN I
on IN N
exercise-induced JJ O
oxidative JJ O
stress NN O
were VBD N
investigated VBN N
in IN N
older JJR P
adults NNS P
(60 VBP P
(SE $ P
1) CD P
years; NN P
BMI NNP P
26 CD P
(SE VBD P
1) CD P
kg/m(2)) NN P
. . P

Subjects NNS N
were VBD N
randomly RB N
divided VBN N
in IN N
two CD N
groups: JJ N
supplementation NN N
(n VBD N
11) CD N
with IN N
100 CD N
mg NNS N
dl-alpha-tocopheryl JJ I
acetate JJ I
200 CD N
mg NN N
ascorbic JJ I
acid NN I
and CC N
2 CD N
mg JJ N
beta-carotene NN I
and CC N
placebo NN I
(n VBP N
9) CD N
. . N

Before IN N
and CC N
after IN N
the DT N
12 CD N
week NN N
supplementation NN N
period NN N
subjects NNS N
cycled VBD N
for IN N
45 CD N
min NN N
at IN N
submaximal JJ N
intensity NN N
(50 NNP N
% NN N
maximal JJ N
workload NN N
capacity) NN N
. . N

Antipyrine NNP I
was VBD N
used VBN N
as IN N
marker NN N
for IN N
oxidative JJ O
stress NN O
. . O

Antipyrine NNP I
reacts VBZ N
quickly RB N
with IN N
hydroxyl JJ N
radicals NNS N
to TO N
form VB N
para- JJ O
and CC O
ortho-hydroxyantipyrine JJ O
. . O

The DT N
latter JJ N
metabolite NN N
is VBZ N
not RB N
formed VBN N
in IN N
man NN N
through IN N
the DT N
mono-oxygenase JJ N
pathway NN N
of IN N
cytochrome JJ N
P450 NNP N
. . N

Daily NNP N
supplementation NN N
significantly RB N
increased VBD N
plasma JJ N
concentrations NNS N
of IN N
alpha-tocopherol NN N
and CC N
beta-carotene NN N
in IN N
the DT N
supplemented JJ N
group NN N
(Delta VBD N
14.4 CD N
(SE JJ N
3.2) CD N
and CC N
0.4 CD N
(se NNS N
0.1) CD N
micromol/l; NN N
P<0.001 NNP N
and CC N
P<0.01) NNP N
. . N

No NNP N
significant JJ N
differences NNS N
within IN N
and CC N
between IN N
groups NNS N
were VBD N
observed VBN N
in IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
the DT N
ratios NNS N
para- JJ O
and CC O
ortho-hydroxyantipyrine JJ O
to TO O
antipyrine VB O
. . O

In IN N
addition NN N
supplementation NN N
did VBD N
not RB N
affect VB N
the DT N
exercise-induced JJ N
increase NN N
in IN N
thiobarbituric JJ O
acid NN O
reactive JJ O
substances NNS O
in IN O
plasma NN O
. . O

In IN N
conclusion NN N
in IN N
60-year-old JJ P
subjects NNS P
antioxidant JJ I
supplementation NN I
had VBD N
no DT N
effect NN N
on IN N
the DT N
exercise-induced JJ N
increase NN N
in IN N
oxidative JJ N
stress NN N
as IN N
measured VBN N
by IN N
free JJ O
radical JJ O
products NNS O
of IN O
antipyrine NN O
. . O

-DOCSTART- -X- O O

Randomized VBN N
trial NN N
of IN N
intensive JJ I
early JJ I
intervention NN I
for IN N
children NNS P
with IN P
pervasive JJ P
developmental JJ P
disorder NN P
. . P

Young NNP P
children NNS P
with IN P
pervasive JJ P
developmental JJ P
disorder NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
intensive VB I
treatment NN I
or CC N
parent NN I
training NN I
. . I

The DT N
intensive JJ I
treatment NN I
group NN N
(7 VBZ P
with IN P
autism NN P
8 CD P
with IN P
pervasive JJ P
developmental JJ P
disorder NN P
not RB P
otherwise RB P
specified--NOS) JJ P
averaged VBD N
24.52 CD N
hours NNS N
per IN N
week NN N
of IN N
individual JJ N
treatment NN N
for IN N
one CD N
year NN N
gradually RB N
reducing VBG N
hours NNS N
over IN N
the DT N
next JJ N
1 CD N
to TO N
2 CD N
years NNS N
. . N

The DT N
parent NN I
training VBG I
group NN N
(7 FW P
with IN P
autism NN P
6 CD P
with IN P
pervasive JJ P
developmental JJ P
disorder NN P
NOS) NNP P
received VBD N
3 CD N
to TO N
9 CD N
months NNS N
of IN N
parent NN I
training NN I
. . I

The DT N
groups NNS N
appeared VBD N
similar JJ N
at IN N
intake NN N
on IN N
all DT N
measures; NN N
however RB N
at IN N
follow-up JJ N
the DT N
intensive JJ I
treatment NN I
group NN N
outperformed VBD N
the DT N
parent NN I
training VBG I
group NN N
on IN N
measures NNS N
of IN N
intelligence NN O
visual-spatial JJ O
skills NNS O
language NN O
and CC O
academics NNS O
though IN N
not RB N
adaptive JJ O
functioning NN O
or CC N
behavior NN O
problems NNS O
. . O

Children NNP P
with IN P
pervasive JJ P
developmental JJ P
disorder NN P
NOS NNP P
may MD N
have VB N
gained VBN N
more JJR N
than IN N
those DT N
with IN N
autism NN P
. . P

-DOCSTART- -X- O O

Quality NN N
of IN N
individual JJ N
INR NNP N
control NN N
and CC N
the DT N
risk NN O
of IN O
stroke NN O
and CC O
bleeding VBG O
events NNS O
in IN N
atrial JJ P
fibrillation NN P
patients: VBZ P
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
of IN N
the DT N
ACTIVE NNP N
W NNP N
study NN N
. . N

INTRODUCTION NNP N
Time NNP O
in IN O
therapeutic JJ O
range NN O
(TTR) NN O
for IN N
international JJ N
normalized JJ N
ratio NN N
(INR) NNP N
is VBZ N
an DT N
accepted JJ N
quality NN N
measure NN N
of IN N
anticoagulation NN N
control NN N
in IN N
patient JJ N
populations NNS N
but CC N
its PRP$ N
usefulness NN N
for IN N
predicting VBG N
stroke NN O
and CC O
bleeding NN O
in IN N
individuals NNS N
is VBZ N
not RB N
well RB N
understood RB N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
In IN N
a DT N
nested JJ N
case NN N
control NN N
analysis NN N
among IN N
ACTIVE NNP P
W NNP P
study NN P
patients NNS P
cases NNS P
with IN P
stroke NN P
and CC P
cases NNS P
with IN P
bleeding NN P
were VBD P
separately RB P
matched VBN P
with IN P
controls NNS P
. . P

Several JJ N
anticoagulation NN O
quality NN O
measures NNS O
were VBD N
compared VBN N
overall JJ N
and CC N
in IN N
a DT N
time-dependent JJ N
manner NN N
. . N

RESULTS CC N
32 CD P
cases NNS P
with IN P
ischemic JJ P
stroke NN P
and CC P
234 CD P
cases NNS P
with IN P
bleeding NN P
in IN P
the DT P
analysis NN P
were VBD P
matched VBN P
in IN N
a DT N
4:1 CD N
ratio NN N
to TO N
122 CD P
and CC P
865 CD P
controls NNS P
respectively RB N
. . N

Follow-up JJ N
duration NN N
was VBD N
257±154days CD N
for IN N
the DT O
stroke NN O
analysis NN O
and CC N
222±146days CD N
for IN N
the DT O
bleeding NN O
analysis NN O
. . N

Compared VBN N
with IN N
their PRP$ N
respective NN N
controls VBZ N
the DT N
study NN N
mean JJ O
TTR NNP O
of IN N
both DT N
stroke NN N
cases NNS N
(53.9%±25.1 VBP N
vs JJ N
63.4%±24.8; CD N
p=0.055) NN N
and CC N
bleeding NN N
cases NNS N
(56.2%±25.4 VBP N
vs JJ N
63.4%±26.8; CD N
p<0.001) NN N
was VBD N
lower JJR O
. . O

Time NNP N
below IN N
range NN N
for IN N
stroke NN O
and CC O
time NN N
above IN N
range NN N
for IN N
bleeding VBG N
were VBD N
only RB N
greater JJR N
in IN N
the DT N
last JJ N
month NN N
leading VBG N
up RP N
to TO N
the DT N
event NN N
not RB N
over IN N
the DT N
entire JJ N
study NN N
period NN N
. . N

Rather CC N
over IN N
the DT N
entire JJ N
study NN N
period NN N
bleeding VBG N
cases NNS N
spent VBD O
more JJR O
time NN N
below IN N
range NN N
than IN N
controls NNS N
(26.8%±25.9 JJ N
vs VBP N
20.8%±24.0; CD N
p=0.001) NN N
. . N

CONCLUSIONS NNP O
TTR NNP N
was VBD N
lower JJR P
in IN P
individual JJ P
AF NNP P
patients NNS P
with IN N
stroke NN N
or CC N
bleeding NN N
compared VBN N
with IN N
matched JJ N
controls NNS N
in IN N
ACTIVE NNP N
W NNP N
. . N

Maintaining VBG O
a DT O
high JJ O
TTR NN N
with IN N
equal JJ N
importance NN N
to TO N
avoid VB N
low JJ N
and CC N
high JJ N
INRs NNP N
is VBZ N
a DT N
relevant JJ N
goal NN N
of IN N
individual JJ N
patient NN N
treatment NN O
to TO O
prevent VB O
stroke NN O
and CC O
bleeding NN O
. . N

-DOCSTART- -X- O O

The DT N
role NN N
of IN N
somatostatin JJ I
(octreotide) NN I
in IN N
the DT N
regulation NN O
of IN O
melatonin JJ O
secretion NN O
in IN N
healthy JJ P
volunteers NNS P
and CC P
in IN P
patients NNS P
with IN P
primary JJ P
hypothyroidism NN P
. . P

Somatostatin NNP I
has VBZ N
been VBN N
found VBN N
in IN N
the DT N
pineal JJ N
gland NN N
of IN N
several JJ N
animal NN N
species NNS N
which WDT N
suggests VBZ N
that IN N
it PRP N
may MD N
be VB N
involved VBN N
in IN N
the DT N
regulation NN O
of IN O
melatonin JJ O
secretion NN O
. . O

Whether NNP N
somatostatin NN I
has VBZ N
regulatory JJ O
influence NN O
on IN O
melatonin NN O
secretion NN O
in IN N
man NN N
has VBZ N
never RB N
been VBN N
unequivocally RB N
shown VBN N
. . N

We PRP N
studied VBD N
the DT N
nocturnal JJ O
melatonin NN O
secretion NN O
in IN N
8 CD P
healthy JJ P
volunteers NNS P
and CC P
6 CD P
women NNS P
with IN P
untreated JJ P
primary JJ P
hypothyroidism NN P
a DT N
disease NN N
state NN N
that WDT N
is VBZ N
associated VBN N
with IN N
increased JJ N
nocturnal JJ N
secretion NN N
of IN N
melatonin NN N
. . N

The DT N
participants NNS N
were VBD N
given VBN N
subcutaneous JJ N
injections NNS N
at IN N
18:00 CD N
h NN N
and CC N
23:00 CD N
h NN N
of IN N
either DT N
saline NN I
or CC N
octreotide JJ I
(Sandostatin; NNP I
each DT N
injection NN N
50 CD N
microg) NN N
. . N

During IN N
the DT N
nights NNS N
when WRB N
the DT N
healthy JJ P
volunteers NNS P
were VBD N
given VBN N
octreotide RB I
melatonin JJ O
secretion NN O
was VBD N
similar JJ N
to TO N
that DT N
recorded VBN N
during IN N
administration NN N
of IN N
saline NN I
. . I

Also RB N
the DT N
urinary JJ O
excretion NN O
of IN O
melatonin NN O
was VBD N
of IN N
similar JJ N
magnitude NN N
at IN N
these DT N
two CD N
occasions NNS N
. . N

By IN N
contrast NN N
the DT N
GH NNP O
secretion NN O
was VBD N
significantly RB N
lower JJR N
the DT N
nights NNS N
the DT N
healthy JJ P
controls NNS P
were VBD N
given VBN N
octreotide RB I
(GH JJ N
AUC NNP N
22.6+/-5.4 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ I
and CC N
126.6+/-21.9 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline; JJ I
p<0.01) NN N
. . N

The DT P
patients NNS P
with IN P
hypothyroidism NN P
also RB N
showed VBD N
similar JJ N
nocturnal JJ O
melatonin NN O
secretion NN O
during IN N
octreotide NN I
and CC N
saline NN I
. . I

Urinary JJ O
excretion NN O
of IN O
melatonin NN O
also RB N
remained VBD N
unchanged JJ N
as IN N
did VBD N
GH NNP N
secretion NN N
. . N

The DT N
total JJ O
nocturnal JJ O
secretion NN O
of IN O
TSH NNP O
was VBD N
however RB N
significantly RB N
reduced VBN N
by IN N
octreotide JJ I
(TSH NNP N
AUC NNP N
562+/-136 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
octreotide JJ I
and CC N
851+/-185 JJ N
mU/l NN N
x NNP N
h NN N
during IN N
saline; JJ I
p<0.05) NN N
thus RB N
suggesting VBG N
that IN N
100 CD N
microg NN N
of IN N
octreotide NN I
should MD N
be VB N
sufficient JJ N
to TO N
inhibit VB N
also RB N
the DT N
pinealocytes NNS N
if IN N
their PRP$ N
function NN N
were VBD N
regulated VBN N
by IN N
somatostatin NN I
. . I

Since IN N
exogenous JJ N
somatostatin--in JJ I
the DT N
form NN N
of IN N
octreotide--fails NNS I
to TO N
influence VB N
nocturnal JJ O
secretion NN O
and CC O
urinary JJ O
excretion NN O
of IN O
melatonin NN O
in IN N
normal JJ P
subjects NNS P
and CC P
in IN P
patients NNS P
with IN P
primary JJ P
hypothyroidism NN P
it PRP N
is VBZ N
reasonable JJ N
to TO N
assume VB N
that DT N
endogenous JJ N
somatostatin NN I
may MD N
not RB N
be VB N
an DT N
important JJ N
regulator NN O
of IN O
melatonin JJ O
secretion NN O
in IN N
man NN N
. . N

-DOCSTART- -X- O O

[Effects NNS N
of IN N
auditory JJ I
integrative JJ I
training NN I
on IN N
autistic JJ P
children] NN P
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
short-term JJ N
treatment NN N
effect NN O
of IN N
the DT N
auditory JJ I
integrative JJ I
training NN I
on IN N
autistic JJ P
children NNS P
and CC N
provide VB N
them PRP N
with IN N
clinical JJ N
support NN N
for IN N
rehabilitative JJ N
treatment NN N
. . N

METHODS NNP N
A NNP P
total NN P
of IN P
81 CD P
cases NNS P
of IN P
autistic JJ P
children NNS P
were VBD P
selected VBN P
through IN N
the DT N
standard NN N
of IN N
DSM-4 NNP N
and CC N
clinical JJ N
case NN N
study NN N
was VBD N
used VBN N
. . N

They PRP N
were VBD N
divided VBN N
randomly RB N
into IN N
experimental JJ N
group NN N
and CC N
control VB N
one CD N
and CC N
respectively RB N
received VBD N
auditory JJ I
integrative JJ I
training NN I
and CC N
no DT N
training NN N
based VBN N
on IN N
the DT N
multiple JJ N
therapies NNS N
. . N

The DT N
patients NNS N
were VBD N
investigated VBN N
using VBG N
clinical JJ O
manifestation NN O
and CC O
Autism NNP O
Behavior NNP O
Checklist NNP O
(ABC) NNP O
and CC O
intelligence NN O
quotient NN O
(IQ) NN O
before IN N
and CC N
after IN N
six CD N
months NNS N
of IN N
treatment NN N
. . N

The DT N
effect NN N
was VBD N
evaluated VBN N
through IN N
the DT N
changes NNS O
of IN O
clinical JJ O
manifestations NNS O
and CC O
scores NNS O
of IN O
ABC NNP O
and CC O
IQ NNP O
. . O

The DT N
changes NNS O
of IN O
scores NNS O
of IN O
IQ NNP O
were VBD O
determined VBN O
with IN O
Gesell NNP O
and CC O
WPPSI NNP O
or CC O
WISC-R NNP O
. . O

RESULTS NNP N
Compared VBD N
with IN N
40 CD N
patients NNS N
of IN N
the DT N
control NN N
group NN N
after IN N
the DT N
six CD N
months NNS N
of IN N
the DT N
auditory JJ I
integrative JJ I
training VBG I
41 CD N
of IN N
the DT N
experimental JJ N
group NN N
had VBD N
greatly RB N
improved VBN N
in IN N
many JJ N
aspects NNS N
such JJ N
as IN N
the DT N
disorders NNS O
of IN O
their PRP$ O
language NN O
social JJ O
interactions NNS O
and CC O
typical JJ O
behavior NN O
symptoms NNS O
while IN N
they PRP N
had VBD N
not RB N
changed VBN N
in IN N
their PRP$ N
abnormal JJ O
behaviors NNS O
. . O

The DT N
scores NNS O
of IN O
IQ NNP O
or CC O
DQ NNP O
had VBD N
increased VBN N
and CC N
scores NNS O
of IN O
ABC NNP O
had VBD N
dropped VBN N
. . N

The DT N
differences NNS N
between IN N
the DT N
two CD N
groups NNS N
were VBD N
greatly RB N
significant JJ N
in IN N
statistics NNS N
(P VBP N
< JJ N
0.01) CD N
. . N

The DT N
decreasing VBG N
level NN N
of IN N
both DT N
ABC NNP O
scores NNS O
and CC N
the DT N
increasing VBG N
level NN N
of IN N
the DT N
IQ NNP O
scores NNS O
were VBD N
negatively RB N
correlated VBN N
with IN N
age NN N
and CC N
the DT N
decreasing VBG N
level NN N
of IN N
ABC NNP O
scores NNS O
was VBD N
in IN N
line NN N
regression(positive JJ N
correlation) NN N
with IN N
base NN N
IQ NNP N
. . N

CONCLUSION NNP N
The DT N
treatment NN N
of IN N
auditory JJ I
integrative JJ I
training NN I
(AIT) NN I
could MD N
greatly RB N
improve VB N
on IN N
language NN O
disorders NNS O
the DT O
difficulties NNS O
of IN O
social JJ O
interactions NNS O
typical JJ O
behavior NN O
symptoms NNS O
and CC O
developmental JJ O
levels NNS O
therefore IN N
it PRP N
is VBZ N
positive JJ N
to TO N
the DT N
autistic JJ P
children NNS P
in IN N
its PRP$ N
short-term JJ N
treatment NN N
effect NN O
. . O

-DOCSTART- -X- O O

Clinical JJ O
effects NNS O
of IN N
root NN N
instrumentation NN N
using VBG N
conventional JJ I
steel NN I
or CC N
non-tooth JJ I
substance NN I
removing VBG I
plastic NN I
curettes NNS I
during IN N
supportive JJ P
periodontal JJ P
therapy NN P
(SPT) NN P
. . P

Although IN N
root NN N
instrumentation NN N
has VBZ N
been VBN N
accepted VBN N
as IN N
the DT N
most RBS N
important JJ N
cause-related JJ N
treatment NN N
of IN N
periodontal JJ N
diseases NNS N
repeated VBD N
scaling NN N
and CC N
root NN N
planing NN N
may MD N
over VB N
time NN N
result NN N
in IN N
substantive JJ N
loss NN N
of IN N
tooth JJ N
substance NN N
and CC N
increased JJ N
sensitivity NN N
of IN N
the DT N
teeth NN N
. . N

In IN N
an DT N
effort NN N
to TO N
minimize VB N
these DT N
side JJ N
effects NNS N
of IN N
therapy NN N
non-root JJ I
substance NN I
removing VBG I
curettes NNS I
have VBP N
been VBN N
developed VBN N
. . N

However RB N
the DT N
clinical JJ O
effects NNS O
of IN N
such JJ N
plastic NN I
curettes NNS I
with IN N
regard NN N
to TO N
the DT N
control NN N
of IN N
the DT N
periodontal JJ N
infection NN N
has VBZ N
not RB N
yet RB N
been VBN N
established VBN N
. . N

The DT N
aims NNS N
of IN N
this DT N
study NN N
were VBD N
therefore RB N
to TO N
compare VB N
the DT N
effects NNS O
of IN N
root NN N
instrumentation NN N
using VBG N
plastic NN I
curettes NNS I
(Universal VBP N
Perio NNP N
Soft NNP N
Scaler NNP N
Hawe-Neos NNP N
Dental NNP N
Bioggio NNP N
TI NNP N
Switzerland) NNP N
versus IN N
conventional JJ I
steel NN I
curettes NNS I
on IN N
the DT N
periodontal JJ N
conditions NNS N
during IN P
supportive JJ P
periodontal JJ P
therapy NN P
. . P

40 CD P
subjects NNS P
participated VBN P
in IN N
this DT N
parallel JJ N
randomized VBN N
double JJ N
blind NN N
prospective JJ N
longitudinal JJ N
clinical JJ N
study NN N
following VBG N
active JJ N
peridontal JJ N
therapy NN N
. . N

20 CD P
subjects NNS P
served VBD P
as IN P
a DT P
control NN P
group NN P
and CC N
were VBD N
treated VBN N
with IN N
conventional JJ I
steel NN I
curettes NNS I
during IN N
a DT N
supportive JJ P
periodontal NN P
care NN P
visit NN N
(SPT) NNP P
. . N

The DT N
other JJ N
20 CD P
subjects NNS P
the DT P
experimental JJ P
group NN P
were VBD N
treated VBN N
using VBG N
plastic NN I
curettes NNS I
during IN N
a DT N
similar JJ N
SPT NNP P
visit NN N
. . N

Clinical JJ N
parameters NNS N
such JJ N
as IN N
bleeding VBG O
on IN O
probing VBG O
(BOP) NN O
and CC O
probing VBG O
pocket NN O
depth NN O
(PPD) NNP O
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
3-6 JJ N
months NNS N
later RB N
at IN N
the DT N
next JJ N
regular JJ N
SPT NNP N
visit NN N
. . N

In IN N
addition NN N
the DT N
BOP NNP O
percentage NN O
was VBD N
determined VBN N
10 CD N
days NNS N
following VBG N
baseline NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
there EX N
were VBD N
no DT N
statistically RB N
significant JJ N
differences NNS N
between IN N
the DT N
2 CD N
treatment NN N
modalities NNS N
regarding VBG N
BOP NNP O
and CC O
PPD NNP O
at IN N
any DT N
observation NN N
time NN N
. . N

Both DT N
treatments NNS N
were VBD N
effective JJ N
in IN N
reducing VBG N
the DT N
BOP NNP O
percentage NN O
which WDT N
ranged VBD N
from IN N
17-42% JJ N
at IN N
baseline NN N
by IN N
about IN N
40% CD N
after IN N
10 CD N
days NNS N
(mean JJ N
BOP NNP O
baseline: NN N
26% CD N
mean NN N
BOP NNP O
after IN N
10 CD N
days: NN N
16%) CD N
. . N

This DT N
clinical JJ N
study NN N
suggests VBZ N
that IN N
non-root JJ I
substance NN I
removing VBG I
curettes NNS I
may MD N
be VB N
valuable JJ N
instruments NNS N
for IN N
periodontally RB N
treated JJ N
patients NNS N
during IN N
maintenance NN N
care NN N
thus RB N
minimizing VBG N
trauma NN N
on IN N
the DT N
hard JJ N
structures NNS N
of IN N
the DT N
teeth NN N
. . N

-DOCSTART- -X- O O

The DT N
immediate JJ O
efficacy NN O
of IN N
adjunctive JJ N
doxycycline NN I
in IN N
treatment NN N
of IN N
localized VBN P
juvenile NN P
periodontitis NN P
. . P

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
on IN N
the DT N
immediate JJ O
clinical JJ O
and CC O
microbiological JJ O
efficacy NN O
of IN N
doxycycline NN I
(100 NNP N
mg NN N
for IN N
14 CD N
days) NN N
was VBD N
carried VBN N
out IN N
to TO N
determine VB N
the DT N
benefit NN N
of IN N
adjunctive JJ N
medication NN N
in IN N
16 CD P
patients NNS P
with IN P
localized JJ P
juvenile NN P
periodontitis NN P
. . P

Measurements NNS N
of IN N
gingival NN O
fluid NN O
flow NN O
probing VBG O
depths NNS O
bleeding VBG O
on IN O
probing VBG O
and CC O
suppuration NN O
were VBD N
determined VBN N
at IN N
2 CD N
periodontal JJ N
sites NNS N
with IN N
and CC N
2 CD N
without IN N
radiographic JJ O
attachment JJ O
loss NN O
at IN N
weeks NNS N
0 CD N
1 CD N
3 CD N
and CC N
8 CD N
. . N

Subgingival JJ O
bacterial JJ O
samples NNS O
were VBD N
taken VBN N
with IN N
curettes NNS N
from IN N
the DT N
same JJ N
sites NNS N
. . N

Spirochaetes NNS O
were VBD N
searched VBN N
for IN N
by IN N
dark-field JJ O
microscopy NN O
. . O

Actinobacillus CC O
actinomycetemcomitans NNS O
pigmented VBN O
and CC O
non-pigmented JJ O
Bacteroides NNP O
spp NN O
. . O

Capnocytophaga NNP O
Fusobacterium NNP O
and CC O
Actinomyces NNP O
spp NN O
. . O

were VBD N
cultured VBN N
on IN N
various JJ N
selective JJ N
and CC N
non-selective JJ N
media NNS N
. . N

Bacterial JJ O
species NNS O
found VBN N
at IN N
least JJS N
in IN N
50% CD N
of IN N
the DT N
patients NNS N
and CC N
comprising VBG N
on IN N
average JJ N
5% CD N
or CC N
more JJR N
of IN N
the DT N
cultivable JJ N
flora NNS N
were VBD N
included VBN N
in IN N
the DT N
analysis NN N
. . N

Neither CC N
short-term JJ O
clinical JJ O
nor CC O
microbiological JJ O
efficacy NN O
beyond IN N
that DT N
of IN N
a DT N
course NN N
of IN N
mechanical JJ N
debridement NN N
alone RB N
was VBD N
found VBN N
by IN N
using VBG N
systemic JJ N
medication NN N
with IN N
doxycycline NN I
in IN N
patients NNS P
with IN P
localized JJ P
juvenile NN P
periodontitis NN P
. . P

-DOCSTART- -X- O O

Efficacy NN O
and CC N
safety NN O
of IN N
selamectin NN I
against IN N
fleas NNS N
and CC N
heartworms NNS N
in IN N
dogs NNS P
and CC P
cats NNS P
presented VBD P
as IN P
veterinary JJ P
patients NNS P
in IN P
North NNP P
America NNP P
. . P

A NNP N
series NN N
of IN N
randomized VBN N
controlled JJ N
masked VBD N
field NN N
studies NNS N
was VBD N
conducted VBN N
to TO N
assess VB N
the DT N
efficacy NN O
and CC N
safety NN O
of IN N
selamectin NN I
in IN N
the DT N
treatment NN N
of IN N
flea NN P
infestations NNS P
on IN P
dogs NNS P
and CC P
cats NNS P
and CC N
in IN N
the DT N
prevention NN N
of IN N
heartworm NN N
infection NN N
in IN N
dogs NNS P
. . P

In IN N
addition NN N
observations NNS N
were VBD N
made VBN N
on IN N
the DT N
beneficial JJ N
effect NN N
of IN N
selamectin NN I
treatment NN N
on IN N
dogs NNS P
and CC P
cats NNS P
showing VBG P
signs NNS P
of IN P
flea NN P
allergy NN P
dermatitis NN P
(FAD) NNP P
. . P

In IN N
all DT N
studies NNS N
selamectin VBP I
was VBD N
applied VBN N
topically RB N
once RB N
per IN N
month NN N
in IN N
unit NN N
doses NNS N
providing VBG N
a DT N
minimum JJ N
dosage NN N
of IN N
6mgkg(-1) JJ N
. . N

Dogs NNS P
and CC P
cats NNS P
with IN P
naturally RB P
occurring VBG P
flea NN P
infestations NNS P
some DT P
of IN P
which WDT P
also RB P
had VBD P
signs NNS P
associated VBN P
with IN P
FAD NNP P
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
three CD N
months NNS N
of IN N
topical JJ N
treatment NN N
with IN N
selamectin JJ I
(220 JJ P
dogs NNS P
189 CD P
cats) NN P
or CC N
a DT N
positive-control JJ N
product NN N
(dogs: NNP N
fenthion NN I
n=81; NN N
cats: NN N
pyrethrins VBZ I
n=66) JJ N
. . N

Selamectin NNP I
was VBD N
administered VBN N
on IN N
days NNS N
0 CD N
30 CD N
and CC N
60 CD N
. . N

Day NNP N
0 CD N
was VBD N
defined VBN N
as IN N
the DT N
day NN N
that IN N
the DT N
animal NN N
first RB N
received VBD N
treatment NN N
. . N

Flea NN N
burdens NNS N
were VBD N
assessed VBN N
by IN N
flea NN O
comb NN O
counts NNS O
and CC O
clinical JJ O
evaluations NNS O
of IN O
FAD NNP O
were VBD N
performed VBN N
before IN N
treatment NN N
and CC N
on IN N
days NNS N
14 CD N
30 CD N
60 CD N
and CC N
90 CD N
. . N

On IN N
days NNS N
30 CD N
60 CD N
and CC N
90 CD N
mean JJ O
flea NN O
counts NNS O
in IN N
selamectin-treated JJ I
dogs NNS N
were VBD N
reduced VBN N
by IN N
92.1 CD N
99.0 CD N
and CC N
99.8% CD N
and CC N
mean JJ O
flea NN O
counts NNS O
in IN N
fenthion-treated JJ I
dogs NNS N
were VBD N
reduced VBN N
by IN N
81.5 CD N
86.8 CD N
and CC N
86.1% CD N
respectively RB N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
. . N

Also RB N
on IN N
days NNS N
30 CD N
60 CD N
and CC N
90 CD N
mean JJ O
flea NN O
counts NNS O
in IN N
selamectin-treated JJ I
cats NNS N
were VBD N
reduced VBN N
by IN N
92.5 CD N
98.3 CD N
and CC N
99.3% CD N
and CC N
mean JJ O
flea NN O
counts NNS O
in IN N
pyrethrin-treated JJ I
cats NNS N
were VBD N
reduced VBN N
by IN N
66.4 CD N
73.9 CD N
and CC N
81.3% CD N
respectively RB N
compared VBN N
with IN N
day NN N
0 CD N
counts NNS N
. . N

Selamectin NNP I
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS O
in IN N
dogs NNS P
and CC P
cats NNS P
diagnosed VBD P
clinically RB P
with IN P
FAD NNP P
. . P

A NNP N
total NN N
of IN N
397 CD P
dogs NNS P
free JJ P
of IN P
adult NN P
heartworm NN P
infection NN P
from IN P
four CD P
heartworm-endemic JJ P
areas NNS P
of IN P
the DT P
USA NNP P
were VBD N
allocated VBN N
randomly RB N
to TO N
six CD N
months NNS N
of IN N
treatment NN N
with IN N
selamectin JJ I
(n=298) NN N
or CC N
ivermectin NN I
(n=99) NN N
. . N

Selamectin NNP I
achieved VBD N
a DT N
heartworm JJ O
prevention NN O
rate NN O
of IN N
100% CD N
with IN N
all DT N
dogs NNS N
testing VBG N
negative JJ N
for IN N
microfilariae NN O
and CC O
adult NN O
heartworm NN O
antigen NN O
on IN N
days NNS N
180 CD N
and CC N
300 CD N
. . N

Selamectin NNP I
was VBD N
administered VBN N
to TO N
a DT P
total NN P
of IN P
673 CD P
dogs NNS P
and CC P
347 CD P
cats NNS P
having VBG P
an DT P
age NN P
range NN P
of IN P
6 CD P
weeks NNS P
to TO P
19 CD P
years NNS P
(3954 JJ N
doses) NN N
. . N

The DT P
animals NNS P
included VBD P
19 CD P
purebred VBD P
or CC P
crossbred JJ P
Collies NNS P
(Bearded VBD P
Border NNP P
and CC P
unspecified) JJ P
. . P

There EX N
were VBD N
no DT N
serious JJ N
adverse JJ O
events NNS O
. . O

Results NNS N
of IN N
these DT N
studies NNS N
indicated VBD N
that IN N
selamectin NN I
was VBD N
highly RB N
effective JJ O
in IN N
the DT N
control NN N
of IN N
flea NN P
infestations NNS P
in IN P
dogs NNS P
and CC P
cats NNS P
without IN N
the DT N
need NN N
for IN N
simultaneous JJ N
treatment NN N
of IN N
the DT N
environment NN N
or CC N
of IN N
in-contact JJ N
animals NNS N
and CC N
also RB N
was VBD N
beneficial JJ N
in IN N
alleviating VBG N
signs NNS O
associated VBN O
with IN O
FAD NNP O
. . O

Selamectin NNP I
also RB N
was VBD N
100% CD N
effective JJ O
in IN N
preventing VBG N
the DT N
development NN N
of IN N
canine NN N
heartworms NNS O
and CC N
was VBD N
safe JJ O
for IN N
topical JJ N
use NN N
in IN N
dogs NNS P
and CC P
cats NNS P
. . P

-DOCSTART- -X- O O

Once-daily RB N
amoxicillin JJ I
versus IN N
twice-daily JJ N
penicillin NN I
V NNP I
in IN N
group NN P
A NNP P
beta-haemolytic JJ P
streptococcal JJ P
pharyngitis NN P
. . P

BACKGROUND NNP N
Rheumatic NNP N
fever NN N
is VBZ N
a DT N
preventable JJ N
chronic JJ N
disease NN N
preceded VBN N
by IN N
group NN P
A NNP P
beta-haemolytic JJ P
streptococcal JJ P
(GABHS) NN P
pharyngitis NN P
. . P

OBJECTIVE UH N
To TO N
test VB N
the DT N
non-inferiority NN O
of IN N
once-daily JJ N
(QD) NNP N
oral JJ N
amoxicillin NN I
to TO N
the DT N
recommended VBN N
twice-daily RB N
(BID) JJ N
oral JJ N
penicillin NN I
V NNP I
in IN N
GABHS NNP P
pharyngitis NN P
. . P

METHODS NNP N
This DT N
was VBD N
a DT N
randomised JJ N
non-inferiority JJ O
trial NN N
carried VBD N
out RP N
in IN N
a DT N
school-based JJ P
clinic NN P
in IN P
New NNP P
Zealand NNP P
. . P

Children NNP P
presenting VBG P
with IN P
GABHS NNP P
pharyngitis NN P
were VBD N
randomised VBN N
to TO N
oral JJ N
amoxicillin NN I
1500 CD N
mg NN N
QD NNP N
(or VBZ N
750 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
<or=30 JJ N
kg) NN N
or CC N
to TO N
oral JJ N
penicillin NN I
V NNP N
500 CD N
mg NN N
BID NNP N
(or VBZ N
250 CD N
mg NN N
if IN N
bodyweight VBN N
was VBD N
<or=20 JJ N
kg) NN N
for IN N
10 CD N
days NNS N
. . N

Observed VBN N
medication NN O
and CC O
weekend NN O
diary JJ O
cards NNS O
were VBD N
used VBN N
to TO N
monitor VB N
adherence NN N
. . N

OUTCOME NNP N
Eradication NNP O
of IN O
GABHS NNP O
determined VBD N
with IN N
follow-up JJ O
throat NN O
cultures NNS O
on IN N
days NNS N
3-6 JJ N
12-16 JJ N
and CC N
26-36 JJ N
. . N

GABHS NNP O
isolates NNS O
were VBD O
serotyped VBN O
to TO N
distinguish VB N
bacteriological JJ O
treatment NN O
failures NNS O
(and VBP N
relapses) NN O
from IN N
new JJ O
acquisitions NNS O
. . O

Non-inferiority NN O
was VBD N
defined VBN N
as IN N
an DT N
upper JJ O
95% CD O
confidence NN O
limit NN O
(CL) NN O
for IN O
the DT O
difference NN O
in IN O
success NN O
of IN O
eradication NN O
in IN N
the DT N
amoxicillin NN I
and CC N
penicillin NN I
V NNP N
treatment NN N
groups NNS N
of IN N
<or=10% NNP N
. . N

RESULTS NNP N
353 CD P
children NNS P
with IN P
positive JJ P
throat NN P
swabs NN P
for IN P
GABHS NNP P
were VBD N
randomised VBN N
to TO N
amoxicillin VB I
(n NNP N
= NNP N
177) CD N
or CC N
penicillin VB I
V NNP N
(n NNP N
= VBD N
176) CD N
. . N

The DT N
upper JJ O
95% CD O
CL NNP O
for IN N
the DT N
differences NNS N
in IN N
positive JJ N
cultures NNS N
between IN N
the DT N
antibiotics NNS N
was VBD N
4.9% CD N
at IN N
days NNS N
3-6 JJ N
6.5% CD N
at IN N
days NNS N
12-16 CD N
and CC N
8.5% CD N
at IN N
days NNS N
26-36 JJ N
. . N

Treatment NN O
failures NNS O
(including VBG N
relapses) NN O
occurred VBD N
at IN N
each DT N
visit NN N
in IN N
5.8% CD N
12.7% CD N
and CC N
10.7% CD N
of IN N
amoxicillin NN I
recipients NNS N
and CC N
6.2% CD N
11.9% CD N
and CC N
11.3% CD N
of IN N
penicillin NN I
V NNP N
recipients VBZ N
respectively RB N
. . N

No UH N
significant JJ N
differences NNS N
in IN N
resolution NN O
of IN O
symptoms NNS O
were VBD N
noted VBN N
between IN N
treatment NN N
groups NNS N
. . N

One CD N
case NN N
of IN N
unsubstantiated JJ N
acute JJ N
rheumatic JJ N
fever NN N
occurred VBD N
after IN N
7 CD N
days NNS N
of IN N
amoxicillin NN I
. . I

CONCLUSION NN N
In IN N
this DT N
adequately RB N
powered VBN N
study NN N
once-daily RB N
oral JJ N
amoxicillin NN I
is VBZ N
not RB O
inferior JJ O
to TO N
twice-daily JJ N
penicillin NN I
V NNP N
for IN N
the DT N
treatment NN N
and CC N
eradication NN N
of IN N
GABHS NNP P
in IN P
children NNS P
with IN P
pharyngitis NN P
. . P

-DOCSTART- -X- O O

Randomized VBN N
phase NN N
II NNP N
study NN N
of IN N
two CD N
different JJ N
schedules NNS N
of IN N
gemcitabine NN I
and CC N
oral JJ N
S-1 NNP I
in IN N
chemo-naïve JJ P
patients NNS P
with IN P
advanced JJ P
non-small JJ P
cell NN P
lung NN P
cancer NN P
. . N

INTRODUCTION NNP N
This DT N
study NN N
was VBD N
conducted VBN N
to TO N
evaluate VB N
the DT O
efficacy NN O
and CC O
safety NN O
and CC N
to TO O
compare VB O
dosing VBG O
schedules NNS O
of IN I
gemcitabine NN I
combined VBN N
with IN I
S-1 NNP I
in IN P
chemo-naïve JJ P
non-small JJ P
cell NN P
lung NN P
cancer NN P
patients NNS P
. . N

METHODS NNP P
Patients NNPS P
with IN P
chemo-naïve JJ P
stage NN P
IIIB/IV NNP P
non-small NN P
cell NN P
lung NN P
cancer NN P
were VBD N
randomized VBN N
into IN N
two CD N
treatment NN N
arms NNS N
. . N

Patients NNS N
were VBD N
given VBN N
oral JJ I
S-1 NNP I
(60 NNP N
mg/m/d NNP N
twice RB N
a DT N
day) NN N
from IN N
days NNS N
1 CD N
to TO N
14 CD N
with IN I
gemcitabine NN I
(1000 CD N
mg/m/d) NN N
on IN N
days NNS N
1 CD N
and CC N
8 CD N
(arm NN N
A) NNP N
or CC N
on IN N
days NNS N
8 CD N
and CC N
15 CD N
(arm NN N
B) NNP N
. . N

This DT N
cycle NN N
was VBD N
repeated VBN N
every DT N
21 CD N
days NNS N
. . N

RESULTS VB P
A DT P
total NN P
of IN P
80 CD P
patients NNS P
were VBD P
entered VBN P
in IN P
this DT P
trial NN P
. . N

The DT N
primary JJ N
end NN N
point NN N
of IN N
this DT N
study NN N
was VBD O
response NN O
rate NN O
. . N

The DT O
response NN O
rates NNS O
of IN N
arm NN N
A NNP N
and CC N
arm NN N
B NNP N
were VBD N
22.0 CD N
and CC N
28.9% CD N
respectively RB N
(p JJ N
= $ N
0.606) CD O
. . O

Median JJ O
time NN O
to TO O
treatment NN O
failure NN O
in IN N
arm NN N
A NN N
was VBD N
3.6 CD N
months NNS N
and CC N
4.8 CD N
months NNS N
in IN N
arm NN N
B NNP O
. . O

Median JJ O
time NN O
to TO O
progression NN O
in IN N
arm NN N
A NN N
was VBD N
4.1 CD N
months NNS N
and CC N
5.5 CD N
months NNS N
in IN N
arm NN N
B NNP O
. . O

Median JJ O
survival JJ O
time NN O
in IN N
arm NN N
A NN N
and CC N
arm NN N
B NNP N
was VBD N
15.5 CD N
months NNS N
and CC N
18.8 CD N
months NNS N
respectively RB N
. . N

The DT O
toxicity NN O
profile NN O
was VBD N
relatively RB N
mild JJ N
and CC N
did VBD N
not RB N
differ VB N
very RB N
much RB N
between IN N
two CD N
arms NNS N
. . N

CONCLUSION VB N
The DT N
combination NN N
of IN I
gemcitabine NN I
and CC I
S-1 NNP I
was VBD N
determined VBN N
to TO N
be VB O
feasible JJ O
and CC O
effective JJ O
for IN P
advanced JJ P
non-small JJ P
cell NN P
lung NN P
cancer NN P
. . N

We PRP N
selected VBD N
arm NN N
B NNP N
for IN N
further JJ N
studies NNS N
because IN N
of IN N
its PRP$ N
higher JJR O
response NN O
rate NN O
and CC O
survival NN O
data NNS O
. . N

-DOCSTART- -X- O O

Randomized VBN N
controlled JJ N
trial NN N
of IN N
acupuncture NN I
versus NN N
sham JJ I
acupuncture NN I
in IN N
autism NN P
spectrum NN P
disorder NN P
. . P

OBJECTIVE IN N
We PRP N
aim VBP N
to TO N
study VB N
the DT N
efficacy NN O
of IN N
acupuncture NN I
versus NN N
sham JJ I
acupuncture NN I
in IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
. . P

METHODS VB N
A DT N
single-blind JJ N
randomized VBN N
control NN N
trial NN N
was VBD N
conducted VBN N
in IN N
50 CD P
children NNS P
. . P

These DT N
children NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
the DT N
treatment NN N
group NN N
with IN N
tongue JJ I
acupuncture NN I
(40 JJ N
sessions NNS N
over IN N
8 CD N
weeks) NNS N
or CC N
the DT N
control NN N
group NN N
(sham NNP I
tongue NN I
acupuncture NN I
to TO N
nonacupoints NNS N
in IN N
the DT N
tongue) NN N
. . N

RESULTS NNP N
There EX N
was VBD N
improvement NN N
in IN N
both CC N
the DT N
treatment NN N
and CC N
control NN N
groups NNS N
in IN N
all DT N
assessed JJ N
measures NNS N
but CC N
more JJR N
so RB N
in IN N
the DT N
treatment NN N
than IN N
in IN N
the DT N
control NN N
group: JJ N
(1) NNP N
eye-hand NN O
coordination NN O
performance NN O
and CC O
practical JJ O
reasoning NN O
of IN O
Griffiths NNP O
Mental NNP O
Developmental NNP O
Scale; NNP O
(2) NNP O
sensory-motor JJ O
social JJ O
affectual JJ O
language NN O
and CC O
total JJ O
score NN O
of IN O
Ritvo-Freeman NNP O
Real NNP O
Life NNP O
Scale; NNP O
(3) NNP O
Comprehension NNP O
Language NNP O
age NN O
in IN O
the DT O
Reynell NNP O
Language NNP O
Developmental NNP O
Scale; NNP O
and CC O
(4) NNP O
Total NNP O
Score NNP O
and CC O
Mental NNP O
Age NNP O
in IN O
Symbolic NNP O
Play NNP O
Test NNP O
. . O

The DT N
only JJ N
statistically RB N
significant JJ N
improvement NN N
in IN N
the DT N
treatment NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
was VBD N
seen VBN N
in IN N
self-care JJ O
and CC O
cognition NN O
domains NNS O
of IN O
the DT O
Functional NNP O
Independence NNP O
Measure NN O
for IN O
children NNS P
. . P

CONCLUSIONS NNP N
We PRP N
had VBD N
demonstrated VBN N
that IN N
a DT N
short JJ N
course NN N
of IN N
acupuncture NN I
had VBD N
efficacy NN O
in IN N
improving VBG N
various JJ N
developmental JJ N
and CC N
behavioral JJ N
aspects NNS N
of IN N
children NNS P
with IN P
autism NN P
. . P

The DT N
long-term JJ N
efficacy NN O
in IN N
functional JJ N
gain NN N
needs NNS N
to TO N
be VB N
further RB N
explored VBN N
. . N

-DOCSTART- -X- O O

Custom-fit NNP N
minimally RB P
invasive JJ P
total JJ P
knee NN P
arthroplasty: NN P
effect NN N
on IN N
blood NN O
loss NN O
and CC O
early JJ O
clinical JJ O
outcomes NNS O
. . O

PURPOSE NNP N
Recently NNP N
new JJ N
custom-fit JJ N
pin NN N
guides NNS N
in IN N
total JJ P
knee NN P
arthroplasty NN P
(TKA) NNS P
have VBP N
been VBN N
introduced VBN N
. . N

Use NN N
of IN N
these DT N
guides NNS N
may MD N
reduce VB N
operating NN N
time NN N
. . N

Use NN N
of IN N
the DT N
guides NNS N
combined VBN N
with IN N
the DT N
absence NN N
of IN N
intramedullary JJ N
alignment NN N
jigs NNS N
may MD N
lead VB N
to TO N
reduced VB N
blood NN O
loss NN O
and CC N
improved VBN N
early JJ O
outcomes NNS O
. . O

Our PRP$ N
aim NN N
was VBD N
to TO N
evaluate VB N
blood NN O
loss NN O
and CC O
early JJ O
clinical JJ O
outcomes NNS O
in IN N
patients NNS P
undergoing VBG P
minimally RB P
invasive JJ P
TKA NNP P
using VBG P
custom-fit JJ P
magnetic JJ P
resonance NN P
imaging VBG P
(MRI)-based JJ P
pin NN P
guides NNS P
. . P

METHODS NNP N
A NNP N
prospective JJ N
study NN N
in IN N
80 CD P
patients NNS P
was VBD N
carried VBN N
out RP N
. . N

Patients NNS N
were VBD N
divided VBN N
randomly RB N
into IN N
2 CD N
equal JJ N
groups NNS N
. . N

In IN N
one CD N
group NN N
intramedullary JJ I
alignment NN I
jigs NNS I
were VBD N
used VBN N
. . N

In IN N
the DT N
second JJ N
group NN N
custom-fit JJ I
MRI-based JJ I
pin NN I
guides NNS I
were VBD N
used VBN N
. . N

All DT N
patients NNS N
received VBD N
the DT N
same JJ N
cemented VBD I
posterior-stabilized JJ I
implant NN I
through IN N
a DT N
mini-midvastus JJ N
approach NN N
. . N

The DT N
volume NN O
in IN O
the DT O
drain NN O
bottles NNS O
was VBD N
recorded VBN N
after IN N
48 CD N
h NN N
. . N

Hb NNP O
loss NN O
was VBD N
estimated VBN N
by IN N
subtracting VBG N
the DT N
postoperative NN N
from IN N
the DT N
preoperative JJ N
Hb NNP O
level NN O
. . O

Transfusion NN O
requirements NNS O
and CC O
surgical JJ O
time NN O
were VBD N
recorded VBN N
. . N

Outcome JJ N
measures NNS N
were VBD N
Knee NNP O
Society NNP O
Scores NNP O
(KSS) NNP O
knee NNP O
flexion NN O
knee NN O
swelling VBG O
and CC O
pain NN O
. . O

RESULTS NNP N
There EX N
was VBD N
lower JJR N
mean JJ N
drainage NN O
of IN O
blood NN O
in IN N
the DT N
custom-fit JJ I
group NN N
(391 NNP N
ml NN N
vs NN N
. . N

603 CD N
ml; JJ N
p NN N
< VBD N
0.0001) CD N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
estimated VBN N
loss NN O
of IN O
Hb NNP O
(3.6 NNP N
g/dl NN N
vs NN N
. . N

4.1 CD N
g/dl; JJ N
n.s.) NN N
and CC N
in IN N
transfusion NN N
requirements NNS N
(7.5 CD N
% NN N
vs NN N
. . N

10 CD N
%; JJ N
n.s.) NN N
. . N

Surgical JJ O
time NN O
was VBD N
reduced VBN N
in IN N
the DT N
custom-fit JJ I
group NN N
(12 NNP N
min VBZ N
less; JJ N
p NN N
= VBD N
0.001) CD N
. . N

KSS VB O
measured VBN N
at IN N
week NN N
2 CD N
6 CD N
and CC N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

Knee NNP O
flexion NN O
measured VBN N
on IN N
days NNS N
7 CD N
10 CD N
and CC N
at IN N
week NN N
6 CD N
12 CD N
and CC N
knee VB O
swelling VBG O
and CC N
pain NN O
measured VBN N
on IN N
days NNS N
1 CD N
3 CD N
10 CD N
and CC N
at IN N
week NN N
6 CD N
12 CD N
showed VBD N
no DT N
significant JJ N
difference NN N
between IN N
groups NNS N
. . N

CONCLUSIONS NNP N
Using VBG N
custom-fit JJ I
pin NN I
guides NNS I
reduces NNS N
blood NN O
drainage NN O
but CC N
not RB N
the DT N
estimated VBN N
Hb NNP O
loss NN O
in IN N
minimally RB P
invasive JJ P
TKA NNP P
and CC N
does VBZ N
not RB N
affect VB N
transfusion NN O
rate NN O
. . O

Surgical JJ O
time NN O
is VBZ N
reduced VBN N
. . N

There EX N
is VBZ N
no DT N
effect NN N
on IN N
the DT N
early JJ O
clinical JJ O
outcomes NNS O
. . O

LEVEL NN N
OF IN N
EVIDENCE NNP N
Therapeutic NNP N
study NN N
Level NNP N
I PRP N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
weight NN I
training NN I
on IN N
bone JJ O
mineral JJ O
density NN O
and CC O
bone NN O
turnover NN O
in IN N
postmenopausal JJ P
breast NN P
cancer NN P
survivors NNS P
with IN P
bone NN P
loss: NN P
a DT N
24-month JJ N
randomized NN N
controlled VBD N
trial NN N
. . N

SUMMARY VB N
This DT N
study NN N
examined VBD N
whether IN N
24 CD N
months NNS N
of IN N
weight JJ I
training NN I
exercises NNS I
enhanced VBD N
the DT N
effectiveness NN O
of IN N
risedronate NN N
calcium NN N
and CC N
vitamin NN N
D NNP N
in IN N
maintaining VBG N
or CC N
improving VBG N
bone JJ O
mineral JJ O
density NN O
(BMD) NNP O
in IN N
223 CD P
postmenopausal NN P
breast NN P
cancer NN P
survivors NNS P
. . P

Subjects NNS N
who WP N
were VBD N
> NNP N
or CC N
=50% VB N
adherent NN N
to TO N
exercise VB N
had VBN N
no DT N
improvement NN N
in IN N
BMD NNP O
but CC N
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP O
. . O

INTRODUCTION NNP N
This DT N
study NN N
examined VBD N
whether IN N
(1) NN N
postmenopausal NN P
breast NN P
cancer NN P
survivors NNS P
(BCS) VBP P
with IN P
bone NN P
loss NN P
taking VBG N
24 CD N
months NNS N
of IN N
risedronate NN I
calcium NN I
and CC N
vitamin NN I
D NNP I
had VBD N
increased VBN N
bone RB O
mineral JJ O
density NN O
(BMD) NN O
at IN O
the DT O
total JJ O
hip NN O
femoral JJ O
neck NN O
L1-L4 NNP O
spine NN O
total JJ O
radius NN O
and CC N
33% CD N
radius NN N
and CC N
decreased VBD N
bone NN O
turnover; NN O
(2) JJ N
subjects NNS N
who WP N
also RB N
participated VBD N
in IN N
strength/weight JJ I
training NN I
(ST) NN I
exercises NNS I
had VBD N
greater JJR N
increases NNS N
in IN N
BMD NNP O
and CC N
greater JJR N
decreases NNS N
in IN N
bone NN O
turnover; NN O
and CC N
(3) JJ N
subjects NNS N
who WP N
also RB N
exercised VBD N
were VBD N
more RBR N
likely JJ N
to TO N
preserve VB N
(at NNP N
least JJS N
maintain) JJ N
BMD NNP O
. . O

METHODS NNP N
Postmenopausal NNP P
BCS NNP P
(223) NNP P
were VBD N
randomly RB N
assigned VBN N
to TO N
exercise VB I
plus JJ I
medication NN I
or CC N
medication NN I
only RB N
groups NNS N
. . N

Both DT N
groups NNS N
received VBD N
24 CD N
months NNS N
of IN N
1 CD N
200 CD N
mg NN N
of IN N
calcium NN I
and CC N
400 CD N
IU NNP N
of IN N
vitamin NNP I
D NNP I
daily RB N
and CC N
35 CD N
mg NN N
of IN N
risedronate JJ I
weekly JJ N
and CC N
the DT N
exercise NN I
group NN N
additionally RB N
had VBD N
ST NNP I
exercises NNS I
twice RB N
weekly RB N
. . N

RESULTS NNP N
After IN N
24 CD N
months NNS N
women NNS N
who WP N
took VBD N
medications NNS I
without IN N
exercising VBG I
had VBD N
significant JJ N
improvements NNS N
in IN N
BMD NNP O
at IN N
the DT N
total JJ N
hip NN N
(+1.81%) NN N
and CC N
spine NN N
(+2.85%) NN N
and CC N
significant JJ N
decreases NNS N
in IN N
Alkphase NNP O
B NNP O
(-8.7%) NN N
and CC N
serum JJ O
NTx NNP O
(-16.7%) NN N
. . N

Women NNS N
who WP N
also RB N
exercised VBD I
had VBD N
additional JJ N
increases NNS N
in IN N
BMD NNP O
at IN N
the DT N
femoral JJ N
neck NN N
(+0.29%) NNP N
total JJ N
hip NN N
(+0.34%) NNP N
spine NN N
(+0.23%) NNP N
total JJ N
radius NN N
(+0.30%) NN N
and CC N
additional JJ N
decreases NNS N
in IN N
Alkphase NNP O
B NNP O
(-2.4%) NN N
and CC N
Serum NNP O
NTx NNP O
(-6.5%) NNP N
. . N

Additional NNP N
changes NNS O
in IN O
BMD NNP O
and CC O
bone NN O
turnover NN O
with IN N
exercise NN I
were VBD N
not RB N
significant JJ N
. . N

Subjects NNS N
who WP N
were VBD N
> NNP N
or CC N
=50% VB N
adherent NN N
to TO N
exercise VB I
were VBD N
less RBR N
likely JJ N
to TO N
lose VB N
BMD NNP O
at IN N
the DT N
total JJ N
hip NN N
(chi-square JJ N
[1] NNP N
= NNP N
4.66 CD N
p NN N
= NN N
0.03) CD N
and CC N
femoral JJ N
neck NN N
(chi-square JJ N
[1] NNP N
= NNP N
4.63 CD N
p NN N
= VBD N
0.03) CD N
. . N

CONCLUSION NNP N
Strength/weight NNP I
training NN I
exercises NNS I
may MD N
prevent VB N
loss NN N
of IN N
BMD NNP O
in IN N
postmenopausal NN P
BCS NNP P
at IN P
risk NN P
for IN P
bone NN P
loss NN P
. . P

-DOCSTART- -X- O O

A DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
personalised JJ I
decision NN I
support NN I
delivered VBD N
via IN N
the DT N
internet NN N
for IN N
bowel NN N
cancer NN N
screening VBG N
with IN N
a DT N
faecal JJ O
occult NN O
blood NN O
test: VBD O
the DT N
effects NNS N
of IN N
tailoring NN N
of IN N
messages NNS N
according VBG N
to TO N
social JJ N
cognitive JJ N
variables NNS N
on IN N
participation NN N
. . N

BACKGROUND NNP N
In IN N
Australia NNP P
bowel NN N
cancer NN N
screening VBG N
participation NN N
using VBG N
faecal JJ O
occult NN O
blood NN O
testing VBG O
(FOBT) NNP O
is VBZ N
low JJ N
. . N

Decision NN N
support NN N
tailored VBD N
to TO N
psychological JJ N
predictors NNS N
of IN N
participation NN N
may MD N
increase VB N
screening VBG N
. . N

The DT N
study NN N
compared VBN N
tailored VBD I
computerised JJ I
decision NN I
support NN I
to TO N
non-tailored JJ I
computer NN I
or CC I
paper NN I
information NN I
. . I

The DT N
primary JJ N
outcome NN N
was VBD N
FOBT NNP O
return NN O
within IN N
12 weeks CD N
. . N

Additional JJ N
analyses NNS N
were VBD N
conducted VBN N
on IN O
movement NN O
in IN O
decision NN O
to TO O
screen NN O
and CC N
change NN N
on IN O
psychological JJ O
variables NNS O
. . N

METHODS NNP N
A NNP N
parallel NN N
randomised VBD N
controlled JJ N
trial NN P
invited VBD P
25 CD P
511 CD P
people NNS P
aged VBN P
50-74 JJ P
years NNS P
to TO N
complete VB N
an DT N
eligibility NN N
questionnaire NN N
. . N

Eligible JJ N
respondents NNS N
(n = 3 VBP P
408) CD N
were VBD N
assigned VBN I
to TO I
Tailored NNP I
Personalised VBD I
Decision NNP I
Support NNP I
(TPDS) VBD I
Non-Tailored NNP I
PDS NNP I
(NTPDS) NNP I
or CC I
Control NNP I
(CG) NNP N
(intention-to-treat JJ N
ITT NNP N
sample) NN I
. . I

TPDS NNP I
and CC I
NTPDS NNP I
groups NNS N
completed VBD N
an DT N
on-line JJ N
baseline NN N
survey NN N
(BS) NNP N
and CC N
accessed VBD N
generic JJ N
information NN N
. . I

The DT I
TPDS NNP N
group NN N
additionally RB N
received VBD N
a DT N
tailored VBN N
intervention NN I
. . N

CG JJ N
participants NNS N
completed VBD N
a DT N
paper NN N
BS NNP N
only RB N
. . N

Those DT N
completing VBG N
the DT N
BS NNP N
(n = 2270) NNP N
were VBD N
mailed VBN N
an DT N
FOBT NNP N
and CC N
requested VBN N
to TO N
complete VB N
an DT N
endpoint NN N
survey NN N
(ES) VBD N
that IN N
re-measured JJ N
BS NNP N
variables NNS N
(per-protocol JJ N
PP NNP N
sample) NN N
. . O

RESULTS NNP O
FOBT NNP O
return: NN N
In IN N
the DT N
ITT NNP N
sample NN N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
any DT N
group NN N
(χ NNP N
(2)(2) = 2.57 NNP N
p = .26; NN N
TPDS NNP N
32.5%; CD N
NTPDS NNP N
33%; CD N
and CC N
CG NNP N
34.5%) CD N
. . N

In IN O
the DT O
PP NNP O
sample NN O
FOBT NNP N
return NN N
in IN N
the DT N
internet NN N
groups NNS N
was VBD N
significantly RB N
higher JJR N
than IN N
the DT N
paper NN N
group NN N
(χ NNP N
(2)(2) = 17.01 NNP N
p < .001; NN N
TPDS NNP N
80%; CD O
NTPDS NNP O
83%; CD N
and CC N
CG NNP I
74%) CD I
. . N

FOBT NNP I
completion NN I
by IN N
TPDS NNP N
and CC N
NTPDS NNP N
did VBD N
not RB N
differ VB N
(χ JJ N
(2)(1) = 2.23 NNP N
p = .13) NN N
. . N

Age NNP N
was VBD N
positively RB N
associated VBN N
with IN N
kit JJ N
return NN N
. . N

Decision NN N
to TO N
screen: VB N
2227/2270 CD N
of IN N
the DT N
PP NNP N
sample NN N
provided VBD N
complete JJ N
BS NNP N
data NN N
. . N

Participants NNS N
not RB N
wanting VBG N
to TO N
screen VB N
at IN N
baseline NN I
(1083/2227) NN I
and CC N
allocated VBD N
to TO N
TPDS NNP N
and CC N
NTPDS NNP N
were VBD N
significantly RB N
more RBR O
likely JJ O
to TO O
decide VB N
to TO N
screen VB N
and CC N
return VB N
an DT N
FOBT NNP O
than IN O
those DT I
assigned VBN I
to TO I
the DT I
CG NNP N
. . N

FOBT NNP N
return NN N
by IN N
TPDS NNP N
and CC N
NTPDS NNP N
did VBD N
not RB N
differ VB N
from IN N
one CD N
another DT O
(OR = 1.16 NN O
p = .42) NN O
. . N

Change NN N
on IN N
psychosocial JJ N
predictors: NN O
Analysis NNP O
of IN O
change NN O
indicated VBD O
that IN O
salience NN O
and CC O
coherence NN N
of IN N
screening VBG N
and CC N
self-efficacy NN N
were VBD N
improved VBN N
and CC N
faecal JJ N
aversion NN N
decreased VBN N
by IN N
tailored JJ N
messaging NN N
. . N

CONCLUSIONS NNP N
Online NNP N
information NN N
resources NNS N
may MD N
have VB N
a DT N
role NN N
in IN N
encouraging VBG N
internet-enabled JJ N
people NNS N
who WP N
are VBP N
uncommitted VBN N
to TO N
screening VBG N
to TO N
change VB N
their PRP$ N
attitudes NNS N
perceptions NNS N
and CC N
behaviour NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
Australian NNP N
New NNP N
Zealand NNP N
Clinical NNP N
Trials NNP N
Registry NNP N
ACTRN12610000095066 NNP N
. . N

-DOCSTART- -X- O O

Rationale NNP N
and CC N
design NN N
of IN N
RE-LY: NNP N
randomized JJ N
evaluation NN N
of IN N
long-term JJ N
anticoagulant JJ N
therapy NN N
warfarin NN I
compared VBN N
with IN N
dabigatran NN I
. . I

Vitamin NNP I
K NNP I
antagonists VBZ I
(VKAs) NNS N
are VBP N
effective JJ N
for IN N
stroke NN O
prevention NN O
in IN N
patients NNS P
with IN P
atrial JJ P
fibrillation NN P
(AF) NN P
but CC N
are VBP N
difficult JJ N
to TO N
use VB N
. . N

Dabigatran NNP I
etexilate NN I
is VBZ N
a DT N
prodrug NN N
that WDT N
is VBZ N
rapidly RB N
converted VBN N
to TO N
the DT N
active JJ N
direct JJ N
thrombin NN N
inhibitor NN N
dabigatran NN I
. . I

It PRP N
is VBZ N
administered VBN N
in IN N
a DT N
fixed JJ N
dose NN N
without IN N
laboratory JJ N
monitoring NN N
and CC N
is VBZ N
being VBG N
compared VBN N
with IN N
warfarin JJ I
(international JJ N
normalized VBN N
ratio NN N
2-3) CD N
in IN N
the DT N
RE-LY JJ N
trial NN N
. . N

Two CD N
doses NNS N
of IN N
dabigatran NN I
(110 NNP N
and CC N
150 CD N
mg NN N
BID) NNP N
are VBP N
being VBG N
evaluated VBN N
. . N

RE-LY NNP N
is VBZ N
a DT N
phase NN N
3 CD N
prospective JJ N
randomized VBN N
open-label JJ N
multinational JJ N
(44 NN N
countries) JJ N
trial NN N
of IN N
patients NNS P
with IN P
nonvalvular JJ P
AF NNP P
and CC P
at IN P
least JJS P
1 CD P
risk NN P
factor NN P
for IN P
stroke NN P
. . P

Recruitment NNP P
concluded VBD P
with IN P
a DT P
total NN P
of IN P
18 CD P
113 CD P
patients NNS P
. . P

Patients NNS P
who WP P
were VBD P
VKA-naive NNP P
and CC P
experienced VBN P
are VBP P
included VBN P
in IN P
balanced JJ P
proportions NNS P
. . P

The DT N
primary JJ N
outcome NN N
is VBZ N
stroke JJ O
(including VBG O
hemorrhagic) NN O
or CC O
systemic JJ O
embolism NN O
. . O

Safety NNP O
outcomes NNS N
are VBP N
bleeding VBG O
liver NN O
function NN O
abnormalities NNS O
and CC O
other JJ O
adverse JJ O
events NNS O
. . O

Adjudication NN N
of IN N
end NN N
points NNS N
is VBZ N
blinded VBN N
to TO N
drug NN N
assignment NN N
. . N

The DT N
trial NN N
is VBZ N
expected VBN N
to TO N
accrue VB N
a DT N
minimum NN N
of IN N
450 CD N
events NNS N
with IN N
a DT N
minimum JJ N
1-year JJ N
of IN N
follow-up JJ N
. . N

RE-LY NN N
is VBZ N
the DT N
largest JJS N
AF NNP P
stroke VBD O
prevention NN N
trial NN N
yet RB N
undertaken VBN N
. . N

It PRP N
is VBZ N
unique JJ N
because IN N
it PRP N
includes VBZ N
equal JJ N
numbers NNS N
of IN N
VKA-experienced NNP N
and CC N
naive JJ N
patients NNS N
and CC N
evaluates VBZ N
2 CD N
different JJ N
dosages NNS N
of IN N
dabigatran NN I
which WDT N
may MD N
allow VB N
tailoring NN N
of IN N
dosing VBG N
to TO N
individual JJ N
patient NN N
needs NNS N
. . N

The DT N
worldwide JJ N
site NN N
distribution NN N
and CC N
broad JJ N
range NN N
of IN N
stroke NN N
risk NN N
further RBR N
increase VB N
the DT N
general JJ N
applicability NN N
of IN N
the DT N
trial NN N
. . N

Results NNS N
are VBP N
expected VBN N
in IN N
2009 CD N
. . N

-DOCSTART- -X- O O

Cancer NNP I
information NN I
and CC N
anxiety: NN O
applying VBG N
the DT N
extended JJ N
parallel NN N
process NN N
model NN N
. . N

There EX N
is VBZ N
concern NN N
that IN N
public JJ I
education NN I
about IN I
testicular JJ I
cancer NN I
(TC) NN I
may MD N
cause VB N
unnecessary JJ N
anxiety NN O
. . O

Psychological JJ N
theory NN N
suggests VBZ N
that IN N
if IN N
threat NN N
(eg NNP N
TC) NNP N
information NN N
is VBZ N
accompanied VBN N
with IN N
threat NN I
control NN I
strategies VBZ I
(eg NNP I
testicular JJ I
self-examination; JJ I
TSE) NNP I
anxiety NN O
is VBZ N
less RBR N
likely JJ N
. . N

Male JJ P
students NNS P
(N=443) VBP P
were VBD N
randomized VBN N
to TO N
either VB N
a DT N
TC NNP I
or CC N
TC NNP I
+TSE NNP I
information NN N
group NN N
or CC N
a DT N
no DT N
information NN N
control NN N
group NN N
and CC N
assessed VBD N
at IN N
three CD N
time NN N
points NNS N
. . N

Anxiety NN O
levels NNS O
did VBD N
not RB N
differ VB N
between IN N
the DT N
groups NNS N
and CC N
exposure NN N
to TO N
TC+TSE NNP I
resulted VBD N
in IN N
greater JJR N
perceived JJ O
message NN O
benefit NN O
increased VBD N
intention NN O
to TO O
self-examine NN O
and CC N
lower JJR N
message NN O
denigration NN O
. . O

This DT N
suggests VBZ N
TC NNP I
information NN N
is VBZ N
not RB N
anxiogenic JJ O
but CC N
inclusion NN N
of IN N
TSE NNP I
information NN N
may MD N
improve VB N
acceptance NN O
of IN O
disease NN O
awareness NN O
information NN O
. . O

-DOCSTART- -X- O O

Superior JJ N
visual JJ I
search NN I
in IN N
adults NNS P
with IN P
autism NN P
. . P

Recent JJ N
studies NNS N
have VBP N
suggested VBN N
that IN N
children NNS N
with IN N
autism NN N
perform NN N
better RBR N
than IN N
matched VBN N
controls NNS N
on IN N
visual JJ I
search NN I
tasks NNS O
and CC N
that IN N
this DT N
stems VBZ N
from IN N
a DT N
superior JJ N
visual JJ N
discrimination NN N
ability NN N
. . N

This DT N
study NN N
assessed VBD N
whether IN N
these DT N
findings NNS N
generalize VBP N
from IN N
children NNS N
to TO N
adults NNS P
with IN P
autism NN P
. . P

Experiments NNS N
1 CD N
and CC N
2 CD N
showed VBD N
that IN N
like IN N
children NNS N
adults NNS P
with IN P
autism NN P
were VBD N
superior JJ N
to TO N
controls NNS N
at IN N
searching VBG O
for IN O
targets NNS O
. . O

Experiment NN N
3 CD N
showed VBD N
that IN N
increases NNS N
in IN N
target-distractor JJ N
similarity NN N
slowed VBD N
the DT N
visual JJ O
search NN O
performance NN O
of IN N
the DT N
control NN N
group NN N
significantly RB N
more RBR N
than IN N
that DT N
of IN N
the DT N
autism NN P
group NN N
suggesting VBG N
that IN N
the DT N
adults NNS P
with IN P
autism NN P
have VBP N
a DT N
superior JJ N
visual JJ O
discrimination NN O
ability NN O
. . O

Thus RB N
these DT N
experiments NNS N
replicate VBP N
in IN N
adults NNS P
previous JJ N
findings NNS N
in IN N
children NNS N
with IN N
autism NN N
. . N

Superior NNP N
unique JJ O
item NN O
detection NN O
in IN N
adults NNS P
with IN P
autism NN P
stemming VBG N
from IN N
enhanced VBN N
discrimination NN O
is VBZ N
discussed VBN N
in IN N
the DT N
light NN N
of IN N
the DT N
possible JJ N
role NN N
of IN N
stimulus JJ N
processing NN N
disturbances NNS N
in IN N
the DT N
disorder NN N
in IN N
general JJ N
. . N

-DOCSTART- -X- O O

Distinct NNP N
fast RB N
and CC N
slow VB N
processes NNS N
contribute VBP N
to TO N
the DT N
selection NN N
of IN N
preferred JJ N
step NN N
frequency NN N
during IN N
human JJ P
walking VBG N
. . N

Humans NNPS N
spontaneously RB N
select VB N
a DT N
step NN O
frequency NN O
that WDT N
minimizes VBZ N
the DT N
energy NN N
expenditure NN N
of IN N
walking VBG N
. . N

This DT N
selection NN N
might MD N
be VB N
embedded VBN N
within IN N
the DT N
neural JJ N
circuits NNS N
that WDT N
generate VBP N
gait NNS N
so RB N
that IN N
the DT N
optimum NN N
is VBZ N
pre-programmed JJ N
for IN N
a DT N
given VBN N
walking VBG N
speed NN N
. . N

Or CC N
perhaps RB N
step JJ N
frequency NN N
is VBZ N
directly RB N
optimized VBN N
based VBN N
on IN N
sensed JJ N
feedback NN N
of IN N
energy NN N
expenditure NN N
. . N

Direct JJ N
optimization NN N
is VBZ N
expected VBN N
to TO N
be VB N
slow JJ N
due JJ N
to TO N
the DT N
compounded JJ N
effect NN N
of IN N
delays NNS N
and CC N
iteration NN N
whereas IN N
a DT N
pre-programmed JJ N
mechanism NN N
presumably RB N
allows VBZ N
for IN N
faster JJR N
step NN N
frequency NN N
selection NN N
albeit IN N
dependent NN N
on IN N
prior JJ N
experience NN N
. . N

To TO N
test VB N
for IN N
both DT N
pre-programmed JJ N
selection NN N
and CC N
direct JJ N
optimization NN N
we PRP N
applied VBD N
perturbations NNS I
to TO I
treadmill VB I
walking VBG I
to TO N
elicit VB N
transient JJ N
changes NNS N
in IN N
step NN N
frequency NN N
. . N

We PRP N
found VBD N
that IN N
human JJ P
step NN O
frequency NN O
adjustments NNS O
(n VBP P
= JJ P
7) CD P
occurred VBD N
with IN N
two CD N
components NNS N
the DT N
first JJ N
dominating VBG N
the DT N
response NN N
(66 NNP N
± NNP N
10% CD N
of IN N
total JJ N
amplitude NN N
change; NN N
mean JJ N
± NNP N
SD) NNP N
and CC N
occurring VBG N
quite RB O
quickly RB O
(1.44 VB N
± JJ N
1.14 CD N
s NN N
to TO N
complete VB N
95% CD N
of IN N
total JJ N
change) NN N
. . N

The DT N
other JJ N
component NN N
was VBD N
of IN N
smaller JJR O
amplitude NN O
(35 NNP N
± NNP N
10% CD N
of IN N
total JJ N
change) NN N
and CC N
took VBD N
tens NNS O
of IN O
seconds NNS O
(27.56 JJ N
± VBP N
16.18 CD N
s NN N
for IN N
95% CD N
completion) NN N
. . N

The DT N
fast JJ N
process NN N
appeared VBD N
to TO N
be VB N
too RB N
fast JJ N
for IN N
direct JJ N
optimization NN N
and CC N
more RBR N
indicative JJ N
of IN N
a DT N
pre-programmed JJ N
response NN N
. . N

It PRP N
also RB N
persisted VBD N
even RB N
with IN N
unusual JJ N
closed-loop JJ N
perturbations NNS N
that WDT N
conflicted VBD N
with IN N
prior JJ N
experience NN N
and CC N
rendered VBD N
the DT N
response NN N
energetically RB N
suboptimal JJ N
. . N

The DT N
slow JJ N
process NN N
was VBD N
more RBR N
consistent JJ N
with IN N
the DT N
timing NN N
expected VBN N
for IN N
direct JJ N
optimization NN N
. . N

Our PRP$ N
interpretation NN N
of IN N
these DT N
results NNS N
is VBZ N
that IN P
humans NNS P
may MD N
rely VB N
heavily RB N
on IN N
pre-programmed JJ N
gaits NNS N
to TO N
rapidly RB N
select VB N
their PRP$ N
preferred JJ O
step NN O
frequency NN O
and CC N
then RB N
gradually RB N
fine-tune JJ N
that IN N
selection NN N
with IN N
direct JJ N
optimization NN N
. . N

-DOCSTART- -X- O O

Virtual JJ I
reality NN I
hypnosis NN I
for IN N
pain NN P
associated VBN N
with IN N
recovery NN N
from IN N
physical JJ P
trauma NN P
. . P

Pain VB P
following VBG N
traumatic JJ P
injuries NNS P
is VBZ N
common JJ N
can MD N
impair VB N
injury JJ N
recovery NN N
and CC N
is VBZ N
often RB N
inadequately RB N
treated VBN N
. . N

In IN N
particular JJ N
the DT N
role NN N
of IN N
adjunctive JJ N
nonpharmacologic JJ N
analgesic JJ N
techniques NNS N
is VBZ N
unclear JJ N
. . N

The DT N
authors NNS N
report VBP N
a DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
21 CD P
hospitalized JJ P
trauma NN P
patients NNS P
to TO N
assess VB N
the DT N
analgesic JJ O
efficacy NN O
of IN N
virtual JJ I
reality NN I
hypnosis NN I
(VRH)-hypnotic JJ I
induction NN I
and CC N
analgesic JJ O
suggestion NN O
delivered VBN N
by IN N
customized JJ N
virtual JJ N
reality NN N
(VR) NNP N
hardware/software NN N
. . N

Subjective JJ O
pain NN O
ratings NNS O
were VBD N
obtained VBN N
immediately RB N
and CC N
8 CD N
hours NNS N
after IN N
VRH NNP I
(used VBD N
as IN N
an DT N
adjunct NN N
to TO N
standard VB N
analgesic JJ N
care) NN N
and CC N
compared VBN N
to TO N
both DT N
adjunctive JJ N
VR NNP I
without IN I
hypnosis NN I
and CC N
standard JJ I
care NN I
alone RB N
. . N

VRH JJ I
patients NNS N
reported VBD N
less RBR N
pain JJ O
intensity NN O
and CC N
less JJR N
pain NN O
unpleasantness JJ O
compared VBN N
to TO N
control VB N
groups NNS N
. . N

These DT N
preliminary JJ N
findings NNS N
suggest VBP N
that IN N
VRH NNP I
analgesia NN N
is VBZ N
a DT N
novel JJ N
technology NN N
worthy NN N
of IN N
further JJ N
study NN N
both DT N
to TO N
improve VB N
pain NN O
management NN O
and CC N
to TO N
increase VB N
availability NN N
of IN N
hypnotic JJ N
analgesia NN N
to TO N
populations NNS N
without IN N
access NN N
to TO N
therapist-provided JJ N
hypnosis NN N
and CC N
suggestion NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
antipyretic JJ I
drugs NNS I
in IN N
children NNS P
with IN P
malaria NN P
. . P

A DT N
comparison NN N
of IN N
different JJ N
antipyretics NNS I
in IN N
children NNS P
with IN P
malaria NN P
showed VBD N
a DT N
small JJ N
effect NN N
of IN N
naproxen NNS I
but CC N
not RB N
of IN N
metamizol NN I
on IN N
the DT N
reduction NN O
of IN O
fever NN O
peaks NNS O
. . O

Antipyretic JJ I
treatment NN N
had VBD N
no DT N
effect NN N
on IN N
fever NN O
clearance NN O
and CC N
therefore NN N
should MD N
be VB N
used VBN N
cautiously RB N
in IN N
the DT N
treatment NN N
of IN N
malaria NN P
. . P

-DOCSTART- -X- O O

Phase NNP N
III NNP N
study NN N
of IN N
two CD N
different JJ N
dosing VBG N
schedules NNS N
of IN N
erythropoietin NN I
in IN N
anemic JJ P
patients NNS P
with IN P
cancer NN P
. . P

PURPOSE NNP N
To TO N
compare VB N
maintenance NN N
epoetin NN I
alfa NN I
administered VBD N
once RB N
every DT N
3 CD N
weeks NNS N
with IN N
continued JJ N
weekly JJ N
epoetin NN I
alfa NN I
for IN N
patients NNS P
with IN P
cancer-associated JJ P
anemia NN P
. . P

PATIENTS NNP N
AND CC N
METHODS NNP N
Eligible JJ N
patients NNS N
were VBD N
randomly RB N
assigned VBN N
at IN N
enrollment NN N
to TO N
receive VB N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN I
alfa NN I
40 CD N
000 CD N
U NNP N
subcutaneously RB N
(SC) VBZ N
followed VBN N
by IN N
either DT N
standard JJ N
weekly JJ N
epoetin NN I
alfa NN I
(40K NNP N
arm) NN N
or CC N
120 CD N
000 CD N
U NNP N
of IN N
epoetin NN I
alfa NN I
(120K NNP N
arm) NN N
SC NNP N
every DT N
3 CD N
weeks NNS N
for IN N
18 CD N
additional JJ N
weeks NNS N
. . N

RESULTS NNP N
Three CD P
hundred VBD P
sixty-five JJ P
patients NNS P
were VBD P
enrolled VBN P
. . P

One CD N
hundred VBD N
eighty-three JJ N
patients NNS N
were VBD N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
and CC N
182 CD N
were VBD N
assigned VBN N
to TO N
the DT N
120K CD N
arm NN N
. . N

There EX N
was VBD N
no DT N
difference NN N
in IN N
the DT N
proportion NN N
of IN N
patients NNS N
requiring VBG O
transfusions NNS O
during IN N
the DT N
study NN N
(23% NNP N
in IN N
40K CD N
arm NN N
and CC N
18% CD N
in IN N
120K CD N
arm NN N
P NNP N
= NNP N
.22) NNP N
or CC N
specifically RB N
during IN N
the DT N
maintenance NN N
phase NN N
(13% NNP N
in IN N
40K CD N
arm NN N
v NN N
15% CD N
in IN N
120K CD N
arm NN N
P NNP N
= NNP N
.58) NNP N
. . N

Patients NNS N
randomly RB N
assigned VBN N
to TO N
the DT N
40K CD N
arm NN N
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
> NN N
or CC N
= VB N
2 CD N
or CC N
> CD N
or CC N
= VB N
3 CD N
g/dL JJ N
hemoglobin NN O
(Hb) NNP O
increment NN O
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
drug NN O
dose RB O
held VBD N
because IN N
of IN N
high JJ N
Hb NNP O
and CC N
had VBD N
higher JJR N
mean JJ N
end-of-study JJ N
Hb NNP O
levels NNS N
. . N

Toxicities NNS O
including VBG O
thromboembolism NN O
and CC N
overall JJ O
survival NN O
were VBD N
similar JJ N
. . N

Patients NNS N
in IN N
the DT N
40K CD N
arm NN N
had VBD N
a DT N
higher JJR N
global JJ O
quality NN O
of IN O
life NN O
(QOL) NN O
at IN N
baseline NN N
for IN N
unclear JJ N
reasons NNS N
whereas VBP N
patients NNS N
in IN N
the DT N
120K CD N
arm NN N
had VBD N
a DT N
greater JJR N
global JJ O
QOL NNP O
improvement NN N
during IN N
the DT N
study NN N
so RB N
end-of-study JJ N
QOL NNP O
was VBD N
equivalent JJ N
. . N

CONCLUSION NN N
After IN N
three CD N
weekly JJ N
doses NNS N
of IN N
epoetin NN I
alfa NN I
40 CD N
000 CD N
U NNP N
a DT N
dose NN N
of IN N
120 CD N
000 CD N
U NNS N
can MD N
be VB N
administered VBN N
safely RB O
once RB N
every DT N
3 CD N
weeks NNS N
without IN N
increasing VBG N
transfusion NN O
needs NNS O
or CC N
sacrificing VBG N
QOL NNP O
. . O

The DT N
Hb NNP O
increment NN O
is VBZ N
somewhat RB N
greater JJR N
with IN N
continued JJ N
weekly JJ N
epoetin NN I
alfa NN I
. . I

Lack NNP N
of IN N
blinding VBG N
as IN N
a DT N
result NN N
of IN N
different JJ N
treatment NN N
schedules NNS N
may MD N
have VB N
confounded VBN N
results NNS N
. . N

-DOCSTART- -X- O O

Protection NN N
of IN N
man NN P
from IN N
natural JJ N
infection NN N
with IN N
influenza JJ N
A2 NNP N
Hong NNP N
Kong NNP N
virus NN N
by IN N
amantadine: VBG I
a DT N
controlled JJ N
field NN N
trial NN N
. . N

Prophylactic JJ N
administration NN N
of IN N
amantadine NN I
in IN N
doses NNS N
of IN N
100 CD N
mg NN N
. . N

twice RB N
a DT N
day NN N
offered VBN N
statistically RB N
significant JJ N
protection NN N
against IN N
influenza JJ N
A2 NNP N
infection NN N
in IN N
a DT N
double-blind JJ N
field NN N
trial NN N
involving VBG N
391 CD P
medical JJ P
student NN P
volunteers NNS P
during IN P
the DT P
influenza JJ P
A2 NNP P
Hong NNP P
Kong NNP P
epidemic VBP P
in IN P
Helsinki NNP P
in IN P
the DT P
winter NN P
of IN P
1969 CD P
. . P

Serologically RB O
verified JJ O
influenza NN O
as IN N
measured VBN N
by IN N
complement JJ O
fixation NN O
and/or NN O
haemagglutination NN O
inhibition NN O
occurred VBD N
in IN N
27 CD N
out IN N
of IN N
192 CD N
students NNS N
in IN N
the DT N
amantadine NN I
group NN N
against IN N
57 CD N
out IN N
of IN N
199 CD N
in IN N
the DT N
placebo NN I
group NN N
giving VBG N
a DT N
protection NN N
rate NN N
of IN N
52% CD N
. . N

-DOCSTART- -X- O O

RESPECT-PTSD: JJ N
re-engineering JJ N
systems NNS N
for IN N
the DT N
primary JJ N
care NN N
treatment NN N
of IN N
PTSD NNP P
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
Although IN N
collaborative JJ I
care NN I
is VBZ N
effective JJ N
for IN N
treating VBG N
depression NN N
and CC N
other JJ N
mental JJ N
disorders NNS N
in IN N
primary JJ N
care NN N
there EX N
have VBP N
been VBN N
no DT N
randomized JJ N
trials NNS N
of IN N
collaborative JJ N
care NN N
specifically RB N
for IN N
patients NNS P
with IN P
Posttraumatic NNP P
stress NN P
disorder NN P
(PTSD) NN P
. . P

OBJECTIVE UH N
To TO N
compare VB N
a DT N
collaborative JJ N
approach NN N
the DT N
Three NNP I
Component NNP I
Model NNP I
(3CM) NNP I
with IN N
usual JJ I
care NN I
for IN N
treating VBG N
PTSD NNP P
in IN N
primary JJ N
care NN N
. . N

DESIGN VB N
The DT N
study NN N
was VBD N
a DT N
two-arm JJ N
parallel NN N
randomized VBD N
clinical JJ N
trial NN N
. . N

PTSD JJ P
patients NNS P
were VBD P
recruited VBN P
from IN P
five CD P
primary JJ P
care NN P
clinics NNS P
at IN P
four CD P
Veterans NNS P
Affairs NNP P
healthcare NN P
facilities NNS P
and CC N
randomized VBN N
to TO N
receive VB N
usual JJ I
care NN I
or CC N
usual JJ I
care NN I
plus CC I
3CM CD I
. . I

Blinded VBN N
assessors NNS N
collected VBD N
data NNS N
at IN N
baseline NN N
and CC N
3-month JJ N
and CC N
6-month JJ N
follow-up NN N
. . N

PARTICIPANTS JJ N
Participants NNS P
were VBD P
195 CD P
Veterans NNPS P
. . P

Their PRP$ P
average JJ P
age NN P
was VBD P
45 CD P
years NNS P
91% CD P
were VBD P
male JJ P
58% CD P
were VBD P
white JJ P
40% CD P
served VBN P
in IN P
Iraq NNP P
or CC P
Afghanistan NNP P
and CC P
42% CD P
served VBD P
in IN P
Vietnam NNP P
. . P

INTERVENTION NNP N
All NNP N
participants NNS N
received VBD N
usual JJ N
care NN N
. . N

Participants NNS N
assigned VBD N
to TO N
3CM CD I
also RB N
received VBD N
telephone NN I
care NN I
management NN I
. . I

Care NN N
managers NNS N
received VBD N
supervision NN N
from IN N
a DT N
psychiatrist NN N
. . N

MAIN NNP N
MEASURES NNP N
PTSD NNP O
symptom NN O
severity NN O
was VBD N
the DT N
primary JJ N
outcome NN N
. . N

Depression NNP O
functioning VBG O
perceived JJ O
quality NN O
of IN O
care NN O
utilization NN O
and CC O
costs NNS O
were VBD N
secondary JJ N
outcomes NNS N
. . N

KEY JJ N
RESULTS NNP N
There EX N
were VBD N
no DT N
differences NNS N
between IN N
3CM CD I
and CC N
usual JJ I
care NN I
in IN N
symptoms NNS O
or CC O
functioning VBG O
. . O

Participants NNS N
assigned VBD N
to TO N
3CM CD I
were VBD N
more RBR N
likely JJ N
to TO N
have VB N
a DT N
mental JJ O
health NN O
visit NN O
fill VBP O
an DT O
antidepressant JJ O
prescription NN O
and CC N
have VBP N
adequate VBN O
antidepressant JJ O
refills NNS O
. . O

3CM CD I
participants NNS N
also RB N
had VBD N
more RBR N
mental JJ O
health NN O
visits NNS O
and CC N
higher JJR N
outpatient NN O
pharmacy NN O
costs NNS O
. . O

CONCLUSIONS NNP N
Results NNP N
suggest VBP N
the DT N
need NN N
for IN N
careful JJ N
examination NN N
of IN N
the DT N
way NN N
that IN N
collaborative JJ I
care NN I
models NNS N
are VBP N
implemented VBN N
for IN N
treating VBG N
PTSD NNP P
and CC N
for IN N
additional JJ N
supports NNS N
to TO N
encourage VB N
primary JJ N
care NN N
providers NNS N
to TO N
manage VB N
PTSD NNP P
. . P

-DOCSTART- -X- O O

[Improving VBG O
wound NN O
healing NN O
after IN P
nose JJ P
surgery NN P
by IN N
combined JJ N
administration NN N
of IN N
xylometazoline NNP I
and CC N
dexpanthenol] NN I
. . N

BACKGROUND IN N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
the DT N
examination NN N
of IN N
efficacy NN O
and CC N
tolerability NN O
of IN N
an DT N
application-form NN N
of IN N
the DT N
new JJ N
combination NN N
of IN N
Xylometazoline NN I
with IN N
Dexpanthenol NNP I
(Nasic) NNP I
versus FW N
Xylometazoline NNP I
alone RB I
. . I

PATIENTS NNP N
AND CC N
METHODS NNP N
Randomized NNP N
verum NN N
controlled VBD N
parallel-group-comparison NN N
of IN N
two CD N
weeks NNS N
treatment NN N
of IN N
a DT N
nasal-spray JJ N
. . N

61 CD P
inpatients NNS P
with IN P
the DT P
diagnosis NN P
Rhinitis NNP P
following VBG P
nasal JJ P
operation NN P
were VBD P
included VBN P
in IN P
this DT P
study NN P
and CC N
30 CD P
patients NNS P
were VBD N
treated VBN N
with IN N
verum NN I
and CC N
placebo NN I
each DT N
. . N

The DT N
assessment NN N
of IN N
nasal-breathing-resistance NN O
according VBG O
to TO O
scores NNS O
was VBD O
defined VBN O
as IN O
target-parameter NN O
. . O

Confirmatory NNP N
statistical JJ N
analysis NN N
was VBD N
carried VBN N
out RP N
according VBG N
to TO N
Wilcoxon-Mann-Whitney-U JJ N
two-sided JJ N
at IN N
alpha JJ N
< NN N
or CC N
= $ N
0.05 CD N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURE NNP N
The DT N
superiority NN O
of IN N
the DT N
combination NN N
of IN N
Xylometazoline-Dexpanthenol JJ I
nasal-spray JJ N
versus NN N
Xylometazoline NNP I
nasal NN N
spray NN N
could MD N
be VB N
proven VBN N
for IN N
the DT N
target-parameter NN O
as IN N
clinically RB N
relevant JJ N
and CC N
statistically RB N
significant JJ N
. . N

The DT N
clinically RB N
proven JJ N
efficacy NN O
is VBZ N
emphasized VBN N
by IN N
good JJ N
tolerability NN O
of IN N
both DT N
treatments NNS N
. . N

Due NNP N
to TO N
easy VB N
handling NN N
of IN N
the DT N
nasal-spray JJ N
a DT N
good JJ N
compliance NN O
was VBD N
confirmed VBN N
. . N

CONCLUSION NNP N
Distinct NNP N
improvement NN O
of IN N
symptoms NNS N
in IN N
patients NNS P
following VBG P
nasal JJ P
operations NNS P
underlines VBP N
the DT N
efficacy NN O
of IN N
both DT N
medications NNS N
. . N

With IN N
respect NN N
to TO N
the DT N
tolerability NN O
therapy NN N
with IN N
the DT N
combination NN N
is VBZ N
more RBR N
beneficial JJ N
in IN N
comparison NN N
to TO N
the DT N
alternative JJ N
therapy NN N
. . N

The DT N
result NN N
of IN N
this DT N
controlled VBN N
clinical JJ N
study NN N
confirms VBZ N
that IN N
the DT N
combination NN N
Xylometazoline-Dexpanthenol NNP I
is VBZ N
an DT N
enlargement NN N
and CC N
improvement NN N
of IN N
effective JJ N
medicinal JJ N
treatment NN N
of IN N
rhinitis NN P
following VBG P
nasal JJ P
operation NN P
in IN N
comparison NN N
to TO N
therapy VB N
with IN N
Xylometazoline NNP I
alone RB N
. . N

-DOCSTART- -X- O O

Psychological JJ O
mediators NNS O
of IN N
bupropion NN I
sustained-release NN I
treatment NN N
for IN N
smoking VBG P
cessation NN P
. . P

AIM IN N
The DT N
study NN N
aimed VBN N
to TO N
test VB N
simultaneously RB N
our PRP$ N
understanding NN N
of IN N
the DT N
effects NNS N
of IN N
bupropion NN I
sustained-release JJ I
(SR) NNP I
treatment NN N
on IN N
putative JJ O
mediators NNS O
and CC N
our PRP$ N
understanding NN N
of IN N
determinants NNS N
of IN N
post-quit JJ O
abstinence NN O
including VBG O
withdrawal NN O
distress NN O
cigarette NN O
craving VBG O
positive JJ O
affect NN O
and CC O
subjective JJ O
reactions NNS O
to TO O
cigarettes NNS O
smoked VBN O
during IN O
a DT O
lapse NN O
. . O

The DT N
specificity NN O
of IN N
bupropion NN I
SR NNP I
effects NNS N
was VBD N
also RB N
tested VBN N
in IN N
exploratory JJ N
analyses NNS N
. . N

DESIGN NNP N
Data NNP N
from IN N
a DT N
randomized VBN N
placebo-controlled JJ N
clinical JJ N
trial NN N
of IN N
bupropion NN I
SR NNP I
were VBD N
submitted VBN N
to TO N
mediation NN N
analyses NNS N
. . N

SETTING NN N
Center NNP N
for IN N
Tobacco NNP N
Research NNP N
and CC N
Intervention NNP N
Madison NNP P
WI NNP P
USA NNP P
. . P

PARTICIPANTS VB N
A DT P
total NN P
of IN P
403 CD P
adult JJ P
daily JJ P
smokers NNS P
without IN P
contraindications NNS P
to TO P
bupropion VB P
SR NNP P
use NN P
. . P

INTERVENTION NN N
Participants NNS N
were VBD N
assigned VBN N
randomly RB N
to TO N
receive VB N
a DT N
9-week JJ N
course NN N
of IN N
bupropion NN I
SR NNP I
or CC N
placebo NN I
pill NN N
and CC N
to TO N
receive VB N
eight CD N
brief JJ N
individual JJ N
counseling NN N
sessions NNS N
or CC N
no DT N
counseling NN N
. . N

MEASUREMENTS NNP N
Ecological NNP O
momentary JJ O
assessment NN O
ratings NNS O
of IN O
smoking VBG O
behavior NN O
and CC O
putative JJ O
mediators NNS O
were VBD N
collected VBN N
pre- JJ N
and CC N
post-quit NN N
. . N

FINDINGS NNP N
Results NNP N
of IN N
structural JJ N
equation NN N
and CC N
hierarchical JJ N
linear JJ N
models NNS N
did VBD N
not RB N
support VB N
the DT N
hypothesis NN N
that WDT N
bupropion NN I
SR NNP I
treatment NN N
improves VBZ N
short-term JJ O
abstinence NN O
by IN N
reducing VBG N
withdrawal NN O
distress NN O
or CC N
affecting VBG N
the DT N
subjective JJ O
effects NNS O
of IN O
a DT O
lapse NN O
cigarette NN O
but CC N
provided VBD N
partial JJ N
support NN N
for IN N
mediation NN N
by IN N
cigarette NN O
craving VBG O
reduction NN O
and CC N
enhanced VBD N
positive JJ O
affect NN O
. . O

Bupropion NNP I
SR NNP I
effects NNS N
on IN N
point-prevalence NN O
abstinence NN O
at IN N
1 CD N
month NN N
post-quit NN N
were VBD N
also RB N
mediated VBN N
partially RB N
by IN N
enhanced JJ N
motivation NN O
to TO N
quit VB N
and CC N
self-efficacy NN O
. . O

CONCLUSIONS NNP N
Results NNP N
provided VBD N
some DT N
support NN N
for IN N
models NNS N
of IN N
bupropion NN I
SR NNP I
treatment NN N
and CC N
relapse NN N
and CC N
suggested VBD N
that IN N
motivational JJ N
processes NNS N
may MD N
partially RB N
account VB N
for IN N
bupropion NN I
SR NNP I
efficacy NN O
. . O

-DOCSTART- -X- O O

Sedation NN N
during IN P
endoscopic NN P
retrograde NN P
cholangiopancreatography: VBD P
a DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
patient-controlled JJ N
propofol NN I
sedation NN N
and CC N
that IN N
given VBN N
by IN N
a DT N
nurse JJ N
anesthetist NN N
. . N

OBJECTIVE CC N
Different JJ N
regimens NNS N
are VBP N
used VBN N
for IN N
sedation NN N
during IN P
endoscopic NN P
retrograde NN P
cholangiopancreatography NN P
(ERCP) NN P
. . P

Our PRP$ N
objectives NNS N
were VBD N
to TO N
compare VB N
safety NN O
ease NN O
of IN O
treatment NN O
recovery NN O
and CC O
patients' NN O
experiences NNS O
using VBG N
patient-controlled JJ I
sedation NN I
(PCS) NN N
with IN N
propofol JJ I
nurse JJ N
anesthetist-controlled JJ I
sedation NN I
(ACS) NN N
or CC N
the DT N
department's JJ N
standard NN I
of IN I
care NN I
midazolam NN I
given VBN N
by IN N
the DT N
procedure NN N
team NN N
(control NNP N
group) NN N
. . N

MATERIAL NNP N
AND CC N
METHODS NNP N
The DT P
study NN P
included VBD P
281 CD P
adults NNS P
in IN P
301 CD P
procedures NNS P
. . P

The DT N
PCS NNP N
group NN N
(n NNP N
= VBZ N
101) CD N
delivered JJ N
bolus NN N
doses NNS N
of IN N
5 CD N
mg NN N
of IN N
propofol NN I
according VBG N
to TO N
their PRP$ N
need NN N
for IN N
sedation NN N
. . N

The DT N
ACS NNP N
group NN N
(n NNP N
= VBZ N
100) CD N
had VBD N
2-8 JJ N
mg/kg/h NN N
of IN N
propofol NN I
infused VBN N
with IN N
the DT N
target NN N
for IN N
sedation NN N
being VBG N
level JJ N
3 CD N
of IN N
the DT N
Observer's NNP O
Assessment NNP O
of IN O
Alertness/Sedation NNP O
(OAA/S) NNP O
scale NN O
. . O

The DT N
control NN N
group NN N
was VBD N
given VBN N
2-3 JJ N
mg NN N
of IN N
midazolam NN I
for IN N
induction NN N
and CC N
additional JJ N
1 CD N
mg NN N
if IN N
required VBN N
. . N

RESULTS NNP N
PCS NNP N
and CC N
ACS NNP N
increased VBD N
the DT N
ease NN O
of IN O
the DT O
procedure NN O
and CC N
reduced VBD N
the DT N
number NN O
of IN O
sedation NN O
failures NNS O
compared VBN N
to TO N
midazolam VB I
sedation NN N
(ACS NNP N
n VBZ N
= $ N
0; CD N
PCS NNP N
n RB N
= VBD N
4; CD N
midazolam NN I
n NN N
= VBD N
20) CD N
. . N

The DT N
ACS NNP N
group NN N
had VBD N
more RBR N
deeply RB N
sedated JJ N
patients NNS N
(OAA/S VBP N
level JJ N
2) CD N
desaturation NN N
and CC N
obstructed VBD N
airways NNS N
than IN N
the DT N
PCS NNP N
and CC N
midazolam NN I
groups NNS N
. . N

Time NN O
to TO O
full JJ O
recovery NN O
(Aldrete NNP O
score NN O
≥9) NN N
was VBD N
shortest JJS N
following VBG N
PCS NNP N
. . N

PCS NNP N
resulted VBD N
in IN N
the DT N
least JJS O
fatigue NN O
and CC O
pain NN O
after IN N
the DT N
procedure NN O
. . O

Patients' NNP O
preference NN O
for IN N
PCS NNP N
and CC N
ACS NNP N
was VBD N
the DT N
same JJ N
. . N

CONCLUSION NNP N
PCS NNP N
with IN I
propofol NN I
is VBZ N
superior JJ N
to TO I
midazolam VB I
and CC N
comparable VB N
to TO N
ACS NNP N
. . N

PCS NNP N
resulted VBD N
in IN N
a DT O
rapid JJ O
recovery NN O
fewer JJR O
respiratory NN O
events NNS O
and CC N
was VBD N
almost RB N
as RB O
effective JJ O
as IN N
ACS NNP N
in IN N
ensuring VBG N
a DT N
successful JJ N
examination NN N
. . N

-DOCSTART- -X- O O

Oral NNP I
contraceptive NN I
use NN N
is VBZ N
associated VBN N
with IN N
increased JJ N
cardiovascular JJ O
reactivity NN O
in IN N
nonsmokers NNS P
. . P

Women NNS N
who WP N
smoke VBD N
and CC N
take VB N
oral JJ I
contraceptives NNS I
(OCs) VBP I
have VBP N
significantly RB N
increased VBN N
risk NN N
of IN N
cardiovascular JJ O
disease NN O
but CC N
the DT N
exact JJ N
mechanismsfor VBZ N
the DT N
increased VBN N
risk NN N
are VBP N
not RB N
known VBN N
. . N

Cardiovascular JJ O
reactivity NN O
to TO N
psychological JJ N
stress NN N
may MD N
be VB N
one CD N
mechanism NN N
for IN N
the DT N
enhanced JJ N
risk NN N
but CC N
the DT N
small JJ N
number NN N
of IN N
studies NNS N
examining VBG N
whether IN N
OC NNP I
users NNS N
who WP N
smoke VBP N
have VBP N
greater JJR N
reactivity NN N
have VBP N
produced VBN N
mixed JJ N
results NNS N
. . N

The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
examine VB N
the DT N
effect NN N
of IN N
chronic JJ N
cigarette NN I
smoking VBG I
acute JJ N
nicotine JJ I
administration NN N
and CC N
OC NNP I
use VBP N
on IN N
cardiovascular NN O
and CC O
lipid JJ O
reactivity NN O
. . O

Sixty NNP P
healthy JJ P
women NNS P
half NN P
of IN P
whom WP P
had VBD P
been VBN P
using VBG P
OCs NNP P
for IN P
at IN P
least JJS P
the DT P
previous JJ P
6 CD P
months NNS P
participated VBN P
in IN P
the DT P
study NN P
. . P

Approximately RB N
two CD P
thirds NNS P
were VBD P
smokers NNS P
and CC N
were VBD N
randomized VBN N
to TO N
be VB N
tested VBN N
after IN N
either DT N
a DT N
12-hr JJ N
nicotine JJ I
deprivation NN I
or CC N
administration NN N
of IN N
nicotine JJ I
gum NN N
. . N

One CD P
third WDT P
were VBD P
nonsmokers NNS P
. . P

Heart NNP O
rate NN O
blood NN O
pressure NN O
and CC O
lipid JJ O
measures NNS O
were VBD N
taken VBN N
at IN N
rest NN N
during IN N
a DT N
videotaped JJ N
speech NN N
task NN N
and CC N
during IN N
recovery NN N
from IN N
the DT N
task NN N
. . N

Results NNS N
indicated VBD N
that IN N
among IN N
OC NNP I
nonusers NNS N
there EX N
was VBD N
no DT N
effect NN N
of IN N
smoking VBG N
status NN N
or CC N
nicotine JJ I
administration NN N
on IN N
cardiovascular JJ N
reactivity NN N
. . N

However RB N
among IN N
OC NNP I
users NNS N
nonsmokers NNS N
had VBD N
significantly RB N
greater JJR N
heart NN O
rate NN O
and CC O
diastolic JJ O
blood NN O
pressure NN O
reactivity NN O
to TO N
stress VB N
. . N

These DT N
data NNS N
show VBP N
that IN N
acute JJ N
nicotine JJ I
administration NN N
in IN N
the DT N
form NN N
of IN N
nicotine JJ I
gum NN N
has VBZ N
no DT N
effect NN N
on IN N
cardiovascular NN O
or CC O
lipid JJ O
stress NN O
reactivity NN O
in IN N
women NNS P
. . P

However RB N
OC NNP I
use NN N
among IN N
nonsmoking JJ P
women NNS P
is VBZ N
associated VBN N
with IN N
greater JJR N
cardiovascular JJ O
reactivity NN O
to TO N
stress VB N
. . N

-DOCSTART- -X- O O

Vibrotactile--auditory JJ N
interactions NNS N
are VBP N
post-perceptual JJ N
. . N

Vibrotactile NNP I
stimuli NN I
can MD N
elicit VB N
compelling VBG O
auditory JJ O
sensations NNS O
even RB N
when WRB N
sound NN N
energy NN N
levels NNS N
are VBP N
minimal JJ N
and CC N
undetectable JJ N
. . N

It PRP N
has VBZ N
previously RB N
been VBN N
shown VBN N
that IN N
subjects NNS N
judge VBP N
auditory JJ O
tones NNS O
embedded VBN N
in IN N
white JJ N
noise NN N
to TO N
be VB N
louder VBN N
when WRB N
they PRP N
are VBP N
accompanied VBN N
by IN N
a DT N
vibrotactile JJ I
stimulus NN I
of IN N
the DT N
same JJ N
frequency NN N
. . N

A DT N
first JJ N
experiment NN N
replicated VBN N
this DT N
result NN N
at IN N
four CD N
different JJ N
levels NNS N
of IN N
auditory JJ O
stimulation NN O
(no NNP O
tone NN O
tone NN O
at IN O
detection NN O
threshold NN O
tone NN O
at IN O
5 CD O
dB NNS O
above IN O
threshold NN O
and CC O
tone NN O
at IN O
10 CD O
dB NNS O
above IN O
threshold) NN O
. . O

The DT N
presence NN N
of IN N
a DT N
vibrotactile JJ I
stimulus NN I
induced VBD N
an DT N
increase NN N
in IN N
the DT N
perceived JJ N
loudness NN N
of IN N
auditory NN O
tones NNS O
at IN N
three CD N
of IN N
the DT N
four CD N
values NNS N
in IN N
this DT N
range NN N
. . N

In IN N
two CD N
further JJ N
experiments NNS N
a DT N
2-interval JJ N
forced-choice JJ N
procedure NN N
was VBD N
used VBN N
to TO N
assess VB N
the DT N
nature NN O
of IN O
this DT O
cross-modal JJ O
interaction NN O
. . O

Subjects NNS N
were VBD N
biased VBN N
when WRB N
vibrotaction NN I
was VBD N
applied VBN N
in IN N
one CD N
interval NN N
but CC N
applying VBG N
vibrotaction NN I
in IN N
both DT N
intervals NNS N
produced VBD N
performance NN N
comparable JJ N
to TO N
conditions NNS N
without IN N
vibrotactile NN I
stimuli NN I
. . I

This DT N
demonstrates VBZ N
that IN N
vibrotaction NN I
is VBZ N
sometimes RB N
ignored VBN N
when WRB N
judging VBG N
the DT N
presence NN N
of IN N
an DT N
auditory JJ O
tone NN O
. . O

Hence NNP N
the DT N
interaction NN N
between IN N
vibrotaction NN I
and CC N
audition NN N
does VBZ N
not RB N
appear VB N
to TO N
occur VB N
at IN N
an DT N
early JJ N
perceptual JJ N
level NN N
. . N

-DOCSTART- -X- O O

[Impact NN N
of IN N
CCND1 NNP N
A870G NNP N
polymorphism NN N
on IN N
acute JJ O
adverse JJ O
events NNS O
in IN N
postoperative JJ P
rectal JJ P
cancer NN P
patients NNS P
treated VBN P
with IN P
adjuvant JJ P
concurrent NN P
chemoradiotherapy] NN P
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
association NN O
between IN N
single JJ O
nucleotide JJ O
polymorphism NN O
(SNP) NN O
of IN O
CCND1 NNP O
A870G NNP O
and CC O
acute JJ O
adverse JJ O
events NNS O
(AEs) VBP O
in IN N
postoperative JJ P
rectal JJ P
cancer NN P
patients NNS P
who WP P
received VBD P
capecitabine-based JJ P
postoperative JJ P
chemoradiotherapy NN P
(CRT) NN P
. . P

METHODS NNP N
Four CD P
hundred VBD P
patients NNS P
with IN P
stage NN P
II NNP P
and CC P
III NNP P
rectal JJ P
cancer NN P
received VBD P
postoperative JJ P
CRT NNP P
of IN P
capecitabine NN P
with IN N
or CC N
without IN N
oxaliplatin NNS I
were VBD N
accumulated VBN N
and CC N
prostectively RB N
studied VBN N
in IN N
this DT N
study NN N
. . N

The DT N
patients NNS N
were VBD N
randomly RB N
divided VBN N
into IN N
two CD N
groups NNS N
. . N

Two CD N
hundred CD N
and CC N
twenty-eight JJ N
patients NNS N
were VBD N
treated VBN N
with IN N
concurrent JJ N
capecitabine NN I
and CC I
radiotherapy VB I
(Cap-CRT) JJ I
and CC N
172 CD N
patients NNS N
were VBD N
treated VBN N
with IN N
capecitabine NN I
and CC I
oxaliplatin JJ I
plus JJ I
radiotherapy NN I
(Cap-Oxa-CRT) NN I
. . I

Adverse JJ O
events NNS O
were VBD O
graded VBN O
according VBG O
to TO O
the DT O
Common NNP O
Terminology NNP O
Criteria NNP O
for IN O
Adverse NNP O
Events NNP O
v NN O
. . O

3.0 CD O
(CTCAE JJ O
v3.0) NN O
. . O

The DT N
genotype NN O
of IN O
CCND1 NNP O
A870G NNP O
in IN N
the DT N
patients NNS N
was VBD N
detected VBN N
by IN N
polymerase NN O
chain NN O
reaction-based JJ O
restriction NN O
fragment NN O
length NN O
polymorphism NN O
(PCR-RFLP) JJ O
analysis NN O
. . O

The DT N
associations NNS O
between IN O
the DT O
SNP NNP O
and CC O
acute JJ O
AEs NNP O
were VBD N
indicated VBN N
by IN N
odds NNS O
ratios NNS O
(ORs) NNP O
and CC N
95% CD N
confidence NN O
intervals NNS O
(CIs) VBP O
which WDT N
were VBD N
computed VBN N
with IN N
logistic JJ O
regression NN O
model NN O
. . O

RESULTS VB N
A DT N
total NN N
of IN N
136 CD N
patients NNS N
presented VBN N
severe JJ N
AEs NNP O
. . O

Among IN N
them PRP N
the DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS O
GG NNP N
GA NNP N
and CC N
AA NNP N
were VBD N
16.9% CD N
50.7% CD N
and CC N
32.4% CD N
compared VBN N
with IN N
24.6% CD N
48.1% CD N
and CC N
27.3% CD N
respectively RB N
among IN N
the DT N
patients NNS N
without IN N
severe JJ N
AEs NNP O
. . O

Diarrhea NNP O
was VBD N
the DT N
most RBS N
common JJ N
AE NNP O
and CC N
severe JJ O
diarrhea NN O
occurred VBD N
in IN N
109 CD N
patients NNS N
. . N

The DT N
frequencies NNS N
of IN N
the DT N
three CD N
genotypes NNS O
GG NNP N
GA NNP N
and CC N
AA NNP N
were VBD N
15.6% CD N
47.7% CD N
and CC N
36.7% CD N
among IN N
these DT N
patients NNS N
compared VBN N
with IN N
24.4% CD N
49.5% CD N
and CC N
26.1% CD N
respectively RB N
among IN N
patients NNS N
without IN N
severe JJ O
diarrhea NN O
. . O

Multivariate NNP N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
a DT N
1.66-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ O
diarrhea NN O
in IN N
patients NNS N
with IN N
AA NNP N
genotype NN N
(95%CI NN N
1.03 CD N
- : N
2.67 CD N
P NNP N
= VBD N
0.038) CD N
compared VBN N
with IN N
the DT N
cases NNS N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
. . N

Stratified VBN N
analysis NN N
showed VBD N
that IN N
in IN N
the DT N
Cap-Oxa-CRT NNP I
group NN N
patients NNS N
with IN N
AA NNP N
genotype NN N
showed VBD N
a DT N
2.34-fold JJ N
increased JJ N
risk NN N
for IN N
severe JJ O
diarrhea NN O
(95%CI VBD N
1.16 CD N
- : N
4.76 CD N
P NNP N
= VBD N
0.018) CD N
compared VBN N
with IN N
those DT N
with IN N
GG NNP N
or CC N
GA NNP N
genotypes NNS N
but CC N
in IN N
the DT N
Cap-CRT NNP I
group NN N
the DT N
SNP NNP N
was VBD N
not RB N
associated VBN N
with IN N
the DT N
risk NN N
of IN N
severe JJ O
diarrhea NN O
. . O

CONCLUSIONS VB N
The DT N
genetic JJ O
polymorphism NN O
of IN O
CCND1 NNP O
A870G NNP O
might MD N
be VB N
a DT N
potential JJ N
biomarker NN N
for IN N
predicting VBG N
acute JJ O
AEs NNP O
in IN N
postoperative JJ P
stage NN P
II NNP P
and CC P
III NNP P
rectal JJ P
cancer NN P
patients NNS P
treated VBN P
with IN P
adjuvant JJ P
concurrent JJ P
chemoradiotherapy NN P
of IN P
capecitabine NN P
and CC N
oxaliplatin NN I
. . I

-DOCSTART- -X- O O

[Double-blind JJ N
placebo-controlled JJ I
study NN N
of IN N
the DT N
effectiveness NN O
and CC N
tolerability NN O
of IN N
10 CD N
and CC N
30 CD N
mg NN N
ketorolac NN I
tromethamine NN I
suppositories NNS N
in IN N
post-cholecystectomy JJ P
pain] NN P
. . N

OBJECTIVE UH N
To TO N
evaluate VB N
the DT N
efficacy NN O
and CC N
tolerability NN O
of IN N
ketorolac NN I
tromethamine NN I
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
in IN N
comparison NN N
to TO N
placebo VB I
after IN N
single JJ N
dose JJ N
administration NN N
in IN N
patients NNS P
suffering VBG P
from IN P
post-operative JJ P
pain NN P
after IN P
cholecystectomy NN P
. . P

DESIGN NNP N
Double-blind NNP N
randomized VBD N
controlled VBN N
study NN N
. . N

SETTING NNP N
Anaesthesia NNP N
Service NNP N
. . N

PATIENTS NNP N
99 CD P
patients NNS P
with IN P
severe JJ P
pain NN P
following VBG P
surgery NN P
. . P

INTERVENTIONS NNP N
Cholecystectomy NNP P
. . P

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
The DT N
analgesia JJ N
activity NN N
of IN N
ketorolac NN I
tromethamine NN I
10 CD N
mg NN N
and CC N
30 CD N
mg NN N
suppositories NNS N
were VBD N
evaluated VBN N
after IN N
single JJ N
dose JJ N
administration NN N
by IN N
assessing VBG N
pain NN O
intensity NN O
and CC O
pain NN O
relief NN O
using VBG N
a DT N
4 CD O
point NN O
scale NN O
(VRS) NN O
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
treatment NN N
period NN N
overall JJ N
assessment NN N
of IN N
safety NN O
and CC N
efficacy NN O
were VBD N
recorded VBN N
by IN N
physician JJ N
and CC N
patient JJ N
. . N

The DT N
results NNS N
show VBP N
that IN N
in IN N
both DT N
active JJ N
groups NNS N
after IN N
30' CD N
and CC N
until IN N
4 CD N
hours NNS N
pain VBP O
intensity NN O
decreased VBN N
significantly RB N
with IN N
respect NN N
to TO N
the DT N
baseline NN N
. . N

However RB N
a DT N
statistically RB N
significant JJ N
difference NN N
between IN N
groups NNS N
of IN N
p NN N
< $ N
0.02 CD N
p NN N
< NN N
0.01 CD N
and CC N
p VB N
< JJ N
0.05 CD N
was VBD N
found VBN N
in IN N
favour NN N
of IN N
the DT N
30 CD N
mg NN N
dose NN N
respectively RB N
at IN N
30' CD N
6 CD N
and CC N
8 CD N
hours NNS N
after IN N
administration NN N
. . N

All PDT N
the DT N
patients NNS N
treated VBN N
with IN N
placebo JJ I
suppositories NNS N
required VBN N
another DT N
rescue NN N
analgesic JJ N
drug NN N
and CC N
withdrew NN N
from IN N
the DT N
trial NN N
. . N

Three CD N
patients NNS N
complained VBD N
adverse JJ O
events NNS O
not RB N
related VBN N
to TO N
treatment: VB N
two CD N
on IN N
placebo NN I
and CC N
one CD N
on IN N
ketorolac NN I
10 CD N
mg NN N
. . N

The DT N
systemic JJ N
and CC N
local JJ N
tolerability NN O
of IN N
the DT N
drug NN N
was VBD N
good JJ N
. . N

CONCLUSIONS VB N
This DT N
study NN N
shows VBZ N
that IN N
ketorolac $ I
30 CD N
mg NN N
suppositories NNS N
are VBP N
effective JJ N
in IN N
clinical JJ N
conditions NNS N
such JJ N
as IN N
after IN P
surgery NN P
in IN N
which WDT N
pain NN N
control NN N
must MD N
be VB N
achieved VBN N
within IN N
the DT N
shortest JJ N
time NN N
interval NN N
and CC N
maintained VBD N
or CC N
improved VBN N
by IN N
means NNS N
of IN N
a DT N
single JJ N
route NN N
of IN N
administration NN N
. . N

-DOCSTART- -X- O O

A DT N
randomized VBN N
controlled VBN N
study NN N
of IN N
a DT N
social JJ I
skills NNS I
training VBG I
for IN N
preadolescent JJ P
children NNS P
with IN P
autism NN P
spectrum NN P
disorders: JJ P
generalization NN N
of IN N
skills NNS N
by IN N
training VBG N
parents NNS N
and CC N
teachers NNS N
BACKGROUND NNP N
Social NNP I
skills NNS I
training VBG I
(SST) NN I
is VBZ N
a DT N
common JJ N
intervention NN N
for IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
(ASDs) VBP P
to TO N
improve VB N
their PRP$ N
social JJ O
and CC O
communication NN O
skills NNS O
. . O

Despite IN N
the DT N
fact NN N
that IN N
SSTs NNP I
are VBP N
often RB N
applied VBN N
in IN N
clinical JJ N
practice NN N
the DT N
evidence NN N
for IN N
the DT N
effectiveness NN O
of IN N
these DT N
trainings NNS N
for IN N
children NNS P
with IN P
ASD NNP P
is VBZ N
inconclusive JJ N
. . N

Moreover RB N
long JJ O
term NN O
outcome NN O
and CC N
generalization NN O
of IN O
learned JJ O
skills NNS O
are VBP N
little JJ N
evaluated JJ N
. . N

Additionally RB N
there EX N
is VBZ N
no DT N
research NN N
on IN N
the DT N
influence NN N
of IN N
involvement NN N
of IN N
parents NNS N
and CC N
teachers NNS N
on IN N
effectiveness NN O
of IN N
SST NNP I
and CC N
on IN N
the DT N
generalization NN O
of IN O
learned VBN O
social JJ O
skills NNS O
to TO O
daily JJ O
life NN O
. . O

We PRP N
expect VBP N
parent NN N
and CC N
teacher NN N
involvement NN N
in IN N
SST NNP I
to TO N
enhance VB N
treatment NN O
efficacy NN O
and CC N
to TO N
facilitate VB N
generalization NN O
of IN O
learned JJ O
skills NNS O
to TO O
daily JJ O
life NN O
. . O

METHOD/DESIGN NNP N
In IN N
a DT N
randomized NN N
controlled VBN N
trial NN N
(RCT) NN N
with IN N
three CD N
conditions NNS N
120 CD P
participants NNS P
with IN P
ASD NNP P
at IN P
the DT P
end NN P
of IN P
primary JJ P
school NN P
(10-12 CD P
years NNS P
of IN P
calendar NN P
age) NNS P
have VBP N
been VBN N
randomized VBN N
to TO N
SST NNP I
SST-PTI NNP I
(SST NN I
with IN I
Parent NNP I
& CC I
Teacher NNP I
Involvement) NNP I
or CC N
care-as-usual JJ I
. . I

The DT N
SST NNP I
consists VBZ N
of IN N
18 CD N
group NN N
sessions NNS N
of IN N
1.5 CD N
hours NNS N
for IN N
the DT N
children NNS N
. . N

In IN N
the DT N
SST-PTI JJ I
condition NN N
parents NNS N
additionally RB N
participate VBP N
in IN N
8 CD N
parent NN N
sessions NNS N
and CC N
parents NNS N
and CC N
teachers NNS N
are VBP N
actively RB N
involved VBN N
in IN N
homework NN N
assignments NNS N
. . N

Assessment NNP N
takes VBZ N
place NN N
at IN N
three CD N
moments: NN N
before IN N
and CC N
immediately RB N
after IN N
the DT N
intervention NN N
period NN N
and CC N
at IN N
6 CD N
months NNS N
follow-up RB N
. . N

Primary JJ N
outcome NN N
is VBZ N
socialization NN O
as IN N
an DT N
aspect NN N
of IN N
adaptive JJ O
functioning NN O
. . O

Secondary JJ N
outcomes NNS N
focus VBP N
on IN N
specific JJ O
social JJ O
skills NNS O
children NNS N
learn VBP N
during IN N
SST NNP I
and CC N
on IN N
more JJR N
general JJ O
social JJ O
skills NNS O
pertaining VBG N
to TO N
home NN N
and CC N
community NN N
settings NNS N
from IN N
a DT N
multi-informant JJ N
perspective NN N
. . N

Additionally NNP N
possible JJ O
predictors NNS O
of IN O
treatment NN O
outcome NN O
will MD N
be VB N
assessed VBN N
. . N

DISCUSSION VB N
The DT N
current JJ N
study NN N
is VBZ N
an DT N
RCT NNP N
study NN N
evaluating VBG N
SST NNP I
in IN N
a DT N
large JJ N
sample NN N
of IN N
Dutch NNP P
children NNS P
with IN P
ASD NNP P
in IN P
a DT P
specific JJ P
age NN P
range NN P
(10-12 JJ P
years) NN P
. . P

Strengths NNP N
of IN N
the DT N
study NN N
are VBP N
the DT N
use NN N
of IN N
one CD N
manualized VBN N
protocol NN N
application NN N
of IN N
standardized JJ N
and CC N
internationally RB N
used VBD N
rating NN N
instruments NNS N
use NN N
of IN N
multiple JJ N
raters NNS N
investigation NN N
of IN N
generalization NN O
of IN N
learned JJ N
skills NNS N
to TO N
daily JJ N
life NN N
and CC N
the DT N
evaluation NN N
of IN N
efficacy NN O
in IN N
the DT N
longer JJR N
term NN N
by IN N
follow-up JJ N
measures NNS N
at IN N
6 CD N
months NNS N
after IN N
the DT N
end NN N
of IN N
training NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
NTR2405 NNP N
. . N

-DOCSTART- -X- O O

Safety NNP O
tolerability NN O
and CC O
immunogenicity NN O
after IN N
1 CD N
and CC N
2 CD N
doses NNS N
of IN N
zoster NN I
vaccine NN I
in IN N
healthy JJ P
adults NNS P
≥60 CD P
years NNS P
of IN P
age NN P
. . N

BACKGROUND NNP N
Incidence NNP N
and CC N
severity NN N
of IN N
herpes NNS N
zoster NNP N
(HZ) NNP N
and CC N
postherpetic JJ N
neuralgia JJ N
increase NN N
with IN N
age NN N
associated VBN N
with IN N
age-related JJ N
decrease NN N
in IN N
immunity NN N
to TO N
varicella-zoster JJ N
virus NN N
(VZV) NN N
. . N

One CD N
dose NN N
of IN I
zoster NN I
vaccine NN I
(ZV) NN I
has VBZ N
demonstrated VBN N
substantial JJ N
protection NN N
against IN N
HZ; NNP N
this DT N
study NN N
examined VBD N
impact NN N
of IN N
a DT N
second JJ N
dose NN N
of IN I
ZV NNP I
. . N

METHODS NNP N
Randomized VBD N
double-blind JJ N
multicenter NN N
study NN N
with IN P
210 CD P
subjects NNS P
≥60 CD P
years NNS P
old JJ N
compared VBN O
immunity NN O
and CC O
safety NN O
profiles NNS O
after IN N
one CD N
and CC N
two CD N
doses NNS I
of IN I
ZV NNP N
separated VBN N
by IN N
6 CD N
weeks NNS N
vs NN I
. . I

placebo NN I
. . O

Immunogenicity NNP O
was VBD O
evaluated VBN O
using VBG O
VZV NNP O
interferon-gamma JJ O
(IFN-γ) JJ O
enzyme-linked JJ O
immunospot NN O
(ELISPOT) NNP O
assay NN O
and CC O
VZV NNP O
glycoprotein VBD O
enzyme-linked JJ O
immunosorbent NN O
antibody NN O
(gpELISA) NNP O
assay NN O
. . O

Adverse JJ O
experiences NNS O
(AEs) VBP O
were VBD N
recorded VBN N
on IN O
a DT O
standardized JJ O
Vaccination NNP O
Report NNP O
Card NNP N
. . N

RESULTS NNP O
No NNP O
serious JJ O
vaccine-related JJ O
AEs NNP N
occurred VBD O
. . O

VZV NNP O
IFN-γ NNP O
ELISPOT NNP O
geometric JJ O
mean NN O
count NN O
(GMC) NN O
of IN O
spot-forming JJ O
cells NNS O
per IN O
10(6) CD O
peripheral JJ O
blood NN O
mononuclear JJ O
cells NNS N
increased VBN N
in IN I
the DT I
ZV NNP N
group NN N
from IN N
16.9 CD N
prevaccination NN N
to TO N
49.5 CD N
and CC N
32.8 CD N
at IN N
2 CD N
and CC N
6 CD N
weeks NNS N
postdose RB N
1 CD N
respectively RB N
. . N

Two CD N
weeks NNS N
6 CD N
weeks NNS N
and CC N
6 CD N
months NNS N
postdose RB N
2 CD N
GMC NNP N
was VBD N
44.3 CD N
42.9 CD N
and CC N
36.5 CD N
respectively RB O
. . N

GMC NNP N
in IN I
the DT I
placebo NN I
group NN N
did VBD N
not RB N
change NN N
during IN N
the DT N
study NN O
. . O

The DT O
peak JJ O
ELISPOT NNP O
response NN O
occurred VBD N
∼2 NNP N
weeks NNS N
after IN I
each DT N
ZV NNP N
dose NN O
. . O

The DT O
gpELISA NN O
geometric JJ O
mean NN O
titers NNS O
(GMTs) VBP I
in IN I
the DT N
ZV NNP N
group NN N
were VBD N
higher JJR N
than IN I
in IN I
the DT I
placebo NN N
group NN N
at IN N
6 CD N
weeks NNS N
after IN N
each DT N
dose NN N
. . N

Correlation NN N
between IN O
the DT O
IFN-γ NNP O
ELISPOT NNP O
and CC O
gpELISA NN O
assays NNS N
was VBD N
poor JJ N
. . N

CONCLUSIONS NNP I
ZV NNP N
was VBD N
generally RB N
well-tolerated JJ N
and CC N
immunogenic JJ P
in IN P
adults NNS P
≥60 CD P
years NNS N
old JJ N
. . N

A DT N
second JJ I
dose NN N
of IN N
ZV NNP N
was VBD O
generally RB O
safe JJ N
but CC N
did VBD N
not RB N
boost VB N
VZV-specific NNP O
immunity NN N
beyond IN N
levels NNS N
achieved VBN N
postdose RB N
1 CD N
. . N

-DOCSTART- -X- O O

Necessary NNP N
but CC N
not RB N
sufficient: VB N
the DT N
effect NN N
of IN N
screening NN N
and CC N
feedback NN N
on IN N
outcomes NNS O
of IN N
primary JJ P
care NN P
patients NNS P
with IN P
untreated JJ P
anxiety NN P
. . P

OBJECTIVE UH N
To TO N
consider VB N
the DT N
impact NN N
on IN N
primary JJ N
care NN N
patient JJ N
outcomes NNS N
of IN N
using VBG N
both DT N
a DT N
screener NN I
to TO N
determine VB N
elevated VBN O
anxiety NN O
levels NNS O
among IN N
patients NNS P
with IN P
previously RB P
undetected VBN P
anxiety NN P
and CC N
a DT N
physician JJ I
intervention NN I
to TO N
inform VB N
physicians NNS N
of IN N
their PRP$ N
patients' JJ N
conditions NNS N
. . N

DESIGN NNP N
Participating VBG N
physicians NNS N
were VBD N
randomized VBN N
to TO N
either CC N
the DT N
demonstration NN I
or CC N
the DT N
control NN N
arm NN N
and CC N
patients NNS N
were VBD N
assigned VBN N
to TO N
a DT N
study NN N
arm NN N
based VBN N
on IN N
the DT N
randomization NN N
of IN N
their PRP$ N
physicians NNS N
. . N

The DT N
patients NNS N
were VBD N
followed VBN N
for IN N
change NN N
in IN N
outcome JJ N
measures NNS N
during IN N
the DT N
five-month JJ N
study NN N
period NN N
. . N

SETTING VB N
A DT N
mixed-model JJ N
health NN N
maintenance NN N
organization NN N
serving VBG N
approximately RB N
110 CD N
000 CD N
enrollees NNS N
in IN N
central JJ P
Colorado NNP P
. . P

PATIENTS/PARTICIPANTS NNP N
573 CD P
patients NNS P
who WP P
had VBD P
unrecognized VBN P
and CC P
untreated JJ P
anxiety NN P
identified VBN P
from IN P
the DT P
approximately RB P
8 CD P
000 CD P
patients NNS P
who WP P
completed VBD P
the DT P
waiting VBG P
room NN P
screening NN P
questionnaire NN P
. . P

INTERVENTIONS VBZ N
A DT N
physician JJ I
intervention NN I
served VBD N
the DT N
dual JJ N
function NN N
of IN N
1) CD N
providing VBG N
an DT N
educational JJ N
demonstration NN N
of IN N
anxiety NN N
in IN N
the DT N
primary JJ N
care NN N
setting VBG N
and CC N
2) CD N
providing VBG N
a DT N
reporting NN N
system NN N
for IN N
summarizing VBG N
the DT N
anxiety NN O
symptom NN O
levels NNS O
and CC N
functioning VBG O
status NN O
of IN N
the DT N
patients NNS N
enrolled VBN N
in IN N
the DT N
study NN N
. . N

MEASUREMENTS NNP N
AND CC N
MAIN NNP N
RESULTS NNP N
Patient NNP O
outcomes NNS O
were VBD N
measured VBN N
as IN N
changes NNS N
in IN N
global JJ O
anxiety NN O
scores NNS O
functioning VBG O
and CC O
well-being JJ O
and CC N
patients' JJ O
reports NNS O
of IN O
global JJ O
improvements NNS O
. . O

CONCLUSIONS VB N
The DT N
findings NNS N
indicate VBP N
that IN N
this DT N
method NN N
of IN N
reporting VBG N
symptoms NNS N
and CC N
functioning VBG N
status NN N
to TO N
primary VB N
care NN N
physicians NNS N
did VBD N
not RB N
significantly RB N
change VBP N
patient JJ N
outcomes NNS N
. . N

Improvement NN N
in IN N
outcomes NNS N
appeared VBD N
to TO N
be VB N
more RBR N
closely RB N
associated VBN N
with IN N
the DT N
patient's JJ N
severity NN N
of IN N
psychological JJ N
distress NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
cuff NN N
inflation NN N
on IN N
self-recorded JJ O
blood NN O
pressure NN O
. . O

Changes NNS N
in IN N
continuously RB O
recorded VBN O
'Finapres' CD O
finger NN O
blood NN O
pressure NN O
in IN N
ten JJ P
normotensive JJ P
and CC P
seven CD P
hypertensive JJ P
subjects NNS P
induced VBN N
by IN N
self-inflation NN I
of IN I
the DT I
cuff NN I
or CC N
just RB I
wearing VBG I
the DT I
inflated JJ I
cuff NN I
were VBD N
studied VBN N
. . N

Inflating VBG I
the DT I
cuff NN I
caused VBD N
an DT N
instantaneous JJ N
rise NN N
in IN N
systolic JJ O
blood NN O
pressure NN O
of IN N
13 CD N
and CC N
12 CD N
mm NN N
Hg NNP N
(hypertensive NNP P
and CC P
normotensive JJ P
subjects NNS P
respectively) VBP N
. . N

Wearing VBG N
the DT N
inflated JJ I
cuff NN I
did VBD N
not RB N
change VB N
blood NN O
pressure NN O
. . O

Thus VB N
the DT N
rise NN N
in IN N
pressure NN O
was VBD N
related VBN N
to TO N
the DT N
muscular JJ N
activity NN N
required VBN N
for IN N
cuff NN I
inflation NN I
. . I

Systolic NNP O
blood NN O
pressure NN O
took VBD N
on IN N
average JJ N
7 CD N
s NN N
and CC N
at IN N
most JJS N
21 CD N
s NN N
to TO N
return VB N
to TO N
baseline VB N
level NN N
after IN N
stopping VBG N
cuff NN I
inflation NN I
. . I

Since IN N
first JJ N
Korotkoff NNP N
sounds NNS N
may MD N
already RB N
be VB N
heard VBN N
after IN N
10-15 JJ N
s NN N
when WRB N
following VBG N
recommended VBD N
procedures NNS N
self-recorded JJ O
systolic JJ O
blood NN O
pressure NN O
may MD N
be VB N
recorded VBN N
as IN N
too RB N
high JJ N
when WRB N
subjects NNS N
inflate VBP I
their PRP$ I
cuff NN I
at IN N
too RB N
low JJ N
a DT N
pressure NN N
or CC N
deflate VB N
it PRP N
too RB N
fast RB N
. . N

-DOCSTART- -X- O O

Conscious JJ N
analgesia/sedation NN N
with IN N
remifentanil NN I
and CC N
propofol NN I
versus NN N
total JJ N
intravenous JJ N
anesthesia NN N
with IN N
fentanyl JJ I
midazolam NN I
and CC N
propofol NN I
for IN N
outpatient JJ P
colonoscopy NN P
. . P

BACKGROUND NNP N
This DT N
study NN N
tested VBD N
the DT N
hypothesis NN N
that IN N
for IN P
colonoscopy NN P
analgesia/sedation NN N
with IN N
remifentanil NN I
and CC N
propofol NN I
might MD N
be VB N
more RBR N
effective JJ O
compared VBN N
with IN N
anesthesia NN N
by IN N
intravenous JJ N
administration NN N
of IN N
midazolam JJ I
fentanyl NN I
and CC N
propofol NN I
. . I

METHODS NNP N
In IN N
a DT N
prospective JJ N
randomized VBN N
trial NN N
100 CD P
adult NN P
patients NNS P
received VBD N
either RB N
conscious JJ N
analgesia/sedation NN N
(Sedation NN N
group) NN N
or CC N
total JJ N
intravenous JJ N
anesthesia NN N
(TIVA NNP N
group) NN N
. . N

Analgesia/sedation NNP N
was VBD N
achieved VBN N
by IN N
infusion NN N
of IN N
remifentanil NN I
(0.20 NN N
to TO N
0.25 CD N
microg/kg/min) NNS N
and CC N
propofol NN I
in IN N
titrated JJ N
doses NNS N
. . N

TIVA NNP N
was VBD N
induced VBN N
by IN N
intravenous JJ N
administration NN N
of IN N
fentanyl JJ I
(2 NNP N
microg/kg) NN N
midazolam NN I
(0.05 NNP N
mg/kg) NN N
and CC N
propofol JJ I
(dosage NN N
titrated) NN N
. . N

Cardiorespiratory JJ O
parameters NNS O
and CC O
bispectral JJ O
index NN O
were VBD O
monitored VBN O
and CC O
recorded VBN O
. . O

The DT O
quality NN O
of IN O
the DT O
analgesia NN O
was VBD O
assessed VBN O
with IN O
a DT O
Numerical JJ O
Pain NN O
Rating NNP O
Scale NNP O
(NRS); JJ O
recovery NN O
level NN O
and CC O
return NN O
of IN O
psychomotor NN O
efficiency NN O
were VBD O
evaluated VBN O
with IN O
respectively RB O
the DT O
Aldrete NNP O
scale NN O
and CC O
a DT O
Modified NNP O
Post NNP O
Anesthesia NNP O
Discharge NNP O
Scoring NNP O
(MPADS) NNP O
system NN O
. . O

RESULTS VB N
Both DT N
groups NNS N
of IN N
50 CD N
patients NNS N
were VBD N
comparable JJ N
with IN N
respect NN N
to TO N
demographic VB N
data NNS N
initial JJ N
parameters NNS N
and CC N
duration NN N
of IN N
colonoscopy NN P
. . P

All DT N
patients NNS N
in IN N
the DT N
TIVA NNP N
group NN N
found VBD N
the DT N
colonoscopy NN N
painless NN N
(NRS NNP O
score VBD N
0) CD N
. . N

In IN N
the DT N
Sedation NNP N
group NN N
the DT N
average NN N
pain NN O
intensity NN O
score NN O
was VBD N
0.4 CD N
(0.8) NN N
. . N

There EX N
was VBD N
a DT N
marked JJ N
difference NN N
between IN N
the DT N
Sedation NNP N
and CC N
TIVA NNP N
groups NNS N
with IN N
respect NN N
to TO N
the DT N
time NN N
from IN N
the DT N
end NN N
of IN N
the DT N
procedure NN N
until IN N
the DT N
maximum JJ O
MPADS NNP O
score NN O
was VBD N
reached: JJ N
respectively RB N
-6.9 JJ N
(4.0) NNP N
versus NN N
25.7 CD N
(8.4) NN N
minutes NNS N
(p VBP N
< JJ N
0.001) CD N
. . N

In IN N
the DT N
TIVA NNP N
group NN N
changes NNS N
in IN N
mean JJ O
arterial JJ O
pressure NN O
and CC O
heart NN O
rate NN O
and CC O
signs NNS O
of IN O
respiratory NN O
depression NN O
were VBD N
significant JJ N
(p NNP N
< NNP N
0.05) CD N
. . N

CONCLUSIONS NNP N
Combined NNP N
administration NN N
of IN N
remifentanil NN I
and CC N
propofol NN I
for IN N
colonoscopy NN P
provides VBZ N
sufficient JJ O
analgesia NN O
satisfactory JJ N
hemodynamic JJ O
stability NN O
minor JJ N
respiratory NN O
depression NN O
and CC N
rapid JJ O
recovery NN O
and CC N
allows VBZ N
patients NNS N
to TO N
be VB N
discharged VBN N
approximately RB N
15 CD N
minutes NNS N
after IN N
the DT N
procedure NN N
. . N

-DOCSTART- -X- O O

Bayesian JJ I
adaptive JJ I
trials NNS I
offer VBP N
advantages NNS N
in IN N
comparative JJ N
effectiveness NN O
trials: VBD N
an DT N
example NN N
in IN N
status NN P
epilepticus NN P
. . P

OBJECTIVE IN N
We PRP N
present VBP N
a DT N
novel JJ N
Bayesian JJ I
adaptive JJ I
comparative NN I
effectiveness NN I
trial NN I
comparing VBG N
three CD N
treatments NNS N
for IN N
status NN P
epilepticus NN P
that WDT N
uses VBZ N
adaptive JJ N
randomization NN N
with IN N
potential JJ N
early JJ N
stopping NN N
. . N

STUDY NNP N
DESIGN NNP N
AND NNP N
SETTING NNP N
The DT N
trial NN N
will MD N
enroll VB N
720 CD P
unique JJ P
patients NNS P
in IN P
emergency NN P
departments NNS P
and CC P
uses VBZ P
a DT P
Bayesian JJ P
adaptive JJ P
design NN P
. . P

RESULTS VB N
The DT N
trial NN N
design NN N
is VBZ N
compared VBN N
to TO N
a DT N
trial NN I
without IN I
adaptive JJ I
randomization NN I
and CC N
produces VBZ N
an DT N
efficient JJ N
trial NN N
in IN N
which WDT N
a DT N
higher JJR N
proportion NN O
of IN O
patients NNS O
are VBP N
likely JJ N
to TO N
be VB N
randomized VBN N
to TO N
the DT N
most RBS N
effective JJ N
treatment NN N
arm NN N
while IN N
generally RB N
using VBG N
fewer JJR N
total JJ O
patients NNS O
and CC N
offers VBZ N
higher JJR N
power NN N
than IN N
an DT N
analogous JJ N
trial NN N
with IN N
fixed JJ N
randomization NN N
when WRB N
identifying VBG N
a DT N
superior JJ N
treatment NN N
. . N

CONCLUSION NN N
When WRB N
one CD N
treatment NN N
is VBZ N
superior JJ N
to TO N
the DT N
other JJ N
two CD N
the DT N
trial NN N
design NN N
provides VBZ N
better RBR N
patient NN O
care NN O
higher JJR N
power NN O
and CC N
a DT N
lower JJR N
expected VBN O
sample JJ O
size NN O
. . O

-DOCSTART- -X- O O

Adherence NN O
to TO N
lifestyle VB I
recommendations NNS I
by IN N
patients NNS P
with IN P
depression NN P
. . P

INTRODUCTION NNP N
There EX N
is VBZ N
an DT N
increasing VBG N
amount NN N
of IN N
evidence NN N
showing VBG N
that DT N
physical JJ N
activity NN N
and CC N
sun NN N
exposure NN N
are VBP N
effective JJ N
coadjuvant JJ N
treatments NNS N
for IN N
patients NNS P
with IN P
mild JJ P
to TO P
moderate VB P
depression NN P
. . P

However RB N
there EX N
is VBZ N
a DT N
lack NN N
of IN N
information NN N
regarding VBG N
patient's NN O
adherence NN O
to TO N
these DT N
recommendations NNS N
in IN N
daily JJ N
clinical JJ N
practice NN N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
study NN N
including VBG N
15 CD P
depressive JJ P
patients NNS P
who WP P
had VBD P
been VBN P
under IN P
antidepressant JJ P
treatment NN P
for IN P
at IN P
least JJS P
one CD P
month NN P
. . P

They PRP N
wore VBD N
a DT N
wrist-watch-like JJ N
actimetry NN N
sensor NN N
to TO N
measure VB N
physical JJ I
activity NN I
and CC O
sun NN I
exposure NN I
24 CD N
hours NNS N
a DT N
day NN N
. . N

After IN N
one CD N
week NN N
of IN N
baseline JJ N
assessment NN N
patients NNS N
were VBD N
randomised VBN N
into IN N
one CD N
of IN N
the DT N
two CD N
arms NNS N
of IN N
the DT N
study NN N
. . N

Patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
received VBD N
a DT N
brief JJ N
note NN N
in IN N
which WDT N
they PRP N
were VBD N
explicitly RB N
asked VBN N
to TO N
increase VB N
both DT N
their PRP$ N
physical JJ I
activity NN I
level NN O
and CC N
time NN O
of IN O
sun NN I
exposure NN I
while IN N
control NN I
group NN N
patients NNS N
did VBD I
not RB I
receive VB I
these DT I
explicit JJ I
recommendations NNS I
. . I

RESULTS NNP N
One CD N
week NN N
after IN N
recommendations NNS N
were VBD N
delivered VBN N
only RB N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
had VBD N
increased VBN N
time NN O
of IN O
sun NN I
exposure NN I
and CC O
physical JJ I
activity NN I
(25.8% NNP N
and CC N
14.3% CD N
respectively) NN N
. . N

CONCLUSIONS NNP N
Depressive JJ P
patients NNS P
are VBP N
able JJ N
to TO N
follow VB N
prescribed JJ N
lifestyle JJ I
recommendations NNS I
in IN N
the DT N
short-term JJ N
. . N

-DOCSTART- -X- O O

Teaching VBG N
emotion NN I
recognition NN I
skills NNS N
to TO N
young JJ P
children NNS P
with IN P
autism: PDT P
a DT N
randomised VBN N
controlled VBN N
trial NN N
of IN N
an DT N
emotion NN I
training NN I
programme NN I
. . I

BACKGROUND NNP N
Children NNP P
with IN P
autism NN P
have VBP N
difficulties NNS N
in IN N
emotion NN N
recognition NN N
and CC N
a DT N
number NN N
of IN N
interventions NNS N
have VBP N
been VBN N
designed VBN N
to TO N
target VB N
these DT N
problems NNS N
. . N

However RB N
few JJ N
emotion NN I
training NN I
interventions NNS N
have VBP N
been VBN N
trialled VBN N
with IN N
young JJ P
children NNS P
with IN P
autism NN P
and CC P
co-morbid JJ P
ID NNP P
. . P

This DT N
study NN N
aimed VBD N
to TO N
evaluate VB N
the DT N
efficacy NN O
of IN N
an DT N
emotion NN I
training NN I
programme NN I
for IN N
a DT N
group NN N
of IN N
young JJ P
children NNS P
with IN P
autism NN P
with IN P
a DT P
range NN P
of IN P
intellectual JJ P
ability NN P
. . P

METHODS NNP N
Participants NNPS P
were VBD P
55 CD P
children NNS P
with IN P
autistic JJ P
disorder NN P
aged VBN P
4-7 CD P
years NNS P
(FSIQ JJ P
42-107) JJ P
. . P

Children NNP N
were VBD N
randomly RB N
assigned VBN N
to TO N
an DT N
intervention NN N
(n NNP N
= VBZ N
28) CD N
or CC N
control VB N
group NN N
(n NNP N
= VBZ N
27) CD N
. . N

Participants NNS N
in IN N
the DT N
intervention NN N
group NN N
watched VBD N
a DT N
DVD NNP N
designed VBN N
to TO N
teach VB N
emotion NN I
recognition NN I
skills NNS I
to TO N
children NNS P
with IN P
autism NN P
(the NNP I
Transporters) NNP I
whereas IN N
the DT N
control NN N
group NN N
watched VBD N
a DT N
DVD NNP N
of IN N
Thomas NNP I
the DT I
Tank NNP I
Engine NNP I
. . I

Participants NNS N
were VBD N
assessed VBN N
on IN N
their PRP$ N
ability NN O
to TO O
complete VB O
basic JJ O
emotion NN O
recognition NN O
tasks NNS O
mindreading VBG O
and CC O
theory NN O
of IN O
mind NN O
(TOM) NNP O
tasks NNS O
before IN N
and CC N
after IN N
the DT N
4-week JJ N
intervention NN N
period NN N
and CC N
at IN N
3-month JJ N
follow-up NN N
. . N

RESULTS NNP N
Analyses NNP N
controlled VBD N
for IN N
the DT N
effect NN N
of IN N
chronological JJ N
age NN N
verbal JJ N
intelligence NN N
gender NN N
and CC N
DVD NNP N
viewing VBG N
time NN N
on IN N
outcomes NNS N
. . N

Children NNP N
in IN N
the DT N
intervention NN N
group NN N
showed VBD N
improved JJ N
performance NN N
in IN N
the DT N
recognition NN O
of IN O
anger NN O
compared VBN N
with IN N
the DT N
control NN N
group NN N
with IN N
few JJ N
improvements NNS N
maintained VBD N
at IN N
3-month JJ N
follow-up NN N
. . N

There EX N
was VBD N
no DT N
generalisation NN N
of IN N
skills NNS N
to TO N
TOM NNP O
or CC O
social JJ O
skills NNS O
. . O

CONCLUSIONS VB N
The DT I
Transporters NNP I
programme NN N
showed VBD N
limited JJ N
efficacy NN O
in IN N
teaching VBG N
basic JJ N
emotion NN O
recognition NN O
skills NNS O
to TO N
young JJ P
children NNS P
with IN P
autism NN P
with IN P
a DT P
lower JJR P
range NN P
of IN P
cognitive JJ P
ability NN P
. . P

Improvements NNS N
were VBD N
limited VBN N
to TO N
the DT N
recognition NN O
of IN O
expressions NNS O
of IN O
anger NN O
with IN N
poor JJ N
maintenance NN N
of IN N
these DT N
skills NNS N
at IN N
follow-up NN N
. . N

These DT N
findings NNS N
provide VBP N
limited JJ N
support NN N
for IN N
the DT N
efficacy NN O
of IN N
the DT I
Transporters NNP I
programme NN N
for IN N
young JJ P
children NNS P
with IN P
autism NN P
of IN P
a DT P
lower JJR P
cognitive JJ P
range NN P
. . P

-DOCSTART- -X- O O

Randomised VBN N
trial NN N
of IN N
text NN I
messaging NN I
on IN N
adherence NN O
to TO O
cardiovascular VB P
preventive JJ P
treatment NN P
(INTERACT NNP N
trial) NN N
. . N

BACKGROUND CC N
About IN N
one CD N
third NN N
of IN N
patients NNS P
prescribed VBN P
blood JJ P
pressure NN P
or CC P
lipid-lowering JJ P
drugs NNS P
for IN P
the DT P
prevention NN P
of IN P
coronary JJ P
heart NN P
disease NN P
and CC P
stroke NN P
do VBP N
not RB N
take VB N
their PRP$ N
medication NN N
as IN N
prescribed JJ N
. . N

We PRP N
conducted VBD N
a DT N
randomized JJ N
trial NN N
to TO N
evaluate VB N
text JJ I
messaging NN I
as IN N
a DT N
means NN N
of IN N
improving VBG N
adherence NN O
to TO O
cardiovascular VB P
disease NN P
preventive JJ P
treatment NN P
. . P

METHODS NNP N
303 CD P
patients NNS P
taking VBG P
blood NN P
pressure NN P
and/or IN P
lipid-lowering JJ P
medications NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
being VBG N
sent VBN N
text NN I
messages NNS I
(Text VBP I
group NN N
151) CD N
or CC N
not RB I
being VBG I
sent VBD I
them PRP I
(No NNP I
text NN I
group NN N
152) CD N
. . N

Texts NNPS N
were VBD N
sent VBN N
daily RB N
for IN N
2 CD N
weeks NNS N
alternate JJ N
days NNS N
for IN N
2 CD N
weeks NNS N
and CC N
weekly JJ N
thereafter NN N
for IN N
22 CD N
weeks NNS N
(6 JJ N
months NNS N
overall) IN N
using VBG N
an DT N
automated VBN N
computer NN N
programme NN N
. . N

Patients NNS N
were VBD N
asked VBN N
to TO N
respond VB N
on IN N
whether IN N
they PRP N
had VBD N
taken VBN N
their PRP$ N
medication NN N
whether IN N
the DT N
text NN I
reminded VBD N
them PRP N
to TO N
do VB N
so RB N
if IN N
they PRP N
had VBD N
forgotten VBN N
and CC N
if IN N
they PRP N
had VBD N
not RB N
taken VBN N
their PRP$ N
medication NN N
to TO N
determine VB N
if IN N
there EX N
was VBD N
a DT N
reason NN N
for IN N
not RB N
doing VBG N
so RB N
. . N

At IN N
6 CD N
months NNS N
use NN O
of IN O
medication NN O
was VBD N
assessed VBN N
. . N

RESULTS NNP N
Two CD N
patients NNS N
were VBD N
lost VBN N
to TO N
follow-up JJ N
providing VBG N
data NNS N
on IN N
301 CD N
for IN N
analysis NN N
. . N

In IN N
the DT N
No NNP N
text NN N
group NN N
38/151 CD N
(25%) NNP N
took VBD N
less JJR N
than IN N
80% CD N
of IN N
the DT N
prescribed JJ O
regimen NNS O
(ie VBP N
. . N

stopped JJ N
medication NN N
completely RB N
or CC N
took VBD N
it PRP N
on IN N
fewer JJR N
than IN N
22 CD N
of IN N
the DT N
last JJ N
28 CD N
days NNS N
of IN N
follow-up) JJ N
compared VBN N
to TO N
14/150 CD N
patients NNS N
(9%) VBP N
in IN N
the DT N
Text NNP I
group NN N
- : N
an DT N
improvement NN N
in IN N
adherence NN O
affecting VBG N
16 CD N
per IN N
100 CD N
patients NNS N
(95% JJ N
CI NNP N
7 CD N
to TO N
24) CD N
p<0.001 NN N
. . N

The DT N
texts NN I
reminded VBD N
98/151 CD N
patients NNS N
(65%) JJ N
to TO N
take VB N
medication NN N
on IN N
at IN N
least JJS N
one CD N
occasion NN N
and CC N
lead NN N
to TO N
20/151 CD N
(13%) NNS N
who WP N
stopped VBD O
taking VBG O
medication NN O
because IN N
of IN N
concern NN N
over IN N
efficacy NN N
or CC N
side-effects NNS N
resuming VBG N
treatment NN N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS P
taking VBG P
blood NN P
pressure NN P
or CC P
lipid-lowering JJ P
treatment NN P
for IN P
the DT P
prevention NN P
of IN P
cardiovascular JJ P
disease NN P
text NN I
messaging VBG I
improved JJ N
medication NN O
adherence NN O
compared VBN N
with IN N
no DT I
text NN I
messaging NN I
. . I

TRIAL NNP N
REGISTRATION NNP N
Controlled-Trials.com NNP N
ISRCTN74757601 NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
treatment NN N
with IN N
paromomycin NN I
on IN N
endotoxemia NN N
in IN N
patients NNS P
with IN P
alcoholic JJ P
liver JJ P
disease--a JJ P
double-blind JJ N
placebo-controlled JJ I
trial NN N
. . N

The DT N
results NNS N
of IN N
experimental JJ N
and CC N
clinical JJ N
studies NNS N
support VBP N
the DT N
hypothesis NN N
that IN N
gut-derived JJ N
endotoxins NNS N
might MD N
be VB N
of IN N
relevance NN N
for IN N
the DT N
development NN N
and CC N
course NN N
of IN N
alcoholic JJ P
liver NN P
disease NN P
. . P

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
test VB N
the DT N
effect NN N
of IN N
a DT N
nonabsorbable JJ N
broad-spectrum JJ N
antibiotic NN I
on IN N
endotoxemia NN N
in IN N
patients NNS P
with IN P
alcoholic JJ P
liver NN P
disease NN P
. . P

Fifty JJ P
patients NNS P
with IN P
alcoholic JJ P
liver NN P
disease NN P
(27 NN P
with IN P
cirrhosis NN P
23 CD P
without IN P
cirrhosis) NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
either DT N
paromomycin NN I
sulfate NN I
(3 NNP N
x VBZ N
1 CD N
g/day) NN N
or CC N
placebo NN I
in IN N
a DT N
double-blind JJ N
fashion NN N
for IN N
at IN N
least JJS N
3 CD N
weeks NNS N
and CC N
if IN N
possible JJ N
4 CD N
weeks NNS N
. . N

Endotoxin NNP O
concentration NN O
liver NN O
function NN O
tests NNS O
and CC O
other JJ O
laboratory NN O
parameters NNS O
were VBD N
determined VBN N
in IN N
weekly JJ N
intervals NNS N
. . N

Endotoxin NNP O
concentration NN O
was VBD N
also RB N
determined VBN N
in IN N
15 CD P
healthy JJ P
controls NNS P
. . P

Groups NNP N
receiving VBG N
paromomycin NN I
or CC N
placebo NN I
were VBD N
similar JJ N
for IN N
clinical JJ N
and CC N
biological JJ N
items NNS N
collected VBN N
initially RB N
. . N

Mean JJ N
initial JJ N
endotoxin NN O
concentrations NNS O
were VBD N
significantly RB N
elevated VBN N
in IN N
both DT N
groups NNS N
(mean VBP N
+/- JJ N
SEM; NNP N
paromomycin NN I
16.7 CD N
+/- JJ N
5.3 CD N
pg/ml; NN N
placebo NN I
17.5 CD N
+/- JJ N
6.9 CD N
pg/ml; NN N
healthy JJ N
controls VBZ N
2.3 CD N
+/- JJ N
0.4 CD N
pg/ml) NN N
. . N

Although IN N
the DT N
mean JJ N
endotoxin NN O
concentration NN O
was VBD N
lower JJR N
in IN N
the DT N
verum NN N
group NN N
after IN N
1 CD N
week NN N
(paromomycin RB I
8.0 CD N
+/- JJ N
1.9 CD N
pg/ml; NN N
placebo NN I
14.6 CD N
+/- JJ N
3.5 CD N
pg/ml; NN N
p NN N
> VBD N
0.05) CD N
paromomycin NN I
treatment NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
endotoxin NN N
concentration NN N
or CC N
liver JJ N
function NN N
tests NNS N
during IN N
the DT N
4-week JJ N
period NN N
. . N

The DT N
beneficial JJ N
effect NN N
of IN N
paromomycin NN I
treatment NN N
on IN N
endotoxemia NN N
in IN N
cirrhotics NNS N
reported VBN N
in IN N
earlier JJR N
studies NNS N
could MD N
not RB N
be VB N
reproduced VBN N
under IN N
the DT N
conditions NNS N
of IN N
this DT N
trial NN N
in IN N
patients NNS P
with IN P
alcoholic JJ P
liver NN P
disease NN P
. . P

-DOCSTART- -X- O O

Influence NN N
of IN N
lime NN I
juice NN I
on IN N
the DT N
severity NN N
of IN N
sickle NN P
cell NN P
anemia NN P
. . P

BACKGROUND NNP N
AND CC N
OBJECTIVES NNP N
The DT N
pain NN N
in IN N
sickle NN P
cell NN P
anemia NN P
(SCA) NNP P
is VBZ N
often RB N
triggered VBN N
by IN N
dehydration NN N
acidosis NN N
and CC N
fever NN N
that WDT N
are VBP N
usually RB N
due JJ N
to TO N
malaria VB N
. . N

Intake NNP N
of IN N
lime JJ I
juice NN I
was VBD N
recently RB N
demonstrated VBN N
to TO N
facilitate VB N
clearance NN N
of IN N
the DT N
malaria NN N
parasite NN N
. . N

It PRP N
was VBD N
therefore RB N
sought VBN N
to TO N
determine VB N
whether IN N
regular JJ N
intake NN N
of IN N
lime JJ I
juice NN I
will MD N
ameliorate VB N
crisis NN O
especially RB N
recurrent JJ O
bone NN O
pain NN O
. . O

DESIGN NN N
In IN N
this DT N
preliminary JJ N
open-labeled JJ N
randomized VBN N
study NN N
the DT N
effects NNS N
of IN N
lime JJ I
juice NN I
on IN N
the DT N
clinical JJ O
and CC O
some DT O
laboratory JJ O
characteristics NNS O
of IN N
children NNS P
with IN P
SCA NNP P
were VBD N
tested VBN N
. . N

RESULTS NNP N
Among IN N
the DT N
113 CD P
children NNS P
with IN P
SCA NNP P
studied VBN P
in IN P
two CD P
hospitals NNS P
the DT N
58 CD N
receiving NN N
lime NN I
treatment NN N
had VBD N
lower JJR N
rates NNS O
of IN O
significant JJ O
painful JJ O
episodes NNS O
than IN N
the DT N
55 CD N
without IN I
lime JJ I
(37 NNP N
versus NN N
83 CD N
crises NNS N
in IN N
6 CD N
months NNS N
and CC N
0.64±0.11 CD N
versus NN N
1.51±0.34 CD N
average JJ N
rates NNS N
per IN N
child NN N
p<0.001) NN N
. . N

Also RB N
fewer JJR N
subjects NNS N
than IN N
the DT N
controls NNS N
had VBD O
significant JJ O
painful JJ O
episodes NNS O
(50.0% VBP N
versus IN N
92.7%); CD O
febrile JJ O
illness NN O
(46.6% NNP N
versus NN N
87.3%) CD N
and CC O
admission NN O
rate NN O
(3.4% NNP N
versus NN N
34.5%) CD N
(p<0.001) NN N
. . N

The DT O
mean JJ O
hematocrit NN O
of IN N
the DT N
subjects NNS N
(26.23±2.03%) VBP N
at IN N
the DT N
end NN N
of IN N
the DT N
study NN N
was VBD N
also RB N
higher JJR N
p<0.001 NN N
. . N

However RB O
transfusion NN O
rate NN O
presence NN O
of IN O
hepatomegaly NN O
splenomegaly NN O
and CC O
jaundice NN O
was VBD N
similar JJ N
. . N

Treatment NN N
with IN I
lime NN I
did VBD N
not RB N
cause VB N
any DT O
significant JJ O
side-effect JJ O
. . N

CONCLUSIONS NNP N
Regular NNP N
intake NN N
of IN I
lime JJ I
juice NN I
may MD N
be VB N
of IN N
great JJ N
therapeutic JJ N
and CC N
nutritional JJ N
relevance NN N
in IN P
children NNS P
with IN P
SCA NNP P
. . N

-DOCSTART- -X- O O

Intervention NN I
pilot NN N
for IN N
parents NNS P
of IN P
children NNS P
with IN P
autistic JJ P
spectrum NN P
disorder NN P
. . P

Parents NNS P
of IN P
children NNS P
who WP P
receive VBP P
the DT P
diagnosis NN P
of IN P
autistic JJ P
spectrum NN P
disorder NN P
(ASD) NNP P
experience NN N
a DT N
situational JJ N
crisis NN N
related VBN N
to TO N
receiving VBG N
the DT N
diagnosis NN N
which WDT N
causes VBZ N
feelings NNS N
of IN N
distress NN N
and CC N
urgency NN N
to TO N
access NN N
services NNS N
for IN N
the DT N
affected JJ N
child NN N
. . N

This DT N
paper NN N
describes VBZ N
a DT N
randomized JJ N
trial NN N
(n NNP P
= VBZ P
31) CD P
that WDT N
was VBD N
conducted VBN N
at IN N
a DT N
regional JJ N
diagnostic JJ N
center NN N
of IN N
a DT N
large JJ N
metropolitan NN N
children's NN N
hospital NN N
to TO N
(a) VB N
refine VB N
a DT N
nursing NN I
intervention NN I
designed VBN N
for IN N
parents NNS P
of IN P
children NNS P
with IN P
ASD NNP P
and CC N
(b) NNP N
to TO N
identify VB N
methodological JJ N
revisions NNS N
for IN N
a DT N
larger JJR N
study NN N
. . N

A DT N
secondary JJ N
purpose NN N
was VBD N
to TO N
test VB N
the DT N
effects NNS O
of IN N
a DT N
post-diagnosis JJ I
nursing NN I
intervention NN I
on IN N
parents' JJ P
reports NNS O
of IN O
stress JJ O
impact NN O
of IN O
event NN O
(diagnosis) NN O
and CC O
use NN O
of IN O
services NNS O
after IN N
a DT N
child NN N
is VBZ N
newly RB N
diagnosed VBN N
with IN N
ASD NNP N
. . N

The DT N
intervention NN N
consisted VBD N
of IN N
usual JJ I
care NN I
plus CC N
3 CD N
hours NNS N
contact NN I
with IN I
a DT I
pediatric JJ I
nurse NN I
practitioner NN I
(PNP) NN I
for IN I
counseling VBG I
instruction NN I
and CC I
assistance NN I
with IN I
implementation NN I
of IN I
the DT I
recommended VBN I
treatment NN I
plan NN I
. . I

The DT N
control NN N
group NN N
received VBD N
only RB N
the DT N
usual JJ I
care NN I
post-diagnosis NN N
which WDT N
consisted VBD N
of IN N
a DT N
1-hour JJ N
consultation NN I
session NN I
to TO I
receive VB I
the DT I
results NNS I
of IN I
diagnostic JJ I
tests NNS I
and CC I
a DT I
written VBN I
copy NN I
of IN I
the DT I
recommended VBN I
treatment NN I
plan NN I
provided VBN N
by IN N
a DT N
developmental JJ N
pediatrician JJ N
and/or NN N
PNP NNP N
. . N

Between NNP N
group NN N
differences NNS N
in IN N
measures NNS N
of IN N
"impact NN O
of IN O
event" NN O
and CC N
"perceived VBD O
stress" NNS O
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

This DT N
was VBD N
attributed VBN N
to TO N
a DT N
small JJ N
sample NN N
size NN N
. . N

A NNP N
larger JJR N
study NN N
is VBZ N
feasible JJ N
and CC N
recommended VBD N
with IN N
an DT N
expanded JJ N
nursing NN I
intervention NN I
and CC N
a DT N
significantly RB N
larger JJR N
sample NN N
recruited VBD N
from IN N
an DT N
additional JJ N
recruitment NN N
site NN N
. . N

Nurses NNS N
working VBG N
with IN N
this DT N
special JJ N
population NN N
must MD N
recognize VB N
that IN N
parents NNS P
have VBP N
information NN N
and CC N
counseling NN N
needs NNS N
that WDT N
begin VBP N
after IN N
they PRP N
receive VBP N
the DT N
diagnosis NN N
of IN N
ASD NNP N
for IN N
their PRP$ N
child NN N
and CC N
can MD N
address VB N
these DT N
needs NNS N
with IN N
a DT N
standardized JJ N
nursing NN I
intervention NN I
. . I

-DOCSTART- -X- O O

Effects NNS N
of IN N
soy JJ I
intake NN N
on IN N
sex NN O
hormone NN O
metabolism NN O
in IN N
premenopausal JJ P
women NNS P
. . P

Studies NNS N
suggest VBP N
that IN N
phytoestrogens NNS N
in IN N
soy JJ I
products NNS N
may MD N
impart VB N
hormonal JJ O
effects NNS O
that WDT N
protect VBP N
women NNS N
against IN N
breast NN N
cancer NN N
. . N

Limited VBN N
research NN N
suggests VBZ N
that IN N
intake NN N
of IN N
soy NN I
products NNS N
high JJ N
in IN N
isoflavonoid JJ N
phytoestrogens NNS N
affects VBZ N
sex NN O
hormone NN O
metabolism NN O
but CC N
it PRP N
is VBZ N
unknown JJ N
whether IN N
phytoestrogens NNS N
in IN N
soy NNS I
have VBP N
any DT N
effect NN N
on IN N
menstrual JJ O
function NN O
or CC O
serum VB O
sex NN O
hormones NNS O
in IN N
women NNS P
on IN P
common JJ P
hormone NN P
therapies NNS P
such JJ P
as IN P
oral JJ P
contraceptives NNS P
(OC) RB P
. . P

We PRP N
studied VBD N
the DT N
effects NNS N
of IN N
soy NN I
in IN N
36 CD P
premenopausal JJ P
women NNS P
20 CD P
of IN P
whom WP P
used VBD P
OC NNP P
. . P

Subjects NNS N
consumed VBD N
their PRP$ N
normal JJ I
diet NNS I
for IN N
two CD N
menstrual JJ N
cycles NNS N
and CC N
added VBD N
a DT N
soy JJ I
beverage NN I
containing VBG N
20 CD N
g NN N
of IN N
protein NN N
and CC N
38 CD N
mg NN N
of IN N
total JJ N
isoflavones NNS N
to TO N
their PRP$ N
usual JJ N
diet NN N
for IN N
another DT N
two CD N
menstrual JJ N
cycles NNS N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
observed VBN N
in IN N
serum NN O
estrone NN O
estradiol JJ O
sex NN O
hormone-binding JJ O
globulin NN O
dehydroepiandrosterone NN O
sulfate NN O
prolactin NN O
or CC O
progesterone NN O
concentrations NNS O
with IN N
soy JJ I
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
. . N

No DT N
changes NNS N
in IN N
menstrual JJ O
cycle NN O
length NN O
or CC O
the DT O
urinary JJ O
estrogen NN O
metabolite NNS O
ratio NN O
of IN O
2-hydroxyestrone CD O
to TO O
16 CD O
alpha-hydroxyestrone NN O
were VBD N
seen VBN N
with IN N
soy JJ N
feeding NN N
in IN N
the DT N
non-OC JJ N
or CC N
the DT N
OC NNP N
group NN N
. . N

Levels NNP N
of IN N
urinary JJ O
estrogen NN O
metabolites NNS O
were VBD N
significantly RB N
different JJ N
between IN N
the DT N
non-OC JJ N
and CC N
the DT N
OC NNP N
group NN N
. . N

Thus RB N
soy JJ I
consumption NN N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
the DT N
menstrual JJ O
cycle NN O
serum NN O
sex NN O
hormones NNS O
or CC O
urinary JJ O
estrogen NN O
metabolite NN O
ratio NN O
in IN N
premenopausal NN P
OC NNP P
or CC P
non-OC JJ P
users NNS P
. . P

-DOCSTART- -X- O O

A DT N
pooled JJ N
analysis NN N
of IN N
eastern JJ N
cooperative JJ N
oncology NN N
group NN N
and CC N
intergroup NN N
trials NNS N
of IN N
adjuvant JJ N
high-dose JJ N
interferon NN I
for IN N
melanoma NN P
. . P

PURPOSE NNP N
Nearly RB P
2000 CD P
patients NNS P
with IN P
stage NN P
IIB NNP P
and CC P
III NNP P
melanoma NNS P
have VBP N
participated VBN N
in IN N
four CD N
multicenter NN N
randomized VBN N
trials NNS N
conducted VBN N
by IN N
the DT N
Eastern NNP N
Cooperative NNP N
Oncology NNP N
Group NNP N
and CC N
the DT N
Intergroup NNP N
investigating VBG N
adjuvant JJ N
high-dose JJ N
IFN-alpha JJ I
2b CD I
therapy NN N
. . N

The DT N
objectives NNS N
of IN N
this DT N
study NN N
were VBD N
to TO N
update VB N
the DT N
analyses NNS N
of IN N
each DT N
individual JJ N
trial NN N
and CC N
to TO N
analyze VB N
prognostic JJ O
factors NNS O
and CC O
treatment NN O
effects NNS O
based VBN N
on IN N
pooled JJ N
data NNS N
. . N

EXPERIMENTAL NNP N
DESIGN NNP N
Survival NNP N
and CC N
disease NN N
status NN N
were VBD N
updated VBN N
to TO N
April NNP N
2001 CD N
. . N

Analysis NN N
of IN N
prognostic JJ O
factors NNS O
using VBG O
optimized JJ O
statistical JJ O
models NNS O
was VBD N
based VBN N
on IN N
data NNS N
from IN N
patients NNS N
in IN N
E1684 NNP N
E1690 NNP N
E1694 NNP N
and CC N
E2696 NNP N
. . N

Analysis NN N
of IN N
treatment NN O
effects NNS O
versus VBP O
observation NN I
(Obs) NN I
was VBD N
based VBN N
on IN N
data NNS N
from IN N
713 CD N
patients NNS N
randomized VBN N
to TO N
high-dose JJ N
IFN-alpha JJ I
2b CD I
(HDI) NN I
or CC N
Obs NNP I
in IN N
Trials NNP N
E1684 NNP N
and CC N
E1690 NNP N
. . N

RESULTS NNP N
Updated VBD N
analysis NN N
of IN N
E1684 NNP N
E1690 NNP N
and CC N
E1694 NNP N
confirmed VBD N
their PRP$ N
original JJ N
conclusions NNS N
now RB N
at IN N
median JJ N
follow-up JJ N
intervals NNS N
of IN N
2.1-12.6 JJ N
years NNS N
. . N

Based VBN N
on IN N
two-sided JJ N
univariate JJ N
log-rank JJ N
analysis NN N
of IN N
pooled VBN N
data NNS N
from IN N
E1684 NNP N
and CC N
E1690 NNP N
(median JJ N
follow-up JJ N
7.2 CD N
years) JJ N
relapse-free JJ O
survival NN O
(RFS)-but NN O
not RB N
overall JJ O
survival JJ O
(OS)-was NN O
significantly RB N
prolonged VBD N
(two-sided JJ N
log-rank JJ N
P NNP N
value NN N
= VBD N
0.006) CD N
for IN N
patients NNS N
treated VBN N
with IN N
HDI NNP I
versus NN N
Obs NNP I
. . I

Among IN N
all DT N
patients NNS N
prognostic JJ O
factors NNS O
that WDT N
significantly RB N
negatively RB N
impacted JJ N
RFS NNP N
and CC N
OS NNP N
included VBD N
ulceration JJ O
recurrent NN O
disease NN O
at IN O
entry NN O
enrollment NN N
in IN N
E1684 NNP N
and CC N
age NN O
> VBP N
49 CD N
years NNS N
. . N

Multivariate NNP N
statistical JJ N
models NNS N
adjusting VBG N
for IN N
these DT N
factors NNS N
confirmed VBD N
the DT N
statistically RB N
significant JJ N
RFS NNP O
benefit NN N
of IN N
HDI NNP I
versus NN N
Obs NNP I
but CC N
did VBD N
not RB N
demonstrate VB N
a DT N
significant JJ N
OS NNP O
benefit NN N
in IN N
the DT N
pooled JJ N
populations NNS N
. . N

CONCLUSIONS NNP N
In IN N
patients NNS P
with IN P
high-risk JJ P
resected JJ P
melanoma NN P
HDI NNP N
is VBZ N
effective JJ N
adjuvant JJ N
therapy NN N
with IN N
strong JJ N
evidence NN N
for IN N
improved JJ N
RFS NNP O
and CC N
evidence NN N
for IN N
moderate JJ N
improvement NN N
in IN N
OS NNP O
based VBN N
on IN N
two CD N
prospective JJ N
randomized VBN N
studies NNS N
but CC N
not RB N
the DT N
pooled JJ N
analysis NN N
. . N

Analyses NNS N
of IN N
predictors NNS O
of IN O
relapse NN O
and CC O
response NN O
are VBP N
now RB N
needed VBN N
to TO N
improve VB N
the DT N
therapeutic JJ N
value NN N
of IN N
this DT N
modality NN N
. . N

-DOCSTART- -X- O O

Local JJ N
immunotherapy NN N
by IN N
inhalation NN N
of IN N
a DT N
powder NN N
extract NN N
in IN N
asthma NN P
due JJ P
to TO P
house NN P
dust NN P
mite NN P
Dermatophagoides NNP P
pteronyssinus: VBZ P
a DT N
double-blind JJ N
comparison NN N
with IN N
parenteral JJ N
immunotherapy NN N
. . N

To TO N
verify VB N
the DT N
efficacy NN O
and CC N
the DT N
tolerability NN O
of IN N
local JJ I
immunotherapy NN I
(LI) NN N
by IN N
inhalation NN N
of IN N
a DT N
powder NN I
extract NN I
of IN I
house NN I
dust NN I
mite NN I
(HDM) NN I
in IN N
comparison NN N
with IN N
parenteral JJ I
immunotherapy NN I
(PI) NN I
by IN N
injection NN N
10 CD P
patients NNS P
with IN P
asthma NNS P
due JJ P
to TO P
HDM NNP P
were VBD N
studied VBN N
in IN N
a DT N
blind JJ N
fashion NN N
. . N

5 CD N
patients NNS N
(Group JJ N
A) NNP N
underwent NN N
LI NNP N
and CC N
subcutaneous JJ N
injections NNS N
of IN N
placebo NN I
5 CD N
patients NNS N
(Group JJ N
B) NNP N
underwent NN N
PI NNP N
and CC N
inhalation NN N
of IN N
lactose NN I
for IN N
6 CD N
months NNS N
. . N

In IN N
both DT N
groups NNS N
each DT N
inhalation NN N
was VBD N
preceded VBN N
by IN N
premedication NN N
with IN N
disodium NN I
cromoglycate NN I
(DSCG) NNP I
(40 NNP N
mg) NN N
. . N

In IN N
Group NNP N
A NNP N
a DT N
significant JJ N
decrease NN N
in IN N
symptoms NNS O
score NN O
and CC N
in IN N
peak JJ O
expiratory JJ O
flow JJ O
(PEF)-derived JJ O
parameters NNS O
was VBD N
observed VBN N
already RB N
after IN N
3 CD N
months NNS N
of IN N
treatment NN N
and CC N
2 CD N
patients NNS N
lost VBD N
the DT N
late JJ N
component NN N
of IN N
the DT N
bronchial JJ O
response NN O
to TO N
the DT N
challenge NN N
with IN N
HDM NNP N
. . N

No NNP N
significant JJ N
variation NN N
was VBD N
found VBN N
in IN N
bronchial JJ O
responsiveness NN O
to TO N
methacholine VB N
and CC N
ultrasonically RB N
nebulized VBN N
distilled JJ N
water NN N
(UNDW) NN N
and CC N
in IN N
immunologic JJ O
humoral JJ O
and CC O
cellular JJ O
parameters NNS O
in IN O
peripheral JJ O
blood NN O
after IN N
treatment NN N
in IN N
either DT N
group NN N
. . N

No DT N
local JJ O
important JJ O
adverse JJ O
reactions NNS O
were VBD N
observed VBN N
in IN N
Group NNP N
A NNP N
and CC N
no DT N
systemic JJ O
side NN O
effects NNS O
were VBD N
observed VBN N
in IN N
either DT N
group NN N
. . N

We PRP N
conclude VBP N
that DT N
LI NNP N
is VBZ N
as RB N
effective JJ O
as IN N
PI NNP N
but CC N
more RBR N
rapid JJ N
in IN N
its PRP$ N
action NN N
in IN N
the DT N
treatment NN N
of IN N
asthma NNS P
due JJ P
to TO P
HDM NNP P
. . P

Moreover RB N
LI NNP N
is VBZ N
locally RB N
well RB N
tolerated JJ O
providing VBG N
DSCG NNP I
is VBZ N
inhaled VBN N
before IN N
each DT N
therapeutic JJ N
inhalation NN N
and CC N
does VBZ N
not RB N
induce VB N
systemic JJ O
side NN O
effects NNS O
. . O

-DOCSTART- -X- O O

Role NNP N
of IN N
angiotensin-converting JJ I
enzyme NN I
inhibitors NNS I
in IN N
early JJ N
antihypertensive JJ N
treatment NN N
in IN N
non-insulin JJ P
dependent NN P
diabetes VBZ P
mellitus NN P
. . P

The DT N
effect NN N
of IN N
captopril NN I
monotherapy NN N
on IN N
blood NN O
pressure NN O
and CC O
metabolism NN O
was VBD N
investigated VBN N
in IN N
a DT N
placebo-controlled JJ I
study NN N
in IN N
30 CD P
non-insulin JJ P
dependent JJ P
(Type NN P
II) NNP P
diabetic JJ P
subjects NNS P
during IN N
a DT N
3-week JJ N
observation NN N
period NN N
(run-in/drug; JJ N
placebo/wash-out) NN I
on IN N
a DT N
metabolic JJ N
ward NN N
. . N

Captopril NNP I
significantly RB N
reduced VBD N
both DT N
systolic JJ O
and CC O
diastolic JJ O
blood NN O
pressure NN O
(154/90 VBD N
+/- JJ N
5/2 CD N
vs NN N
. . N

144/86 CD N
+/- JJ N
4/3 CD N
mmHg) NN N
without IN N
major JJ N
side NN N
effects NNS N
. . N

Mean JJ N
run-in JJ N
postprandial JJ O
blood NN O
glucose JJ O
concentrations NNS O
were VBD N
also RB N
reduced VBN N
upon IN N
ACE-inhibition NNP N
(9 NNP N
a.m.: VBZ N
12.7 CD N
+/- JJ N
0.4 CD N
vs NN N
. . N

11.1 CD N
+/- JJ N
0.4 CD N
mmol/l; NN N
1 CD N
p.m.: NN N
11.0 CD N
+/- JJ N
0.3 CD N
vs NN N
. . N

8.9 CD N
+/- JJ N
0.3 CD N
mmol/l; NN N
P NNP N
less JJR N
than IN N
0.05) CD N
while IN N
blood NN O
kinin NN O
concentrations NNS O
(40.0 VBP N
+/- JJ N
2.5 CD N
pmol/l) NN N
were VBD N
approximately RB N
doubled JJ N
(108.8 JJ N
+/- JJ N
23.5 CD N
pmol/l; NN N
P NNP N
less JJR N
than IN N
0.05) CD N
. . N

Body NNP O
mass JJ O
index NN O
fasting VBG O
plasma JJ O
insulin NN O
serum NN O
electrolyte NN O
pattern NN O
uric JJ O
acid JJ O
white JJ O
blood NN O
count NN O
lipid JJ O
profile NN O
as RB O
well RB O
as IN O
hepatic JJ O
and CC O
renal JJ O
function NN O
parameters NNS N
remained VBD N
unaltered JJ N
throughout IN N
the DT N
observation NN N
period NN N
. . N

The DT N
data NNS N
are VBP N
in IN N
line NN N
with IN N
recent JJ N
experimental JJ N
studies NNS N
showing VBG N
a DT N
beneficial JJ N
metabolic JJ O
effect NN O
of IN N
captopril NN I
in IN N
Type NNP P
II NNP P
diabetes VBZ P
. . P

ACE NNP I
inhibitors NNS I
might MD N
therefore VB N
become JJ N
first-line JJ N
drugs NNS N
in IN N
early JJ N
antihypertensive JJ N
intervention NN N
in IN N
Type NNP P
II NNP P
diabetic JJ P
patients NNS P
. . P

-DOCSTART- -X- O O

Amonafide: NNP I
An DT N
active JJ N
agent NN N
in IN N
the DT N
treatment NN N
of IN N
previously RB P
untreated VBN P
advanced JJ P
breast NN P
cancer--a JJ P
cancer NN N
and CC N
leukemia NN N
group NN N
B NNP N
study NN N
(CALGB VBD N
8642) CD N
. . N

Amonafide NNP I
is VBZ N
a DT N
new JJ N
imide JJ N
derivative NN N
of IN N
naphthalic JJ N
acid NN N
. . N

The DT N
drug NN N
had VBD N
demonstrated VBN N
significant JJ N
activity NN N
in IN N
preclinical JJ N
studies NNS N
and CC N
some DT N
activity NN N
in IN N
Phase NNP N
I PRP N
trials NNS N
. . N

The DT N
drug NN N
is VBZ N
extensively RB N
metabolized VBN N
and CC N
detected VBN N
in IN N
plasma NN N
and CC N
urine NN N
. . N

Its PRP$ N
toxicity NN N
has VBZ N
previously RB N
been VBN N
correlated VBN N
to TO N
the DT N
formation NN N
of IN N
an DT N
active JJ N
metabolite NN N
N-acetyl-amonafide NNP N
. . N

Amonafide NNP I
was VBD N
chosen VBN N
for IN N
inclusion NN N
in IN N
the DT N
Cancer NNP N
and CC N
Leukemia NNP N
Group NNP N
B NNP N
(CALGB) NNP N
master NN N
metastatic JJ N
breast NN N
cancer NN N
protocol NN N
. . N

CALGB NNP N
8642 CD N
randomizes VBZ N
previously RB P
untreated VBN P
metastatic JJ P
breast NN P
cancer NN P
patients NNS P
either CC N
to TO N
one CD N
of IN N
several JJ N
Phase NNP N
II NNP N
agents NNS N
given VBN N
for IN N
up IN N
to TO N
four CD N
cycles NNS N
and CC N
then RB N
followed VBN N
by IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN I
or CC N
to TO N
immediate VB N
treatment NN N
with IN N
standard JJ N
cyclophosphamide-doxorubicin-5-fluorouracil NN I
. . I

The DT N
end NN N
point NN N
of IN N
CALGB NNP N
8642 CD N
is VBZ N
to TO N
assess VB N
the DT N
difference NN O
in IN O
survival JJ O
toxicity NN O
and CC O
overall JJ O
response NN O
when WRB N
limited JJ N
exposure NN N
to TO N
Phase NNP N
II NNP N
agents NNS N
precedes VBZ N
standard JJ N
chemotherapy NN N
. . N

This DT N
report NN N
deals VBZ N
only RB N
with IN N
amonafide RB I
as IN N
a DT N
Phase NNP N
II NNP N
agent NN N
. . N

Comparisons NNS N
with IN N
the DT N
cyclophosphamide-doxorubicin-5-fluorouracil JJ I
arm NN N
will MD N
not RB N
be VB N
addressed VBN N
. . N

Patients NNS P
had VBD P
to TO P
have VB P
histologically RB P
documented VBN P
measurable JJ P
breast NN P
cancer NN P
and CC P
a DT P
performance NN P
status NN P
of IN P
0-1 NNP P
. . P

Patients NNS P
could MD P
not RB P
have VB P
had VBN P
prior JJ P
chemotherapy NN P
for IN P
metastatic JJ P
disease NN P
. . P

Prior NNP P
adjuvant JJ P
chemotherapy NN P
was VBD P
permitted VBN P
. . P

Patients NNS P
could MD P
not RB P
have VB P
visceral JJ P
crisis NN P
. . P

Amonafide NNP I
was VBD N
given VBN N
at IN N
300 CD N
mg/m2/day JJ N
i.v NN N
. . N

for IN N
5 CD N
days NNS N
and CC N
repeated VBN N
at IN N
21-day JJ N
intervals NNS N
for IN N
a DT N
maximum NN N
of IN N
four CD N
cycles NNS N
. . N

Escalation NN N
and CC N
reduction NN N
in IN N
dose NN N
was VBD N
mandated VBN N
dependent NN N
on IN N
hematotoxicity NN N
or CC N
lack NN N
thereof NN N
. . N

Toxicity NN O
was VBD N
primarily RB N
hematological JJ N
and CC N
bimodal: JJ N
32% CD N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
leukopenia NN O
and CC N
24% CD N
had VBD N
grade VBN N
3 CD N
or CC N
4 CD N
thrombocytopenia; JJ O
22% CD N
had VBD N
no DT N
leukopenia NN O
and CC N
44% CD N
had VBD N
no DT N
thrombocytopenia NN O
. . O

The DT N
response NN N
rate NN N
was VBD N
18% CD N
including VBG N
one CD N
complete JJ N
response NN N
. . N

When WRB N
response NN N
was VBD N
analyzed VBN N
by IN N
hematological JJ O
toxicity NN O
there EX N
was VBD N
a DT N
35.7% CD N
response NN N
if IN N
patients NNS N
had VBD N
leukopenia VBN O
grade RB N
3/4 CD N
(versus NN N
8.3% CD N
P NNP N
= VBD N
0.08) CD N
. . N

There EX N
was VBD N
a DT N
50% CD N
response NN N
if IN N
patients NNS N
had VBD N
thrombocytopenia VBN O
grade RB N
3/4 CD N
(versus NN N
7.1% CD N
P NNP N
= NNP N
<0.01) NNP N
. . N

We PRP N
conclude VBP N
that DT N
amonafide NN I
is VBZ N
somewhat RB N
active JJ N
in IN N
previously RB P
untreated VBN P
breast NN P
cancer NN P
patients NNS P
. . P

There EX N
may MD N
be VB N
a DT N
steep JJ N
dose-response NN N
curve NN N
based VBN N
on IN N
the DT N
significant JJ N
correlation NN N
between IN N
myelosuppression NN N
and CC N
response NN N
. . N

Rates NNS O
of IN O
responses NNS O
in IN N
patients NNS N
adequately RB N
dosed VBD N
(i.e NNP N
. . N

with IN N
significant JJ N
hematotoxicity) NN N
with IN N
amonafide JJ I
ranged VBD N
from IN N
35 CD N
to TO N
50% CD N
. . N

Further JJ N
studies NNS N
will MD N
incorporate VB N
individualized JJ N
dosing NN N
based VBN N
on IN N
pretreatment NN N
acetylator NN N
phenotyping NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
tryptophan JJ I
depletion NN I
in IN N
drug-free JJ P
adults NNS P
with IN P
autistic JJ P
disorder NN P
. . P

BACKGROUND IN N
The DT N
primary JJ N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
behavioral JJ O
and CC O
biochemical JJ O
responses NNS O
to TO N
acute VB N
tryptophan JJ I
depletion NN I
in IN N
drug-free JJ P
adult NN P
patients NNS P
with IN P
autistic JJ P
disorder NN P
. . P

METHODS NNP N
Twenty NNP P
drug-free JJ P
adults NNS P
with IN P
autistic JJ P
disorder NN P
(16 NNP P
men NNS P
and CC P
4 CD P
women) JJ P
(mean JJ P
[+/- JJ P
SD] NNP P
age NN P
30.5 CD P
+/- JJ P
8.5 CD P
years) JJ P
underwent JJ N
short-term JJ N
tryptophan NN I
depletion NN I
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized VBN N
crossover NN N
design NN N
. . N

Patients NNS N
received VBD N
a DT N
24-hour JJ N
low-tryptophan JJ I
diet NN I
followed VBD N
the DT N
next JJ N
morning NN N
by IN N
an DT N
amino NN I
acid NN I
drink NN I
. . I

Behavioral JJ O
ratings NNS O
were VBD N
obtained VBN N
on IN N
the DT N
morning NN N
of IN N
the DT N
amino NN I
acid NN I
drink VBP I
(baseline) NN N
and CC N
180 CD N
300 CD N
and CC N
420 CD N
minutes NNS N
after IN N
the DT N
drink NN N
. . N

Plasma NNP O
free JJ O
and CC O
total JJ O
tryptophan NN O
levels NNS O
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
5 CD N
hours NNS N
after IN N
the DT N
drink NN N
. . N

The DT N
active JJ N
and CC N
sham JJ N
testing NN N
sessions NNS N
were VBD N
separated VBN N
by IN N
7 CD N
days NNS N
. . N

RESULTS NNP N
Eleven NNP N
(65%) NNP N
of IN N
the DT N
17 CD N
patients NNS N
who WP N
completed VBD N
both DT N
test NN N
days NNS N
showed VBD N
a DT N
significant JJ N
global JJ N
worsening NN N
of IN N
behavioral JJ O
symptoms NNS O
with IN N
short-term JJ N
tryptophan NN I
depletion NN I
but CC N
none NN N
of IN N
the DT N
17 CD N
patients NNS N
showed VBD N
any DT N
significant JJ N
change NN N
in IN N
clinical JJ N
status NN N
from IN N
baseline NN N
after IN N
sham JJ I
depletion NN I
(P NNP N
= NNP N
.001) NNP N
. . N

Tryptophan NNP I
depletion NN I
led VBD N
to TO N
a DT N
significant JJ N
increase NN N
in IN N
behaviors NNS O
such JJ O
as IN O
whirling VBG O
flapping VBG O
pacing VBG O
banging NN O
and CC O
hitting VBG O
self NN O
rocking NN O
and CC O
toe NN O
walking VBG O
(P NNP N
< NNP N
.05) NNP N
. . N

In IN N
addition NN N
patients NNS N
were VBD N
significantly RB N
less JJR N
calm JJ O
and CC N
happy JJ O
and CC N
more RBR N
anxious JJ O
. . O

No DT N
significant JJ N
change NN N
was VBD N
observed VBN N
in IN N
social JJ O
relatedness NN O
or CC O
repetitive JJ O
thoughts NNS O
and CC O
behavior NN O
. . O

Plasma NNP O
total JJ O
and CC O
free JJ O
tryptophan NN O
levels NNS O
were VBD N
reduced VBN N
86% CD N
and CC N
69% CD N
respectively RB N
5 CD N
hours NNS N
after IN N
the DT N
tryptophan-deficient JJ I
amino NN I
acid NN I
drink NN I
. . I

Patients NNS N
who WP N
had VBD N
a DT N
significant JJ N
global JJ N
exacerbation NN N
of IN N
symptoms NNS N
had VBD N
significantly RB N
higher JJR N
baseline NN N
plasma IN O
total JJ O
tryptophan NN O
levels NNS O
(P VBP N
< JJ N
.001) NNP N
and CC N
Autism NNP O
Behavior NNP O
Checklist NNP O
scores VBZ O
(P NNP N
= NNP N
.005) NNP N
than IN N
did VBD N
patients NNS N
who WP N
showed VBD N
no DT N
significant JJ N
change NN N
in IN N
symptoms NNS N
after IN N
tryptophan JJ I
depletion NN I
. . I

CONCLUSIONS VB N
The DT N
results NNS N
of IN N
this DT N
study NN N
are VBP N
consistent JJ N
with IN N
previous JJ N
research NN N
that WDT N
has VBZ N
implicated VBN N
a DT N
dysregulation NN N
in IN N
serotonin JJ N
function NN N
in IN N
some DT N
patients NNS P
with IN P
autism NN P
. . P

These DT N
data NNS N
suggest VBP N
that IN N
the DT N
short-term JJ N
reduction NN N
of IN N
serotonin NN N
precursor NN N
availability NN N
may MD N
exacerbate VB N
some DT N
symptoms NNS N
characteristic JJ N
of IN N
autism NN P
in IN N
some DT N
patients NNS N
. . N

Continued JJ N
investigation NN N
into IN N
the DT N
role NN N
of IN N
serotonin NN N
in IN N
the DT N
pathogenesis NN N
and CC N
treatment NN N
of IN N
autistic JJ P
disorder NN P
is VBZ N
warranted VBN N
. . N

-DOCSTART- -X- O O

To TO N
compare VB N
the DT N
efficacy NN O
and CC N
safety NN O
of IN N
nifedipine NN I
sustained VBN I
release NN I
with IN N
Ginkgo NNP I
biloba NN I
extract NN I
to TO N
treat VB N
patients NNS P
with IN P
primary JJ P
Raynaud's NNP P
phenomenon NN P
in IN P
South NNP P
Korea; NNP P
Korean NNP N
Raynaud NNP N
study NN N
(KOARA NNP N
study) NN N
. . N

This DT N
study NN N
examined VBD N
the DT N
efficacy NN O
and CC N
safety NN O
of IN N
nifedipine NN I
sustained VBN I
release NN I
(nifedipine NN I
SR) NNP I
compared VBN N
with IN N
Ginkgo NNP I
biloba NN I
extract NN I
as IN N
treatment NN N
for IN N
primary JJ P
Raynaud's NNP P
phenomenon NN P
(RP) NN P
in IN P
Korea NNP P
. . P

Primary NNP P
RP NNP P
were VBD N
screened VBN N
and CC N
assigned VBN N
to TO N
either CC N
the DT N
nifedipine JJ I
SR NNP I
group NN N
(Group NNP N
N) NNP N
or CC N
the DT N
Ginkgo NNP I
biloba NN I
extract NN I
group NN N
(Group NNP N
G) NNP N
in IN N
the DT N
ratio NN N
of IN N
2:1 CD N
. . N

After IN N
a DT N
run-in JJ N
period NN N
of IN N
2 CD N
weeks NNS N
patients NNS N
received VBD N
treatment NN N
for IN N
8 CD N
weeks NNS N
. . N

We PRP N
observed VBD N
the DT N
percent NN O
improvement NN O
of IN O
the DT O
RP NNP O
attack NN O
rate NN O
between IN O
before IN O
and CC O
after IN O
the DT O
8-week JJ O
treatment NN O
. . O

Ninety-three JJ P
subjects NNS P
were VBD N
randomly RB N
assigned VBN N
. . N

The DT N
percent NN O
improvement NN O
in IN N
Group NNP N
N NNP N
was VBD N
50.1% CD N
at IN N
8 CD N
weeks NNS N
after IN N
treatment NN N
while IN N
it PRP N
was VBD N
31.0% CD N
in IN N
Group NNP N
G NNP N
(p NNP N
= VBD N
0.03) CD N
. . N

No DT N
serious JJ O
adverse JJ O
events NNS O
occurred VBD N
and CC N
almost RB N
adverse JJ O
events NNS O
were VBD N
mild JJ N
and CC N
improved VBN N
without IN N
specific JJ N
treatment NN N
. . N

nifedipine JJ I
SR NNP I
was VBD N
more RBR N
effective JJ O
than IN N
Ginkgo NNP I
biloba NN I
extract NN I
for IN N
treatment NN N
of IN N
primary JJ P
RP NNP P
in IN P
Korean JJ P
patients NNS P
. . P

Both DT N
drugs NNS N
were VBD N
tolerable JJ O
with IN N
primary JJ P
RP NNP P
patients NNS P
. . P

-DOCSTART- -X- O O

Double-blind NNP N
randomized JJ N
evaluation NN N
of IN N
intercostal JJ I
nerve NN I
blocks NNS I
as IN N
an DT N
adjuvant NN N
to TO N
subarachnoid VB N
administered JJ N
morphine NN I
for IN N
post-thoracotomy JJ P
analgesia NN N
. . N

BACKGROUND NNP N
AND NNP N
OBJECTIVES NNP N
Thoracotomy NNP P
is VBZ N
associated VBN N
with IN N
pain NN O
and CC N
compromised VBD N
pulmonary JJ O
function NN O
. . O

Intercostal NNP I
nerve NN I
blocks NNS I
(INB) VBP I
and CC N
subarachnoid VBP I
morphine NN I
(SM) NNP I
act NN N
on IN N
different JJ N
portions NNS N
of IN N
the DT N
pain NN N
pathway RB N
. . N

Each DT N
is VBZ N
effective JJ N
for IN N
post-thoracotomy JJ P
pain NN N
relief NN N
. . N

The DT N
combination NN N
of IN N
these DT N
two CD N
modalities NNS N
in IN N
relieving VBG N
post-thoracotomy JJ P
pain NN O
and CC N
improving VBG N
postoperative JJ O
pulmonary JJ O
function NN O
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
In IN N
a DT N
double-blind NN N
study NN N
20 CD P
patients NNS P
undergoing JJ P
lateral JJ P
thoracotomy NN P
for IN P
lung NN P
resection NN P
were VBD N
randomized VBN N
to TO N
receive VB N
0.5 CD N
mg NN N
SM NNP I
preoperatively RB N
and CC N
INB NNP I
with IN N
bupivacaine NN I
(INB+) NN N
prior RB N
to TO N
wound VB N
closure NN N
or CC N
0.5 CD N
mg NNS N
SM NNP I
with IN N
INB NNP I
using VBG N
saline JJ I
(INB-) JJ I
. . N

Visual JJ O
analog NN O
scale NN O
pain NN O
scores NNS O
at IN O
rest NN O
with IN O
cough NN O
and CC O
with IN O
movement NN O
of IN O
the DT O
ipsilateral JJ O
arm NN O
forced VBD O
expiratory JJ O
volume NN O
in IN O
1 CD O
second JJ O
(FEV1) NN O
and CC O
forced VBD O
vital JJ O
capacity NN O
(FVC) NNP O
were VBD N
measured VBN N
at IN N
4 CD N
24 CD N
48 CD N
and CC N
72 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

Opioid NNP O
use NN O
was VBD N
measured VBN N
during IN N
the DT N
initial JJ N
24 CD N
hours NNS N
after IN N
the DT N
operation NN N
. . N

RESULTS NNP N
At IN N
4 CD N
hours NNS N
the DT N
INB+ NNP I
group NN N
demonstrated VBD N
better JJR N
FEV1 NNP O
(56.6% NNP N
vs NN N
. . N

40.4% CD N
of IN N
baseline NN N
P NNP N
< NNP N
.05) NNP N
and CC N
FVC NNP O
values NNS N
(54.6% NNP N
vs NN N
. . N

39.6% CD N
of IN N
baseline NN N
P NNP N
< NNP N
.05) NNP N
and CC N
less JJR N
resting VBG O
and CC O
cough JJ O
pain NN O
(P NNP N
< NNP N
.05) NNP N
. . N

However RB N
FEV1 NNP O
continued VBD N
to TO N
decline VB N
in IN N
the DT N
INB+ NNP I
group NN N
at IN N
24 CD N
hours NNS N
to TO N
lower JJR N
than IN N
the DT N
INB- NNP I
group NN N
although IN N
pain NN O
scores NNS O
were VBD N
similar JJ N
beyond IN N
4 CD N
hours NNS N
. . N

Opioid JJ O
usage NN O
during IN N
the DT N
first JJ N
24 CD N
hours NNS N
was VBD N
similar JJ N
(INB- JJ I
16.7 CD N
mg NN N
vs NN N
. . N

INB+ NNP I
13.2 CD N
mg NN N
P NNP N
= NNP N
.7) NNP N
. . N

CONCLUSIONS NNP N
Although IN N
postoperative JJ N
INB NNP I
provided VBD N
modest JJ N
improvements NNS N
in IN N
pain NN O
and CC N
pulmonary JJ O
function NN O
when WRB N
used VBN N
as IN N
an DT N
adjuvant NN N
to TO N
0.5 CD N
mg NNS N
SM NNP I
for IN N
post-thoracotomy JJ P
analgesia NN N
the DT N
benefits NNS N
were VBD N
transient JJ N
. . N

The DT N
authors NNS N
do VBP N
not RB N
recommend VB N
adding VBG N
INB NNP I
for IN N
patients NNS P
undergoing JJ P
lateral JJ P
thoracotomy NN P
who WP N
receive VBP N
0.5 CD N
mg NN N
SM NNP I
. . I

-DOCSTART- -X- O O

Eltrombopag NNP I
for IN N
management NN N
of IN N
chronic JJ P
immune NN P
thrombocytopenia NN P
(RAISE): VBD N
a DT N
6-month JJ N
randomised JJ N
phase NN N
3 CD N
study NN N
. . N

BACKGROUND NNP N
Eltrombopag NNP I
is VBZ N
an DT N
oral JJ N
thrombopoietin NN N
receptor NN N
agonist NN N
for IN N
the DT N
treatment NN N
of IN N
thrombocytopenia NN P
. . P

We PRP N
aimed VBD N
to TO N
compare VB N
the DT N
response NN O
to TO N
once RB N
daily JJ N
eltrombopag NNS I
versus VBP N
placebo NN I
in IN N
patients NNS P
with IN P
chronic JJ P
immune JJ P
thrombocytopenia NN P
during IN N
a DT N
6-month JJ N
period NN N
. . N

METHODS NNP N
We PRP N
undertook VBD N
a DT N
phase NN N
3 CD N
double-blind JJ N
placebo-controlled JJ N
study NN N
in IN N
adults NNS P
with IN P
previously RB P
treated VBN P
immune JJ P
thrombocytopenia NN P
of IN P
more JJR P
than IN P
6 CD P
months' JJ P
duration NN P
who WP P
had VBD P
baseline NN P
platelet NN P
counts VBZ P
lower JJR P
than IN P
30 CD P
000 CD P
per IN P
μL NN P
. . N

Patients NNS N
were VBD N
randomly RB N
allocated VBN N
(in VBZ N
a DT N
2:1 CD N
ratio) NN N
treatment NN N
with IN N
local JJ N
standard NN N
of IN N
care NN N
plus CC N
50 CD N
mg NN I
eltrombopag NN I
or CC N
matching VBG I
placebo JJ I
once RB N
daily JJ N
for IN N
6 CD N
months NNS N
. . N

Randomisation NN N
was VBD N
done VBN N
centrally RB N
with IN N
a DT N
computer-generated JJ N
randomisation NN N
schedule NN N
and CC N
was VBD N
stratified VBN N
by IN N
baseline JJ N
platelet NN N
count NN N
(≤ VBD N
15 CD N
000 CD N
per IN N
μL) NN N
use NN N
of IN N
treatment NN N
for IN N
immune JJ N
thrombocytopenia NN N
and CC N
splenectomy NN N
status NN N
. . N

Patients NNS N
investigators NNS N
and CC N
those DT N
assessing VBG N
data NNS N
were VBD N
masked VBN N
to TO N
allocation NN N
. . N

Dose JJ N
modifications NNS N
were VBD N
made VBN N
on IN N
the DT N
basis NN N
of IN N
platelet NN N
response NN N
. . N

Patients NNS N
were VBD N
assessed VBN N
for IN O
response NN O
to TO O
treatment NN O
(defined VBN O
as IN O
a DT O
platelet NN O
count NN O
of IN O
50 CD O
000-400 JJ O
000 CD O
per IN O
μL) JJ N
weekly JJ N
during IN N
the DT N
first JJ N
6 CD N
weeks NNS N
and CC N
at IN N
least JJS N
once RB N
every DT N
4 CD N
weeks NNS N
thereafter; VBD N
the DT N
primary JJ N
endpoint NN N
was VBD O
the DT O
odds NNS O
of IN O
response NN I
to TO I
eltrombopag VB I
versus NN I
placebo NN I
. . N

Analysis NN N
was VBD N
by IN N
intention NN N
to TO N
treat VB N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
at IN N
ClinicalTrials.gov NNP N
number NN N
NCT00370331 NNP N
. . N

FINDINGS NNP P
Between NNP P
Nov NNP P
22 CD P
2006 CD P
and CC P
July NNP P
31 CD P
2007 CD P
197 CD P
patients NNS P
were VBD N
randomly RB N
allocated VBN N
to TO N
treatment NN N
groups NNS N
and CC N
were VBD N
included VBN N
in IN N
the DT N
intention-to-treat JJ N
analysis NN N
(135 NNP I
eltrombopag VBZ I
62 CD I
placebo) NN I
. . N

106 CD N
(79%) JJ N
patients NNS N
in IN I
the DT I
eltrombopag NN I
group NN O
responded VBD O
to TO N
treatment NN N
at IN N
least JJS N
once RB N
during IN N
the DT N
study NN N
compared VBN N
with IN N
17 CD N
(28%) JJ N
patients NNS N
in IN I
the DT I
placebo NN I
group NN N
. . O

The DT O
odds NNS O
of IN O
responding VBG O
were VBD N
greater JJR N
in IN N
patients NNS N
in IN I
the DT I
eltrombopag NN I
group NN N
compared VBN N
with IN N
those DT N
in IN I
the DT I
placebo NN I
group NN N
throughout IN N
the DT N
6-month JJ N
treatment NN N
period NN N
(odds NNP N
ratio VBZ N
8·2 CD N
99% CD N
CI NNP N
3·59-18·73; JJ N
p<0·0001) NN N
. . N

37 CD N
(59%) JJ N
patients NNS N
receiving VBG I
eltrombopag NN I
reduced VBD O
concomitant JJ O
treatment NN O
versus NN N
ten JJ N
(32%) JJ N
patients NNS N
receiving VBG I
placebo NN N
(p=0·016) NNP N
. . N

24 CD N
(18%) JJ N
patients NNS N
receiving VBG I
eltrombopag NN I
needed VBN O
rescue NN O
treatment NN N
compared VBN N
with IN N
25 CD N
(40%) JJ N
patients NNS N
receiving VBG I
placebo NN N
(p=0·001) NN N
. . N

Three CD N
(2%) JJ N
patients NNS I
receiving VBG I
eltrombopag NN I
had VBD O
thromboembolic JJ O
events NNS N
compared VBN N
with IN N
none NN N
in IN N
patients NNS I
on IN N
placebo NN N
. . I

Nine NNP I
(7%) JJ I
eltrombopag-treated JJ I
patients NNS N
and CC N
two CD N
(3%) NN I
in IN I
the DT I
placebo NN N
group NN N
had VBD N
mild VBN N
increases NNS O
in IN O
alanine JJ O
aminotransferase NN O
concentration NN O
and CC I
five CD I
(4%) JJ I
eltrombopag-treated JJ I
patients NNS N
(vs VBP N
none RB N
allocated VBN I
to TO N
placebo) VB N
had VBD N
increases NNS O
in IN O
total JJ O
bilirubin NN N
. . N

Four CD N
(7%) NN N
patients NNS I
taking VBG I
placebo NN O
had VBD O
serious JJ O
bleeding VBG O
events NNS N
compared VBN N
with IN N
one CD N
(<1%) NN N
patient NN N
treated VBN I
with IN I
eltrombopag NN I
. . N

INTERPRETATION NNP I
Eltrombopag NNP I
is VBZ O
effective JJ N
for IN N
management NN P
of IN P
chronic JJ P
immune NN P
thrombocytopenia NN P
and CC N
could MD N
be VB N
particularly RB N
beneficial JJ N
for IN N
patients NNS N
who WP N
have VBP N
not RB N
responded VBN N
to TO N
splenectomy VB N
or CC N
previous JJ N
treatment NN N
. . N

These DT N
benefits NNS N
should MD N
be VB N
balanced VBN N
with IN N
the DT N
potential JJ N
risks NNS N
associated VBN I
with IN I
eltrombopag JJ I
treatment NN N
. . N

FUNDING NN N
GlaxoSmithKline NNP N
. . N

-DOCSTART- -X- O O

A DT N
New NNP N
Interactive NNP I
Screening NNP I
Test NNP I
for IN N
Autism NNP P
Spectrum NNP P
Disorders NNP P
in IN P
Toddlers NNP P
. . P

OBJECTIVE NNP N
To TO N
develop VB N
a DT N
clinically RB N
valid JJ N
interactive JJ N
level NN N
2 CD N
screening NN N
assessment NN N
for IN N
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
in IN P
toddlers NNS P
that WDT N
is VBZ N
brief JJ N
easily RB N
administered VBN N
and CC N
scored VBN N
by IN N
clinicians NNS N
. . N

STUDY NNP N
DESIGN NNP N
We PRP N
describe VBP N
the DT N
development NN N
training NN N
standardization NN N
and CC N
validation NN N
of IN N
the DT N
Rapid NNP I
Interactive NNP I
Screening NNP I
Test NNP I
for IN O
Autism NNP O
in IN O
Toddlers NNP P
(RITA-T) JJ O
with IN N
ASD-specific NNP N
diagnostic JJ N
instruments NNS N
. . N

The DT N
RITA-T JJ I
can MD N
be VB N
administered VBN N
and CC N
scored VBN N
in IN N
10 CD N
minutes NNS N
. . N

We PRP N
studied VBD N
the DT N
validity NN N
of IN N
the DT N
RITA-T NNP I
to TO N
distinguish VB N
between IN N
toddlers NNS P
with IN P
ASD NNP P
from IN P
toddlers NNS P
with IN P
developmental JJ P
delay NN P
(DD)/non-ASD NN P
in IN P
an DT P
early JJ P
childhood NN P
clinic NN P
. . P

We PRP N
also RB N
evaluated VBD N
the DT N
test's JJ O
performance NN O
in IN N
toddlers NNS P
with IN P
no DT P
developmental JJ P
concerns NNS P
. . P

We PRP N
identified VBD N
a DT N
cutoff NN O
score NN O
based VBN N
on IN N
sensitivity NN O
specificity NN O
and CC O
positive JJ O
predictive JJ O
value NN O
of IN O
the DT O
RITA-T NNP I
that WDT N
best JJS N
differentiates NNS N
between IN N
ASD NNP N
and CC N
DD/non-ASD NNP N
. . N

RESULTS VB N
A DT P
total NN P
of IN P
61 CD P
toddlers NNS P
were VBD P
enrolled VBN P
. . P

RITA-T JJ O
scores NNS O
were VBD N
correlated VBN N
with IN N
ASD-specific NNP N
diagnostic JJ N
tools NNS N
(r VBP N
= $ N
0.79; CD N
P NNP N
< NNP N
.01) NNP N
and CC N
ASD NNP N
clinical JJ N
diagnoses NNS N
(r VBP N
= $ N
0.77; CD N
P NNP N
< NNP N
.01) NNP N
. . N

Mean NNP N
scores NNS O
were VBD N
significantly RB N
different JJ N
in IN N
subjects NNS N
with IN N
ASD NNP N
those DT N
with IN N
DD/non-ASD NNP N
and CC N
those DT N
with IN N
no DT N
developmental JJ N
concerns NNS N
(20.8 VBD N
vs JJ N
13 CD N
vs NN N
10.6 CD N
respectively; NN N
P NNP N
< NNP N
.0001) NNP N
. . N

At IN N
a DT N
cutoff NN N
score NN N
of IN N
>14 $ N
the DT N
RITA-T NNP I
had VBD N
a DT N
sensitivity NN O
of IN N
1.00 CD N
specificity NN O
of IN N
0.84 CD N
and CC N
positive JJ O
predictive JJ O
value NN O
of IN N
0.88 CD N
for IN N
identifying VBG N
ASD NNP N
risk NN N
in IN N
a DT N
high-risk JJ N
group NN N
. . N

CONCLUSION VB N
The DT N
RITA-T NNP I
is VBZ N
a DT N
promising JJ N
new JJ N
level NN N
2 CD N
interactive JJ N
screening VBG N
tool NN N
for IN N
improving VBG N
the DT N
early JJ N
identification NN N
of IN N
ASD NNP P
in IN P
toddlers NNS P
in IN N
general JJ N
pediatric NN N
and CC N
early JJ N
intervention NN N
settings NNS N
and CC N
allowing VBG N
access NN N
to TO N
treatment NN N
. . N

-DOCSTART- -X- O O

Methodology NNP N
of IN N
serial JJ N
ECG NNP N
classification NN N
using VBG N
an DT N
adaptation NN N
of IN N
the DT N
NOVACODE NNP N
for IN N
Q NNP N
wave VBP N
myocardial JJ N
infarction NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
(BARI) NNP N
. . N

Serial NNP N
electrocardiographic JJ N
(ECG) NN N
changes NNS N
are VBP N
a DT N
critical JJ N
component NN N
of IN N
the DT N
diagnostic JJ N
algorithm NN N
for IN N
classification NN N
of IN N
myocardial JJ N
ischemic JJ N
events NNS N
in IN N
large-scale JJ N
clinical JJ N
trials NNS N
. . N

This DT N
study NN N
describes VBZ N
a DT N
computerized JJ N
serial JJ N
ECG NNP N
classification NN N
program NN N
developed VBN N
at IN N
the DT N
St NNP N
. . N

Louis NNP N
University NNP N
Core NNP N
ECG NNP N
Laboratory NNP N
for IN N
use NN N
in IN N
the DT N
Bypass NNP N
Angioplasty NNP N
Revascularization NNP N
Investigation NNP N
(BARI) NNP N
trial NN N
in IN N
which WDT N
patients NNS P
with IN P
multivessel JJ P
coronary JJ P
artery NN P
disease NN P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
coronary JJ I
artery NN I
bypass NN I
grafting NN I
or CC N
percutaneous JJ I
transluminal JJ I
coronary JJ I
angioplasty NN I
. . I

The DT N
St NNP N
. . N

Louis NNP N
University NNP N
program NN N
detects NNS N
and CC N
codes VBZ N
serial JJ O
changes NNS O
in IN O
Q NNP O
ST NNP O
and CC O
T NNP O
wave VBP O
items NNS O
according VBG O
to TO O
Minnesota NNP O
code NN O
(MC) NNP O
criteria NNS O
using VBG N
a DT N
modified JJ N
NOVACODE NNP N
hierarchical JJ N
classification NN N
system NN N
. . N

Measurements NNS N
using VBG N
a DT N
seven-power NN N
calibrated VBN N
coding NN N
loupe NN N
are VBP N
used VBN N
to TO N
generate VB N
the DT N
MC NNP N
from IN N
a DT N
customized JJ N
software NN N
program NN N
. . N

Significant NNP N
minor VBD N
or CC N
major JJ N
changes NNS N
are VBP N
detected VBN N
by IN N
the DT N
serial JJ N
comparison NN N
program NN N
and CC N
referred VBD N
to TO N
a DT N
physician JJ N
coder NN N
for IN N
verification NN N
. . N

Serial JJ N
comparison NN N
coding NN N
rules NNS N
are VBP N
used VBN N
to TO N
adjust VB N
for IN N
weaknesses NNS N
in IN N
the DT N
standard JJ N
MC NNP N
classification NN N
system NN N
resulting VBG N
from IN N
instability NN N
at IN N
decision NN N
boundaries NNS N
. . N

Of IN N
4 CD P
244 CD P
BARI NNP P
randomized VBN P
and CC P
registry NN P
study NN P
participants NNS P
with IN P
follow-up JJ P
ECGs NNP P
received VBD P
at IN P
the DT P
Core NNP P
ECG NNP P
Laboratory NNP P
as IN P
of IN P
March NNP P
1995 CD P
a DT N
grade NN N
2 CD N
MC NNP O
Q NNP O
wave VBP O
progression NN O
was VBD N
noted VBN N
in IN N
568 CD N
participants NNS N
(13.4%) JJ N
using VBG N
MC NNP N
criteria NNS N
alone RB N
as IN N
compared VBN N
with IN N
367 CD N
(8.6%) NNS N
after IN N
the DT N
St NNP N
. . N

Louis NNP N
University NNP N
coding NN N
rules NNS N
were VBD N
applied VBN N
. . N

The DT N
incidence NN N
of IN N
grade NN N
1 CD N
MC NNP O
Q NNP O
wave VBP O
progressions NNS O
was VBD N
16.4% CD N
(697/4 JJ N
244) CD N
versus NN N
6.1% CD N
(259/4 NN N
244) CD N
when WRB N
the DT N
St NNP N
. . N

Louis NNP N
University NNP N
program NN N
was VBD N
applied VBN N
. . N

Intraobserver NNP N
variability NN N
for IN N
grade NN N
2 CD N
Q NNP O
wave VBP O
progression NN O
codes NNS O
determined VBD N
from IN N
a DT N
sample NN N
of IN N
812 CD N
serial NN N
. . N

-DOCSTART- -X- O O

Inverse JJ N
Effect NNP N
of IN N
Fluoxetine NNP I
on IN N
Medial NNP O
Prefrontal NNP O
Cortex NNP O
Activation NNP O
During IN N
Reward NNP N
Reversal NNP N
in IN N
ADHD NNP P
and CC P
Autism NNP P
. . P

Attention NNP P
deficit NN P
hyperactivity NN P
disorder NN P
(ADHD) NN P
and CC P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNP P
share NN N
brain NN N
function NN N
abnormalities NNS N
during IN N
cognitive JJ N
flexibility NN N
. . N

Serotonin NNP N
is VBZ N
involved VBN N
in IN N
both DT N
disorders NNS N
and CC N
selective JJ N
serotonin NN N
reuptake NN N
inhibitors NNS N
(SSRIs) VBP N
can MD N
modulate VB N
cognitive JJ N
flexibility NN N
and CC N
improve VB N
behavior NN N
in IN N
both DT N
disorders NNS N
. . N

Thus RB N
this DT N
study NN N
investigates VBZ N
shared VBN O
and CC O
disorder-specific JJ O
brain NN O
dysfunctions NNS O
in IN N
these DT N
2 CD N
disorders NNS N
during IN N
reward NN N
reversal NN N
and CC N
the DT N
acute JJ N
effects NNS N
of IN N
an DT N
SSRI NNP N
on IN N
these DT N
. . N

Age-matched JJ P
boys NNS P
with IN P
ADHD NNP P
(15) NNP P
ASD NNP P
(18) NNP P
and CC P
controls NNS P
(21) VBP P
were VBD N
compared VBN N
with IN N
functional JJ O
magnetic JJ O
resonance NN O
imaging VBG O
(fMRI) NNP O
during IN N
a DT N
reversal NN N
task NN N
. . N

Patients NNS N
were VBD N
scanned VBN N
twice RB N
under IN N
either DT N
an DT N
acute NN N
dose NN N
of IN N
Fluoxetine NNP I
or CC N
placebo NN I
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ N
randomized VBN N
design NN N
. . N

Repeated-measures JJ N
analyses NNS N
within IN N
patients NNS N
assessed JJ N
drug NN N
effects NNS N
. . N

Patients NNS N
under IN N
each DT N
drug NN N
condition NN N
were VBD N
compared VBN N
with IN N
controls NNS N
to TO N
assess VB N
normalization NN N
effects NNS N
. . N

fMRI NN O
data NNS N
showed VBD N
that IN N
under IN N
placebo NN I
ASD NNP N
boys VBZ N
underactivated JJ N
medial JJ O
prefrontal NN O
cortex NN O
(mPFC) NNS O
compared VBN N
with IN N
control NN N
and CC N
ADHD NNP N
boys NNS N
. . N

Both DT N
patient JJ N
groups NNS N
shared VBD N
decreased JJ N
precuneus NN O
activation NN O
. . O

Under IN N
Fluoxetine NNP I
mPFC FW O
activation NN O
was VBD N
up-regulated JJ N
and CC N
normalized VBN N
in IN N
ASD NNP N
boys NNS N
relative VBP N
to TO N
controls NNS N
but CC N
down-regulated JJ N
in IN N
ADHD NNP N
boys NNS N
relative VBP N
to TO N
placebo VB I
which WDT N
was VBD N
concomitant NN N
with IN N
worse JJR N
task NN O
performance NN O
in IN N
ADHD NNP N
. . N

Fluoxetine NNP I
therefore NN N
has VBZ N
inverse JJ N
effects NNS O
on IN N
mPFC JJ O
activation NN O
in IN N
ASD NNP P
and CC P
ADHD NNP P
during IN N
reversal NN N
learning VBG N
suggesting VBG N
dissociated VBN N
underlying JJ N
serotonin NN N
abnormalities NNS N
. . N

-DOCSTART- -X- O O

Salbutamol NNP I
or CC N
mist NN I
in IN N
acute JJ P
bronchiolitis NN P
. . P

BACKGROUND IN N
The DT N
role NN N
of IN N
bronchodilators NNS N
in IN N
the DT N
treatment NN N
of IN N
bronchiolitis NN P
remains VBZ N
controversial JJ N
. . N

METHODS VB N
A DT N
double-blind JJ N
placebo NN I
controlled VBD N
trial NN N
was VBD N
performed VBN N
to TO N
evaluate VB N
the DT N
clinical JJ O
response NN O
to TO N
nebulized VBN N
salbutamol NN I
. . I

One CD P
hundred CD P
and CC P
fifty-six JJ P
infants NNS P
aged VBN P
between IN P
7 CD P
weeks NNS P
and CC P
24 CD P
months NNS P
who WP P
had VBD P
had VBN P
an DT P
episode NN P
of IN P
wheezing NN P
and CC P
other JJ P
signs NNS P
and CC P
symptoms NNS P
of IN P
bronchiolitis NN P
were VBD N
randomized VBN N
to TO N
three CD N
groups NNS N
as IN N
follows: JJ N
(i) NNP N
nebulized VBD N
salbutamol NN I
was VBD N
administered VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
I PRP N
at IN N
a DT N
dose NN N
of IN N
0.15 CD N
mg/kg NNS N
in IN N
2 CD N
mL NNS N
saline; JJ I
(ii) NNP N
saline NN I
was VBD N
nebulized VBN N
to TO N
52 CD N
patients NNS N
in IN N
group NN N
II NNP N
and CC N
(iii) NNP N
in IN N
group NN N
III NNP N
52 CD N
patients NNS N
received JJ N
mist NN I
in IN N
a DT N
tent NN N
. . N

All DT N
three CD N
groups NNS N
were VBD N
administered VBN N
oxygen NN I
during IN N
the DT N
procedures NNS N
. . N

Treatment NNP N
was VBD N
repeated VBN N
with IN N
the DT N
same JJ N
agent NN N
after IN N
30 CD N
min NN N
if IN N
the DT N
respiratory NN O
score NN O
was VBD N
5 CD N
or CC N
more JJR N
. . N

Respiratory JJ O
rate NN O
heart NN O
rate NN O
oxygen NN O
saturation NN O
and CC O
presence NN O
of IN O
cyanosis NN O
wheezing VBG O
retractions NNS O
were VBD N
recorded VBN N
before IN N
and CC N
after IN N
each DT N
treatment NN N
. . N

RESULTS VB N
The DT N
decrease NN N
in IN N
the DT N
respiratory NN N
score NN N
was VBD N
5.2 CD N
+/- JJ N
1.8 CD N
0.82 CD N
+/- JJ N
2.4 CD N
and CC N
1.7 CD N
+/- JJ N
1.3 CD N
in IN N
group NN N
I PRP N
II NNP N
and CC N
III NNP N
respectively RB N
. . N

The DT N
decrease NN N
in IN N
group NN N
I PRP N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

Heart NNP O
rate NN O
was VBD N
similar JJ N
between IN N
groups NNS N
. . N

Oxygen NNP O
saturation NN O
decreased VBD N
in IN N
group NN N
I PRP N
without IN N
reaching VBG N
statistical JJ N
significance NN N
. . N

CONCLUSIONS NNP N
Salbutamol NNP I
was VBD N
shown VBN N
to TO N
be VB N
effective JJ O
and CC N
safe JJ O
in IN N
the DT N
treatment NN N
of IN N
acute JJ P
bronchiolitis NN P
. . P

-DOCSTART- -X- O O

Assessment NN N
of IN N
acute JJ N
bronchodilator NN I
effects NNS O
from IN N
specific JJ N
airway NN N
resistance NN N
changes NNS N
in IN N
stable JJ P
COPD NNP P
patients NNS P
. . P

BACKGROUND NNP N
In IN N
COPD NNP P
patients NNS P
reversibility NN N
is VBZ N
currently RB N
evaluated VBN N
from IN N
the DT N
changes NNS N
of IN N
forced JJ O
expiratory NN O
volume NN O
at IN O
1s CD O
(ΔFEV1) NN O
and CC O
forced VBD O
vital JJ O
capacity NN O
(ΔFVC) NNP O
. . N

By IN N
lowering VBG N
peripheral JJ N
airway RB N
smooth JJ N
muscle NN N
tone NN I
bronchodilators NNS I
should MD N
decrease VB O
dynamic JJ O
hyperinflation NN O
gas NN O
trapping NN O
and CC N
possibly RB O
dyspnea VB O
at IN O
rest NN O
. . N

Hence NNP N
we PRP N
hypothesize VBP N
that IN O
specific JJ O
airway NN O
resistance NN O
changes NNS O
(ΔsRAW) VBP O
should MD N
better RBR N
characterize VB N
the DT N
acute JJ N
response NN N
to TO I
bronchodilators NNS I
. . N

METHODS NNP N
On IN N
two CD N
days NNS P
60 CD P
COPD NNP P
patients NNS P
underwent JJ O
dyspnea JJ O
evaluation NN O
(VAS NNP O
score) NN O
and CC O
pulmonary JJ O
function NN O
testing VBG O
at IN N
baseline NN N
and CC N
one CD N
hour NN N
after IN I
placebo NN I
or CC N
300μg CD I
indacaterol JJ I
administration NN N
. . N

RESULTS NNP O
Spirographic NNP O
and CC O
ΔsRAW-based JJ O
criteria NNS O
identified VBN N
as IN N
responders NNS N
24 CD N
and CC N
45 CD N
patients NNS N
respectively RB N
. . N

ΔsRAW NN N
correlated VBD N
with IN N
changes NNS O
of IN O
intrathoracic NN O
gas NN O
volume NN O
(ΔITGV) NNP O
(r=0.61; NNP N
p<0.001) VBP O
residual JJ O
volume NN O
(ΔRV) NNP N
(r=0.60; NNP N
p<0.001) NN O
ΔFVC NNP N
(r=0.44; NNP N
p=0.001) NN O
and CC N
ΔVAS NNP N
(r=0.73; NNP N
p<0.001) NN O
while IN O
ΔFEV1 NN N
correlated VBD O
only RB O
with IN N
ΔFVC NNP N
(r=0.34; NNP N
p=0.008) NN N
. . N

Significant JJ N
differences NNS N
in IN O
terms NNS O
of IN N
ΔITGV NNP O
(p=0.002) NNP O
ΔRV NNP N
(p=0.023) NNP O
and CC N
ΔVAS NNP N
(p<0.001) NNP N
occurred VBD N
only RB N
if IN N
patients NNS N
were VBD N
stratified VBN O
according VBG O
to TO N
ΔsRAW NNP N
. . N

CONCLUSIONS NNP N
In IN N
assessing VBG N
the DT N
acute JJ N
functional JJ I
effect NN I
of IN I
bronchodilators NNS N
ΔsRAW-based JJ N
criterion NN N
is VBZ N
preferable JJ N
to TO N
FEV1-FVC-based JJ N
criteria NNS N
being VBG N
more RBR N
closely RB I
related VBN I
to TO I
bronchodilator-induced JJ O
improvements NNS O
of IN O
lung NN O
mechanics NNS O
and CC O
dyspnea NN N
at IN N
rest NN N
. . N

-DOCSTART- -X- O O

[Effect NN N
of IN N
liu JJ I
wei NN I
di NN I
huang NN I
or CC N
jin NN I
gui NN I
shen NN I
qi JJ I
decoction NN N
as IN N
on IN N
adjuvant JJ N
treatment NN N
in IN N
small JJ P
cell NN P
lung NN P
cancer] NN P
. . N

Eighty-three JJ P
patients NNS P
with IN P
small JJ P
cell NN P
lung NN P
cancer NN P
were VBD N
randomized VBN N
with IN N
or CC N
without IN N
using VBG N
a DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP I
decoction NN I
(Liu NNP I
Wei NNP I
Di NNP I
Huang NNP I
or CC N
Jin NNP I
Gui NNP I
Shen NNP I
Qi NNP I
medicinal JJ N
decoction) NN N
in IN N
chemotherapy NN N
or CC N
radiotherapy NN N
courses NNS N
. . N

74 CD P
patients NNS P
were VBD N
availble JJ N
to TO N
be VB N
analysis NN N
. . N

The DT N
two CD N
treatment NN N
groups NNS N
were VBD N
well-matched JJ N
in IN N
age NN N
sex NN N
stage NN N
and CC N
performance NN N
status NN N
. . N

There EX N
was VBD N
a DT N
statistically RB N
significant JJ N
difference NN N
in IN N
response NN O
rate NN O
and CC O
the DT O
median JJ O
survival NN O
between IN N
two CD N
groups NNS N
. . N

The DT N
overall JJ O
response NN O
rate NN O
(CR+PR) NNP N
was VBD N
91.5% CD N
for IN N
Chinese JJ I
herb NN I
group NN N
and CC N
46.9% CD N
for IN N
control NN N
group NN N
(P NNP N
less JJR N
than IN N
0.001) CD N
. . N

The DT N
median JJ O
survival NN O
was VBD N
16 CD N
months NNS N
for IN N
the DT N
traditional JJ N
Chinese JJ N
Kidney-tonifying NNP I
decoction NN I
group NN N
and CC N
10 CD N
months NNS N
for IN N
the DT N
control NN N
group NN N
(P NNP N
less JJR N
than IN N
0.05) CD N
. . N

Survival JJ O
curve JJ O
(Kaplan-meire's) NN O
of IN N
the DT N
Chinese NNP N
herb NN N
group NN N
was VBD N
better JJR N
than IN N
that DT N
of IN N
the DT N
control NN N
group NN N
. . N

10 CD N
patients NNS N
of IN N
Chinese JJ I
herb NN I
group NN N
was VBD N
alive JJ N
beyond IN N
more JJR N
than IN N
2 CD N
years NNS N
. . N

Until IN N
now RB N
4 CD N
patients NNS N
in IN N
the DT N
Chinese JJ I
herb NN I
group NN N
one CD N
in IN N
the DT N
control NN N
group NN N
are VBP N
still RB N
enjoying VBG N
their PRP$ N
disease-free JJ O
life NN O
for IN N
more JJR N
than IN N
7 CD N
years NNS N
. . N

Hematologic NNP O
toxicities NNS O
were VBD N
observed VBN N
much RB N
frequently RB N
in IN N
the DT N
patients NNS N
of IN N
the DT N
control NN N
group NN N
(P NNP N
less JJR N
than IN N
0.005 CD N
and CC N
0.01/WBC CD N
and CC N
BPC) NNP N
. . N

Results NNP N
of IN N
animal JJ N
experiments NNS N
with IN N
the DT N
same JJ N
traditional JJ N
medicinal JJ N
decoctions NNS N
as IN N
used VBN N
in IN N
clinic NN N
have VBP N
showed VBN N
immuno-enhancement JJ O
activities NNS O
. . O

These DT N
results NNS N
have VBP N
showed VBN N
that IN N
the DT N
traditional JJ N
Chinese JJ I
Kidney-tonifying NNP I
decoction NN I
may MD N
enhance VB N
non-specific JJ O
immunology NN O
activities NNS O
and CC N
may MD N
be VB N
much JJ N
useful JJ N
for IN N
solid JJ P
cancer NN P
patients NNS P
as IN N
an DT N
adjuvant JJ N
treatment NN N
. . N

-DOCSTART- -X- O O

Low JJ N
doses NNS N
of IN N
ketazolam NN I
in IN N
anxiety: NN P
a DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
. . N

A DT N
multicenter JJ N
double-blind JJ N
between-patient JJ N
trial NN N
comparing VBG N
two CD N
doses NNS N
of IN N
ketazolam NN I
(15 NNP N
and CC N
30 CD N
mg) NN N
with IN N
placebo JJ I
each DT N
given VBN N
once RB N
daily JJ N
in IN N
the DT N
evening NN N
to TO N
92 CD P
outpatients NNS P
affected VBN P
by IN P
generalized JJ P
anxiety NN P
disorders NNS P
for IN P
at IN P
least JJS P
1 CD P
month NN P
was VBD N
carried VBN N
out RP N
. . N

After IN N
1-week JJ N
washout NN N
period NN N
47 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
ketazolam VB I
15 CD N
mg NN N
and CC N
45 CD N
to TO N
placebo VB I
for IN N
15 CD N
days NNS N
(first RB N
period) VBP N
. . N

At IN N
the DT N
end NN N
of IN N
this DT N
period NN N
if IN N
the DT N
patient NN N
experienced VBD N
a DT N
decrease NN N
on IN N
the DT N
total JJ O
Hamilton NNP O
Anxiety NNP O
Rating NNP O
Scale NNP O
(HAM-A) NN O
of IN N
at IN N
least JJS N
25% CD N
of IN N
basal NN N
value NN N
the DT N
treatment NN N
was VBD N
kept VBN N
unchanged JJ N
for IN N
a DT N
further JJ N
15 CD N
days NNS N
otherwise RB N
15 CD N
mg NN N
of IN N
ketazolam NNS I
were VBD N
added VBN N
to TO N
the DT N
previous JJ N
treatment NN N
(second NN N
period) NN N
. . N

Anxiety NN O
was VBD N
rated VBN N
after IN N
2 CD N
and CC N
4 CD N
weeks NNS N
with IN N
the DT N
Italian JJ O
HAM-A NNP O
scale NN O
and CC O
with IN O
a DT O
4-point JJ O
scale NN O
(patient's NNP O
assessment) NN O
. . O

Seventy-eight JJ P
patients NNS P
completed VBD P
the DT P
first JJ P
period NN P
and CC P
75 CD P
the DT P
whole NN P
study NN P
. . P

During IN N
the DT N
first JJ N
period NN N
the DT N
percentage NN N
of IN N
responders NNS N
was VBD N
almost RB N
identical JJ N
in IN N
both DT N
treatment NN N
groups NNS N
but CC N
during IN N
the DT N
second JJ N
period NN N
a DT N
further JJ N
slight NN N
improvement NN N
was VBD N
observed VBN N
in IN N
the DT N
early JJ N
placebo NN I
responders NNS N
while IN N
the DT N
HAM-A NNP O
score NN O
of IN N
patients NNS N
on IN N
ketazolam NNS I
continued VBN N
to TO N
improve VB N
significantly RB N
(p NNP N
less JJR N
than IN N
0.01) CD N
throughout IN N
the DT N
study NN N
. . N

Likewise VB N
a DT N
significant JJ N
(p NN N
less JJR N
than IN N
0.001) CD N
difference NN N
between IN N
treatments NNS N
was VBD N
observed VBN N
on IN N
the DT N
4-point JJ O
scale NN O
in IN N
the DT N
population NN N
as IN N
a DT N
whole JJ N
(end NN N
of IN N
first JJ N
period) NN N
as RB N
well RB N
as IN N
in IN N
responder NN N
patients NNS N
(end VBP N
second JJ N
period) NN N
. . N

Tolerability NN N
was VBD N
good JJ N
except IN N
in IN N
1 CD N
patient NN N
on IN N
placebo NN I
who WP N
was VBD N
withdrawn VBN N
from IN N
the DT N
study NN N
because IN N
of IN N
severe JJ O
headache NN O
. . O

-DOCSTART- -X- O O

Development NNP O
of IN O
renal JJ O
disease NN O
in IN P
people NNS P
at IN P
high JJ P
cardiovascular JJ P
risk: NN P
results NNS N
of IN N
the DT N
HOPE NNP N
randomized VBD N
study NN N
. . N

In IN N
people NNS P
with IN P
diabetes NNS P
renal JJ N
disease NN N
tends VBZ N
to TO N
progress VB O
from IN O
microalbuminuria NN O
to TO N
clinical JJ O
proteinuria NN O
to TO N
renal JJ O
insufficiency NN O
. . O

Little JJ N
evidence NN N
has VBZ N
been VBN N
published VBN N
for IN N
the DT N
nondiabetic JJ N
population NN N
. . N

This DT N
study NN N
retrospectively RB N
analyzed VBD N
changes NNS O
of IN O
proteinuria NN O
over IN N
4.5 CD N
yr NNS N
in IN N
the DT N
HOPE NNP N
(Heart NNP N
Outcomes NNP N
and CC N
Prevention NNP N
Evaluation) NNP N
study NN N
which WDT N
compared VBN N
ramipril's NN I
effects NNS N
to TO N
placebo VB I
in IN N
9297 CD N
participants NNS N
including VBG N
3577 CD N
with IN N
diabetes NNS N
and CC N
1956 CD N
with IN N
microalbuminuria NN N
. . N

This DT N
report NN N
is VBZ N
restricted VBN N
to TO N
7674 CD P
participants NNS P
with IN P
albuminuria NNS P
data NNS P
at IN P
baseline NN P
and CC P
at IN P
follow-up JJ P
. . P

Inclusion NN P
criteria NNS P
were VBD P
known VBN P
vascular JJ P
disease NN P
or CC P
diabetes VBZ P
plus CC P
one CD P
other JJ P
cardiovascular JJ P
risk NN P
factor NN P
exclusion NN P
criteria NNS P
included VBD P
heart NN P
failure NN P
or CC P
known VBN P
impaired JJ P
left VBD P
ventricular JJ P
function NN P
dipstick-positive JJ P
proteinuria NN P
(>1+) NN P
and CC P
serum JJ P
creatinine NN P
>2.3 NNP P
mg/dl NN P
(200 NNP P
microM) NN P
. . P

Baseline NNP N
microalbuminuria NN N
predicted VBD N
subsequent JJ N
clinical JJ O
proteinuria NN O
for IN N
the DT N
study NN N
participants NNS N
overall JJ N
(adjusted VBD N
odds NNS N
ratio VB N
[OR] RB N
17.5; CD N
95% CD N
confidence NN N
interval NN N
[CI] VBD N
12.6 CD N
to TO N
24.4) CD N
in IN N
participants NNS N
without IN N
diabetes NNS N
(OR VBP N
16.7; CD N
95% CD N
CI NNP N
8.6 CD N
to TO N
32.4) CD N
and CC N
in IN N
participants NNS N
with IN N
diabetes NNS N
(OR VBP N
18.2; CD N
95% CD N
CI NNP N
12.4 CD N
to TO N
26.7) CD N
. . N

Any DT N
progression NN O
of IN O
albuminuria NN O
(defined VBN N
as IN N
new JJ O
microalbuminuria NNS O
or CC O
new JJ O
clinical JJ O
proteinuria) NN O
occurred VBD N
in IN N
1859 CD N
participants; NN N
1542 CD N
developed VBD N
new JJ O
microalbuminuria NNS O
and CC N
317 CD N
participants NNS N
developed VBD N
clinical JJ O
proteinuria NN O
. . O

Ramipril NNP I
reduced VBD N
the DT N
risk NN N
for IN N
any DT N
progression NN O
(OR VBZ N
0.87; CD N
95% CD N
CI NNP N
0.78 CD N
to TO N
0.97; CD N
P NNP N
= VBD N
0.0146) CD N
. . N

People NNS P
without IN P
and CC P
with IN P
diabetes NNS P
who WP P
are VBP P
at IN P
high JJ P
risk NN P
for IN P
cardiovascular JJ P
disease NN P
are VBP N
also RB N
at IN N
risk NN N
for IN N
a DT N
progressive JJ N
rise NN N
in IN N
albuminuria NN O
. . O

Microalbuminuria NNP N
itself PRP N
predicts VBZ N
clinical JJ O
proteinuria NNS O
in IN N
nondiabetic JJ P
and CC P
in IN P
diabetic JJ P
people NNS P
. . P

Ramipril JJ I
prevents NNS N
or CC N
delays VBZ N
the DT N
progression NN O
of IN O
albuminuria NN O
. . O

-DOCSTART- -X- O O

A DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
cross-over JJ N
trial NN N
of IN N
the DT N
impact NN N
on IN N
quality NN O
of IN O
life NN O
of IN N
continuing VBG N
dexamethasone JJ I
beyond IN N
24 h CD N
following VBG P
adjuvant JJ P
chemotherapy NN P
for IN P
breast NN P
cancer NN P
. . N

Uncertainty NN N
remains VBZ N
about IN N
the DT N
optimal JJ N
anti-emetic JJ N
regimen NNS N
for IN N
control NN N
of IN N
delayed JJ N
nausea NN N
and CC N
vomiting NN N
after IN P
adjuvant JJ P
chemotherapy NN P
for IN P
breast NN P
cancer NN P
. . N

Many JJ N
patients NNS N
receive VBP I
dexamethasone NN I
but CC N
complain NN N
of IN N
insomnia JJ N
anxiety/agitation NN N
and CC N
indigestion NN N
. . N

The DT N
aim NN N
was VBD N
to TO N
determine VB N
if IN P
patients NNS P
receiving VBG P
chemotherapy NN P
for IN P
breast NN P
cancer NN P
prefer VBP O
treatment NN N
with IN I
dexamethasone NN I
or CC I
placebo NN I
for IN N
prophylaxis NN N
against IN N
delayed VBN N
nausea NN N
and CC N
vomiting NN N
and CC N
to TO N
compare VB O
quality NN O
of IN O
life NN O
(QOL) NN O
between IN N
the DT N
two CD N
treatments NNS N
. . N

In IN N
this DT N
randomized JJ N
double-blind JJ N
cross-over JJ N
trial NN N
we PRP N
compared VBN N
oral JJ I
dexamethasone NN I
(4 mg NNP N
twice RB N
daily RB N
for IN N
2 days) CD N
versus NN I
placebo NN I
for IN P
chemotherapy-naïve JJ P
patients NNS P
with IN P
breast JJ P
cancer NN P
. . N

All DT N
patients NNS N
received VBD N
intravenous JJ I
granisetron NN I
and CC I
dexamethasone NN I
pre-chemotherapy NN N
and CC N
oral JJ I
granisetron NN I
on IN N
day NN N
2 CD N
. . N

Primary JJ N
endpoints NNS N
were: VBP N
(i) JJ O
patient NN O
preference; NN O
(ii) VBD N
difference NN N
between IN N
cycles NNS O
in IN O
change NN O
of IN O
QOL NNP N
from IN N
days NNS N
1 CD N
to TO P
8 CD P
. . P

Median JJ P
age NN P
of IN P
the DT P
94 CD P
women NNS P
was VBD P
51 years CD P
(range JJ P
27-76): JJ P
79 CD N
received VBN I
fluorouracil/epirubicin/cyclophosphamide RB I
and CC N
15 CD N
received VBD I
doxorubicin/cyclophosphamide NN I
. . N

Thirteen JJ N
withdrew VBD N
pre-cycle JJ N
2 CD N
with IN N
no DT N
differences NNS N
between IN N
arms NNS N
. . N

Of IN N
80 CD N
patients NNS N
stating VBG O
a DT O
preference NN O
31 CD O
preferred JJ I
placebo NN I
(39 % VBD N
95 % CD N
CI: NNP N
28-50 %) JJ N
and CC N
37 CD N
(46 % NNS N
95 % CD N
CI: NNP O
35-58 %) JJ I
preferred VBD I
dexamethasone; JJ I
12 CD O
had VBD O
no DT O
preference NN N
. . N

There EX N
were VBD N
no DT N
differences NNS O
in IN O
intensity NN O
of IN O
vomiting VBG O
nausea NN O
or CC O
time NN O
to TO O
onset VB O
of IN O
vomiting VBG N
. . N

There EX N
was VBD N
greater JJR N
decrease NN O
in IN O
global JJ N
QOL NNP N
(p = 0.06) NN N
when WRB N
patients NNS I
received VBD I
dexamethasone NN I
. . O

No DT O
other JJ O
symptom/QOL NN N
domains NNS N
differed VBD N
significantly RB N
. . N

In IN N
conclusion NN N
no DT N
significant JJ N
difference NN N
was VBD O
found VBN O
in IN O
patient JJ O
preference NN O
QOL NNP O
or CC N
symptoms NNS N
regardless RB I
of IN I
whether IN I
dexamethasone NN I
or CC N
placebo NN N
was VBD P
used VBN P
after IN P
adjuvant JJ P
chemotherapy NN N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
indomethacin JJ I
phonophoresis NN I
on IN N
the DT N
relief NN N
of IN N
temporomandibular JJ P
joint NN P
pain NN P
. . P

The DT N
pain-relieving JJ N
effect NN N
of IN N
indomethacin JJ I
phonophoresis NN I
on IN N
temporomandibular JJ P
(TMJ) NNS P
joint JJ P
pain NN P
was VBD N
evaluated VBN N
in IN N
a DT N
double-blind JJ N
placebo-controlled JJ I
clinical JJ N
trial NN N
. . N

Twenty NNP P
subjects NNS P
who WP P
have VBP P
TMJ NNP P
pain NN P
were VBD P
included VBN P
for IN P
this DT P
study NN P
and CC N
randomly RB N
assigned VBN N
to TO N
either CC N
the DT N
experimental JJ N
group NN N
(n NNP N
= VBZ N
10) CD N
or CC N
the DT N
control NN N
group NN N
(n NNP N
= VBZ N
10) CD N
. . N

Each DT N
treatment NN N
consisted VBN N
of IN N
the DT N
application NN N
of IN N
ultrasound JJ N
massage NN N
(1.0 VBD N
MHz NNP N
0.8 CD N
to TO N
1.5 CD N
W/cm2 NNP N
continuous JJ N
output) NN N
for IN N
15 CD N
minutes NNS N
to TO N
the DT N
painful JJ N
temporomandibular JJ N
joint NN N
. . N

As IN N
a DT N
conducting NN N
medium NN N
1% CD N
indomethacin NN I
cream NN N
was VBD N
used VBN N
for IN N
the DT N
experimental JJ N
group NN N
and CC N
placebo NN I
cream NN N
for IN N
the DT N
control NN N
group NN N
respectively RB N
. . N

Pre- JJ O
and CC O
post-treatment JJ O
pain NN O
levels NNS O
and CC O
pain NN O
sensitivity NN O
were VBD N
assessed VBN N
with IN N
visual JJ O
analogue NN O
scales NNS O
(VAS) NNP O
and CC N
pressure NN O
pain VBP O
threshold JJ O
(PPT) NN O
. . O

Mean NNP N
data NNS N
indicated VBD N
that IN N
post-treatment JJ O
VAS NNP O
was VBD N
significantly RB N
decreased VBN N
and CC N
post-treatment JJ O
PPT NNP O
was VBD N
significantly RB N
increased VBN N
in IN N
the DT N
experimental JJ N
group NN N
not RB N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
indomethacin JJ I
phonophoresis NN I
provides VBZ N
significant JJ N
pain NN N
relieving VBG N
effect NN N
over IN N
the DT N
TMJ NNP P
pain NN P
. . P

-DOCSTART- -X- O O

Insulin NNP I
pump NN I
therapy NN N
started VBD N
at IN N
the DT N
time NN N
of IN N
diagnosis: JJ N
effects NNS N
on IN N
glycemic JJ O
control NN O
and CC O
pancreatic JJ O
β-cell NN O
function NN O
in IN P
type NN P
1 CD P
diabetes NNS P
. . N

BACKGROUND NNP N
In IN N
the DT N
interest NN N
of IN N
preserving VBG N
residual JJ N
insulin NN N
secretory NN N
capacity NN N
present NN N
at IN N
the DT N
time NN N
of IN N
diagnosis NN N
with IN P
type JJ P
1 CD P
diabetes NNS P
(T1D) IN P
we PRP N
compared VBN N
the DT O
efficacy NN O
of IN N
starting VBG I
insulin JJ I
pump NN I
therapy NN N
at IN N
diagnosis NN N
with IN N
standard JJ N
multiple JJ N
daily JJ I
insulin NN I
injections NNS N
(MDIs) VBP N
. . N

METHODS NNP N
We PRP N
conducted VBD N
a DT N
prospective JJ N
randomized VBN N
pilot NN N
trial NN N
comparing VBG I
MDI NNP I
therapy NN N
with IN N
continuous JJ N
subcutaneous JJ I
insulin NN I
therapy NN I
(pump NN I
therapy) NN I
in IN P
24 CD P
patients NNS P
8-18 CD P
years NNS P
old JJ P
with IN P
newly RB P
diagnosed VBN P
T1D NNP P
. . N

Subjects NNS N
were VBD N
evaluated VBN N
at IN N
enrollment NN N
and CC N
1 CD N
3 CD N
6 CD N
9 CD N
and CC N
12 CD N
months NNS N
after IN N
initial JJ N
diagnosis NN N
of IN N
T1D NNP N
. . O

Preservation NN O
of IN O
insulin NN O
secretion NN O
measured VBN O
by IN O
mixed-meal-stimulated JJ O
C-peptide JJ O
secretion NN O
was VBD N
compared VBN N
after IN N
6 CD N
and CC N
12 CD N
months NNS N
of IN N
treatment NN N
. . N

Between-group JJ N
differences NNS N
in IN O
glycosylated JJ O
hemoglobin NN O
(HbA1c) NNP O
continuous JJ O
glucose NN O
sensor NN O
data NNS O
insulin NN O
utilization NN O
anthropometric JJ O
measures NNS O
and CC O
patient JJ O
satisfaction NN O
with IN O
therapy NN O
were VBD N
also RB N
compared VBN N
at IN N
multiple JJ N
time NN N
points NNS N
. . N

RESULTS NNP N
Initiation NNP N
of IN I
pump NN I
therapy NN I
within IN N
1 CD N
month NN N
of IN N
diagnosis NN N
resulted VBD N
in IN N
consistently RB N
higher JJR O
mixed-meal JJ O
tolerance NN O
test-stimulated JJ O
C-peptide JJ O
values NNS O
at IN N
all DT N
time NN N
points NNS N
although IN N
these DT N
differences NNS N
were VBD N
not RB N
statistically RB N
significant JJ N
. . N

Nonetheless RB N
improved JJ O
glycemic JJ O
control NN O
was VBD N
observed VBN N
in IN I
insulin JJ I
pump-treated JJ N
subjects NNS N
(more JJ N
time NN N
spent VBN N
with IN N
normoglycemia JJ N
better JJR N
mean NN O
HbA1c) NNP O
and CC N
pump-treated JJ N
subjects NNS N
reported VBN N
comparatively RB N
greater JJR O
satisfaction NN O
with IN N
route NN N
of IN N
treatment NN N
administration NN N
. . N

CONCLUSIONS NNP N
Initiation NNP N
of IN I
insulin NN I
pump NN I
therapy NN I
at IN N
diagnosis NN N
improved JJ O
glycemic JJ O
control NN O
was VBD N
well RB N
tolerated VBN N
and CC N
contributed VBN N
to TO N
improved VBN O
patient JJ O
satisfaction NN O
with IN N
treatment NN N
. . N

This DT N
study NN N
also RB N
suggests VBZ N
that IN N
earlier JJR N
use NN N
of IN N
pump NN N
therapy NN N
might MD N
help VB N
to TO N
preserve VB O
residual JJ O
β-cell NNP O
function NN O
although IN N
a DT N
larger JJR N
clinical JJ N
trial NN N
would MD N
be VB N
required VBN N
to TO N
confirm VB N
this DT N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
weakness NN O
progression NN O
in IN N
inclusion NN P
body NN P
myositis NN P
during IN N
treatment NN N
with IN N
methotrexate NN I
or CC N
placebo NN I
. . I

We PRP N
investigated VBD N
whether IN N
5 CD N
to TO N
20mg CD N
per IN N
week NN N
oral JJ N
methotrexate NN I
could MD N
slow VB N
down RP N
disease NN O
progression NN O
in IN N
44 CD P
patients NNS P
with IN P
inclusion NN P
body NN P
myositis NN P
in IN N
a DT N
randomized JJ N
double-blind JJ N
placebo-controlled JJ N
study NN N
over IN N
48 CD N
weeks NNS N
. . N

Mean NNP O
change NN O
of IN O
quantitative JJ O
muscle NN O
strength NN O
testing VBG O
sum NN O
scores NNS O
was VBD N
the DT N
primary JJ N
study NN N
outcome JJ N
measure NN N
. . N

Quantitative JJ O
muscle NN O
strength NN O
testing VBG O
sum NN O
scores NNS O
declined VBD N
in IN N
both DT N
treatment NN N
groups NNS N
-0.2% VBP N
for IN N
methotrexate NN I
and CC N
-3.4% NN N
for IN N
placebo NN I
(95% NNP N
confidence NN N
interval NN N
= NNP N
-2.5% NNP N
to TO N
+9.1% VB N
for IN N
difference) NN N
. . N

There EX N
were VBD N
also RB N
no DT N
differences NNS N
in IN N
manual JJ O
muscle NN O
testing VBG O
sum JJ O
scores NNS O
activity NN O
scale NN O
scores NNS O
and CC O
patients' VB O
own JJ O
assessments NNS O
after IN N
48 CD N
weeks NNS N
of IN N
treatment NN N
. . N

Serum NNP O
creatine JJ O
kinase NN O
activity NN O
decreased VBN N
significantly RB N
in IN N
the DT N
methotrexate NN I
group NN N
. . N

We PRP N
conclude VBP N
that IN N
oral JJ N
methotrexate NN I
did VBD N
not RB N
slow VB N
down RP N
progression NN O
of IN O
muscle NN O
weakness NN O
but CC N
decreased VBD N
serum JJ O
creatine JJ O
kinase NN O
activity NN O
. . O

-DOCSTART- -X- O O

Gastric NNP O
dysrhythmia NN O
in IN N
infants NNS P
with IN P
gastrointestinal JJ P
diseases NNS P
measured VBN N
by IN N
epigastric JJ O
impedance NN O
. . O

BACKGROUND NNP N
Gastrointestinal NNP N
symptoms NNS N
have VBP N
been VBN N
reported VBN N
in IN N
association NN N
with IN N
myoelectrical JJ O
dysrhythmia NN O
where WRB N
different JJ N
types NNS N
of IN N
gastric JJ O
electrical JJ O
activity NN O
have VBP N
been VBN N
described VBN N
. . N

These DT N
types NNS N
of IN N
gastric JJ O
myoelectrical JJ O
activity NN O
and CC O
dysrhythmia NN O
can MD N
be VB N
measured VBN N
by IN N
electrogastrography NN O
using VBG N
cutaneous JJ N
electrodes NNS N
. . N

Epigastric JJ I
impedance NN I
is VBZ N
a DT N
non-invasive JJ N
method NN N
used VBN N
to TO N
study VB N
gastric JJ O
emptying VBG O
time NN O
and CC O
gastric JJ O
phasic JJ O
activity NN O
. . O

At IN N
present JJ N
no DT N
study NN N
of IN N
gastric JJ O
dysrhythmia NN O
measured VBN N
with IN N
epigastric JJ I
impedance NN I
has VBZ N
been VBN N
presented VBN N
and CC N
the DT N
purpose NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
gastric JJ O
rhythms NN O
by IN N
means NNS N
of IN N
impedance NN O
gastrography NN O
in IN N
control NN P
infants NNS P
compared VBN P
to TO P
infants NNS P
with IN P
different JJ P
gastrointestinal JJ P
diseases NNS P
before IN P
and CC P
after IN P
treatment NN P
of IN P
their PRP$ P
disease NN P
. . P

METHOD NNP N
21 CD P
patients NNS P
(age JJ P
0-2 JJ P
months) NN P
and CC P
40 CD P
healthy JJ P
infants NNS P
(age VB P
0-2 JJ P
months) NNS P
were VBD N
investigated VBN N
. . N

The DT N
patients NNS P
suffered VBD P
from IN P
partial JJ P
or CC P
total JJ P
intestinal JJ P
obstruction NN P
necrotizing VBG P
enterocolitis NN P
or CC P
pyloric JJ P
stenosis.All NN P
infants NNS P
were VBD P
fasting VBG P
and CC N
studied VBN N
during IN N
periods NNS N
of IN N
at IN N
least JJS N
one CD N
hour NN N
. . N

The DT N
patients NNS N
were VBD N
examined VBN N
in IN N
the DT N
acute NN N
state NN N
and CC N
after IN N
treatment NN N
when WRB N
possible JJ N
. . N

RESULTS VB N
A DT N
pathologic JJ N
result NN N
was VBD N
found VBN N
in IN N
90% CD N
of IN N
the DT N
patients NNS N
. . N

A DT N
persistent JJ N
phasic JJ O
activity NN O
pattern NN N
was VBD N
found VBN N
in IN N
19 CD N
of IN N
the DT N
21 CD N
patients NNS N
high JJ N
frequency NN O
phasic JJ O
activity NN O
in IN N
11 CD N
of IN N
the DT N
21 CD N
patients NNS N
. . N

Short-term JJ N
phasic JJ O
activity NN O
was VBD N
only RB N
found VBN N
in IN N
13 CD N
out IN N
of IN N
40 CD N
of IN N
the DT N
normal JJ N
infants NNS N
(32.5%) VBP N
. . N

CONCLUSION NNP N
Using NNP N
epigastric JJ I
impedance NN I
we PRP N
found VBD N
that IN N
infants NNS P
with IN P
partial JJ P
or CC P
total JJ P
intestinal JJ P
obstruction NN P
had VBD N
gastric JJ N
phasic JJ N
activity NN N
which WDT N
was VBD N
not RB N
found VBN N
in IN N
the DT N
control NN N
infants NNS P
. . P

The DT N
origin NN N
of IN N
the DT N
gastric JJ O
phasic JJ O
activity NN O
patterns NNS O
is VBZ N
unknown JJ N
but CC N
they PRP N
may MD N
be VB N
related VBN N
to TO N
electrical JJ N
control NN N
activity NN N
. . N

-DOCSTART- -X- O O

Therapeutic JJ O
effects NNS O
of IN N
combined JJ N
treatment NN N
using VBG N
tetracycline-immobilized JJ I
collagen NN I
film NN I
and CC I
root NN I
planing NN I
in IN N
periodontal JJ P
furcation NN P
pockets NNS P
. . P

46 CD P
upper JJ P
and CC P
lower JJR P
molars NNS P
with IN P
furcation NN P
grade NN P
II NNP P
involvement NN P
were VBD N
selected VBN N
from IN N
16 CD P
patients NNS P
with IN P
periodontal JJ P
disease NN P
. . P

The DT N
teeth NNS N
were VBD N
randomly RB N
allocated VBN N
to TO N
the DT N
following VBG N
groups NNS N
according VBG N
to TO N
treatment; VB N
(1) JJ N
4 CD N
consecutive JJ N
administrations NNS N
of IN N
tetracycline-immobilized JJ I
cross-linked JJ I
collagen NN I
film NN I
(TC NNP I
film) NN I
at IN N
intervals NNS N
of IN N
1 CD N
week NN N
(TC NNP N
group); NN N
(2) VBD N
1 CD N
root NN I
planing VBG I
treatment NN I
(RP NNP I
group); NN N
(3) NNP N
combination NN N
treatment NN N
(TC NNP I
+ NNP I
RP NNP I
group); NN N
(4) VBZ N
no DT N
treatment NN N
(control NN N
group) NN N
. . N

The DT N
therapeutic JJ O
effects NNS O
of IN N
each DT N
treatment NN N
were VBD N
compared VBN N
both DT N
clinically RB N
and CC N
microbiologically RB N
. . N

Records NNS N
of IN N
plaque NN O
index NN O
gingival NN O
index NN O
bleeding VBG O
on IN O
probing VBG O
probing VBG O
depth JJ O
probing VBG O
attachment JJ O
level NN O
and CC O
microscopic NN O
counts NNS O
were VBD N
obtained VBN N
at IN N
0 CD N
4 CD N
6 CD N
and CC N
8 CD N
weeks NNS N
. . N

The DT N
results NNS N
showed VBD N
marked JJ N
decreases NNS N
in IN N
probing VBG O
depth NN O
and CC O
density NN O
of IN O
micro-organisms NN O
in IN N
both CC N
the DT N
RP NNP I
and CC N
TC NNP I
+ NNP I
RP NNP I
groups NNS N
. . N

In IN N
particular JJ N
the DT N
TC NNP I
+ NNP I
RP NNP I
group NN N
was VBD N
characterized VBN N
by IN N
a DT N
decreased JJ N
rate NN O
of IN O
bleeding VBG O
on IN O
pocket NN O
probing NN O
and CC N
an DT N
increased JJ N
probing NN O
attachment NN O
gain NN O
. . O

The DT N
above JJ N
findings NNS N
demonstrated VBD N
that IN N
root NN I
planning NN I
is VBZ N
effective JJ N
in IN N
the DT N
treatment NN N
of IN N
furcation NN N
involvement NN N
and CC N
that IN N
the DT N
effects NNS N
are VBP N
enhanced VBN N
by IN N
the DT N
local JJ N
administration NN N
of IN N
TC NNP I
films NNS I
. . I

-DOCSTART- -X- O O

Salmeterol NNP I
plus CC N
fluticasone JJ I
propionate NN I
versus IN N
fluticasone NN I
propionate NN I
plus CC N
montelukast: VB I
a DT N
randomised JJ N
controlled VBN N
trial NN N
investigating VBG N
the DT N
effects NNS O
on IN O
airway JJ O
inflammation NN O
in IN N
asthma NN P
. . P

BACKGROUND NNP N
Few NNP N
studies NNS N
have VBP N
compared VBN N
treatment NN N
strategies NNS N
in IN N
patients NNS P
with IN P
asthma JJ P
poorly RB P
controlled VBN P
on IN P
low JJ P
dose NN P
inhaled VBN P
corticosteroids NNS P
and CC N
little JJ N
is VBZ N
known VBN N
about IN N
the DT N
effects NNS N
of IN N
different JJ N
treatments NNS N
on IN N
airway JJ N
inflammation NN N
. . N

In IN N
this DT N
double-blind JJ N
placebo-controlled JJ N
parallel NN N
group NN N
study NN N
we PRP N
compared VBN N
the DT N
effects NNS N
of IN N
salmeterol NN I
plus CC N
fluticasone NN I
propionate NN I
(FP) NNP I
(Seretide; NNP I
SFC) NNP I
and CC N
FP NNP I
plus CC N
montelukast JJ I
(FP/M) NN I
on IN N
sputum NN O
inflammatory NN O
markers NNS O
airway RB O
responsiveness JJ O
lung NN O
function NN O
and CC O
symptoms NNS O
in IN N
adult NN P
asthmatics NNS P
. . P

METHODS NNP N
Sixty-six JJ P
subjects NNS P
were VBD N
randomised VBN N
to TO N
SFC NNP I
or CC N
FP/M NNP I
for IN N
12 CD N
weeks NNS N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
changes NNS O
in IN O
neutrophil JJ O
eosinophil JJ O
macrophage NN O
lymphocyte NN O
and CC O
epithelial JJ O
cell NN O
levels NNS O
in IN O
induced JJ O
sputum NN O
. . O

Additional NNP N
outcomes NNS N
included VBD N
the DT N
change NN O
in IN O
other JJ O
sputum JJ O
markers NNS O
of IN O
airway JJ O
inflammation NN O
airway RB O
responsiveness JJ O
symptom NN O
control NN O
and CC O
lung NN O
function NN O
. . O

RESULTS NNP N
Both NNP N
treatments NNS N
had VBD N
no DT N
significant JJ N
effect NN N
on IN N
induced JJ O
sputum NN O
inflammatory NN O
cells NNS O
although IN N
there EX N
was VBD N
a DT N
trend NN N
for IN N
a DT N
reduction NN N
in IN N
sputum NN O
eosinophils NNS O
. . O

Both DT N
treatments NNS N
significantly RB N
improved VBN N
airway RB O
responsiveness JJ O
whereas NNS N
SFC NNP I
generally RB N
led VBD N
to TO N
greater JJR N
improvements NNS N
in IN N
symptom JJ O
control NN O
and CC O
lung NN O
function NN O
than IN N
FP/M NNP I
. . I

FP/M NNP I
led VBD N
to TO N
significantly RB N
greater JJR N
reductions NNS N
in IN N
sputum NN O
cysteinyl NN O
leukotrienes NNS O
than IN N
SFC NNP I
(treatment NNP N
ratio VBD N
1.80; CD N
95% CD N
CI NNP N
1.09 CD N
2.94) CD N
. . N

CONCLUSION NNP N
Both DT N
treatments NNS N
led VBD N
to TO N
similar JJ N
control NN N
of IN N
eosinophilic JJ O
airway NN O
inflammation NN O
although IN N
PEF NNP N
and CC N
symptom VB O
control NN O
were VBD N
better JJR N
with IN N
SFC NNP I
. . I

STUDY NNP N
NUMBER: NNP N
SAM40030 NNP N
(SOLTA) NNP N
. . N

-DOCSTART- -X- O O

Intermediate-term JJ O
mortality NN O
and CC O
cardiac JJ I
transplantation NN I
in IN N
infants NNS P
with IN P
single-ventricle NN P
lesions: NN P
risk NN O
factors NNS O
and CC N
their PRP$ N
interaction NN N
with IN N
shunt NN N
type NN N
. . N

OBJECTIVE CC N
The DT N
study NN N
objective NN N
was VBD N
to TO N
identify VB N
factors NNS O
associated VBN O
with IN O
death NN O
and CC O
cardiac JJ I
transplantation NN I
in IN N
infants NNS P
undergoing VBG P
the DT P
Norwood NNP P
procedure NN P
and CC N
to TO N
determine VB N
differences NNS N
in IN N
associations NNS N
that WDT N
might MD N
favor VB N
the DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
or CC N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
. . N

METHODS NNP N
We PRP N
used VBD N
competing VBG N
risks NNS N
methodology NN N
to TO N
analyze VB N
death NN O
without IN O
transplantation NN O
cardiac JJ I
transplantation NN I
and CC O
survival NN O
without IN O
transplantation NN O
. . O

Parametric NNP O
time-to-event JJ O
modeling NN O
and CC O
bootstrapping NN O
were VBD O
used VBN O
to TO O
identify VB O
independent JJ O
predictors NNS O
. . O

RESULTS NNP N
Data NNP N
from IN N
549 CD P
subjects NNS P
(follow-up JJ P
2.7 CD P
± JJ P
0.9 CD P
years) NNS P
were VBD N
analyzed VBN N
. . O

Mortality NNP O
risk NN O
was VBD N
characterized VBN N
by IN N
early JJ N
and CC N
constant JJ N
phases; NN N
transplant NN N
was VBD N
characterized VBN N
by IN N
only RB N
a DT N
constant JJ N
phase NN N
. . N

Early JJ N
phase NN N
factors NNS N
associated VBN N
with IN O
death NN O
included VBD N
lower JJR O
socioeconomic JJ O
status NN O
(P NNP N
= NNP N
.01) NNP N
obstructed VBD O
pulmonary JJ O
venous JJ O
return NN O
(P NNP N
< NNP N
.001) NNP N
smaller JJR O
ascending VBG O
aorta JJ O
(P NNP N
= NNP N
.02) NNP N
and CC O
anatomic JJ O
subtype NN O
. . N

Constant JJ N
phase NN N
factors NNS N
associated VBN N
with IN O
death NN O
included VBD O
genetic JJ O
syndrome NN O
(P NNP N
< NNP N
.001) NNP N
and CC N
lower JJR O
gestational JJ O
age NN O
(P NNP N
< NNP N
.001) NNP N
. . N

The DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
demonstrated VBD N
better JJR O
survival NN O
in IN N
the DT N
51% CD N
of IN N
subjects NNS N
who WP N
were VBD N
full JJ N
term NN N
with IN N
aortic JJ N
atresia NN N
(P NNP N
< NNP N
.001) NNP N
. . N

The DT N
modified JJ N
Blalock-Taussig NNP N
shunt NN N
was VBD N
better RBR N
among IN N
the DT N
4% CD N
of IN N
subjects NNS N
who WP N
were VBD N
preterm VBN N
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
(P NNP N
= NNP N
.003) NNP N
. . N

Lower JJR O
pre-Norwood NN O
right JJ O
ventricular JJ O
fractional JJ O
area NN O
change NN O
pre-Norwood NN O
surgery NN O
and CC O
anatomy VBZ O
other JJ O
than IN O
hypoplastic JJ O
left JJ O
heart NN O
syndrome NN O
were VBD N
independently RB N
associated VBN N
with IN N
transplantation NN N
(all NN N
P NNP N
< NNP N
.03) NNP N
but CC N
shunt NN N
type NN N
was VBD N
not RB N
(P JJ N
= NNP N
.43) NNP N
. . N

CONCLUSIONS NNP N
Independent NNP O
risk NN O
factors NNS O
for IN O
intermediate-term JJ O
mortality NN O
include VBP N
lower JJR N
socioeconomic JJ N
status NN N
anatomy JJ N
genetic JJ N
syndrome NN N
and CC N
lower JJR N
gestational JJ N
age NN N
. . N

Term JJ P
infants NNS P
with IN N
aortic JJ N
atresia NN N
benefited VBD N
from IN N
a DT N
right JJ N
ventricle-to-pulmonary JJ N
artery NN N
shunt NN N
and CC N
preterm JJ P
infants NNS P
with IN N
a DT N
patent NN N
aortic JJ N
valve NN N
benefited VBD N
from IN N
a DT N
modified VBN N
Blalock-Taussig NNP N
shunt NN N
. . O

Right NNP O
ventricular JJ O
function NN O
and CC O
anatomy NN O
but CC N
not RB O
shunt VB O
type NN O
were VBD N
associated VBN N
with IN N
transplantation NN N
. . N

-DOCSTART- -X- O O

In IN N
school-aged JJ P
children NNS P
a DT N
combination NN N
of IN N
galacto-oligosaccharides NNS I
and CC I
Lactobacillus NNP I
GG NNP I
increases VBZ N
bifidobacteria RB O
more JJR N
than IN N
Lactobacillus NNP I
GG NNP I
on IN N
its PRP$ N
own JJ N
. . N

The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
a DT N
combination NN N
of IN N
Lactobacillus NNP I
GG NNP I
(LGG) NNP I
and CC I
galacto-oligosaccharides NNS I
(GOS) NN I
with IN N
LGG NNP I
on IN N
its PRP$ N
own JJ N
and CC N
their PRP$ N
effects NNS N
on IN N
the DT N
intestinal JJ O
microbiota NN O
in IN N
school-aged JJ P
children NNS P
. . P

The DT N
randomized JJ N
double-blinded JJ N
crossover NN N
study NN N
comprised VBD N
30 CD P
healthy JJ P
children NNS P
. . P

There EX N
were VBD N
two CD N
3-week JJ N
study NN N
periods NNS N
with IN N
a DT N
4-week JJ N
wash-out JJ N
period NN N
in IN N
between IN N
. . N

The DT N
children NNS N
ingested VBD N
daily RB N
65 CD N
ml NN N
of IN N
milk-based JJ N
fruit NN N
juice NN N
containing VBG N
either CC N
LGG NNP I
alone RB N
(6.5 VBD N
x JJ N
10(9) CD N
CFU) NNP N
or CC N
LGG NNP I
plus CC N
2 CD N
g NN N
of IN N
GOS NNP I
. . I

Symptom NNP O
diaries NNS N
were VBD N
filled VBN N
during IN N
the DT N
study NN N
periods NNS N
. . N

Fecal JJ O
samples NNS O
were VBD N
collected VBN N
at IN N
the DT N
beginning NN N
and CC N
end NN N
of IN N
both DT N
study NN N
periods NNS N
. . N

At IN N
the DT N
end NN N
of IN N
both DT N
study NN N
periods VBD N
the DT N
amount NN O
of IN O
bifidobacteria NN O
was VBD N
significantly RB N
greater JJR N
after IN N
the DT N
ingestion NN N
of IN N
LGG NNP I
+ NNP I
GOS NNP I
compared VBN N
with IN N
LGG NNP I
alone RB N
(geometric JJ N
mean JJ N
9.33 CD N
x $ N
10(9) CD N
vs NN N
. . N

4.28 CD N
x JJ N
10(9) CD N
CFU/g NNP N
p NN N
< VBD N
0.001) CD N
. . N

No DT N
significant JJ N
differences NNS N
were VBD N
seen VBN N
in IN N
the DT N
amount NN N
of IN N
lactobacilli NN O
or CC N
LGG NNP I
nor CC N
did VBD N
gastrointestinal JJ O
symptoms NNS O
defecation NN O
frequency NN O
consistency NN O
of IN O
stools NNS O
or CC O
ease NN O
of IN O
defecation NN O
differ NN N
between IN N
the DT N
two CD N
study NN N
periods NNS N
. . N

Ingestion NN N
of IN N
LGG NNP I
combined VBD N
with IN N
2 CD N
g NN N
of IN N
GOS NNP I
increased VBD N
the DT N
bifidobacteria NN O
more JJR N
than IN N
LGG NNP I
on IN N
its PRP$ N
own JJ N
and CC N
thus RB N
GOS NNP I
clearly RB N
has VBZ N
a DT N
prebiotic JJ O
effect NN O
in IN N
children NNS P
. . P

The DT N
children NNS P
tolerated VBN O
well RB N
a DT N
daily JJ N
intake NN N
of IN N
2 CD N
g NN N
of IN N
GOS NNP I
. . I

-DOCSTART- -X- O O

Ascaris NNP P
and CC N
growth NN O
rates: VBP O
a DT N
randomized JJ N
trial NN N
of IN N
treatment NN N
. . N

Three CD P
hundred VBD P
forty-one NN P
Tanzanian JJ P
preschool NN P
children NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
levamisole VB I
or CC N
placebo VB I
treatment NN N
given VBN N
at IN N
three-month JJ N
intervals NNS N
. . N

Weights NNS O
and CC O
heights NNS O
were VBD N
measured VBN N
at IN N
the DT N
tri-monthly JJ N
treatment NN N
visits NNS N
for IN N
a DT N
period NN N
of IN N
one CD N
year NN N
. . N

Among IN N
the DT N
273 CD N
children NNS P
who WP N
were VBD N
seen VBN N
and CC N
weighed VBN N
at IN N
the DT N
one-year JJ N
follow-up JJ N
visit IN N
the DT N
rate NN O
of IN O
weight NN O
gain NN O
was VBD N
8 CD N
per IN N
cent NN N
greater JJR N
for IN N
those DT N
receiving VBG N
levamisole JJR I
than IN N
for IN N
placebo-treated JJ I
controls NNS N
(p VBP N
= JJ N
.06) NNP N
. . N

In IN N
78 CD N
children NNS P
known VBN N
to TO N
be VB N
infected VBN N
with IN N
Ascaris NNP N
at IN N
baseline PDT N
the DT N
rate NN O
of IN O
weight NN O
gain NN O
was VBD N
21 CD N
per IN N
cent NN N
greater JJR N
in IN N
children NNS N
treated VBN N
with IN N
levamisole NN I
than IN N
in IN N
those DT N
receiving VBG N
placebo NN I
(p NNP N
= NNP N
.03) NNP N
. . N

The DT N
rate NN O
of IN O
height NN O
gain NN O
was VBD N
no DT N
different JJ N
for IN N
treatment NN N
and CC N
placebo NN I
groups NNS N
. . N

-DOCSTART- -X- O O

Visual JJ I
and CC I
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
integrated VBN I
with IN I
auditory JJ I
step NN I
rhythm NN I
for IN N
walking VBG O
performance NN O
of IN N
patients NNS P
with IN P
chronic JJ P
stroke NN P
. . P

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
visual JJ I
and CC I
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
on IN N
walking VBG O
performance NN O
and CC N
to TO N
determine VB N
the DT N
clinical JJ N
feasibility NN N
of IN N
incorporating VBG N
auditory JJ I
step NN I
rhythm NN I
into IN N
the DT N
training NN N
. . N

DESIGN NNP N
Randomized NNP N
crossover NN N
trial NN N
. . N

SETTING NNP N
Laboratory NNP N
of IN N
a DT N
Department NNP N
of IN N
Physical NNP N
Therapy NNP N
. . N

SUBJECTS NNP N
Fifteen NNP P
subjects VBZ P
with IN P
post-stroke JJ P
hemiparesis NN P
. . P

INTERVENTION NNP N
Four NNP N
locomotor NN I
imagery NN I
trainings NNS I
on IN N
walking VBG N
performance: JJ N
visual JJ I
locomotor NN I
imagery NN I
training NN I
kinesthetic JJ I
locomotor NN I
imagery NN I
training VBG I
visual JJ I
locomotor NN I
imagery NN I
training NN I
with IN I
auditory JJ I
step NN I
rhythm NN I
and CC N
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
with IN I
auditory JJ I
step NN I
rhythm NN I
. . I

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
The DT O
timed JJ O
up-and-go JJ O
test NN O
and CC O
electromyographic JJ O
and CC O
kinematic JJ O
analyses NNS O
of IN O
the DT O
affected JJ O
lower JJR O
limb NN O
during IN N
one CD N
gait NN N
cycle NN N
. . N

RESULTS NNP N
After IN N
the DT N
interventions NNS N
significant JJ N
differences NNS N
were VBD N
found VBN N
in IN N
the DT N
timed JJ O
up-and-go JJ O
test NN O
results NNS N
between IN N
the DT N
visual JJ I
locomotor NN I
imagery NN I
training NN I
(25.69 NNP N
± VBZ N
16.16 CD N
to TO N
23.97 CD N
± NNS N
14.30) CD N
and CC N
the DT I
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
with IN I
auditory JJ I
step NN I
rhythm NN I
(22.68 NNP N
± VBZ N
12.35 CD N
to TO N
15.77 CD N
± NNS N
8.58) CD N
(P NNP N
< VBD N
0.05) CD N
. . N

During IN N
the DT N
swing NN N
and CC N
stance NN N
phases VBZ N
the DT I
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
exhibited VBN N
significantly RB N
increased VBN N
activation NN N
in IN N
a DT N
greater JJR O
number NN O
of IN O
muscles NNS O
and CC N
increased VBD O
angular JJ O
displacement NN O
of IN O
the DT O
knee NN O
and CC O
ankle NN O
joints NNS O
compared VBN N
with IN N
the DT I
visual JJ I
locomotor NN I
imagery NN I
training NN I
and CC N
these DT N
effects NNS N
were VBD N
more RBR N
prominent JJ N
when WRB I
auditory JJ I
step NN I
rhythm NN I
was VBD N
integrated VBN N
into IN N
each DT N
form NN I
of IN I
locomotor NN I
imagery NN I
training NN I
. . N

The DT N
activation NN N
of IN N
the DT N
hamstring NN N
during IN N
the DT N
swing JJ N
phase NN N
and CC N
the DT N
gastrocnemius NN N
during IN N
the DT N
stance NN N
phase NN N
as RB N
well RB O
as IN O
kinematic JJ O
data NNS O
of IN O
the DT O
knee NN O
joint NN O
were VBD N
significantly RB N
different JJ N
for IN N
posttest JJS N
values NNS N
between IN N
the DT I
visual JJ I
locomotor NN I
imagery NN I
training NN I
and CC N
the DT I
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
with IN I
auditory JJ I
step NN I
rhythm NN I
(P NNP N
< VBZ N
0.05) CD N
. . N

CONCLUSIONS VB N
The DT O
therapeutic JJ O
effect NN O
may MD N
be VB N
further RB N
enhanced VBN N
in IN N
the DT I
kinesthetic JJ I
locomotor NN I
imagery NN I
training NN I
than IN N
in IN N
the DT I
visual JJ I
locomotor NN I
imagery NN I
training NN I
. . N

The DT I
auditory JJ I
step NN I
rhythm VBZ I
together RB N
with IN N
the DT I
locomotor NN I
imagery NN I
training NN I
produces VBZ N
a DT N
greater JJR N
positive JJ N
effect NN N
in IN N
improving VBG N
the DT O
walking VBG O
performance NN P
of IN P
patients NNS P
with IN P
post-stroke JJ P
hemiparesis NN P
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
simvastatin NN I
on IN N
hemostasis NN O
in IN N
patients NNS P
with IN P
isolated JJ P
hypertriglyceridemia NN P
. . P

BACKGROUNDS/AIMS NNP N
Elevated NNP N
triglyceride NN N
levels NNS N
seem VBP N
to TO N
predispose VB N
to TO N
the DT N
earlier JJR N
development NN N
and CC N
accelerated JJ N
progression NN N
of IN N
coronary JJ N
artery NN N
disease NN N
. . N

In IN N
our PRP$ N
study NN N
we PRP N
assessed VBD N
for IN N
the DT N
first JJ N
time NN N
whether IN N
simvastatin JJ I
treatment NN N
affects NNS N
coagulation NN O
and CC O
fibrinolysis NN O
in IN N
patients NNS P
with IN P
isolated JJ P
hypertriglyceridemia NN P
. . P

METHODS NNP N
The DT N
study NN N
included VBD N
39 CD P
patients NNS P
with IN P
elevated JJ P
triglyceride NN P
levels NNS P
and CC P
peripheral JJ P
artery NN P
sclerosis NN P
treated VBD N
for IN N
90 CD N
days NNS N
with IN N
either DT N
simvastatin NN I
(40 NN N
mg NN N
daily) NN N
or CC N
placebo NN I
. . I

Plasma NNP O
lipids NNS O
glucose VBP O
homeostasis NN O
markers NNS O
and CC O
hemostasic JJ O
variables NNS O
were VBD N
assessed VBN N
at IN N
baseline NN N
and CC N
after IN N
treatment NN N
. . N

RESULTS NNP N
Simvastatin NNP I
but CC N
not RB N
placebo RB I
administered VBN N
to TO N
these DT N
patients NNS N
reduced VBD N
plasma JJ O
levels/activity NN O
of IN O
fibrinogen NN O
(from IN N
3.5 CD N
± $ N
0.4 CD N
to TO N
2.8 CD N
± NNS N
0.3 CD N
g/l NNS N
p JJ N
< VBP N
0.01) CD O
factor NN O
VII NNP O
(from VBZ N
144.2 CD N
± NN N
16.9 CD N
to TO N
112.5 CD N
± NNS N
14.0% CD N
p NN N
< NN N
0.01) CD N
and CC O
plasminogen JJ O
activator NN O
inhibitor-1 JJ O
(from NN N
76.9 CD N
± $ N
13.5 CD N
to TO N
50.2 CD N
± NNS N
9.2 CD N
ng/ml JJ N
p NN N
< VBD N
0.001) CD N
without IN N
a DT N
significant JJ N
reduction NN O
in IN O
von NN O
Willebrand NNP O
factor NN O
levels NNS O
and CC N
tended VBD N
to TO N
prolong VB O
the DT O
prothrombin NN O
and CC O
partial JJ O
thromboplastin NN O
times NNS N
. . N

CONCLUSION NNP N
Our PRP$ N
results NNS N
suggest VBP I
that IN I
statin NN I
treatment NN N
produces VBZ N
a DT N
multidirectional JJ N
effect NN O
on IN O
coagulation NN O
and CC O
fibrinolysis NN P
in IN P
patients NNS P
with IN P
isolated JJ P
hypertriglyceridemia NN P
and CC N
that IN N
this DT N
treatment NN N
may MD N
bring VB N
some DT N
benefits NNS P
to TO P
patients NNS P
with IN P
elevated JJ P
triglyceride NN P
levels NNS P
. . N

-DOCSTART- -X- O O

Long-term JJ O
survival NN O
in IN N
a DT N
phase NN N
III NNP N
randomised VBD N
study NN N
of IN N
topotecan JJ I
versus NN N
paclitaxel NN I
in IN N
advanced JJ P
epithelial JJ P
ovarian JJ P
carcinoma NN P
. . P

BACKGROUND IN N
We PRP N
have VBP N
continued VBN N
to TO N
monitor VB N
the DT N
survival NN O
of IN N
patients NNS N
randomised VBN N
in IN N
a DT N
previously RB N
reported VBN N
multicentre JJ N
phase NN N
III NNP N
study NN N
of IN N
topotecan JJ I
versus NN N
paclitaxel NN I
in IN N
patients NNS P
with IN P
advanced JJ P
epithelial JJ P
ovarian JJ P
cancer NN P
who WP P
had VBD P
failed VBN P
one CD P
prior JJ P
platinum-based JJ P
regimen NNS P
. . P

PATIENTS NNP N
AND CC N
METHODS NNP N
Patients NNPS P
with IN P
bidimensionally RB P
measurable JJ P
disease NN P
were VBD N
randomised VBN N
to TO N
topotecan VB I
(1.5 NNP N
mg/m(2)/day NN N
for IN N
5 CD N
days) NN N
or CC N
paclitaxel NN I
(175 RB N
mg/m(2)/day RB N
as IN N
a DT N
3-h JJ N
infusion) NN N
every DT N
21 CD N
days NNS N
. . N

Patients NNS N
were VBD N
eligible JJ N
for IN N
treatment NN N
with IN N
the DT N
alternate NN N
therapy NN N
at IN N
third JJ N
line NN N
. . N

The DT O
European JJ O
Organisation NNP O
for IN O
Research NNP O
and CC O
Treatment NNP O
of IN O
Cancer NNP O
Quality NNP O
of IN O
Life NNP O
(EORTC NNP O
QOL)-C30 NNP O
questionnaire NN O
was VBD N
also RB N
used VBN N
to TO N
measure VB N
eight CD N
symptoms NNS N
at IN N
baseline NN N
and CC N
during IN N
each DT N
course NN N
(pain VBP O
anorexia JJ O
diarrhoea NN O
fatigue NN O
nausea NN O
and CC O
vomiting VBG O
dyspnea NN O
constipation NN O
and CC O
insomnia) NN O
. . N

RESULTS VB N
A DT P
total NN P
of IN P
226 CD P
patients NNS P
were VBD P
evaluable JJ P
for IN P
response NN P
. . P

Demographic JJ N
characteristics NNS N
were VBD N
similar JJ N
in IN N
both DT N
treatment NN N
groups NNS N
as IN N
were VBD N
results NNS N
of IN N
the DT N
EORTC NNP O
QOL-30 NNP O
questionnaire NN O
. . O

For IN N
the DT N
topotecan JJ I
group NN N
median JJ N
time NN N
to TO N
progression NN O
was VBD N
18.9 CD N
weeks NNS N
(range VBP N
<1 NN N
to TO N
92.6+ CD N
weeks; NNS N
25% CD N
censored) NNS N
and CC N
for IN N
paclitaxel JJ I
14.7 CD N
weeks NNS N
(range VBP N
<1 NN N
to TO N
137.3+ CD N
weeks; NNS N
12.3% CD N
censored); NN N
P NNP N
= VBZ N
0.076 CD N
. . N

At IN N
4 CD N
years NNS N
post-randomisation JJ N
median JJ O
survival NN O
in IN N
the DT N
topotecan JJ I
group NN N
was VBD N
63.0 CD N
weeks NNS N
(range VBP N
<1 NN N
to TO N
238.4+ CD N
weeks; NNS N
20.5% CD N
censored) NNS N
and CC N
for IN N
paclitaxel JJ I
53.0 CD N
weeks NNS N
(range VBP N
<1 NN N
to TO N
226.3+ CD N
weeks; NNS N
12.3% CD N
censored); NN N
P NNP N
= VBZ N
0.44 CD N
. . N

CONCLUSION NNP N
Topotecan NNP I
continues VBZ N
to TO N
demonstrate VB N
comparable JJ N
efficacy NN O
and CC N
survival NN O
to TO N
paclitaxel VB I
with IN N
manageable JJ N
and CC N
non-cumulative JJ N
haematological JJ O
toxicity NN O
. . O

Non-haematological JJ O
toxicity NN O
was VBD N
generally RB N
mild VBN N
for IN N
both DT N
groups NNS N
. . N

The DT N
long-term JJ O
survival NN O
rate NN O
indicates VBZ N
substantial JJ N
therapeutic JJ N
benefit NN N
for IN N
this DT N
group NN N
of IN N
patients NNS N
receiving VBG N
topotecan JJ I
at IN N
relapse NN P
of IN P
ovarian JJ P
cancer NN P
. . P

-DOCSTART- -X- O O

Regional JJ N
ventricular JJ N
performance NN N
and CC N
exercise NN I
training NN I
in IN N
children NNS P
and CC P
young JJ P
adults NNS P
after IN P
repair NN P
of IN P
tetralogy NN P
of IN P
Fallot: NNP P
randomized VBD N
controlled VBN N
pilot NN N
study NN N
. . N

BACKGROUND NNP N
Public-health NNP N
guidelines NNS N
recommend VBP N
patients NNS P
with IN P
congenital JJ P
heart NN P
disease NN P
to TO N
exercise VB N
. . N

Studies NNS N
have VBP N
shown VBN N
that IN N
patients NNS P
with IN P
congenital JJ P
heart NN P
disease NN P
can MD N
improve VB N
physical JJ N
exercise NN N
capacity NN N
. . N

The DT N
effect NN N
of IN N
training VBG I
on IN N
regional JJ O
ventricular JJ O
performance NN O
has VBZ N
hardly RB N
been VBN N
studied VBN N
. . N

We PRP N
performed VBD N
a DT N
pilot NN N
study NN N
to TO N
assess VB N
whether IN N
an DT N
exercise NN I
training NN I
program NN I
would MD N
result VB N
in IN N
adverse JJ O
changes NNS O
of IN O
regional JJ O
ventricular JJ O
performance NN O
in IN N
patients NNS P
with IN P
corrected JJ P
tetralogy NN P
of IN P
Fallot NNP P
. . P

METHODS NNP N
AND CC N
RESULTS NNP N
Multicenter NNP N
prospective JJ N
randomized VBN N
controlled VBN N
pilot NN N
study NN N
in IN N
patients NNS P
with IN P
tetralogy NN P
of IN P
Fallot NNP P
aged VBD P
10 CD P
to TO P
25 CD P
years NNS P
. . P

A DT N
12-week JJ N
standardized JJ N
aerobic JJ N
dynamic JJ N
exercise NN I
training NN I
program NN I
(3 VBZ N
one-hour JJ N
sessions NNS N
per IN N
week) NN N
was VBD N
used VBN N
. . N

Pre- JJ N
and CC N
post-training JJ N
cardiopulmonary JJ O
exercise NN O
tests NNS O
MRI NNP O
and CC O
echocardiography NN O
including VBG O
tissue-Doppler JJ O
imaging NN O
were VBD N
performed VBN N
. . N

Patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
exercise NN I
group NN N
(n=28) VBD N
or CC N
control VB I
group NN N
(n=20) NNP N
. . N

One CD N
patient NN N
in IN N
the DT N
exercise NN I
group NN N
dropped VBD N
out RP N
. . N

Change VB O
in IN O
tissue-Doppler NN O
imaging NN O
parameters NNS O
was VBD N
similar JJ N
in IN N
the DT N
exercise NN I
group NN N
and CC N
control NN I
group NN N
(change VBP N
in IN N
right JJ N
ventricle NN N
free JJ N
wall NN N
peak NN N
velocity NN N
E' NNP N
exercise NN I
group NN N
0.8±2.6 CD N
cm/s; NN I
control NN I
group NN N
0.9±4.1; CD N
peak NN N
velocity NN N
A' NNP I
exercise NN I
group NN N
0.4±2.4 CD N
m/s; NN I
control NN I
group NN N
4.6±18.1 CD N
cm/s) NN N
. . N

CONCLUSIONS VB N
This DT N
randomized VBN N
controlled VBD N
pilot NN N
study NN N
provides VBZ N
preliminary JJ N
data NNS N
suggesting VBG N
that IN O
regional JJ O
ventricular JJ O
performance NN O
is VBZ N
well RB N
maintained VBN N
during IN N
3-month JJ N
aerobic JJ N
dynamic JJ I
exercise NN I
training NN P
in IN P
children NNS P
and CC P
young JJ P
adults NNS P
with IN P
repaired JJ P
tetralogy NN P
of IN P
Fallot NNP P
. . N

This DT N
information NN N
might MD N
help VB N
patients NNS N
adhere VB N
to TO N
current JJ N
public-health NN N
guidelines NNS N
. . N

CLINICAL JJ N
TRIAL NNP N
REGISTRATION NNP N
URL: NNP N
http//:www.trialregister.nl NN N
. . N

Unique NNP N
identifier: JJ N
NTR2731 NNP N
. . N

-DOCSTART- -X- O O

Safety NN O
and CC N
preliminary JJ O
immunogenicity NN O
of IN N
Cuban NNP P
pneumococcal JJ P
conjugate NN P
vaccine NN P
candidate NN P
in IN P
healthy JJ P
children: NN P
a DT N
randomized JJ N
phase NN N
I PRP N
clinical JJ N
trial NN N
. . N

A DT N
new JJ N
heptavalent NN I
conjugate NN I
vaccine NN I
(PCV7-TT) NN I
is VBZ N
under IN N
development NN N
in IN N
Cuba NNP N
. . N

PCV7-TT NNP I
contains VBZ N
2 CD N
μg NN N
of IN N
serotypes NNS N
1 CD N
5 CD N
14 CD N
18C CD N
19F CD N
23F CD N
and CC N
4 CD N
μg NN N
of IN N
6B CD N
each DT N
one CD N
conjugated VBN N
to TO N
tetanus VB N
toxoid JJ N
(TT) NN N
. . N

This DT N
vaccine NN N
was VBD N
designed VBN N
with IN N
the DT N
serotypes NNS N
that WDT N
cause VBP N
most RBS N
invasive JJ N
pneumococcal JJ N
diseases NNS N
(IPD) VBP N
worldwide NN N
. . N

In IN N
the DT N
present JJ N
study NN N
we PRP N
investigated VBD N
the DT O
safety NN O
and CC N
explored VBD N
the DT O
immunogenicity NN O
of IN I
PCV7-TT NNP I
during IN N
a DT N
controlled VBN N
randomized NN N
and CC N
double JJ N
blind NN N
clinical JJ N
trial NN N
phase NN N
I PRP N
in IN P
4-5-year-old JJ P
children NNS P
. . I

PCV7-TT NN I
was VBD N
well RB O
tolerated JJ O
and CC N
as RB O
safe JJ O
as IN I
Synflorix NNP I
used VBD N
as IN N
control NN N
vaccine NN N
. . N

Following VBG N
a DT N
single-dose JJ N
vaccination NN N
all DT N
individual JJ N
serotypes NNS N
included VBN N
in IN I
PCV7-TT NNP I
induced VBD N
statistically RB N
significant JJ N
increase NN N
of IN O
IgG NNP O
GMC NNP O
and CC O
OPA NNP O
GMT NNP O
. . N

These DT N
are VBP N
the DT N
first JJ N
clinical JJ N
results NNS N
of IN I
PCV7-TT NNP I
in IN P
children NNS P
and CC N
they PRP N
pave VBP N
the DT N
way NN N
toward IN N
next JJ N
clinical JJ N
trials NNS N
in IN N
children NNS N
and CC N
infants NNS N
. . N

This DT N
clinical JJ N
trial NN N
was VBD N
published VBN N
in IN N
the DT N
Cuban NNP N
Public NNP N
Register NNP N
of IN N
Clinical NNP N
Trials NNP N
with IN N
code NN N
RPCEC00000173 NNP N
. . N

-DOCSTART- -X- O O

The DT N
prophylactic JJ O
effect NN O
of IN N
itraconazole JJ I
capsules NNS N
and CC N
fluconazole JJ I
capsules NNS N
for IN N
systemic JJ N
fungal JJ N
infections NNS N
in IN N
patients NNS P
with IN P
acute JJ P
myeloid NN P
leukemia NN P
and CC P
myelodysplastic JJ P
syndromes: NN P
a DT N
Japanese JJ P
multicenter NN N
randomized VBD N
controlled VBN N
study NN N
. . N

We PRP N
performed VBD N
a DT N
randomized VBN N
controlled VBN N
study NN N
comparing VBG N
the DT N
prophylactic JJ O
effects NNS O
of IN N
capsule NN N
forms NNS N
of IN N
fluconazole JJ I
(n NNP N
= NNP N
110) CD N
and CC N
itraconazole JJ I
(n NNP N
= NNP N
108) CD N
in IN N
patients NNS P
with IN P
acute JJ P
myeloid NN P
leukemia NN P
(AML) NN P
or CC P
myelodysplastic JJ P
syndromes NNS P
(MDS) VBP P
during IN P
and CC P
after IN P
chemotherapy NN P
. . P

There EX N
were VBD N
4 CD N
cases NNS N
with IN N
possible JJ N
systemic JJ N
fungal JJ N
infection NN N
in IN N
the DT N
itraconazole JJ I
group NN N
and CC N
there EX N
were VBD N
8 CD N
possible JJ N
and CC N
3 CD N
probable JJ N
cases NNS N
in IN N
the DT N
fluconazole JJ I
group NN N
. . N

Adverse JJ O
events NNS O
did VBD N
not RB N
significantly RB N
differ VB N
in IN N
the DT N
2 CD N
groups NNS N
. . N

In IN N
patients NNS N
with IN N
MDS NNP N
or CC N
in IN N
the DT N
remission-induction JJ N
phase NN N
of IN N
chemotherapy NN N
the DT N
numbers NNS N
of IN N
cases NNS O
with IN O
probable JJ O
or CC O
possible JJ O
infections NNS O
were VBD N
lower JJR N
in IN N
the DT N
itraconazole NN I
group NN N
than IN N
in IN N
the DT N
fluconazole JJ I
group NN N
whereas VBZ N
no DT N
difference NN N
was VBD N
seen VBN N
in IN N
patients NNS N
with IN N
AML NNP N
or CC N
in IN N
the DT N
consolidation NN N
phase NN N
of IN N
therapy NN N
. . N

In IN N
patients NNS N
with IN N
neutrophil JJ N
counts NNS N
of IN N
>0.1 NNP N
x NNP N
10(9)/L CD N
lasting VBG N
for IN N
more JJR N
than IN N
4 CD N
weeks NNS N
the DT N
frequency NN O
of IN O
infection NN O
in IN N
the DT N
fluconazole JJ I
group NN N
(5 NNP N
of IN N
9 CD N
patients) NN N
was VBD N
significantly RB N
higher JJR N
than IN N
in IN N
the DT N
itraconazole JJ I
group NN N
(0 NNP N
of IN N
7 CD N
patients; NNS N
P NNP N
= NNP N
.03) NNP N
. . N

Our PRP$ N
results NNS N
suggest VBP N
that IN N
both DT N
drugs NNS N
were VBD N
well RB N
tolerated VBN N
in IN N
patients NNS P
with IN P
AML NNP P
or CC P
MDS NNP P
who WP P
received VBD P
chemotherapy NN P
and CC N
that IN N
the DT N
efficacy NN O
of IN N
itraconazole NN I
for IN N
prophylaxis NN N
against IN N
systemic JJ N
fungal JJ N
disease NN N
is VBZ N
not RB N
inferior JJ N
to TO N
that DT N
of IN N
fluconazole NN I
. . I

-DOCSTART- -X- O O

Use NNP N
of IN N
hormonal JJ I
contraceptives NNS I
and CC N
risk NN O
of IN O
HIV-1 NNP O
transmission: NN O
a DT N
prospective JJ N
cohort NN N
study NN N
. . N

BACKGROUND NNP N
Hormonal NNP I
contraceptives NNS I
are VBP N
used VBN N
widely RB N
but CC N
their PRP$ N
effects NNS N
on IN N
HIV-1 NNP N
risk NN N
are VBP N
unclear JJ N
. . N

We PRP N
aimed VBD N
to TO N
assess VB N
the DT N
association NN N
between IN N
hormonal JJ I
contraceptive NN I
use NN N
and CC N
risk NN O
of IN O
HIV-1 NNP O
acquisition NN O
by IN N
women NNS N
and CC N
HIV-1 JJ O
transmission NN O
from IN N
HIV-1-infected JJ N
women NNS N
to TO N
their PRP$ N
male JJ N
partners NNS N
. . N

METHODS NNP N
In IN N
this DT N
prospective JJ N
study NN N
we PRP N
followed VBD N
up RP N
3790 CD P
heterosexual JJ P
HIV-1-serodiscordant JJ P
couples NNS P
participating VBG P
in IN P
two CD P
longitudinal JJ P
studies NNS P
of IN P
HIV-1 NNP P
incidence NN P
in IN P
seven CD P
African JJ P
countries NNS P
. . P

Among IN N
injectable JJ N
and CC N
oral JJ N
hormonal JJ I
contraceptive NN I
users NNS N
and CC N
non-users NNS N
we PRP N
compared VBN N
rates NNS O
of IN O
HIV-1 NNP O
acquisition NN O
by IN N
women NNS N
and CC N
HIV-1 JJ O
transmission NN O
from IN N
women NNS N
to TO N
men NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
HIV-1 JJ O
seroconversion NN O
. . O

We PRP N
used VBD N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
and CC N
marginal JJ N
structural JJ N
modelling NN N
to TO N
assess VB N
the DT N
effect NN N
of IN N
contraceptive NN N
use NN N
on IN N
HIV-1 NNP O
risk NN O
. . O

FINDINGS NNP N
Among IN P
1314 CD P
couples NNS P
in IN P
which WDT P
the DT P
HIV-1-seronegative JJ P
partner NN P
was VBD P
female JJ P
(median JJ N
follow-up JJ N
18·0 CD N
[IQR JJ N
12·6-24·2] JJ N
months) NN N
rates NNS N
of IN O
HIV-1 NNP O
acquisition NN O
were VBD N
6·61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
women NNS N
who WP N
used VBD I
hormonal JJ I
contraception NN I
and CC N
3·78 CD N
per IN N
100 CD N
person-years NNS N
in IN N
those DT N
who WP N
did VBD N
not RB N
(adjusted VBN N
hazard NN N
ratio NN N
1·98 CD N
95% CD N
CI NNP N
1·06-3·68 JJ N
p=0·03) NN P
. . P

Among IN P
2476 CD P
couples NNS P
in IN P
which WDT P
the DT P
HIV-1-seronegative JJ P
partner NN P
was VBD N
male JJ N
(median JJ N
follow-up JJ N
18·7 CD N
[IQR JJ N
12·8-24·2] JJ N
months) NN O
rates NNS O
of IN O
HIV-1 NNP O
transmission NN O
from IN N
women NNS N
to TO N
men NNS N
were VBD N
2·61 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT I
women NNS I
used VBD I
hormonal JJ I
contraception NN I
and CC N
1·51 CD N
per IN N
100 CD N
person-years NNS N
in IN N
couples NNS N
in IN N
which WDT N
women NNS I
did VBD I
not RB I
use VB I
hormonal JJ I
contraception NN N
(adjusted VBD N
hazard RB N
ratio JJ N
1·97 CD N
95% CD N
CI NNP N
1·12-3·45 JJ N
p=0·02) NN N
. . N

Marginal JJ N
structural JJ N
model NN N
analyses NNS N
generated VBD N
much RB N
the DT N
same JJ N
results NNS N
to TO N
the DT N
Cox NNP N
proportional JJ N
hazards NNS N
regression NN N
. . N

INTERPRETATION NNP N
Women NNP N
should MD N
be VB N
counselled VBN N
about IN N
potentially RB O
increased VBN O
risk NN O
of IN O
HIV-1 NNP O
acquisition NN O
and CC N
transmission NN I
with IN I
hormonal JJ I
contraception NN N
especially RB N
injectable JJ N
methods NNS N
and CC N
about IN N
the DT N
importance NN N
of IN N
dual JJ N
protection NN N
with IN N
condoms NNS N
to TO N
decrease VB N
HIV-1 NNP N
risk NN N
. . N

Non-hormonal JJ I
or CC I
low-dose JJ I
hormonal JJ I
contraceptive NN N
methods NNS N
should MD N
be VB P
considered VBN P
for IN N
women NNS N
with IN N
or CC N
at-risk JJ N
for IN N
HIV-1 NNP N
. . N

FUNDING NNP N
US NNP N
National NNP N
Institutes NNP N
of IN N
Health NNP N
and CC N
the DT N
Bill NNP N
& CC N
Melinda NNP N
Gates NNP N
Foundation NNP N
. . N

-DOCSTART- -X- O O

Subjective JJ N
and CC N
objective JJ N
levels NNS N
of IN N
physical JJ I
activity NN I
and CC N
their PRP$ N
association NN N
with IN N
cardiorespiratory NN N
fitness NN N
in IN N
rheumatoid JJ P
arthritis NN P
patients NNS P
. . P

INTRODUCTION NNP N
The DT N
aims NNS N
of IN N
the DT N
present JJ N
study NN N
were: VBD N
(a) NNP N
to TO N
examine VB N
the DT N
agreement NN O
between IN N
subjective JJ O
(assessed VBN O
via IN O
the DT O
International NNP O
Physical NNP O
Activity NNP O
Questionnaire; NNP O
IPAQ) NNP O
and CC O
objective JJ O
(accelerometry; NN O
GT3X) NNP O
physical JJ I
activity NN I
(PA) NN I
levels NNS O
in IN N
patients NNS P
with IN P
rheumatoid JJ P
arthritis NN P
(RA) NN P
and CC N
(b) NN N
to TO N
evaluate VB N
the DT N
associations NNS O
of IN N
RA NNP P
patients' FW P
subjective JJ O
and CC O
objective JJ O
PA NNP I
to TO N
their PRP$ N
scores NNS O
on IN O
the DT O
maximal JJ O
oxygen NN O
uptake JJ O
test NN O
(VO2max) NN O
. . O

METHODS NNP N
The DT N
participants NNS N
wore VBD N
the DT N
GT3X NNP N
for IN N
seven CD N
days NNS N
before IN N
completing VBG N
the DT N
IPAQ NNP O
and CC O
VO2max NNP O
test NN O
. . O

The DT N
Bland-Altman NNP O
plot NN O
was VBD N
used VBN N
to TO N
illustrate VB N
the DT N
agreement NN O
between IN N
the DT N
objective NN N
and CC N
subjective JJ N
PA NNP I
data NN N
and CC N
the DT N
Wilcoxon NNP O
test NN O
was VBD N
employed VBN N
to TO N
examine VB N
the DT N
differences NNS N
. . N

The DT N
association NN O
between IN O
the DT O
PA NNP I
measurement NN O
and CC O
VO2max NNP O
test NN O
was VBD O
examined VBN O
via IN O
the DT O
correlations NNS O
and CC O
the DT O
magnitude NN O
was VBD O
presented VBN O
by IN O
the DT O
Steiger's NNP O
Z NNP O
value NN O
. . O

RESULTS NNP N
Sixty-eight JJ P
RA NNP P
patients NNS P
(age=55±13 CD P
years NNS P
body JJ P
mass NN P
index: NN P
27.8±5.4 CD P
kg/m2 NN P
median NN P
of IN P
disease NN P
duration=5 JJ P
(2-8) JJ P
yrs) NN P
were VBD P
recruited VBN P
. . N

Smaller NNP N
differences NNS N
between IN N
the DT O
subjective JJ O
and CC O
objective JJ O
measures NNS O
were VBD N
found VBN N
when WRB I
PA NNP I
was VBD N
assessed VBN N
at IN N
the DT N
moderate JJ N
level NN O
. . O

Wilcoxon NNP O
tests NNS O
revealed VBD N
that IN N
patients NNS N
reported VBD N
less JJR N
time NN N
spent VBN N
engaged VBN N
in IN O
sedentary JJ O
behaviours NNS O
(Z=-6.80 JJ N
P<0.01) NNP N
and CC O
light JJ O
PA NNP O
(Z=-6.89 JJ N
P<0.01) NNP N
and CC N
more JJR O
moderate JJ O
PA NNP O
(Z=-6.26 NN N
P<0.01) NNP N
than IN N
was VBD N
objectively RB N
indicated VBN N
. . N

Significant NNP N
positive JJ N
correlations NNS N
were VBD N
revealed VBN N
between IN O
VO2max NNP O
with IN N
all DT I
PA NNP I
levels NNS N
derived VBN N
from IN O
accelerometry NN O
(light NNP N
PA NNP N
rho=.35 NN N
P<.01; NNP N
moderate JJ N
PA NNP N
rho=.34 NN N
P=.01; NNP N
moderate NN N
and CC N
vigorous JJ N
PA NNP N
(MVPA) NNP N
rho=.33 NN N
P=.01) NNP N
and CC N
a DT N
negative JJ N
association NN N
to TO O
sedentary JJ O
time NN O
(ST) NNS O
emerged VBD N
(rho=-.27 JJ N
P=.04) NNP O
. . O

IPAQ-reported JJ O
moderate JJ I
PA NNP I
and CC O
MVPA NNP O
positively RB N
correlated VBD N
with IN O
maxV02 JJ O
(rho=.25 NNP N
P=.01 NNP N
rho=.27 NN N
P=.01 NNP N
respectively) NN N
. . N

Differences NNS N
between IN N
the DT N
magnitude NN N
of IN N
correlations NNS N
between IN N
the DT O
IPAQ-VO2 NNP O
max NN O
and CC O
GT3X-VO2 NNP O
max NN O
were VBD N
only RB N
significant JJ N
for IN N
ST NNP N
(Z=3.43 NNP N
P<.01) NNP N
. . N

CONCLUSIONS NNP N
Via NNP N
responses VBZ N
to TO N
the DT O
IPAQ NNP P
RA NNP P
patients NNS P
reported VBD N
that IN N
they PRP N
were VBD N
less JJR O
sedentary JJ O
and CC N
engaged VBN N
in IN N
more RBR N
higher JJR N
intensity NN I
PA NNP I
than IN N
what WP N
was VBD N
objectively RB N
assessed VBN O
. . O

Accelerometry NNP O
data NNS N
correlated VBD N
with IN O
VO2max NNP O
at IN N
all DT I
PA NNP I
levels NNS N
. . N

Only RB N
subjective JJ N
moderate NN N
and CC O
MPVA NNP O
correlated VBD N
with IN O
VO2max NNP O
. . N

Findings NNS N
suggest VBP N
that IN N
self-reported JJ I
PA NNP I
and CC O
ST NNP O
should MD N
be VB N
interpreted VBN N
with IN N
caution NN N
in IN P
people NNS P
with IN P
RA NNP P
and CC N
complemented VBN N
with IN O
accelerometry NN O
when WRB N
possible JJ N
. . N

TRIAL NNP N
REGISTRATION NNP N
Trial NNP N
registration: NN N
ClinicalTrials.gov NNP N
ISRCTN04121489 NNP N
. . N

Registered VBD N
5 CD N
September NNP N
2012 CD N
. . N

-DOCSTART- -X- O O

Youth NN P
with IN P
autism NN P
spectrum NN P
disorder NN P
comprehend NN N
lexicalized VBN I
and CC N
novel JJ N
primary JJ I
conceptual JJ I
metaphors NNS I
. . I

Individuals NNS P
with IN P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNS P
have VBP N
difficulty NN N
comprehending VBG O
metaphors NNS I
. . I

However RB N
no DT N
study NN N
to TO N
date NN N
has VBZ N
examined VBN N
whether IN N
or CC N
not RB N
they PRP N
understand VBP N
conceptual JJ I
metaphors NNS I
(i.e VBP N
. . N

mappings NNS N
between IN N
conceptual JJ N
structures) NN N
which WDT N
could MD N
be VB N
the DT N
building NN N
blocks NNS N
of IN N
metaphoric JJ N
thinking NN N
and CC N
understanding NN N
. . N

We PRP N
investigated VBD N
whether IN N
13 CD P
participants NNS P
with IN P
ASD NNP P
(age NNP P
7;03-22;03) JJ P
and CC P
13 CD P
age-matched JJ P
typically RB P
developing VBG P
(TD) NNP P
controls NNS P
could MD N
comprehend VB N
lexicalized JJ O
conceptual JJ I
metaphors NNS I
(e.g VBP N
. . N

Susan NNP N
is VBZ N
a DT N
warm JJ N
person) NN N
and CC N
novel JJ O
ones NNS O
(e.g NNP N
. . N

Susan NNP N
is VBZ N
a DT N
toasty JJ N
person) NN N
. . N

Individuals NNS P
with IN P
ASD NNP P
performed VBD N
at IN N
greater JJR N
than IN N
chance NN N
levels NNS N
on IN N
both DT N
metaphor NN I
types NNS N
although IN N
their PRP$ N
performance NN N
was VBD N
lower JJR N
than IN N
TD CD N
participants NNS N
. . N

We PRP N
discuss VBP N
the DT N
theoretical JJ N
relevance NN N
of IN N
these DT N
findings NNS N
and CC N
educational JJ N
implications NNS N
. . N

-DOCSTART- -X- O O

Combined VBN I
descriptive JJ I
and CC I
explanatory JJ I
information NN I
improves VBZ N
peers' JJ P
perceptions NNS O
of IN N
autism NN N
. . N

Authors NNS N
examined VBD N
the DT N
combined JJ N
effects NNS N
of IN N
descriptive JJ I
and CC I
explanatory JJ I
information NN I
on IN N
peers' NN P
perceptions NNS O
and CC O
behavioral JJ O
intentions NNS O
toward IN N
an DT N
unfamiliar JJ N
child NN P
with IN P
autism NN P
. . P

Children NNP P
(N NNP P
= VBZ P
576; CD P
M NNP P
age NN P
= VBD P
10.06) CD P
were VBD N
randomly RB N
assigned VBN N
to TO N
view VB N
two CD N
videotapes NNS N
of IN N
a DT N
boy NN N
engaging VBG N
in IN N
typical JJ N
and CC N
autistic JJ N
behaviors NNS N
receiving VBG N
either RB N
descriptive JJ I
(AUT-D) NN I
or CC N
descriptive JJ I
and CC I
explanatory JJ I
information NN I
(AUT-D JJ I
+ NN I
E) NNP I
. . I

Children NNP N
responded VBD N
to TO N
measures NNS O
of IN O
attitudes NNS O
(Adjective JJ O
Checklist) NNP O
and CC O
behavioral JJ O
intentions NNS O
(Shared VBD O
Activities NNPS O
Questionnaire) NNP O
. . O

Children NNP N
rated VBD N
the DT N
typical JJ N
boy NN N
more RBR N
favorably RB N
than IN N
the DT N
boy NN N
showing VBG N
autistic JJ N
symptoms NNS N
. . N

When WRB N
compared VBN N
to TO N
descriptive VB I
information NN I
alone RB N
the DT N
combination NN I
of IN I
descriptive JJ I
and CC I
explanatory JJ I
information NN I
resulted VBD N
in IN N
improved JJ N
third- JJ N
and CC N
fourth-graders' JJ N
but CC N
not RB N
fifth-graders' JJ N
attitudes NNS N
toward IN N
the DT N
child NN N
with IN N
autism NN N
. . N

Combined VBN N
information NN N
improved VBN N
behavioral JJ O
intentions NNS O
across IN N
grades; NN N
however RB N
girls JJ N
(vs NNP N
. . N

boys) NN N
were VBD N
more RBR N
responsive JJ N
to TO N
information NN N
as IN N
evidenced VBN N
by IN N
differences NNS N
in IN N
academic JJ O
intentions NNS O
. . O

The DT N
combination NN I
of IN I
descriptive JJ I
and CC I
explanatory JJ I
information NN I
about IN N
autism NN N
appears VBZ N
to TO N
have VB N
a DT N
positive JJ N
effect NN N
on IN N
children's NN P
attitudes NNS O
and CC O
behavioral JJ O
intentions NNS O
. . O

Implications NNS N
of IN N
the DT N
findings NNS N
are VBP N
briefly RB N
discussed VBN N
as RB N
well RB N
as IN N
study NN N
limitations NNS N
and CC N
recommendations NNS N
for IN N
future JJ N
research NN N
. . N

-DOCSTART- -X- O O

Influence NN N
of IN N
diets NNS N
rich JJ N
in IN N
Maillard NNP I
reaction NN I
products NNS I
on IN N
calcium NN O
bioavailability NN O
. . O

Assays NNS N
in IN N
male JJ P
adolescents NNS P
and CC N
in IN N
Caco-2 NNP N
cells NNS N
. . N

The DT N
effects NNS N
of IN N
the DT N
high JJ N
intake NN N
of IN N
Maillard NNP I
reaction NN I
products NNS I
(MRP) VBP I
on IN N
calcium NN O
availability NN O
in IN N
adolescents NNS P
and CC N
across IN N
Caco-2 NNP N
cell NN N
monolayers NNS N
were VBD N
examined VBN N
. . N

In IN N
a DT N
2 CD N
week NN N
randomized VBN N
two-period JJ N
crossover NN N
trial NN N
18 CD P
male NN P
adolescents NNS P
consumed VBD N
two CD N
diets NNS N
named VBN N
white JJ I
diet JJ I
(WD) NN I
and CC N
brown JJ I
diet NN I
(BD) NN I
which WDT N
were VBD N
poor JJ N
and CC N
rich JJ N
in IN N
MRP NNP I
respectively RB N
. . N

A DT N
3 CD N
day NN N
balance NN N
was VBD N
performed VBN N
at IN N
the DT N
end NN N
of IN N
each DT N
period NN N
and CC N
fasting VBG O
blood NN O
samples NNS O
were VBD N
collected VBN N
. . N

Calcium NNP O
solubility NN O
and CC O
absorption NN O
across IN O
Caco-2 NNP O
cells NNS O
were VBD N
studied VBN N
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
of IN N
the DT N
diets NNS N
. . N

The DT N
in IN N
vitro NN N
assay NN N
showed VBD N
similar JJ N
solubility NN O
after IN N
the DT N
in IN N
vitro JJ N
digestion NN N
and CC N
similar JJ N
transport NN N
across IN N
Caco-2 NNP N
cells NNS N
. . N

In IN N
accordance NN N
calcium NN O
bioavailability NN O
in IN N
adolescents NNS N
did VBD N
not RB N
vary JJ N
between IN N
the DT N
diets NNS N
(%WD VBP N
= JJ N
40.4 CD N
+/- JJ N
5.1 CD N
%BD JJ N
= JJ N
38.2 CD N
+/- JJ N
3.6) CD N
. . N

Serum NN O
and CC O
urine JJ O
biochemical JJ O
parameters NNS O
related VBN O
to TO O
calcium NN O
status NN O
and CC O
bone NN O
metabolism NN O
remained VBD N
unaltered JJ N
. . N

Only RB N
deoxypyridinoline JJ O
values NNS N
were VBD N
significantly RB N
lower JJR N
after IN N
consumption NN N
of IN N
the DT N
BD NNP N
(13.0 NNP N
+/- JJ N
1.1 CD N
compared VBN N
to TO N
18.3 CD N
+/- JJ N
2.1 CD N
nM/Mm JJ N
Cr NNP N
in IN N
the DT N
WD) NNP N
possibly RB N
indicative CD N
of IN N
less JJR N
efficient JJ N
bone NN O
turnover NN O
during IN N
this DT N
period NN N
. . N

As IN N
calcium NN N
acquired VBD N
during IN N
adolescence NN P
is VBZ N
essential JJ N
to TO N
maximize VB N
peak JJ N
bone NN N
mass NN N
and CC N
to TO N
prevent VB N
osteoporosis NN N
possible JJ N
long-term JJ N
effects NNS N
of IN N
excessive JJ N
MRP NNP I
intake NN N
during IN N
this DT N
period NN N
warrant JJ N
attention NN N
. . N

-DOCSTART- -X- O O

Analysis NN N
of IN N
prevention NN I
program NN I
effectiveness NN O
with IN N
clustered VBN N
data NNS N
using VBG N
generalized JJ N
estimating NN N
equations NNS N
. . N

Experimental JJ N
studies NNS N
of IN N
prevention NN I
programs NNS I
often RB N
randomize VBP N
clusters NNS N
of IN N
individuals NNS N
rather RB N
than IN N
individuals NNS N
to TO N
treatment NN N
conditions NNS N
. . N

When WRB N
the DT N
correlation NN N
among IN N
individuals NNS N
within IN N
clusters NNS N
is VBZ N
not RB N
accounted VBN N
for IN N
in IN N
statistical JJ N
analysis NN N
the DT N
standard JJ N
errors NNS N
are VBP N
biased VBN N
potentially RB N
resulting VBG N
in IN N
misleading VBG N
conclusions NNS N
about IN N
the DT N
significance NN N
of IN N
treatment NN N
effects NNS N
. . N

This DT N
study NN N
demonstrates VBZ N
the DT N
generalized JJ I
estimating NN I
equations NNS I
(GEE) VBP I
method NN N
focusing VBG N
specifically RB N
on IN N
the DT N
GEE-independent JJ I
method NN N
to TO N
control VB N
for IN N
within-cluster JJ N
correlation NN N
in IN N
regression NN N
models NNS N
with IN N
either DT N
continuous JJ N
or CC N
binary JJ N
outcomes NNS N
. . N

The DT N
GEE-independent JJ I
method NN N
yields NNS N
consistent JJ N
and CC N
robust JJ N
variance NN N
estimates NNS N
. . N

Data NNS N
from IN N
project NN N
DARE NNP N
a DT N
youth NN P
substance NN N
abuse NN N
prevention NN N
program NN N
are VBP N
used VBN N
for IN N
illustration NN N
. . N

-DOCSTART- -X- O O

Comparison NNP N
of IN N
propofol NN I
droperidol NN I
and CC N
metoclopramide NN I
for IN N
prophylaxis NN O
of IN O
postoperative JJ O
nausea NN O
and CC O
vomiting NN O
after IN N
breast NN P
cancer NN P
surgery: VBZ P
a DT N
prospective JJ N
randomized VBN N
double-blind JJ N
placebo-controlled JJ N
study NN N
in IN N
Japanese JJ P
patients NNS P
. . P

BACKGROUND NNP N
Breast NNP P
cancer NN P
surgery NN P
performed VBN P
with IN P
the DT P
patient NN P
under IN P
general JJ P
anesthesia NN P
has VBZ N
been VBN N
associated VBN N
with IN N
a DT N
relatively RB N
high JJ N
incidence NN O
of IN O
postoperative JJ O
nausea NN O
and CC O
vomiting VBG O
(PONV) NN O
. . O

Between CC N
60% CD N
and CC N
80% CD N
of IN N
patients NNS N
who WP N
undergo VBP N
mastectomy NN N
(with NNP N
axillary JJ N
dissection) NN N
experience NN N
PONV NNP O
. . O

We PRP N
previously RB N
reported VBD N
that IN N
propofol NN I
at IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
0.5 CD N
mg/kg NN N
was VBD N
more RBR N
effective JJ N
than IN N
placebo NN I
in IN N
preventing VBG N
PONV NNP O
in IN N
women NNS N
who WP N
undergo VBP N
mastectomy NN N
. . N

OBJECTIVE CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficacy NN O
of IN N
a DT N
subhypnotic JJ N
dose NN N
of IN N
propofol NN I
with IN N
the DT N
conventional JJ N
antiemetics NNS N
droperidol NN I
and CC N
metoclopramide NN I
for IN N
the DT N
prophylaxis NN O
of IN O
PONV NNP O
after IN N
breast NN P
cancer NN P
surgery NN P
in IN P
Japanese JJ P
patients NNS P
. . P

METHODS NNP N
In IN N
this DT N
prospective JJ N
randomized VBN N
double-blind JJ N
placebo-controlled JJ N
study NN N
Japanese JJ P
women NNS P
were VBD N
randomized VBN N
to TO N
1 CD N
of IN N
4 CD N
groups NNS N
to TO N
receive VB N
IV NNP N
administration NN N
of IN N
propofol JJ I
0.5 CD N
mg/kg NN N
droperidol NN I
20 CD N
microg/kg NN N
metoclopramide RB I
0.2 CD N
mg/kg NN N
or CC N
placebo NN I
(isotonic JJ I
saline) NN I
immediately RB N
after IN N
skin JJ N
suture NN N
. . N

A DT N
standard JJ N
general JJ N
anesthetic JJ N
technique NN N
including VBG N
sevoflurane NN I
and CC N
air NN N
in IN N
oxygen NN I
was VBD N
used VBN N
. . N

All DT N
episodes NNS O
of IN O
PONV NNP O
during IN O
the DT O
first JJ O
24 CD O
hours NNS O
after IN O
anesthesia JJ O
administration NN O
were VBD N
recorded VBN N
by IN N
an DT N
investigator NN N
who WP N
was VBD N
blinded VBN N
to TO N
treatment NN N
assignment NN N
. . N

The DT N
investigator NN N
questioned VBD N
the DT N
patients NNS N
as IN N
to TO N
whether IN N
they PRP N
experienced VBD N
extrapyramidal NN O
symptoms NNS O
. . O

To TO N
maintain VB N
the DT N
integrity NN N
of IN N
the DT N
study NN N
results NNS N
none NN N
of IN N
the DT N
patients NNS N
received VBD N
preanesthetic JJ N
medication NN N
. . N

RESULTS VB N
A DT P
total NN P
of IN P
100 CD P
women NNS P
(mean JJ P
[SD] NNP P
age NN P
52 CD P
[7] NN P
years; NN P
height VBD P
154 CD P
[6] NNP P
cm; NN P
weight VBD P
54 CD P
[7] NNS P
kg) NNS P
were VBD P
included VBN P
in IN P
the DT P
study NN P
. . P

Each DT N
study NN N
group NN N
comprised VBD N
25 CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS N
between IN N
treatment NN N
groups NNS N
with IN N
regard NN N
to TO N
patient VB O
demographics NNS O
surgery JJ O
type NN O
or CC O
awakening JJ O
time NN O
. . O

The DT N
prevalences NNS O
of IN O
PONV NNP O
0 CD O
to TO O
24 CD O
hours NNS O
after IN N
anesthesia NN N
were VBD N
28% CD N
with IN N
propofol NN I
(P NNP N
= VBD N
0.005) CD N
32% CD N
with IN N
droperidol NN I
(P NNP N
= VBZ N
0.011) CD N
and CC N
60% CD N
with IN N
metoclopramide JJ I
(P NNP N
= NNP N
NS) NNP N
compared VBN N
with IN N
placebo NN I
(68%) NNP N
. . N

No NNP N
significant JJ N
difference NN N
in IN N
the DT N
prevalence NN O
of IN O
PONV NNP O
was VBD N
found VBN N
between IN N
patients NNS N
receiving VBG N
propofol NN I
and CC N
those DT N
receiving VBG N
droperidol NN I
and CC N
propofol NN I
and CC N
droperidol NN I
were VBD N
associated VBN N
with IN N
significantly RB N
lower JJR N
prevalences NNS O
of IN O
PONV NNP O
compared VBN N
with IN N
metoclopramide JJ I
(P NNP N
= NNP N
0.022 CD N
and CC N
P NNP N
= NNP N
0.043 CD N
respectively) NN N
. . N

Extrapyramidal NNP O
symptoms NNS O
were VBD N
not RB N
reported VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

CONCLUSIONS VB N
The DT N
prevalences NNS O
of IN O
PONV NNP O
were VBD N
not RB N
significantly RB N
different JJ N
between IN N
propofol NN I
0.5 CD N
mg/kg NN N
and CC N
droperidol NN I
20 CD N
microg/kg NN N
0 CD N
to TO N
24 CD N
hours NNS N
after IN N
anesthesia NN N
in IN N
this DT N
small JJ N
select JJ N
group NN N
of IN N
Japanese JJ P
women NNS P
who WP P
underwent VBP P
breast NN P
cancer NN P
surgery NN P
. . P

The DT N
prevalences NNS O
of IN O
PONV NNP O
were VBD N
significantly RB N
lower JJR N
with IN N
propofol NN I
and CC N
droperidol NN I
compared VBN N
with IN N
metoclopramide JJ I
0.2 CD N
mg/kg NN N
and CC N
placebo NN I
. . I

-DOCSTART- -X- O O

[Effect NN N
of IN N
transcranial JJ I
electrostimulation NN I
on IN N
clinical JJ N
and CC N
laboratory JJ N
characteristics NNS N
in IN N
patients NNS P
with IN P
gastric JJ P
ulcer] NN P
. . N

The DT N
study NN N
included VBD N
100 CD P
patients NNS P
with IN P
gastric JJ P
ulcer NNS P
aged VBN P
from IN P
16 CD P
to TO P
60 CD P
years NNS P
. . P

In IN N
58 CD N
patients NNS N
traditional JJ I
treatment NN I
was VBD N
supplemented VBN N
by IN N
transcranial JJ I
electrotherapy NN I
using VBG N
a DT N
TRANSAIR-02 JJ N
apparatus NN N
. . N

Laboratory NNP O
studies NNS O
included VBD N
measurements NNS O
of IN O
lactoferrin JJ O
(LF) NNP O
and CC O
tumour JJ O
necrosis NN O
factor-alpha JJ O
(TNF-alpha) JJ O
besides NNS O
standard JJ O
analyses NNS O
. . O

Combined VBN N
treatment NN N
(traditional JJ I
therapy NN I
plus CC I
electrostimulation) NN I
resulted VBD N
in IN N
a DT N
significant JJ N
reduction NN N
in IN N
duration NN O
of IN O
the DT O
main JJ O
symptoms NNS O
of IN O
the DT O
gastric JJ P
ulcer NN P
depending VBG N
on IN N
the DT N
severity NN N
of IN N
ulceration NN N
process NN N
patients' NN O
age NN O
and CC O
sex NN O
. . O

Moreover RB N
it PRP N
facilitated VBD N
ulcer JJ O
scarring NN O
and CC N
had VBD N
beneficial JJ N
effect NN N
on IN N
dynamics NNS N
of IN N
serum NN O
LF NNP O
and CC O
TNF-alpha NNP O
levels NNS O
. . O

-DOCSTART- -X- O O

Goal NNP O
attainment NN O
scaling NN O
as IN N
an DT N
outcome NN N
measure NN N
in IN N
randomized VBN N
controlled JJ N
trials NNS N
of IN N
psychosocial JJ I
interventions NNS I
in IN N
autism NN P
. . P

Goal NNP O
attainment JJ O
scaling VBG O
(GAS) JJ O
holds VBZ N
promise RB N
as IN N
an DT N
idiographic JJ N
approach NN N
for IN N
measuring VBG N
outcomes NNS N
of IN N
psychosocial JJ I
interventions NNS I
in IN N
community NN N
settings NNS N
. . N

GAS NNP N
has VBZ N
been VBN N
criticized VBN N
for IN N
untested JJ N
assumptions NNS N
of IN N
scaling VBG O
level NN O
(i.e NN N
. . N

interval NN N
or CC N
ordinal) JJ N
inter-individual JJ O
equivalence NN O
and CC N
comparability NN O
and CC N
reliability NN O
of IN O
coding VBG O
across IN O
different JJ O
behavioral JJ O
observation NN O
methods NNS O
. . O

We PRP N
tested VBD N
assumptions NNS O
of IN O
equality NN O
between IN N
GAS NNP N
descriptions NNS N
for IN N
outcome JJ N
measurement NN N
in IN N
a DT N
randomized JJ N
trial NN N
(i.e NN N
. . N

measurability NN O
equidistance NN O
level NN O
of IN O
difficulty NN O
comparability NN O
of IN O
behavior NN O
samples NNS O
collected VBN O
from IN O
teachers NNS O
vs NNS O
. . O

researchers NNS O
and CC O
live JJ O
vs NN O
. . O

videotape) NN O
. . N

Results NNP N
suggest VBP N
GAS NNP O
descriptions NNS N
can MD N
be VB N
evaluated VBN N
for IN N
equivalency NN N
that IN N
teacher NN N
collected VBD N
behavior JJ N
samples NNS N
are VBP N
representative JJ N
and CC N
that DT N
varied VBD N
sources NNS N
of IN N
behavior NN N
samples NNS N
can MD N
be VB N
reliably RB N
coded VBN N
. . N

GAS NNP O
is VBZ N
a DT N
promising JJ N
measurement NN N
approach NN N
. . N

Recommendations NNS N
are VBP N
provided VBN N
to TO N
ensure VB N
methodological JJ N
quality NN N
. . N

-DOCSTART- -X- O O

Spotty JJ N
calcification NN N
as IN N
a DT N
marker NN N
of IN N
accelerated JJ N
progression NN O
of IN O
coronary JJ P
atherosclerosis: NNS P
insights NNS N
from IN N
serial JJ N
intravascular JJ N
ultrasound NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
atheroma JJ O
progression NN O
in IN N
patients NNS P
with IN P
spotty JJ P
calcification NN P
. . P

BACKGROUND NNP N
Although IN N
extensively RB N
calcified VBN N
atherosclerotic JJ N
lesions NNS N
have VBP N
been VBN N
proposed VBN N
to TO N
be VB N
clinically RB N
quiescent JJ N
the DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
within IN N
plaque NN N
has VBZ N
been VBN N
reported VBN N
to TO N
be VB N
associated VBN N
with IN N
an DT N
increased JJ N
incidence NN N
of IN N
ischemic JJ N
cardiovascular JJ N
events NNS N
. . N

The DT N
relationship NN N
between IN N
spotty JJ O
calcification NN O
and CC N
disease NN O
progression NN O
has VBZ N
not RB N
been VBN N
investigated VBN N
. . N

METHODS NNP N
A NNP P
total NN P
of IN P
1 CD P
347 CD P
stable JJ P
patients NNS P
with IN P
angiographic JJ P
coronary JJ P
artery NN P
disease NN P
underwent JJ N
serial JJ N
evaluation NN N
of IN N
atheroma JJ O
burden NN O
with IN O
intravascular JJ O
ultrasound NN O
imaging NN O
. . O

Patients NNS P
with IN P
spotty JJ P
calcification NN P
were VBD P
identified VBN P
based VBN P
on IN P
the DT P
presence NN P
of IN P
lesions NNS P
(1 VBP P
to TO P
4 CD P
mm NNS P
in IN P
length) NN P
containing VBG P
an DT P
arc NN P
of IN P
calcification NN P
of IN P
<90° NNP P
. . O

Clinical JJ O
characteristics NNS O
and CC O
disease NN O
progression NN O
were VBD N
compared VBN N
between IN N
patients NNS N
with IN N
spotty JJ N
calcification NN N
(n NNP N
= VBZ N
922) CD N
and CC N
those DT N
with IN N
no DT N
calcification NN N
(n VBZ N
= $ N
425) CD N
. . N

RESULTS JJ P
Patients NNS P
with IN P
spotty JJ P
calcification NN P
were VBD P
older JJR P
(age NN P
56 CD P
years NNS P
vs RB P
. . P

54 CD P
years; JJ P
p NN P
= VBD P
0.001) CD P
more RBR P
likely JJ P
to TO P
be VB P
male JJ P
(68% JJ P
vs NN P
. . P

54%; CD P
p JJ N
= NN N
0.01) CD N
and CC N
have VBP N
a DT N
history NN N
of IN N
diabetes NNS N
mellitus VBP N
(30% JJ N
vs NN N
. . N

24%; CD N
p JJ N
= NN N
0.01) CD N
and CC N
myocardial JJ N
infarction NN N
(28% NNP N
vs NN N
. . N

20%; CD N
p JJ N
= NN N
0.004) CD N
and CC N
have VB N
lower JJR N
on-treatment JJ O
high-density NN O
lipoprotein NN O
cholesterol NN O
levels NNS O
(48 VBP N
± RB N
16 CD N
mg/dl NN N
vs NN N
. . N

51 CD N
± JJ N
17 CD N
mg/dl; NN N
p NN N
= VBD N
0.001) CD P
. . N

Patients NNS N
with IN N
spotty JJ N
calcification NN N
demonstrated VBD N
a DT N
greater JJR O
percent JJ O
atheroma NN O
volume NN O
(PAV) NNP O
(36.0 NNP N
± VBD N
7.6% CD N
vs NN N
. . N

29.0 CD N
± JJ N
8.5%; CD N
p NN N
< NN N
0.001) CD O
and CC O
total JJ O
atheroma NN O
volume NN O
(174.6 NNP N
± VBZ N
71.9 CD N
mm(3) NN N
vs NN N
. . N

133.9 CD N
± JJ N
64.9 CD N
mm(3); NN N
p NN N
< VBD N
0.001) CD N
. . N

On IN N
serial JJ N
evaluation NN N
spotty JJ N
calcification NN N
was VBD N
associated VBN N
with IN N
greater JJR O
progression NN O
of IN N
PAV NNP N
(+0.43 NNP N
± VBD N
0.07% CD N
vs NN N
. . N

+0.02 VB N
± JJ N
0.11%; CD N
p NN N
= VBD N
0.002) CD N
. . N

Although IN N
intensive JJ N
low-density NN N
lipoprotein NN N
cholesterol NN N
and CC N
blood NN N
pressure NN N
lowering VBG N
therapy NN N
slowed VBD N
disease JJ N
progression NN N
these DT N
efficacies NNS N
were VBD N
attenuated VBN P
in IN P
patients NNS P
with IN P
spotty JJ P
calcification NN P
. . N

CONCLUSIONS VB N
The DT N
presence NN N
of IN N
spotty JJ N
calcification NN N
is VBZ N
associated VBN N
with IN N
more RBR N
extensive JJ N
and CC P
diffuse NN P
coronary JJ P
atherosclerosis NN P
and CC N
accelerated JJ O
disease NN O
progression NN O
despite IN N
use NN N
of IN N
medical JJ N
therapies NNS N
. . N

-DOCSTART- -X- O O

[The JJ N
effect NN N
of IN N
ionic JJ I
and CC N
nonionic JJ I
x-ray JJ I
contrast NN I
media NNS N
on IN N
myocardial JJ O
perfusion NN O
and CC O
myocardial JJ O
function] NN O
. . N

The DT N
influence NN N
of IN N
injections NNS N
of IN N
Amidotrizoate NNP I
and CC N
Iopromide NNP I
into IN N
the DT N
left JJ N
coronary JJ N
artery NN N
on IN N
global JJ O
myocardial JJ O
perfusion NN O
and CC O
function NN O
(pressures NNS O
in IN O
the DT O
left JJ O
ventricle NN O
heart NN O
rate) NN O
as RB N
well RB N
as IN N
excitation NN O
formation NN O
and CC O
transmission NN O
was VBD N
studied VBN N
in IN N
16 CD P
patients NNS P
with IN P
ischaemic JJ P
heart NN P
disease NN P
. . P

No DT N
statistically RB N
significant JJ N
differences NNS N
in IN N
myocardial JJ O
perfusion NN O
measured VBN N
were VBD N
found VBN N
with IN N
xenon-133 JJ N
in IN N
this DT N
small JJ N
group NN N
between IN N
rest NN N
and CC N
dipyridamole JJ I
load NN N
for IN N
ionic JJ N
and CC N
non-ionic JJ N
contrast NN N
media NNS N
. . N

-DOCSTART- -X- O O

Review NN N
of IN N
the DT N
Multicenter NNP N
Trial NNP N
Committee NNP N
report: VBZ N
a DT N
prospective JJ N
randomized VBN N
study NN N
on IN N
the DT N
prophylaxis NN O
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
. . N

The DT N
etiology NN N
of IN N
postoperative JJ N
deep JJ N
venous JJ N
thrombosis NN N
(DVT) NN N
is VBZ N
thought VBN N
to TO N
be VB N
due JJ N
to TO N
a DT N
combination NN N
of IN N
factors NNS N
including VBG N
stasis NN O
a DT O
hypercoagulable JJ O
state NN O
and CC O
venous JJ O
endothelial JJ O
damage NN O
. . O

Methods NNS N
of IN N
prophylaxis NN N
are VBP N
directed VBN N
toward IN N
correcting VBG N
one CD N
or CC N
more JJR N
of IN N
these DT N
pathologic JJ N
events NNS N
. . N

Methods NNS N
counteracting VBG N
more JJR N
than IN N
one CD N
of IN N
these DT N
factors NNS N
can MD N
be VB N
expected VBN N
to TO N
be VB N
even RB N
more RBR N
effective JJ N
. . N

The DT N
combination NN N
of IN N
dihydroergotamine NN I
(DHE) NN I
and CC N
heparin NN I
was VBD N
anticipated VBN N
to TO N
minimize VB N
stasis NN O
and CC O
the DT O
hypercoagulable JJ O
state NN O
respectively RB N
. . N

Based VBN N
upon IN N
current JJ N
experimental JJ N
evidence NN N
and CC N
current JJ N
theory NN N
an DT N
additional JJ N
benefit NN N
might MD N
include VB N
minimizing VBG N
venous JJ N
endothelial JJ N
injury NN N
by IN N
controlling VBG N
venomotor NN N
tone NN N
. . N

A DT N
prospective JJ N
randomized VBN N
double-blind NN N
multicenter NN N
trial NN N
was VBD N
designed VBN N
and CC N
performed VBN N
in IN N
the DT P
United NNP P
States NNPS P
evaluating VBG N
the DT N
prophylactic JJ O
efficacy NN O
of IN N
DHE NNP I
0.5 CD N
mg NN N
plus CC N
heparin JJ I
5000 CD N
U NNP N
DHE NNP I
0.5 CD N
mg NN N
plus CC N
heparin JJ I
2500 CD N
U NNP N
heparin NN I
5000 CD N
U NNP N
and CC N
DHE NNP I
0.5 CD N
mg NN N
versus NN N
placebo NN I
. . I

General NNP P
surgical JJ P
patients NNS P
including VBG P
those DT P
undergoing JJ P
noncardiac JJ P
thoracic NN P
and CC P
pelvic JJ P
operations NNS P
who WP P
were VBD P
identified VBN P
at IN P
moderate JJ P
to TO P
high JJ P
risk NN P
for IN P
postop JJ P
DVT NNP P
were VBD P
included VBN P
. . P

Study NNP N
medications NNS N
were VBD N
injected VBN N
subcutaneously RB N
two CD N
hours NNS N
preoperatively RB N
and CC N
every DT N
12 CD N
hours NNS N
postoperatively RB N
for IN N
5-7 JJ N
days NNS N
or CC N
until IN N
the DT N
125I-fibrinogen-uptake JJ N
test NN N
(RFUT) NN N
became VBD N
positive JJ N
. . N

Eight NNP P
hundred VBD P
and CC P
eighty JJ P
eight CD P
patients NNS P
were VBD P
entered VBN P
into IN P
this DT P
trial NN P
and CC P
744 CD P
(85%) NN P
completed VBD P
the DT P
study NN P
. . P

Results NNP N
showed VBD N
a DT N
statistically RB N
significant JJ N
benefit NN N
from IN N
DHE/Hep NNP I
5000 CD N
compared VBN N
to TO N
placebo VB I
(p NNP N
less JJR N
than IN N
0.01) CD N
and CC N
compared VBN N
to TO N
other JJ N
active JJ N
agents NNS N
(p VBZ N
less JJR N
than IN N
0.05) CD N
. . N

-DOCSTART- -X- O O

Time-varying JJ N
smoking NN N
abstinence NN N
predicts VBZ N
lower JJR N
depressive JJ O
symptoms NNS O
following VBG N
smoking VBG P
cessation NN N
treatment NN N
. . N

INTRODUCTION NNP N
The DT N
question NN N
of IN N
whether IN N
abstinence NN N
during IN N
the DT N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
exacerbates VBZ N
or CC N
improves VBZ N
depressive JJ O
symptoms NNS O
is VBZ N
an DT N
important JJ N
clinical JJ N
issue NN N
. . N

Extant NNP N
research NN N
has VBZ N
primarily RB N
modeled VBN N
between-person JJ N
covariation NN N
between IN N
postquit NN N
abstinence NN O
and CC O
depressive JJ O
symptom NN O
trajectories NNS N
. . N

However RB N
this DT N
approach NN N
cannot NN N
account NN N
for IN N
potential JJ N
third JJ N
variables NNS N
between IN N
participants NNS N
that WDT N
may MD N
affect VB N
both DT N
smoking NN N
and CC N
depression NN N
. . N

Accordingly RB N
the DT N
current JJ N
study NN N
examined VBD N
within-person JJ N
covariation NN N
between IN N
time-varying JJ O
abstinence NN O
and CC O
depressive JJ O
symptom NN O
in IN N
a DT N
multilevel JJ N
model NN N
(MLM) NN N
which WDT N
allowed VBD N
for IN N
transitions NNS N
between IN N
smoking VBG N
statuses NNS N
within IN N
a DT N
participant NN N
. . N

METHODS JJ N
Participants NNS P
were VBD P
236 CD P
heavy JJ P
drinking NN P
smokers NNS P
in IN N
a DT N
randomized JJ N
clinical JJ N
trial NN N
testing VBG N
the DT N
efficacy NN O
of IN N
incorporating VBG N
brief JJ N
alcohol NN I
intervention NN I
into IN N
smoking VBG N
cessation NN N
treatment NN N
. . N

Depressive NNP O
symptoms NNS O
and CC O
biochemically RB O
verified JJ O
abstinence NN O
were VBD N
assessed VBN N
1 CD N
week NN N
prior RB N
to TO N
and CC N
2 CD N
8 CD N
16 CD N
and CC N
26 CD N
weeks NNS N
after IN N
quit NN N
date NN N
. . N

RESULTS NNP N
MLMs NNP N
indicated VBD N
a DT N
slight JJ N
increase NN N
in IN N
depressive JJ O
symptoms NNS O
over IN N
time NN N
in IN N
the DT N
sample NN N
as IN N
a DT N
whole NN N
. . N

However RB N
there EX N
was VBD N
an DT N
inverse JJ N
relation NN N
between IN N
time-varying JJ O
abstinence NN O
(vs NN O
. . O

smoking) NN O
and CC N
concurrent JJ N
level NN O
of IN O
depressive JJ O
symptoms NNS O
indicating VBG N
that IN N
transitions NNS N
from IN N
smoking VBG N
to TO N
abstinence VB N
within IN N
individuals NNS N
were VBD N
associated VBN N
with IN N
reductions NNS N
in IN N
depressive JJ O
symptoms NNS O
. . O

CONCLUSIONS NNP N
During IN N
the DT N
first JJ N
6 CD N
months NNS N
following VBG N
a DT N
planned VBN N
quit NN N
attempt NN N
being VBG N
abstinent NN N
in IN N
a DT N
particular JJ N
week NN N
appears VBZ N
to TO N
be VB N
associated VBN N
with IN N
lower JJR N
levels NNS N
of IN N
concurrent NN N
depressive NN O
symptoms NNS O
. . O

These DT N
results NNS N
are VBP N
not RB N
concordant JJ N
with IN N
the DT N
view NN N
that IN N
intentional JJ N
smoking NN N
abstinence NN N
exacerbates VBZ N
depressive JJ O
symptoms NNS O
. . O

Efforts NNS N
to TO N
promote VB N
smoking VBG N
cessation NN N
should MD N
highlight VB N
that IN N
individuals NNS N
are VBP N
likely JJ N
to TO N
feel VB N
more RBR N
rather RB N
than IN N
less JJR N
psychologically RB N
healthy JJ N
when WRB N
they PRP N
successfully RB N
quit VBP N
smoking NN N
. . N

-DOCSTART- -X- O O

Atomoxetine NNP I
in IN N
autism NN P
spectrum NN P
disorder: VBZ P
no DT N
effects NNS N
on IN N
social JJ O
functioning; NN O
some DT N
beneficial JJ N
effects NNS N
on IN N
stereotyped JJ O
behaviors NNS O
inappropriate VBP O
speech NN O
and CC O
fear NN O
of IN O
change NN O
. . O

UNLABELLED NNP N
Abstract NNP N
Objective: NNP N
The DT N
objective NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
short-term JJ N
treatment NN N
effects NNS O
of IN N
atomoxetine NN I
on IN N
autism NN P
spectrum NN P
disorder NN P
(ASD) NN P
symptoms NNS N
in IN N
children NNS P
and CC P
adolescents NNS P
with IN P
both DT P
ASD NNP P
and CC P
attention-deficit/hyperactivity JJ P
disorder NN P
(ADHD) NN P
. . P

METHODS NNP N
A NNP N
total NN N
of IN N
97 CD P
patients NNS P
6-17 JJ P
years NNS P
of IN P
age NN P
with IN P
ASD NNP P
and CC P
ADHD NNP P
were VBD N
treated VBN N
with IN N
1.2 mg/kg/day CD N
of IN I
atomoxetine NN I
during IN N
an DT N
8 CD N
week NN N
double-blind JJ I
placebo-controlled JJ I
period NN N
. . N

Here RB N
we PRP N
investigated JJ N
effects NNS N
on IN N
two CD N
parent-based JJ N
secondary JJ N
outcome NN N
measures VBZ O
the DT O
Aberrant NNP O
Behavior NNP O
Checklist NNP O
(ABC) NNP O
and CC O
the DT O
Children's NNP O
Social NNP O
Behavior NNP O
Questionnaire NNP O
(CSBQ) NNP O
. . N

RESULTS NNP N
After IN N
8 CD N
weeks NNS N
of IN N
double-blind JJ N
treatment NN I
atomoxetine JJ I
administration NN N
was VBD N
associated VBN N
with IN N
significant JJ N
treatment NN N
effects NNS N
on IN N
the DT O
ABC NNP O
subscales VBZ O
Hyperactivity NNP O
Inappropriate NNP O
Speech NNP O
and CC O
Stereotypic NNP O
Behavior NNP O
and CC N
on IN N
the DT O
CSBQ NNP O
subscale NN O
Fear NNP O
for IN O
Changes NNP O
. . N

CONCLUSIONS NNP N
Our PRP$ N
study NN N
results NNS N
indicate VBP N
no DT N
beneficial JJ N
effects NNS N
of IN I
atomoxetine NN I
on IN N
social JJ N
functioning NN N
. . N

However RB I
atomoxetine NN I
may MD N
ameliorate VB O
restricted VBN O
and CC O
stereotyped VBN O
behaviors NNS O
and CC O
communication NN O
. . N

This DT N
study NN N
has VBZ N
been VBN N
registered VBN N
in IN N
ClinicalTrials.gov NNP N
( ( N
www.clinicaltrials.gov NN N
) ) N
under IN N
registration NN N
number NN N
NCT00380692 NNP N
. . N

-DOCSTART- -X- O O

The DT N
safety NN O
of IN N
whey JJ I
protein NN I
concentrate NN I
derived VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
immunized VBN N
against IN N
Clostridium NNP N
difficile NN N
. . N

A DT N
whey JJ I
protein NN I
concentrate NN I
prepared VBN N
from IN N
the DT N
milk NN N
of IN N
cows NNS N
that WDT N
have VBP N
been VBN N
immunized VBN I
against IN I
Clostridium NNP I
difficile NN I
(C NN I
. . I

difficile) NN I
and CC I
its PRP$ I
toxins NNS I
toxin VB I
A NNP I
and CC I
toxin NN I
B NNP I
is VBZ N
produced VBN N
for IN N
use NN N
as IN N
a DT N
medical JJ N
food NN N
for IN N
the DT N
dietary JJ N
management NN N
of IN N
patients NNS P
with IN P
C NNP P
. . P

difficile-associated JJ P
diarrhea NN P
(CDAD) NN P
to TO N
prevent VB N
a DT N
relapse NN N
of IN N
the DT N
infection NN N
. . N

The DT N
safety NN O
of IN N
anti-C JJ I
. . I

difficile NN I
whey NN I
protein VBP I
concentrate JJ I
(anti-CD JJ I
WPC) NNP I
is VBZ N
supported VBN N
by IN N
analytical JJ N
data NNS N
comparing VBG N
the DT N
composition NN N
of IN N
raw JJ N
milk NN N
from IN N
immunized JJ N
cows NNS N
versus VBP N
that IN N
from IN N
non-immunized JJ N
cows NNS N
and CC N
the DT N
composition NN N
of IN N
anti-CD JJ I
WPC NNP I
versus NN N
that IN N
of IN N
regular JJ I
whey NN I
protein NN I
concentrate NN I
. . I

Additionally RB N
a DT N
prospective JJ N
clinical JJ N
study NN N
was VBD N
conducted VBN N
in IN N
77 CD P
patients NNS P
with IN P
CDAD NNP P
to TO N
demonstrate VB N
the DT N
safety NN O
of IN N
consuming VBG N
anti-CD JJ I
WPC NNP I
to TO N
prevent VB N
relapse NN O
of IN O
the DT O
infection NN O
. . O

This DT N
study NN N
which WDT N
included VBD N
adverse JJ O
event NN O
monitoring VBG O
physical JJ O
examinations NNS O
and CC O
extensive JJ O
hematological NN O
and CC O
biochemical JJ O
assessments NNS O
showed VBD N
that IN N
anti-CD JJ I
WPC NNP I
is VBZ N
safe JJ O
to TO N
consume VB N
by IN N
patients NNS P
with IN P
CDAD NNP P
. . P

The DT N
available JJ N
analytical JJ N
and CC N
clinical JJ N
evidence NN N
demonstrate NN N
that IN N
anti-CD JJ I
WPC NNP I
is VBZ N
safe JJ O
for IN N
use NN N
by IN N
individuals NNS P
with IN P
CDAD NNP P
under IN N
the DT N
described JJ N
conditions NNS N
of IN N
use NN N
. . N

-DOCSTART- -X- O O

EORTC NNP N
protocols NNS N
in IN N
prostatic JJ P
cancer NN P
. . P

An DT N
interim JJ N
report NN N
. . N

Two CD N
parallel JJ N
prospective JJ N
randomized VBN N
studies NNS N
have VBP N
been VBN N
undertaken VBN N
by IN N
the DT N
EORTC NNP N
Urological NNP N
Group NNP N
in IN N
previously RB P
untreated JJ P
patients NNS P
with IN P
prostatic JJ P
cancer NN P
in IN N
order NN N
to TO N
compare VB N
low JJ N
dose JJ N
Stilboestrol NNP I
versus NN N
Cyproterone NNP I
acetate NN I
versus NN N
Medroxyprogesterone NNP I
acetate NN I
in IN N
the DT N
first JJ N
trial NN N
and CC N
Stilboestrol NNP I
versus VBP N
Estracyt NNP I
in IN N
the DT N
second JJ N
trial NN N
. . N

Although IN N
the DT N
follow JJ N
up NN N
is VBZ N
still RB N
short JJ N
no DT N
superiority NN N
of IN N
the DT N
other JJ N
drugs NNS N
over IN N
Stilboestrol NNP I
had VBD N
appeared VBN N
so RB N
far RB N
with IN N
regard NN N
to TO N
either DT N
objective JJ N
response NN N
or CC N
significant JJ N
side NN O
effects NNS O
apart RB N
from IN N
gynaecomastia NN O
. . O

In IN N
the DT N
third JJ N
trial NN N
patients NNS P
with IN P
advanced JJ P
disease NN P
no RB P
longer RBR P
responsive VB P
to TO P
hormonal JJ P
treatment NN P
were VBD N
randomized VBN N
to TO N
either DT N
Adriamycin NNP I
or CC N
Procarbazine NNP I
. . I

Toxicity NN O
and CC O
early JJ O
death NN O
were VBD N
particularly RB N
frequent JJ N
in IN N
Procarbazine NNP I
treated VBD N
patients NNS N
whereas IN N
most JJS N
patients NNS N
progressed VBN N
in IN N
both DT N
treatment NN N
groups NNS N
. . N

-DOCSTART- -X- O O

Is VBZ N
a DT N
2-week JJ N
duration NN O
sufficient NN N
for IN N
stenting VBG I
in IN N
endopyelotomy JJ P
PURPOSE NNP N
Internal NNP I
stenting NN I
is VBZ N
an DT N
integral JJ N
part NN N
of IN N
endopyelotomy NN N
. . N

Studies NNS N
in IN N
animals NNS N
show VBP N
good JJ N
healing NN N
after IN N
1 CD N
to TO N
2 CD N
weeks NNS N
of IN N
ureterotomy JJ N
. . N

Inherent JJ N
stent NN I
related VBN N
problems NNS N
warrant VBP N
a DT N
minimum JJ N
possible JJ N
duration NN N
of IN N
stenting VBG N
without IN N
compromising VBG N
the DT N
results NNS N
of IN N
endopyelotomy JJ N
. . N

We PRP N
performed VBD N
a DT N
prospective JJ N
randomized VBN N
trial NN N
to TO N
evaluate VB N
the DT N
optimum JJ O
duration NN O
of IN O
stenting VBG I
after IN N
endopyelotomy NN N
. . N

MATERIALS NNP N
AND NNP N
METHODS NNP N
A NNP P
total NN P
of IN P
57 CD P
consecutive JJ P
patients NNS P
with IN P
primary JJ P
ureteropelvic JJ P
junction NN P
obstruction NN P
were VBD N
randomized VBN N
to TO N
undergo VB N
7/14Fr CD I
internal JJ I
endopyelotomy NN I
stent JJ I
placement NN I
for IN N
2 CD N
(group NN N
1) CD N
and CC N
4 CD N
(group RB N
2) CD N
weeks NNS N
. . N

A DT N
symptom NN O
based VBN O
questionnaire NN O
was VBD N
administered VBN N
to TO N
all DT N
patients NNS N
at IN N
stent JJ N
removal NN N
. . N

Followup NNP N
was VBD N
done VBN N
with IN N
diuretic JJ O
scanning NN O
at IN N
3 CD N
6 CD N
9 CD N
and CC N
12 CD N
months NNS N
and CC N
then RB N
yearly RB N
and CC N
thereafter RB N
with IN N
diuretic JJ O
renography NN O
. . O

RESULTS NNP N
In IN N
each DT N
group NN N
26 CD N
patients NNS N
were VBD N
available JJ N
for IN N
evaluation NN N
. . N

The DT N
2 CD N
groups NNS N
were VBD N
comparable JJ N
in IN N
terms NNS N
of IN N
age NN N
sex NN N
symptoms NNS O
and CC O
ipsilateral JJ O
glomerular JJ O
filtration NN O
rate NN O
. . O

Mean NNP N
followup NN N
was VBD N
22.3 CD N
(range NN N
12 CD N
to TO N
36) CD N
and CC N
21.3 CD N
months NNS N
(range RB N
12 CD N
to TO N
35) CD N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
respectively RB N
. . N

At IN N
the DT N
end NN N
of IN N
1 CD N
year NN N
24 CD N
group NN N
1 CD N
(92.3%) NN N
and CC N
23 CD N
group NN N
2 CD N
(90.3%) NN N
patients NNS N
had VBD N
an DT N
improved JJ N
drainage NN O
pattern NN O
. . O

This DT N
difference NN N
was VBD N
not RB N
significant JJ N
. . N

Stent NNP I
related JJ O
symptoms NNS O
were VBD N
present JJ N
in IN N
a DT N
good JJ N
proportion NN N
of IN N
patients NNS N
in IN N
groups NNS N
1 CD N
and CC N
2 CD N
but CC N
there EX N
was VBD N
a DT N
significant JJ N
difference NN N
in IN N
the DT N
incidence NN N
of IN N
urinary JJ O
tract NN O
infections NNS O
(11.5% VBP N
versus IN N
38.1% CD N
p NN N
= VBD N
0.04) CD N
. . N

Of IN N
the DT N
group NN N
2 CD N
patients NNS N
64% CD N
preferred JJ N
2 CD N
weeks NNS N
of IN N
stenting VBG N
. . N

CONCLUSIONS NNP N
Two CD N
weeks NNS N
seems VBZ N
to TO N
be VB N
a DT N
sufficient JJ N
duration NN O
to TO N
allow VB N
functional JJ N
restoration NN N
across IN N
the DT N
ureteropelvic JJ N
junction NN N
after IN N
endopyelotomy NN P
and CC N
decrease NN N
stent NN O
related JJ O
complications NNS O
. . O

-DOCSTART- -X- O O

Why WRB N
were VBD N
the DT N
results NNS N
of IN N
the DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
(HOPE) NNP N
trial NN N
so RB N
astounding VBG N
The DT N
Heart NNP N
Outcomes NNP N
Prevention NNP N
Evaluation NNP N
(HOPE) NNP N
study NN N
was VBD N
important JJ N
because IN N
it PRP N
showed VBD N
the DT N
benefits NNS N
of IN N
ramipril NN I
- : N
an DT N
angiotensin-converting JJ I
enzyme NN I
(ACE) NNP I
inhibitor NN I
- : N
in IN N
patients NNS P
at IN P
high JJ P
risk NN P
for IN P
cardiovascular JJ P
events NNS P
. . P

Treatment NN N
with IN N
ramipril NN I
significantly RB N
reduced VBD N
the DT N
rates NNS O
of IN O
death NN O
myocardial JJ O
infarction NN O
stroke VBD O
coronary JJ O
revascularization NN O
cardiac NN O
arrest NN O
and CC O
heart NN O
failure NN O
as RB N
well RB N
as IN N
the DT N
risk NN O
of IN O
diabetes-related JJ O
complications NNS O
and CC O
of IN O
diabetes NNS O
itself PRP O
. . O

The DT N
effects NNS N
of IN N
therapy NN N
with IN N
vitamin JJ I
E NN I
were VBD N
also RB N
evaluated VBN N
but CC N
no DT N
statistical JJ N
benefits NNS N
were VBD N
shown VBN N
. . N

The DT N
benefits NNS N
of IN N
ACE NNP I
inhibitor NN I
therapy NN N
that WDT N
were VBD N
observed VBN N
were VBD N
likely JJ N
due JJ N
to TO N
a DT N
variety NN N
of IN N
mechanisms NNS N
not RB N
just RB N
a DT N
reduction NN N
in IN N
blood NN N
pressure NN N
. . N

-DOCSTART- -X- O O

Clinical JJ O
performance NN O
of IN N
the DT N
Reichert NNP I
AT550: NNP I
a DT N
new JJ N
non-contact JJ N
tonometer NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
assess VB N
the DT N
level NN O
of IN O
accuracy NN O
for IN N
measurements NNS O
of IN O
intra-ocular JJ O
pressure NN O
(IOP) NN O
obtained VBN N
with IN N
a DT N
new JJ N
non-contact JJ N
tonometer NN N
(NCT) VBD N
the DT N
Reichert NNP I
AT550 NNP I
. . I

Measurements NNS N
were VBD N
compared VBN N
against IN N
those DT N
obtained VBN N
with IN N
the DT N
Reichert NNP I
Xpert NNP I
Plus NNP I
Goldmann NNP I
applanation NN I
tonometer NN I
and CC N
Perkins NNP I
tonometer NN I
. . I

Thirty-five JJ P
university NN P
students NNS P
were VBD P
assessed VBN P
with IN N
the DT N
four CD N
tonometers NNS N
in IN N
a DT N
randomised JJ N
order NN N
with IN N
non-contact JJ N
tonometry NN N
performed VBD N
first RB N
. . N

Each DT N
of IN N
the DT N
four CD N
measurement NN N
devices NNS N
had VBD N
its PRP$ N
own JJ N
trained JJ N
clinical JJ N
observer NN N
. . N

Plots NNP N
of IN N
differences NNS N
of IN N
IOP NNP O
as IN N
a DT N
function NN N
of IN N
the DT N
mean NN N
for IN N
each DT N
pair NN N
of IN N
instruments NNS N
were VBD N
obtained VBN N
. . N

No DT N
statistically RB N
significant JJ N
differences NNS N
were VBD N
found VBN N
when WRB N
comparing VBG N
the DT N
AT550 NNP I
NCT NNP I
with IN N
contact JJ N
applanation NN N
tonometry NN N
(AT) NNP N
(p> VBZ N
0.05) CD N
displaying VBG N
the DT N
closest JJS N
level NN N
of IN N
agreement NN N
(as NN N
represented VBN N
by IN N
the DT N
lowest JJS N
mean JJ N
difference NN N
and CC N
the DT N
narrowest JJS N
confidence NN N
interval) NN N
with IN N
the DT N
Goldmann NNP I
tonometer NN I
(limits NNS N
of IN N
agreement NN N
0.12+/-2.17) NN N
. . N

In IN N
conclusion NN N
readings NNS N
of IN N
IOP NNP O
with IN N
the DT N
AT550 NNP I
NCT NNP I
are VBP N
clinically RB N
comparable JJ N
with IN N
those DT N
obtained VBN N
with IN N
Goldmann NNP I
tonometry NN I
in IN N
a DT N
population NN P
with IN P
IOP NNP P
within IN P
the DT P
normal JJ P
range NN P
. . P

-DOCSTART- -X- O O

[The JJ O
sympatho-adrenergic JJ O
stress NN O
reaction NN O
in IN N
ear JJ P
surgery NN P
using VBG N
various JJ N
anesthesia JJ N
technics] NN N
. . N

The DT N
aim NN N
of IN N
the DT N
present JJ N
study NN N
was VBD N
to TO N
investigate VB N
the DT N
effects NNS N
of IN N
various JJ N
anaesthetic JJ N
procedures NNS N
on IN N
the DT N
endocrine NN O
stress NN O
responses NNS O
during IN N
ear JJ P
microsurgical JJ P
operations NNS P
. . P

Simple JJ P
mastoidectomies NNS P
radical JJ P
mastoidectomies NNS P
and CC P
tympano NN P
plastics NNS P
were VBD P
carried VBN P
out IN P
in IN P
49 CD P
patients NNS P
under IN N
the DT N
following VBG N
randomised JJ N
anaesthetic JJ N
procedures: NN N
Group NNP N
1 CD N
halothane NN I
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN I
and CC N
ornipressin NN I
(n NNP N
= NNP N
14) CD N
Group NNP N
2 CD N
fentanyl NN I
anaesthesia NN N
and CC N
retroauricular JJ N
anaesthesia NN N
with IN N
lidocaine NN I
and CC N
ornipressin NN I
(n NNP N
= NNP N
10) CD N
Group NNP N
3 CD N
fentanyl NN I
anaesthesia NN N
and CC N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
lidocaine NN I
and CC N
epinephrine NN I
(n NNP N
= VBZ N
14) CD N
and CC N
Group NNP N
4 CD N
retroauricular JJ N
infiltration NN N
anaesthesia NN N
with IN N
prilocaine NN I
and CC N
epinephrine NN I
(n NNP N
= VBZ N
14) CD N
. . N

The DT N
plasma NN O
levels NNS O
of IN O
epinephrine JJ O
norepinephrine NN O
glucose NN O
lactate NN O
and CC O
free JJ O
glycerol NN O
were VBD N
measured VBN N
in IN N
addition NN N
to TO N
mean VB O
arterial JJ O
pressure NN O
(MAP) NN O
and CC O
heart NN O
rate NN O
(HR) NNP O
immediately RB N
before IN N
anaesthesia JJ N
10 CD N
minutes NNS N
after IN N
skin JJ N
incision NN N
10 CD N
minutes NNS N
after IN N
having VBG N
started VBD N
bone CD N
drilling NN N
at IN N
the DT N
end NN N
of IN N
the DT N
operation NN N
and CC N
3 CD N
hours NNS N
after IN N
operation NN N
. . N

All DT N
data NNS N
were VBD N
subjected VBN N
to TO N
covariance VB N
analysis NN N
including VBG N
the DT N
age NN N
factor NN N
. . N

Plasma NNP O
catecholamine JJ O
concentrations NNS O
remained VBD N
within IN N
the DT N
normal JJ N
range NN N
during IN N
the DT N
investigation NN N
in IN N
patients NNS N
subjected VBN N
to TO N
general JJ N
anaesthesia NN N
(Groups VBD N
1-3) JJ N
. . N

Plasma NNP O
catecholamines NNS O
(epinephrine NNP O
and CC O
norepinephrine) RB O
increased VBD N
significantly RB N
in IN N
Group NNP N
4 CD N
(retroauricular JJ N
infiltration NN N
anaesthesia) NN N
. . N

There EX N
were VBD N
no DT N
group NN N
variabilities VBZ N
with IN N
regard NN N
to TO N
MAP NNP O
and CC N
HR NNP O
. . O

The DT N
plasma NN O
levels NNS O
of IN O
epinephrine NN O
and CC O
norepinephrine JJ O
demonstrate NN N
a DT N
direct JJ N
response NN N
to TO N
stress NN N
followed VBN N
by IN N
a DT N
secondary JJ N
change NN N
in IN N
glucose JJ O
lactate NN O
and CC O
free JJ O
glycerol NN O
. . O

-DOCSTART- -X- O O

Inhaled VBN N
fluticasone NN I
reduces NNS N
sputum VBP O
inflammatory JJ O
indices NNS O
in IN N
severe JJ P
bronchiectasis NN P
. . P

Although IN N
corticosteroid JJ N
therapy NN N
might MD N
be VB N
clinically RB N
beneficial JJ N
for IN N
bronchiectasis NN N
very RB N
little JJ N
is VBZ N
known VBN N
of IN N
its PRP$ N
effects NNS N
on IN N
the DT N
inflammatory NN O
and CC O
infective JJ O
markers NNS O
in IN N
bronchiectasis NN P
. . P

We PRP N
have VBP N
therefore RB N
performed VBN N
a DT N
double-blind JJ N
placebo-controlled JJ I
study NN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
a DT N
4-wk JJ N
administration NN N
of IN N
inhaled JJ N
fluticasone NN I
in IN N
bronchiectasis NN P
. . P

Twenty-four CD P
patients NNS P
(12 JJ P
female; JJ P
mean JJ P
age NN P
51 CD P
yr) NN P
were VBD N
randomized VBN N
into IN N
receiving VBG N
either CC N
inhaled JJ N
fluticasone NN I
(500 NN N
microgram NN N
twice RB N
daily) RB N
via IN N
the DT N
Accuhaler NNP N
device NN N
(n NNP N
= VBZ N
12) CD N
or CC N
placebo NN I
. . I

At IN N
each DT N
visit NN N
spirometry NN O
24-h JJ O
sputum NN O
volume NN O
sputum NN O
leukocyte JJ O
density NN O
bacterial JJ O
densities NNS O
and CC O
concentrations NNS O
of IN O
interleukin JJ O
(IL)-1beta JJ O
IL-8 JJ O
tumor NN O
necrosis IN O
factor-alpha JJ O
(TNF-alpha) JJ O
and CC O
leukotriene JJ O
B4 NNP O
(LTB4) NNP O
were VBD N
determined VBN N
. . N

There EX N
was VBD N
a DT N
significant JJ N
(p NN N
< VBD N
0.05) CD N
decrease NN N
in IN N
sputum NN O
leukocyte NN O
density NN O
and CC O
IL-1beta NNP O
IL-8 NNP O
and CC O
LTB4 NNP O
after IN N
fluticasone NN I
treatment NN N
. . N

The DT N
fluticasone NN I
group NN N
had VBD N
one CD N
and CC N
the DT N
placebo NN I
group NN N
three CD N
episodes NNS N
of IN N
exacerbation NN N
. . N

There EX N
were VBD N
no DT N
significant JJ N
changes NNS N
in IN N
spirometry NN O
(p NNP N
> VBZ N
0.05) CD N
or CC N
any DT N
reported JJ N
adverse JJ O
reactions NNS O
in IN N
either DT N
group NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show VB N
that IN N
high-dose JJ N
fluticasone NN I
is VBZ N
effective JJ N
in IN N
reducing VBG N
the DT N
sputum NN O
inflammatory NN O
indices NNS O
in IN N
bronchiectasis NN P
. . P

Large-scale JJ N
and CC N
long-term JJ N
studies NNS N
are VBP N
indicated VBN N
to TO N
evaluate VB N
the DT N
effects NNS N
of IN N
inhaled JJ N
steroid JJ I
therapy NN N
on IN N
the DT N
inflammatory JJ O
components NNS O
in IN N
bronchiectasis NN P
. . P

-DOCSTART- -X- O O

[Clinical JJ N
study NN N
on IN N
treatment NN N
of IN N
endometriosis-related JJ P
infertility NN P
patients NNS P
by IN N
laparoscopic NN I
surgery NN I
in IN N
combination NN N
of IN N
quyu JJ I
jiedu NN I
recipe] NN I
. . N

OBJECTIVE UH N
To TO N
study VB N
the DT N
clinical JJ O
efficacy NN O
of IN N
the DT N
laparoscopic NN I
surgery NN I
in IN N
combination NN N
of IN N
Quyu NNP I
Jiedu NNP I
Recipe NNP I
(QYJDR) NNP I
on IN N
endometriosis NN P
(EMs)-related JJ P
infertility NN P
patients NNS P
. . P

METHODS NNP N
130 CD P
EMs-related JJ P
infertility NN P
patients NNS P
of IN P
blood NN P
stasis NN P
and CC P
toxin NN P
accumulation NN P
syndrome NN P
diagnosed VBD P
and CC P
treated VBN P
by IN P
laparoscopic NN P
surgery NN P
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
groups NNS N
i.e VBP N
. . N

the DT N
test NN N
group NN N
(75 NNP N
cases) NN N
and CC N
the DT N
control NN N
group NN N
(55 NNP N
cases) NN N
. . N

All DT N
patients NNS N
received VBD N
routine JJ N
progesterone NN I
treatment NN N
after IN N
laparoscopic NN N
surgery NN N
. . N

QYJDR NNP I
was VBD N
given VBN N
to TO N
patients NNS N
in IN N
the DT N
test NN N
group NN N
after IN N
laparoscopic NN N
surgery NN N
lasting VBG N
for IN N
twelve JJ N
months NNS N
. . N

The DT N
pregnancy NN O
rate NN O
within IN O
one CD O
year NN O
after IN O
laparoscopic NN O
surgery NN O
were VBD N
compared VBN N
between IN N
the DT N
two CD N
groups NNS N
. . N

The DT N
Chinese JJ O
medicine NN O
syndrome NN O
integrals NNS O
serum VBP O
endometrium NN O
antibody NN O
(EMAb) NNP O
and CC O
cancer NN O
antigen NN O
125 CD O
(CA125) NN O
levels NNS O
were VBD N
compared VBN N
between IN N
before RB N
drug NN N
therapy NN N
and CC N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
. . N

RESULTS VB N
The DT N
pregnancy NN O
rate NN O
within IN N
one CD N
year NN N
after IN N
laparoscopic NN N
surgery NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
[61.33% NNP N
(46/75) NNP N
vs VBD N
45.45% CD N
(25/55)] JJ N
showing VBG N
significant JJ N
difference NN N
(P<0.05) NN N
. . N

The DT N
Chinese JJ O
medicine NN O
syndrome JJ O
integral NN O
was VBD N
(16.07 JJ N
+/- JJ N
6.77) CD N
score NN N
and CC N
(7.25 VB N
+/- JJ N
3.27) CD N
score NN N
before IN N
and CC N
3 CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
while IN N
it PRP N
was VBD N
(15.92 JJ N
+/- JJ N
7.51) CD N
score NN N
and CC N
(12.73 VB N
+/- JJ N
6.12) CD N
score NN N
in IN N
the DT N
control NN N
group NN N
. . N

The DT N
Chinese JJ O
medicine NN O
syndrome JJ O
integral JJ O
after IN N
drug NN N
therapy NN N
was VBD N
lower JJR N
than IN N
that DT N
before IN N
drug NN N
therapy NN N
in IN N
the DT N
same JJ N
group NN N
. . N

Besides IN N
the DT N
integral JJ O
difference NN N
between IN N
before IN N
and CC N
after IN N
drug NN N
therapy NN N
was VBD N
higher RBR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
[(9.12 VBD N
+/- JJ N
6.16) CD N
score NN N
vs NN N
(3.48 VBD N
+/- JJ N
2.06) CD N
score)] NN N
showing VBG N
statistical JJ N
difference NN N
(P<0.05) NN N
. . N

After IN N
three-month JJ N
drug NN N
therapy VBZ N
the DT N
serum NN O
EMAb NNP O
negative JJ N
conversion NN N
rate NN N
was VBD N
obviously RB N
higher JJR N
in IN N
the DT N
test NN N
group NN N
than IN N
in IN N
the DT N
control NN N
group NN N
(44.44% NNP N
vs VBZ N
15.62%) CD N
showing VBG N
statistical JJ N
difference NN N
(P<0.05) NN N
. . N

The DT N
serum NN O
CA125 NNP O
level NN O
was VBD N
(31.88 JJ N
+/- JJ N
15.78) CD N
U/mL NNP N
before IN N
drug NN N
therapy NN N
and CC N
(18.82 VB N
+/- JJ N
10.08) CD N
U/mL NNP N
three CD N
months NNS N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
test NN N
group NN N
while IN N
it PRP N
was VBD N
(30.63 JJ N
+/- JJ N
19.28) CD N
U/mL NNP N
and CC N
(18.05 NNP N
+/- JJ N
11.20) CD N
U/mL NNP N
respectively RB N
in IN N
the DT N
control NN N
group NN N
. . N

It PRP N
was VBD N
lowered VBN N
after IN N
drug NN N
therapy NN N
in IN N
the DT N
two CD N
groups NNS N
with IN N
statistical JJ N
difference NN N
(P<0.05) NN N
. . N

There EX N
was VBD N
no DT N
statistical JJ N
difference NN N
between IN N
the DT N
two CD N
groups NNS N
after IN N
drug NN N
therapy NN N
(P>0.05) NNP N
. . N

CONCLUSIONS NNP N
The DT N
laparoscopic NN I
surgery NN I
in IN N
combination NN N
of IN N
QYJDR NNP I
could MD N
effectively RB N
improve VB N
clinical JJ O
symptoms NNS O
of IN N
EMs NNP P
patients NNS P
of IN P
blood NN P
stasis NN P
and CC P
toxin NN P
accumulation NN P
syndrome JJ P
promote NN N
negative JJ O
conversion NN O
of IN O
EMAb NNP O
lower JJR N
serum NN O
CA125 NNP O
levels NNS O
and CC N
elevate VB N
the DT N
clinical JJ O
pregnancy NN O
rate NN O
. . O

QYJDR NNP I
is VBZ N
an DT N
effective JJ N
formula NN N
in IN N
treatment NN N
of IN N
EMs-related JJ P
infertility NN P
. . P

-DOCSTART- -X- O O

A DT N
comparison NN N
of IN N
continuous JJ I
femoral JJ I
nerve NN I
block NN I
(CFNB) NNP I
and CC N
continuous JJ I
epidural JJ I
infusion NN I
(CEI) NN I
in IN N
postoperative JJ P
analgesia NN P
and CC N
knee NN N
rehabilitation NN N
after IN P
total JJ P
knee NN P
arthroplasty NN P
(TKA) NN P
. . P

BACKGROUND NNP N
Postoperative NNP N
epidural JJ N
analgesia NN N
(EA) NN N
and CC N
femoral JJ I
nerve NN I
block NN I
(FNB) NNP I
provided VBD N
effective JJ N
pain NN O
relief NN O
However RB N
EA NNP N
has VBZ N
common JJ N
side NN O
effects NNS O
such JJ N
as IN N
nausea NN O
vomiting VBG O
pruritus NN O
dizziness NN O
and CC O
hypotension NN O
. . O

Some DT N
investigations NNS N
found VBD N
that IN N
those DT N
side JJ N
effects NNS N
were VBD N
less RBR N
in IN N
FNB NNP N
than IN N
in IN N
EA NNP N
. . N

However RB N
the DT N
analgesic JJ N
equivalent NN N
of IN N
both DT N
techniques NNS N
have VBP N
not RB N
been VBN N
confirmed VBN N
. . N

OBJECTIVE IN N
The DT N
authors NNS N
compared VBN N
continuous JJ I
epidural JJ I
infusion NN I
(CEI) NN I
with IN N
continuous JJ I
femoral JJ I
nerve NN I
block NN I
(CFNB) NNP I
regarding VBG N
the DT N
postoperative JJ O
analgesic JJ O
efficacy NN O
side NN O
effects NNS O
postoperative JJ O
knee NN O
rehabilitation NN O
and CC O
hospital JJ O
length NN O
of IN O
stay NN O
(LOS) NNP O
. . O

MATERIAL NNP N
AND NNP N
METHOD NNP N
In IN N
this DT N
prospective JJ N
randomized NN N
controlled VBD N
study NN N
61 CD P
ASA NNP P
physical JJ P
status NN P
I-III NNP P
patients NNS P
scheduled VBN P
for IN P
elective JJ P
unilateral JJ P
total NN P
knee NN P
arthroplasty IN P
(TKA) NNP P
under IN P
spinal JJ P
anesthesia NN P
(SA) NN P
participated VBD N
. . N

The DT N
patients NNS N
were VBD N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

In IN N
the DT N
ward NN N
patients NNS N
in IN N
Group NNP N
I PRP N
(CEI) VBP I
were VBD N
maintained VBN N
by IN N
continuous JJ N
infusion NN N
of IN N
0.125% CD N
levobupivacaine NN I
with IN N
morphine JJ I
0.0125 CD N
mg/ml NN N
(4 NNP N
ml/hr) NNP N
Group NNP N
II NNP N
(CFNB) NNP I
were VBD N
maintained VBN N
by IN N
0.125% CD N
levobupivacaine JJ I
(8 NNP N
ml/hr) NN N
. . N

RESULTS JJ N
Patients NNPS N
in IN N
the DT N
CFNB NNP I
group NN N
the DT N
VAS NNP O
scores NNS O
at IN N
PO6-12 NNP N
hr NN N
and CC N
tramadol NN O
IV NNP O
requirement NN O
were VBD N
significantly RB N
greater JJR N
than IN N
the DT N
CEI NNP I
group NN N
(VAS: NNP N
PO6 NNP N
hr VBD N
p-value JJ N
= NN N
0.001 CD N
PO12 NNP N
hr VBD N
p-value JJ N
= NN N
0.004) CD N
. . N

Patients NNS N
in IN N
the DT N
CEI NNP I
group NN N
experienced VBD N
dizziness NN O
pruritus NN O
and CC O
PONV NNP O
more JJR N
than IN N
the DT N
CFNB NNP I
group NN N
significantly RB N
. . N

Patient JJ O
satisfaction NN O
was VBD N
greater JJR N
with IN N
the DT N
CFNB NNP I
group NN N
although IN N
postoperative JJ O
knee NN O
rehabilitation NN O
and CC O
the DT O
hospital NN O
LOS NNP O
were VBD N
not RB N
different JJ N
. . N

CONCLUSION NNP N
CFNB NNP I
represents VBZ N
the DT N
optimal JJ N
analgesia NN N
with IN N
fewer JJR N
side NN O
effects NNS O
and CC N
greater JJR N
patient JJ O
satisfaction NN O
. . O

The DT N
rehabilitation NN O
indices NNS O
and CC O
duration NN O
of IN O
hospital NN O
stay NN O
are VBP N
comparable JJ N
in IN N
both DT N
groups NNS N
. . N

-DOCSTART- -X- O O

Epidemiology NN N
of IN N
stroke NN N
. . N

Importance NN N
of IN N
preventive JJ N
pharmacological JJ N
strategies NNS N
in IN N
elderly JJ P
patients NNS P
and CC N
associated JJ N
costs NNS N
. . N

Stroke NNP N
is VBZ N
a DT N
major JJ N
cause NN N
of IN N
death NN N
and CC N
disability NN N
in IN N
developed JJ N
countries NNS N
. . N

The DT N
incidence NN O
of IN O
stroke NN O
increases NNS N
exponentially RB N
with IN N
age NN N
yet RB N
traditionally RB N
many JJ N
medical JJ N
practitioners NNS N
have VBP N
been VBN N
reluctant JJ N
to TO N
treat VB N
hypertension NN P
in IN P
older JJR P
patients NNS P
. . P

Since IN N
1991 CD N
the DT N
results NNS N
of IN N
3 CD N
major JJ N
trials--the JJ N
British NNP N
Medical NNP N
Research NNP N
Council NNP N
(MRC) NNP N
trial NN N
of IN N
treatment NN N
in IN N
older JJR P
adults NNS P
the DT N
Swedish JJ N
Trial NNP N
in IN N
Old NNP P
Patients NNPS P
with IN P
Hypertension NNP P
(STOP-Hypertension) NN N
and CC N
the DT N
Systolic NNP N
Hypertension NNP N
in IN N
the DT N
Elderly JJ N
Program NNP N
(SHEP)--have NN N
conclusively RB N
established VBD N
the DT N
benefits NNS N
of IN N
treating VBG N
older JJR P
patients NNS P
(> VBP P
60 CD P
years) NN P
with IN P
both DT P
diastolic JJ P
and CC P
isolated JJ P
systolic JJ P
hypertension NN P
. . P

International NNP N
guidelines NNS N
for IN N
the DT N
management NN N
of IN N
hypertension--including VBG N
the DT N
Fifth NNP N
Report NNP N
of IN N
the DT N
Joint NNP N
National NNP N
Committee NNP N
the DT N
1993 CD N
report NN N
of IN N
the DT N
World NNP N
Health NNP N
Organization NNP N
and CC N
the DT N
International NNP N
Society NNP N
of IN N
Hypertension NNP N
and CC N
the DT N
second JJ N
report NN N
of IN N
the DT N
British JJ N
Hypertension NNP N
Society NNP N
Working NNP N
Party--have NNP N
all DT N
been VBN N
modified VBN N
to TO N
reflect VB N
the DT N
emerging VBG N
evidence NN N
concerning VBG N
the DT N
benefits NNS N
of IN N
treating VBG N
older JJR P
patients NNS P
. . P

Cost-effectiveness JJ O
data NNS O
are VBP N
similarly RB N
in IN N
accord NN N
with IN N
giving VBG N
high JJ N
priority NN N
to TO N
the DT N
treatment NN N
of IN N
older JJR P
individuals NNS P
with IN P
hypertension NN P
. . P

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
tunnelling VBG I
on IN N
epidural JJ N
catheter NN N
migration NN N
. . N

A DT N
prospective JJ N
randomised VBN N
study NN N
of IN N
82 CD P
patients NNS P
having VBG P
postoperative JJ P
epidural JJ P
analgesia NN P
was VBD N
performed VBN N
to TO N
determine VB N
whether IN N
the DT N
tunnelling NN I
of IN N
an DT N
epidural JJ N
catheter NN N
influences VBZ N
its PRP$ N
migration NN O
. . O

Tunnelling NN I
of IN N
the DT N
catheter NN N
subcutaneously RB N
for IN N
a DT N
distance NN N
of IN N
5 CD N
cm NN N
reduced VBD N
the DT N
incidence NN N
of IN N
inward JJ N
migration NN N
of IN N
1 CD N
cm NN N
or CC N
more JJR N
(p JJ N
< NN N
0.01) CD N
compared VBN N
to TO N
a DT N
standard JJ N
method NN N
of IN N
fixation NN N
with IN N
a DT N
transparent JJ N
adhesive JJ N
dressing NN N
. . N

This DT N
effect NN N
was VBD N
more RBR N
marked JJ N
if IN N
the DT N
epidural JJ N
catheter NN N
was VBD N
sited VBN N
in IN N
the DT N
thoracic NN N
rather RB N
than IN N
the DT N
lumbar JJ N
area NN N
. . N

Sixty CD N
two CD N
percent NN N
(n VBD N
= JJ N
26) CD N
of IN N
tunnelled JJ I
catheters NNS I
remained VBD N
within IN N
0.5 CD N
cm NNS N
of IN N
their PRP$ N
original JJ N
position NN N
compared VBN N
to TO N
38% CD N
(n NNS N
= JJ N
16) CD N
of IN N
non-tunnelled JJ I
catheters NNS I
although IN N
this DT N
difference NN N
was VBD N
not RB N
statistically RB N
significant JJ N
. . N

Outward NNP N
catheter NN O
migration NN O
was VBD N
not RB N
reduced VBN N
by IN N
subcutaneous JJ N
tunnelling NN I
. . I

-DOCSTART- -X- O O

Effect NN N
of IN N
the DT N
essential JJ I
oils NNS I
of IN I
garlic NN I
and CC I
onion NN I
on IN N
alimentary JJ N
hyperlipemia NN N
. . N

SUMMARY VB N
The DT N
effect NN N
of IN N
garlic NN I
and CC I
onion NN I
on IN N
alimentary JJ N
hyperlipemia NN N
induced VBN N
by IN N
feeding VBG N
100 CD N
g NN N
butter NN N
has VBZ N
been VBN N
studied VBN N
in IN N
10 CD P
healthy JJ P
subjects NNS P
. . P

The DT N
freshly RB N
extracted JJ N
juice NN N
of IN N
50 CD N
g NN N
of IN N
garlic NN I
or CC I
onion NN I
as RB N
well RB N
as IN N
an DT N
equivalent JJ N
amount NN N
of IN N
their PRP$ N
ether-extracted JJ N
essential JJ I
oils NNS I
was VBD N
administered VBN N
randomly RB N
on IN N
four CD N
different JJ N
days NNS N
during IN N
a DT N
one-week JJ N
period NN N
. . N

Garlic NNP I
and CC I
onion NN I
have VBP N
a DT N
significant JJ N
protective JJ N
action NN N
against IN N
fat-induced JJ N
increases NNS N
in IN N
serum NN O
cholesterol NN O
and CC O
plasma NN O
fibrinogen NN O
and CC N
decreases NNS N
in IN N
coagulation NN O
time NN O
and CC N
fibrinolytic JJ O
activity NN O
. . O

The DT N
essential JJ I
oil NN I
fraction NN N
which WDT N
contains VBZ N
all PDT N
the DT N
taste NN N
and CC N
odour NN N
exactly RB N
duplicated VBD N
the DT N
beneficial JJ N
effects NNS O
of IN N
whole JJ N
garlic NN I
and CC N
onion NN I
. . I

It PRP N
is VBZ N
therefore RB N
concluded VBD N
that IN N
the DT N
active JJ N
principle NN N
of IN N
garlic JJ I
and CC I
onion NN I
is VBZ N
the DT N
essential JJ I
oil NN I
which WDT N
chemically RB N
is VBZ N
a DT N
combination NN N
of IN N
sulphur-containing JJ N
compounds NNS N
mainly RB N
allyl VBP N
propyl JJ N
disulphide NN N
and CC N
diallyl JJ N
disulphide NN N
. . N

-DOCSTART- -X- O O

The DT N
course NN N
of IN N
depression NN N
in IN N
recent JJ P
onset NN P
rheumatoid NN P
arthritis: IN P
the DT N
predictive JJ N
role NN O
of IN N
disability NN O
illness NN O
perceptions NNS O
pain VBP O
and CC O
coping VBG O
. . O

BACKGROUND NNP N
This DT N
study NN N
aimed VBD N
to TO N
investigate VB N
the DT N
course NN N
of IN N
depression NN N
for IN N
patients NNS P
with IN P
recently RB P
diagnosed VBN P
rheumatoid NN P
arthritis NN P
(RA) NN P
and CC N
to TO N
investigate VB N
predictors NNS O
of IN O
depression NN O
. . O

METHODS NNP N
Twenty-two JJ P
patients NNS P
with IN P
a DT P
history NN P
of IN P
recently RB P
diagnosed VBN P
RA NNP P
of IN P
less JJR P
than IN P
2 CD P
years NNS P
were VBD N
assessed VBN N
on IN N
a DT N
variety NN N
of IN N
clinical JJ O
outcome NN O
and CC O
process NN O
measures NNS O
on IN N
six CD N
assessment JJ N
occasions NNS N
over IN N
a DT N
21-month JJ N
period NN N
. . N

These DT N
22 CD P
patients NNS P
constituted VBD N
the DT N
control NN N
group NN N
of IN N
a DT N
controlled VBN N
trial NN N
and CC N
received VBN N
standard JJ I
outpatient NN I
clinic JJ I
treatment NN I
during IN N
follow-up JJ N
. . N

RESULTS JJ N
Patients NNPS N
became VBD N
significantly RB N
more RBR N
depressed JJ N
over IN N
time NN N
. . N

A DT N
set NN N
of IN N
five CD N
factors NNS N
were VBD N
found VBN N
to TO N
consistently RB N
predict VB O
depression NN O
at IN N
the DT N
following JJ N
assessment NN N
. . N

These DT N
were VBD N
initial JJ O
level NN O
of IN O
depression NN O
disability NN O
pain NN O
beliefs NNS O
about IN O
the DT O
consequences NNS O
of IN O
arthritis NN O
and CC O
coping VBG O
strategies NNS O
. . O

CONCLUSIONS VB N
The DT N
results NNS N
confirm VBP N
the DT N
importance NN N
of IN N
psychological JJ N
factors NNS N
in IN N
early JJ P
RA NNP P
and CC N
their PRP$ N
relative JJ N
independence NN N
from IN N
physical JJ N
findings NNS N
. . N

This DT N
is VBZ N
the DT N
first JJ N
study NN N
to TO N
document VB N
the DT N
importance NN N
of IN N
illness JJ N
perceptions NNS N
in IN N
recent JJ P
onset NN P
RA NNP P
. . P

-DOCSTART- -X- O O

Effect NN N
of IN N
different JJ N
rates NNS N
of IN N
infusion NN N
of IN N
propofol NN I
for IN N
induction NN N
of IN N
anaesthesia NN N
in IN N
elderly JJ P
patients NNS P
. . P

The DT N
effect NN N
of IN N
changing VBG N
the DT N
rate NN N
of IN N
infusion NN N
of IN N
propofol NN I
for IN N
induction NN N
of IN N
anaesthesia NN N
was VBD N
studied VBN N
in IN N
60 CD P
elderly JJ P
patients NNS P
. . P

Propofol NNP I
was VBD N
administered VBN N
at IN N
300 CD N
600 CD N
or CC N
1200 CD N
ml JJ N
h-1 JJ N
until IN N
loss NN O
of IN O
consciousness NN O
(as NNS O
judged VBN O
by IN O
loss NN O
of IN O
verbal JJ O
contact NN O
with IN O
the DT O
patient) NN O
had VBD N
been VBN N
achieved VBN N
. . N

The DT N
duration NN O
of IN O
induction NN O
was VBD N
significantly RB N
longer JJR N
(P VBZ N
less JJR N
than IN N
0.001) CD N
with IN N
the DT N
slower JJR N
infusion NN O
rates NNS O
(104 VBP N
68 CD N
and CC N
51 CD N
s) NN N
but CC N
the DT N
total JJ O
dose NN O
used VBN N
was VBD N
significantly RB N
less JJR N
(P RB N
less JJR N
than IN N
0.001) CD N
in IN N
these DT N
patients NNS N
(1.2 VBP N
1.6 CD N
and CC N
2.5 CD N
mg JJ N
kg-1 JJ N
respectively) NN N
. . N

The DT N
decrease NN N
in IN N
systolic JJ O
and CC O
diastolic JJ O
arterial JJ O
pressure NN O
was VBD N
significantly RB N
less RBR N
in IN N
the DT N
300-ml JJ N
h-1 JJ N
group NN N
at IN N
the DT N
end NN N
of IN N
induction NN N
and CC N
immediately RB N
after IN N
induction NN N
(P RB N
less JJR N
than IN N
0.01) CD N
. . N

The DT N
incidence NN O
of IN O
apnoea NN O
was VBD N
also RB N
significantly RB N
less RBR N
in IN N
the DT N
slower JJR N
infusion NN N
group NN N
. . N

-DOCSTART- -X- O O

Systemic NNP O
hemodynamic JJ O
neurohormonal JJ O
and CC O
renal JJ O
effects NNS O
of IN N
a DT N
steady-state JJ N
infusion NN N
of IN N
human JJ I
brain NN I
natriuretic JJ I
peptide NN I
in IN N
patients NNS P
with IN P
hemodynamically RB P
decompensated VBN P
heart NN P
failure NN P
. . P

BACKGROUND NNP N
Human NNP I
brain NN I
natriuretic JJ I
peptide NN I
(hBNP) NNP I
is VBZ N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
treatment NN N
of IN N
decompensated JJ P
cardiac JJ P
failure NN P
. . P

However RB N
the DT N
systemic JJ O
hemodynamic JJ O
neurohormonal JJ O
and CC O
renal JJ O
effects NNS O
of IN N
hBNP NNS I
have VBP N
been VBN N
incompletely RB N
studied VBN N
in IN N
human JJ N
heart NN N
failure NN N
. . N

METHODS NNP N
AND CC N
RESULTS NNP N
The DT N
effects NNS N
of IN N
a DT N
continuous JJ N
4-hour JJ N
infusion NN N
of IN N
hBNP NN I
were VBD N
determined VBN N
in IN N
16 CD P
decompensated JJ P
heart NN P
failure NN P
patients NNS P
in IN N
an DT N
invasive JJ N
randomized JJ N
double-blind JJ N
placebo-controlled JJ I
study NN N
. . N

Patients NNS N
were VBD N
evaluated VBN N
during IN N
three CD N
4-hour JJ N
study NN N
periods: JJ N
baseline NN N
treatment NN N
(placebo NNP I
[n NNP N
= VBD N
4] CD N
versus NN N
hBNP NN I
0.025 CD N
or CC N
0.05 CD N
microgram/kg/min NNS N
[n JJ N
= VBP N
12]) CD N
and CC N
post-treatment JJ N
. . N

Urinary JJ N
volume NN N
losses NNS N
were VBD N
replaced VBN N
hourly RB N
to TO N
separate VB N
the DT N
vasodilatory NN N
and CC N
diuretic JJ N
effects NNS N
of IN N
hBNP NN I
. . I

Two CD N
patients NNS N
in IN N
the DT N
hBNP NN I
group NN N
were VBD N
excluded VBN N
from IN N
the DT N
analysis NN N
because IN N
of IN N
adverse JJ O
events NNS O
. . O

hBNP NN I
significantly RB N
(P NNP N
< NNP N
.001) NNP N
reduced VBD N
right JJ O
atrial JJ O
pressure NN O
and CC O
pulmonary JJ O
capillary JJ O
wedge NN O
pressure NN O
by IN N
approximately RB N
30% CD N
and CC N
40% CD N
respectively RB N
. . N

hBNP NN I
also RB N
significantly RB N
lowered VBN N
systemic JJ O
vascular JJ O
resistance NN O
from IN N
1722 CD N
+/- JJ N
139 CD N
to TO N
1101 CD N
+/- JJ N
83 CD N
dynes.s.cm-5 JJ N
(P NNP N
< NNP N
.05) NNP N
. . N

These DT N
unloading JJ N
effects NNS N
of IN N
hBNP NN I
produced VBD N
a DT N
28% CD N
increase NN N
in IN N
cardiac JJ O
index NN O
(P NNP N
< NNP N
.05) NNP N
with IN N
no DT N
change NN N
in IN N
heart NN O
rate NN O
. . O

Compared VBN N
to TO N
placebo VB I
hBNP NN I
decreased VBN N
plasma JJ O
norepinephrine NN O
and CC O
aldosterone NN O
. . O

Renal JJ O
hemodynamics NNS O
were VBD N
unaffected VBN N
by IN N
hBNP; NN I
however RB N
most JJS N
patients NNS N
were VBD N
resistant JJ N
to TO N
its PRP$ N
natriuretic JJ N
effect NN N
. . N

CONCLUSIONS CC N
1) CD N
The DT N
predominant JJ N
hemodynamic JJ O
effects NNS O
of IN N
hBNP NN I
were VBD N
a DT N
decrease NN N
in IN N
cardiac JJ O
preload NN O
and CC O
systemic JJ O
vascular JJ O
resistance NN O
. . O

2) CD N
hBNP NN I
also RB N
improved VBD N
cardiac JJ O
output NN O
without IN N
increasing VBG N
heart NN O
rate NN O
. . O

3) CD N
Plasma NNP O
norepinephrine NN O
and CC O
aldosterone NN O
levels NNS O
decreased VBN N
during IN N
hBNP JJ I
infusion NN N
. . N

4) CD N
hBNP NN I
is VBZ N
pharmacologically RB N
active JJ N
and CC N
has VBZ N
potential VBN N
in IN N
the DT N
therapy NN N
for IN N
decompensated JJ P
heart NN P
failure NN P
. . P

-DOCSTART- -X- O O

[Clinical JJ N
study NN N
of IN N
the DT N
efficacy NN O
of IN N
and CC N
tolerance NN O
to TO N
nimesulide VB I
in IN N
suppository JJ N
formulation NN N
in IN N
pain-inflammatory JJ P
pathologies NNS P
of IN P
the DT P
ear NN P
nose NN P
and CC P
throat] NN P
. . N

The DT N
efficacy NN O
and CC N
tolerability NN O
of IN N
a DT N
new JJ N
pharmaceutical JJ N
form NN N
of IN N
the DT N
non-steroid JJ I
anti-inflammatory JJ I
drug NN I
. . I

Nimesulide NNP I
have VBP N
been VBN N
studied VBN N
in IN N
a DT N
double JJ N
blind NN N
study NN N
compared VBN N
with IN N
flurbiprofen NN I
in IN N
98 CD P
patients NNS P
aged VBN P
between IN P
18 CD P
and CC P
75 CD P
suffering VBG P
from IN P
pain-inflammatory JJ P
pathologies NNS P
of IN P
ENT NNP P
nature NN P
. . P

Both DT N
drugs NNS N
administered VBN N
in IN N
a DT N
dose NN N
of IN N
one CD N
suppository NN N
twice RB N
a DT N
day NN N
for IN N
7 CD N
days NNS N
showed VBD N
marked JJ N
anti-inflammatory JJ O
analgesic JJ O
and CC O
antipyretic JJ O
activity NN O
and CC N
produced VBD N
a DT N
significant JJ N
progressive JJ N
improvement NN N
in IN N
the DT N
typical JJ N
symptoms NNS O
of IN O
the DT O
inflammatory NN O
state NN O
up IN N
to TO N
their PRP$ N
complete JJ N
remission NN N
. . N

Nimesulide NNP I
evidenced VBD N
greater JJR N
speed NN N
and CC N
duration NN O
of IN N
therapeutic JJ N
action NN N
. . N

Assessment NN N
on IN N
the DT N
effectiveness NN O
and CC N
tolerability NN O
as IN N
expressed VBN N
separately RB N
by IN N
the DT N
physician NN N
and CC N
patient NN N
were VBD N
positive JJ N
in IN N
almost RB N
all DT N
cases NNS N
of IN N
both DT N
treatments NNS N
. . N

-DOCSTART- -X- O O

[Postural JJ N
biofeedback NN N
and CC N
locomotion NN N
reeducation NN N
in IN N
stroke NN P
patients] NN P
. . N

AIMS NNP N
To TO N
compare VB N
in IN N
post-acute JJ P
hemiparetic JJ P
patients NNS P
gait VBP O
improvement NN O
after IN N
conventional JJ I
physical JJ I
therapy NN I
alone RB I
or CC N
with IN I
a DT I
specialised JJ I
balance NN I
retraining VBG I
program NN I
. . I

PATIENTS VB N
Twenty-six JJ P
patients NNS P
within IN P
3 CD P
months NNS P
of IN P
onset NN P
of IN P
stroke NN P
were VBD N
randomised VBN N
to TO N
receive VB N
physical JJ I
therapy NN I
(control NN N
group) NN N
or CC N
therapy NN I
and CC I
retraining VBG I
(experimental JJ N
group) NN N
most JJS N
of IN N
the DT N
patients NNS N
in IN N
both DT N
groups NNS N
with IN N
left JJ N
hemiplegia NN P
. . P

The DT N
experimental JJ N
group NN N
was VBD N
significantly RB N
older JJR N
than IN N
the DT N
control NN N
group NN N
. . N

METHOD NNP N
Thirteen NNP N
patients NNS N
received VBD N
early JJ N
conventional JJ I
therapy NN I
and CC N
13 CD N
received VBD N
therapy NN I
combined VBN I
with IN I
standing VBG I
balance NN I
training NN I
by IN I
biofeedback NN I
(BPM NNP I
Monitor) NNP I
. . I

Clinical JJ O
measures NNS O
were VBD N
collected VBN N
at IN N
entry NN N
(J0) NN N
once RB N
when WRB N
subjects NNS N
began VBD N
to TO N
walk VB N
(JM) NNP N
and CC N
30 CD N
days NNS N
later RB N
(JM VBP N
+ JJ N
30) CD N
. . N

Gait NNP O
spatiotemporal JJ O
parameters NNS O
were VBD N
collected VBN N
by IN N
use NN N
of IN N
the DT N
Vicon NNP N
system NN N
at IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
. . N

RESULTS VB N
Whatever IN N
the DT N
method NN N
of IN N
rehabilitation NN N
the DT N
clinical JJ O
scores NNS O
improved VBN N
significantly RB N
between IN N
J0 NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
except IN N
for IN N
spasticity NN N
. . N

The DT N
time NN O
between IN O
stroke NN O
and CC O
the DT O
beginning NN O
of IN O
walking NN O
was VBD N
not RB N
significantly RB N
different JJ N
between IN N
both DT N
groups NNS N
. . N

Gait NNP O
velocity NN O
increased VBD N
significantly RB N
between IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
in IN N
both DT N
groups NNS N
with IN N
no DT N
difference NN N
between IN N
groups NNS N
. . N

The DT N
walking NN O
pattern NN O
was VBD N
improved VBN N
for IN N
both DT N
groups NNS N
with IN N
a DT N
significant JJ N
increase NN N
of IN N
the DT N
duration NN O
of IN O
the DT O
paretic JJ O
limb NN O
single JJ O
stance NN O
. . O

The DT N
experimental JJ N
group NN N
significantly RB N
improved VBD N
the DT N
duration NN O
of IN O
the DT O
reception NN O
double JJ O
stance NN O
on IN O
the DT O
paretic JJ O
limb NN O
between IN N
JM NNP N
and CC N
JM NNP N
+ NNP N
30 CD N
compared VBN N
with IN N
the DT N
control NN N
group NN N
(P NNP N
= VBZ N
0.03) CD N
. . N

CONCLUSION NNP N
Both NNP N
groups NNS N
demonstrated VBD N
improvement NN N
in IN N
the DT N
rehabilitation NN N
unit NN N
. . N

The DT N
benefits NNS N
of IN N
visual JJ N
biofeedback NN N
by IN N
forceplate NN N
system NN N
training VBG N
suggest JJ N
particular JJ N
improvement NN N
of IN N
anticipation NN O
equilibrium NN O
with IN N
conventional JJ I
therapy NN I
. . I

-DOCSTART- -X- O O

Social NNP I
skills NNS I
improvement NN N
in IN N
children NNS P
with IN P
high-functioning JJ P
autism: NN P
a DT N
pilot NN N
randomized VBN N
controlled VBN N
trial NN N
. . N

High-functioning JJ P
autism NN P
(HFA) NNP P
is VBZ N
characterized VBN N
by IN N
persistent JJ N
impairment NN N
in IN N
social JJ N
interaction NN N
despite IN N
the DT N
absence NN N
of IN N
mental JJ N
retardation NN N
. . N

Although IN N
an DT N
increasing VBG N
number NN N
of IN N
group-based JJ N
programs NNS N
for IN N
the DT N
improvement NN N
of IN N
social JJ O
skills NNS O
have VBP N
been VBN N
described VBN N
randomized VBN N
controlled VBN N
trials NNS N
are VBP N
needed VBN N
to TO N
evaluate VB N
their PRP$ N
efficacy NN O
. . O

To TO N
compare VB N
the DT N
effect NN N
of IN N
a DT N
Social NNP I
Skills NNP I
Training NNP I
Group-based JJ I
Program NNP I
(SST-GP) NN I
and CC N
a DT N
Leisure NN I
Activities VBZ I
Group-based JJ I
Program NNP I
(LA-GP) NN I
on IN N
the DT N
perception NN O
of IN O
facial JJ O
emotions NNS O
and CC O
quality NN O
of IN O
life NN O
(QoL) NN O
in IN N
young JJ P
people NNS P
with IN P
HFA NNP P
. . P

Eligible JJ P
patients NNS P
were VBD P
children NNS P
and CC P
adolescents NNS P
with IN P
HFA NNP P
. . P

Participants NNS N
were VBD N
randomized VBN N
to TO N
the DT N
SST NNP I
or CC N
LA NNP I
group NN N
. . N

The DT N
primary JJ N
outcome NN N
was VBD N
defined VBN N
as IN N
an DT N
improvement NN O
of IN O
2 CD O
points NNS O
in IN O
error NN O
rates NNS O
for IN O
facial JJ O
emotion NN O
labeling VBG O
(DANVA2) NN O
from IN O
baseline NN O
. . O

After IN N
the DT N
6-month JJ N
training NN N
period NN N
the DT N
SST NNP I
Group NNP N
made VBD N
fewer JJR N
errors NNS N
in IN N
labeling VBG O
anger NN O
on IN N
adult NN N
faces VBZ N
whereas JJ N
error NN N
rates NNS N
in IN N
the DT N
LA NNP I
Group NNP N
remained VBD N
stable JJ N
. . N

Progress NN N
in IN N
the DT N
ability NN O
to TO O
recognize VB O
anger NN O
in IN N
the DT N
SST NNP I
Group NNP N
was VBD N
due JJ N
to TO N
better JJR N
recognition NN N
of IN N
low JJ N
intensity NN N
stimuli NN N
on IN N
adult NN N
faces VBZ N
. . N

QoL NNP O
increased VBD N
in IN N
the DT N
SST NNP I
Group NNP N
in IN N
the DT N
dimension NN N
of IN N
school NN N
environment NN N
as IN N
a DT N
marker NN N
of IN N
the DT N
transfer NN N
of IN N
skills NNS N
acquired VBN N
in IN N
the DT N
treatment NN N
setting VBG N
to TO N
their PRP$ N
use NN N
in IN N
the DT N
community NN N
. . N

The DT N
SST-GP NNP I
had VBD N
higher JJR N
efficacy NN O
than IN N
the DT N
LA-GP NNP I
. . I

Data NNP N
justify NN N
replication NN N
using VBG N
larger JJR N
samples NNS N
. . N

-DOCSTART- -X- O O

[Intravenous JJ N
treatment NN N
of IN N
postpartum NN P
anemia NN P
with IN N
trivalent JJ I
ferrum NN I
preparation] NN I
. . N

AIM NNP N
OF IN N
THE NNP N
STUDY NNP N
To TO N
assess VB N
the DT N
effectivity NN O
and CC N
safeness NN O
of IN N
intravenous JJ N
treatment NN N
of IN N
pospartal JJ P
anemia NN P
with IN N
trivalent JJ I
ferrum NN I
preparation NN I
. . I

TYPE NNP N
OF IN N
THE NNP N
STUDY NNP N
Prospective NNP N
randomized VBD N
study NN N
. . N

SETTING NNP N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
2nd CD N
Medical NNP N
Faculty NNP N
Charles NNP N
University NNP N
and CC N
Teaching NNP N
Hospital NNP N
Motol NNP N
Prague NNP P
and CC N
Department NNP N
of IN N
Obstetric NNP N
and CC N
Gynecology NNP N
1st CD N
Medical NNP N
Faculty NNP N
and CC N
Teaching NNP N
Hospital NNP N
Bulovka NNP N
Prague NNP P
. . P

METHODS NNP N
500 CD N
mg NN N
of IN N
sacharose JJ I
ferric JJ I
oxide NN I
(Venofer) NN I
was VBD N
intravenously RB N
administered VBN N
in IN N
two CD N
days NNS N
regimen NNS N
to TO N
50 CD P
women NNS P
with IN P
clinical JJ P
and CC P
lab JJ P
signs NNS P
of IN P
postpartal JJ P
anemia NN P
. . P

The DT N
effect NN N
of IN N
administered JJ N
drug NN N
was VBD N
determined VBN N
by IN N
comparsion NN N
of IN N
values NNS O
of IN O
red JJ O
blood NN O
count NN O
recovered VBD N
before IN N
the DT N
treatment NN N
2nd CD N
or CC N
3rd CD N
day NN N
post NN N
administration NN N
and CC N
two CD N
weeks NNS N
later RB N
. . N

The DT N
serum NN O
values NNS O
of IN O
soluble JJ O
transferrin NN O
receptors NNS O
and CC O
ferritin NNS O
were VBD N
observed VBN N
as IN N
markers NNS N
of IN N
iron NN O
cell NN O
saturation NN O
and CC O
body NN O
iron NN O
reserves NNS O
too RB N
. . N

Integral JJ N
part NN N
of IN N
the DT N
study NN N
was VBD N
the DT N
monitoring NN N
of IN N
adverse JJ O
events NNS O
during IN N
the DT N
treatment NN N
. . N

RESULTS NNP N
Venofer NNP I
came VBD N
in IN N
sight NN N
as IN N
effective JJ O
drug NN N
in IN N
the DT N
treatment NN N
of IN N
pospartal JJ P
anemia NN P
and CC N
could MD N
become VB N
as IN N
the DT N
alternative NN N
to TO N
blood VB N
transfusion NN N
in IN N
mid-severe JJ N
cases NNS N
. . N

It PRP N
should MD N
be VB N
emphasized VBN N
that IN N
we PRP N
have VBP N
not RB N
encountered VBN N
any DT N
serious JJ O
adverse JJ O
event NN O
with IN N
intravenous JJ N
trivalent NN I
saccharose VBD I
ferric JJ I
oxide JJ I
treatment NN N
. . N

-DOCSTART- -X- O O

Neural JJ O
basis NN O
of IN O
self NN O
and CC O
other JJ O
representation NN O
in IN N
autism: NN P
an DT N
FMRI NNP O
study NN N
of IN N
self-face JJ O
recognition NN O
. . O

BACKGROUND NNP N
Autism NNP P
is VBZ N
a DT N
developmental JJ N
disorder NN N
characterized VBN N
by IN N
decreased JJ N
interest NN N
and CC N
engagement NN N
in IN N
social JJ N
interactions NNS N
and CC N
by IN N
enhanced JJ N
self-focus NN N
. . N

While IN N
previous JJ N
theoretical JJ N
approaches NNS N
to TO N
understanding VBG N
autism NN P
have VBP N
emphasized VBN N
social JJ N
impairments NNS N
and CC N
altered VBD N
interpersonal JJ N
interactions NNS N
there EX N
is VBZ N
a DT N
recent JJ N
shift NN N
towards NNS N
understanding VBG N
the DT N
nature NN N
of IN N
the DT N
representation NN N
of IN N
the DT N
self NN N
in IN N
individuals NNS P
with IN P
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
. . P

Still RB N
the DT N
neural JJ O
mechanisms NNS O
subserving VBG N
self-representations NNS N
in IN N
ASD NNP P
are VBP N
relatively RB N
unexplored JJ N
. . N

METHODOLOGY/PRINCIPAL NNP N
FINDINGS NNP N
We PRP N
used VBD N
event-related JJ N
fMRI NN O
to TO N
investigate VB N
brain NN O
responsiveness NN O
to TO O
images NNS O
of IN O
the DT O
subjects' NN O
own JJ O
face NN O
and CC O
to TO O
faces VBZ O
of IN O
others NNS O
. . O

Children NNP P
with IN P
ASD NNP P
and CC P
typically RB P
developing VBG P
(TD) JJ P
children NNS P
viewed VBD N
randomly RB N
presented VBN N
digital JJ N
morphs NN N
between IN N
their PRP$ N
own JJ N
face NN N
and CC N
a DT N
gender-matched JJ N
other JJ N
face NN N
and CC N
made VBD N
"self/other" JJ N
judgments NNS N
. . N

Both DT N
groups NNS N
of IN N
children NNS P
activated VBD N
a DT N
right JJ O
premotor/prefrontal NN O
system NN O
when WRB N
identifying VBG N
images NNS N
containing VBG N
a DT N
greater JJR N
percentage NN N
of IN N
the DT N
self JJ N
face NN N
. . N

However RB N
while IN N
TD NNP N
children NNS P
showed VBD N
activation NN N
of IN N
this DT N
system NN O
during IN N
both DT N
self- JJ N
and CC N
other-processing JJ N
children NNS P
with IN N
ASD NNP N
only RB N
recruited VBD N
this DT N
system NN N
while IN N
viewing VBG N
images NNS N
containing VBG N
mostly RB N
their PRP$ N
own JJ N
face NN N
. . N

CONCLUSIONS/SIGNIFICANCE VB N
This DT N
functional JJ N
dissociation NN N
between IN N
the DT N
representation NN N
of IN N
self NN N
versus NN N
others NNS N
points NNS N
to TO N
a DT N
potential JJ N
neural JJ N
substrate NN N
for IN N
the DT N
characteristic JJ N
self-focus NN N
and CC N
decreased VBN N
social JJ N
understanding NN N
exhibited VBN N
by IN N
these DT N
individuals NNS N
and CC N
suggests VBZ N
that IN N
individuals NNS N
with IN N
ASD NNP N
lack VBP N
the DT N
shared JJ N
neural JJ O
representations NNS O
for IN O
self NN O
and CC O
others NNS O
that IN N
TD NNP N
children NNS P
and CC N
adults NNS N
possess NN N
and CC N
may MD N
use VB N
to TO N
understand VB N
others NNS N
. . N

-DOCSTART- -X- O O

Intrathecal JJ N
morphine NN I
suppresses NNS N
NK NNP O
cell NN O
activity NN O
following VBG N
abdominal JJ P
surgery NN P
. . P

PURPOSE VB N
The DT N
effects NNS N
of IN N
morphine NN I
on IN N
natural JJ O
killer NN O
(NK) NNP O
cell NN O
activity NN O
were VBD N
investigated VBN N
in IN N
patients NNS P
who WP P
underwent JJ P
hysterectomy NN P
. . P

METHODS NNP N
Forty NNP P
patients NNS P
were VBD P
divided VBN P
into IN P
four CD P
groups NNS P
of IN P
ten NN P
. . P

The DT N
groups NNS N
received VBD N
intrathecal JJ N
0.5 CD N
mg JJ N
morphine NN I
(Group NNP N
IT0.5) NNP N
intrathecal JJ N
0.1 CD N
mg JJ N
morphine NN I
(Group NNP N
IT0.1) NNP N
or CC N
10 CD N
mg NNS N
morphine JJ I
i.v NN N
. . N

(Group JJ N
IV) NNP N
. . N

The DT N
remaining VBG N
ten JJ N
patients NNS N
served VBD N
as IN N
controls NNS N
and CC N
received VBN N
inhalation NN N
anesthesia IN N
alone RB N
(Group JJ N
C) NNP N
. . N

Blood NN N
samples NNS N
were VBD N
withdrawn VBN N
before RB N
and CC N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
days NNS N
one CD N
and CC N
two CD N
to TO N
determine VB N
the DT N
blood NN O
NK NNP O
cell NN O
activity NN O
using VBG N
a DT N
chromium NN O
release NN O
assay VBP O
with IN O
K562 NNP O
cells NNS O
as IN O
targets NNS O
plasma VBP O
catecholamines NNS O
and CC O
cortisol NN O
levels NNS O
. . O

The DT N
postoperative JJ O
pain NN O
score NN O
and CC O
side NN O
effects NNS O
were VBD N
studied VBN N
in IN N
the DT N
four CD N
groups NNS N
. . N

RESULTS NNP N
In IN N
Group NNP N
IT0.5 NNP N
the DT N
NK NNP O
cell NN O
activity NN O
was VBD N
lower JJR N
on IN N
postoperative JJ N
day NN N
1 CD N
(23.9 JJ N
+/- JJ N
8.4%) CD N
than IN N
the DT N
baseline JJ N
level NN N
(45.7 VBD N
+/- JJ N
13%) CD N
before IN N
surgery NN N
and CC N
recovered VBN N
on IN N
postoperative JJ N
day NN N
2 CD N
. . N

In IN N
Groups NNP N
IT0.1 NNP N
C NNP N
and CC N
IV NNP N
the DT N
NK NNP O
cell NN O
activities NNS O
showed VBD N
no DT N
significant JJ N
changes NNS N
. . N

In IN N
all DT N
four CD N
groups NNS N
neither CC N
plasma JJ O
adrenaline NN O
nor CC N
noradrenaline JJ O
concentrations NNS O
changed VBD N
. . N

In IN N
all DT N
four CD N
groups NNS N
the DT N
plasma NN O
cortisol NN O
levels NNS O
increased VBN N
after IN N
surgery NN N
on IN N
postoperative JJ N
days NNS N
1 CD N
and CC N
2 CD N
. . N

The DT N
pain NN O
score NN O
was VBD N
lower JJR N
two CD N
hours NNS N
after IN N
surgery NN N
and CC N
on IN N
postoperative JJ N
day NN N
1 CD N
in IN N
Group NNP N
IT0.5 NNP N
than IN N
in IN N
the DT N
other JJ N
groups NNS N
. . N

CONCLUSION NNP N
These DT N
results NNS N
suggest VBP N
that IN N
long-lasting JJ N
analgesic JJ N
effects NNS N
of IN N
intrathecal JJ N
0.5 CD N
mg JJ N
morphine NN I
suppress NN N
the DT N
immune JJ N
response NN N
following VBG P
abdominal JJ P
surgery NN P
. . P

-DOCSTART- -X- O O

[Limbal JJ I
epithelial JJ I
autograft NN I
transplantation NN I
in IN N
treatment NN N
of IN N
pterygium] NN P
. . N

OBJECTIVE UH N
To TO N
observe VB N
the DT N
therapeutic JJ O
effects NNS O
of IN N
limbal JJ I
epithelial JJ I
autograft NN I
transplantation NN I
and CC N
pterygium NN I
excision NN I
in IN N
the DT N
treatment NN N
of IN N
pterygium NN P
. . P

METHODS NNP N
A NNP N
prospective JJ N
randomized VBN N
paired-eye JJ N
trial NN N
was VBD N
studied VBN N
. . N

There EX P
were VBD P
208 CD P
patients NNS P
(229 JJ P
eyes) NN P
with IN P
initial JJ P
pterygium NN P
and CC N
they PRP N
were VBD N
allocated VBN N
to TO N
two CD N
groups: JJ N
excision NN I
of IN I
pterygium NN I
with IN N
limbal JJ I
epithelial JJ I
autograft NN I
transplantation NN I
surgery NN I
(A NNP N
group NN N
106 CD N
cases NNS N
and CC N
124 CD N
eyes) NN N
and CC N
simple JJ I
pterygium NN I
excision NN I
(B NNP N
group NN N
102 CD N
cases NNS N
and CC N
105 CD N
eyes) NN N
. . N

The DT N
criteria NN N
for IN N
recovery NN N
were VBD N
corneal JJ O
transparency NN O
with IN O
stable JJ O
epithelial JJ O
healing NN O
and CC O
no DT O
abnormal JJ O
proliferation NN O
of IN O
pterygium-like JJ O
tissue NN O
. . O

The DT N
post-operative JJ N
follow-up JJ N
periods NNS N
ranged VBD N
from IN N
18 CD N
approximately RB N
28 CD N
(22.4 JJ N
+/- JJ N
4.9) CD N
months NNS N
. . N

RESULTS NNP N
Some DT N
of IN N
the DT N
patients NNS N
lost VBD N
follow-up JJ N
. . N

In IN N
the DT N
eyes NNS N
followed VBD N
up RP N
5 CD N
of IN N
11 CD N
2 CD N
eyes NNS N
(4.5%) VBP N
in IN N
A NNP N
group NN N
and CC N
41 CD N
of IN N
96 CD N
eyes NNS N
(42.7%) VBP N
in IN N
B NNP N
group NN N
were VBD N
recurred VBN N
the DT N
difference NN N
being VBG N
very RB N
significant JJ N
(P NNP N
< NNP N
0.001) CD N
. . N

CONCLUSION NN N
To TO N
provide VB N
a DT N
new JJ N
stem NN N
cell NN N
source NN N
limbal JJ I
epithelial JJ I
autograft NN I
transplantation NN I
for IN N
an DT N
injured JJ N
limb NN N
us PRP N
is VBZ N
a DT N
reasonable JJ N
therapeutic JJ N
method NN N
for IN N
the DT N
treatment NN N
of IN N
pterygium NN P
. . P

-DOCSTART- -X- O O

Changes NNS O
in IN O
the DT O
fatty JJ O
acid JJ O
composition NN O
of IN O
the DT O
plasma NN O
lipid JJ O
esters NNS O
during IN N
lipid-lowering JJ N
treatment NN N
with IN N
diet JJ I
clofibrate NN I
and CC N
niceritrol NN I
. . I

Reduction NN N
of IN N
the DT N
proportion NN O
of IN O
linoleate NN O
by IN N
clofibrate NN I
but CC N
not RB N
by IN N
niceritrol NN I
. . I

The DT N
fatty JJ O
acid JJ O
composition NN O
of IN O
the DT O
plasma NN O
lipid JJ O
esters NNS O
has VBZ N
been VBN N
studied VBN N
during IN N
lipid-lowering JJ N
treatment NN N
of IN N
95 CD P
patients NNS P
with IN P
atherosclerotic JJ P
disease NN P
. . P

During IN N
the DT N
first JJ N
two CD N
months NNS N
of IN N
the DT N
trial NN N
only RB N
a DT N
diet NN N
was VBD N
prescribed VBN N
. . N

During IN N
the DT N
ensuing VBG N
two CD N
months NNS N
either CC N
clofibrate NN I
or CC N
niceritrol VB I
a DT N
nicotinic JJ N
acid NN N
ester NN N
was VBD N
added VBN N
in IN N
a DT N
randomized JJ N
order NN N
. . N

During IN N
the DT N
last JJ N
two CD N
months NNS N
the DT N
second JJ N
drug NN N
was VBD N
added VBN N
. . N

The DT N
combined JJ N
treatment NN N
with IN N
diet JJ I
clofibrate NN I
and CC N
niceritrol NN I
caused VBN N
highly RB N
significant JJ N
serum NN O
lipid JJ O
reductions NNS O
. . O

The DT N
fatty JJ O
acid JJ O
composition NN O
in IN O
the DT O
plasma NN O
lipid JJ O
esters NNS O
was VBD N
determined VBN N
in IN N
samples NNS N
from IN N
each DT N
trial NN N
period NN N
to TO N
measure VB N
the DT N
degree NN O
of IN O
dietary JJ O
adherence NN O
. . O

During IN N
dietary JJ I
treatment NN I
the DT N
relative JJ N
content NN O
of IN O
saturated JJ O
and CC O
monounsaturated VBD O
fatty JJ O
acids NNS O
secreased VBD N
and CC N
the DT N
polyunsaturated JJ O
fatty JJ O
acids NNS O
increased VBD N
with IN N
an DT N
increasing VBG N
ratio NN O
between IN O
pulyunsaturated VBN O
and CC O
saturated VBN O
fatty JJ O
acids NNS O
(P/S VBP O
ratio) NN O
in IN O
the DT O
cholesterol NN O
esters NNS O
and CC O
triglycerides NNS O
. . O

Only RB N
minor JJ N
changes NNS N
were VBD N
seen VBN N
in IN N
the DT N
phospholipids NNS O
. . O

The DT N
changes NNS N
caused VBN N
by IN N
the DT N
diet NN I
were VBD N
partly RB N
reversed VBN N
by IN N
clofibrate NN I
while IN N
niceritrol NN I
did VBD N
not RB N
cause VB N
any DT N
major JJ N
changes NNS O
of IN O
the DT O
fatty JJ O
acid JJ O
composition NN O
. . O

Clofibrate NNP I
treatment NN N
coincided VBD N
with IN N
increasing VBG N
amounts NNS O
of IN O
monounsaturated JJ O
fatty JJ O
acids NNS O
especially RB O
oleate VBP O
(18 NNS O
: : O
1) CD O
in IN O
the DT O
cholesterol NN O
esters VBZ O
triglycerides NNS O
and CC O
phospholipids NNS O
while IN N
there EX N
were VBD N
significant JJ N
reductions NNS N
of IN N
the DT N
content NN O
of IN O
linoleic JJ O
(18 NN O
: : O
2) CD O
acid NN O
in IN O
both CC O
the DT O
cholesterol NN O
esters NNS O
and CC O
triglycerides NNS O
. . O

The DT N
18 CD N
: : N
2/18 CD N
: : N
1 CD N
ratio NN N
decreased VBN N
significantly RB N
in IN N
all PDT N
the DT N
lipid JJ N
esters NNS N
analyzed VBD N
. . N

However RB N
the DT N
P/S NNP O
ratio NN O
was VBD N
not RB N
significantly RB N
affected VBN N
partly RB N
because IN N
the DT N
relative JJ O
content NN O
of IN O
saturated JJ O
fatty JJ O
acids NNS O
also RB N
tended VBD N
to TO N
decrease VB N
during IN N
clofibrate JJ I
treatment NN N
. . N

It PRP N
is VBZ N
concluded VBN N
that IN N
addition NN N
of IN N
clofibrate NN I
treatment NN N
to TO N
patients NNS N
who WP N
are VBP N
on IN N
a DT N
diet JJ I
enriched VBN N
with IN N
polyunsaturated JJ N
fats NNS N
is VBZ N
associated VBN N
with IN N
a DT N
change NN O
from IN O
polyunsaturated VBN O
to TO O
monounsaturated VBN O
fatty JJ O
acids NNS O
in IN O
the DT O
plasma NN O
lipid JJ O
esters NNS O
but CC N
does VBZ N
not RB N
significantly RB N
effect NN N
the DT N
ratio NN O
between IN O
polyunsaturated VBN O
and CC O
saturated VBN O
fatty JJ O
acids NNS O
. . O

The DT O
fatty JJ O
acid NN O
changes NNS O
caused VBN N
by IN N
clofibrate NN I
treatment NN N
and CC N
counteracted VBN N
by IN N
an DT N
increased JJ N
amount NN N
of IN N
polyunsaturated JJ N
fat NN N
in IN N
the DT N
diet NN I
. . I

-DOCSTART- -X- O O

Reduced VBN N
platelet NN O
thromboxane NN O
formation NN O
after IN N
long-term JJ N
administration NN N
of IN N
a DT N
dihydropyridine JJ I
calcium NN I
channel NN I
blocker: VBZ I
a DT N
prospective JJ N
double-blind NN N
placebo-controlled JJ N
study NN N
with IN N
nitrendipine NN I
in IN N
borderline JJ P
hypertensive JJ P
patients NNS P
with IN P
IDDM-type NNP P
diabetes NNS P
mellitus NN P
. . P

Twenty-nine JJ P
IDDM NNP P
patients NNS P
with IN P
borderline JJ P
hypertension NN P
were VBD N
randomly RB N
allocated VBN N
to TO N
placebo VB I
or CC N
nitrendipine VB I
treatment NN N
. . N

Nitrendipine NNP I
was VBD N
given VBN N
orally RB N
at IN N
a DT N
dosage NN N
of IN N
20 CD N
mg NNS N
once RB N
daily RB N
over IN N
4 CD N
weeks NNS N
. . N

Stimulated VBN O
platelet NN O
thromboxane NN O
formation NN O
at IN N
rest NN N
and CC N
after IN N
standardized JJ N
non NN O
exhausting VBG O
exercise NN O
was VBD N
measured VBN N
by IN N
standard JJ N
methods NNS N
. . N

In IN N
addition NN N
plasma NN O
levels NNS O
of IN O
platelet NN O
factor NN O
4 CD O
and CC O
aggregation NN O
responses NNS O
to TO O
collagen VB O
and CC O
ADP NNP O
were VBD N
determined VBN N
. . N

In IN N
the DT N
treatment NN N
group NN N
thromboxane NN O
formation NN O
after IN N
stimulation NN N
with IN N
collagen NN N
(0.3 NN N
and CC N
1.0 CD N
micrograms/ml) NN N
and CC N
1 CD N
mM NN N
arachidonic JJ N
acid NN N
(AA) NN N
was VBD N
reduced VBN N
in IN N
the DT N
resting NN N
state NN N
. . N

Exercise NN O
induced JJ O
change NN O
of IN O
thromboxane NN O
synthesis NN O
in IN N
response NN N
to TO N
1.0 CD N
micrograms/ml NNS N
collagen NN N
was VBD N
significantly RB N
lower JJR N
as IN N
compared VBN N
to TO N
placebo VB I
(p NNP N
< NNP N
0.05) CD N
. . N

In IN N
parallel JJ N
PF4 NNP O
plasma NN O
levels NNS O
were VBD N
significantly RB N
lowered VBN N
(p NNP N
< $ N
0.05) CD N
. . N

Whole JJ O
blood NN O
aggregation NN O
after IN O
collagen NN O
stimulation NN O
(1.0 NNP N
micrograms/ml) NN N
was VBD N
reduced VBN N
after IN N
4 CD N
weeks NNS N
of IN N
nitrendipine JJ I
treatment NN N
but CC N
ADP NNP N
(5 NNP N
microM) NN N
induced VBD N
aggregation NN O
was VBD N
not RB N
. . N

These DT N
effects NNS N
of IN N
nitrendipine NN I
were VBD N
not RB N
seen VBN N
in IN N
platelet NN N
rich JJ N
plasma NN N
. . N

In IN N
conclusion NN N
long-term JJ N
nitrendipine JJ I
treatment NN N
may MD N
inhibit VB N
collagen NN O
dependent JJ O
platelet NN O
activation NN O
in IN N
the DT N
blood NN N
of IN N
diabetic JJ P
patients NNS P
with IN P
borderline JJ P
hypertension NN P
. . P

-DOCSTART- -X- O O

Fluoroscopic NNP N
functional JJ N
evaluation NN N
of IN N
bileaflet NN P
prostheses: JJ P
effect NN N
of IN N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
. . N

Fluoroscopy NNP N
is VBZ N
a DT N
reliable JJ N
easy JJ N
and CC N
readily RB N
available JJ N
technique NN N
to TO N
follow-up JJ N
prosthesis NN N
functioning NN N
after IN P
heart NN P
valve NN P
surgery NN P
. . P

The DT N
different JJ N
orientation NN N
given VBN N
to TO N
the DT N
prosthesis NN I
may MD N
represent VB N
a DT N
limitation NN N
of IN N
the DT N
technique NN N
accounting NN N
for IN N
unsatisfactory JJ N
results NNS N
in IN N
10% CD N
to TO N
40% CD N
of IN N
the DT N
cases NNS N
. . N

The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
whether IN N
and CC N
to TO N
what WP N
extent VB N
different JJ N
intraoperative JJ N
valve NN N
orientation NN N
influence NN N
feasibility NN O
and CC N
accuracy NN O
of IN N
postoperative JJ N
fluoroscopic JJ N
evaluation NN N
of IN N
bileaflet NN P
prostheses NNS P
. . P

We PRP N
prospectively RB N
evaluated VBD N
90 CD P
patients NNS P
who WP P
had VBD P
aortic JJ P
mitral JJ P
and/or NN P
tricuspid JJ P
valve FW P
replacement NN P
with IN P
Sorin NNP P
Bicarbon NNP P
or CC P
CarboMedics NNPS P
bileaflet NN P
prostheses NNS P
. . P

Fifty NNP N
percent NN N
of IN N
the DT N
patients NNS N
in IN N
each DT N
group NN N
were VBD N
randomly RB N
assigned VBN N
to TO N
receive VB N
prostheses NNS I
oriented VBN N
in IN N
a DT N
perpendicular NN N
or CC N
a DT N
parallel JJ N
position NN N
with IN N
respect NN N
to TO N
the DT N
ventricular JJ N
septum NN N
. . N

Fluoroscopic NNP N
evaluation NN N
was VBD N
considered VBN N
appropriate JJ N
when WRB N
the DT N
prosthesis' NN I
"tilting VBG N
disk" JJ N
projection NN N
was VBD N
obtained VBN N
. . N

The DT N
valve's JJ O
hemodynamic JJ O
performance NN O
was VBD N
investigated VBN N
through IN N
Doppler NNP O
study NN O
. . O

A DT N
proper JJ N
fluoroscopic NN N
evaluation NN N
was VBD N
rapidly RB N
(15 JJ N
+/- JJ N
5 CD N
seconds) NN N
achieved VBN N
in IN N
all DT N
patients NNS N
with IN N
the DT N
former JJ N
orientation NN N
whereas IN N
it PRP N
was VBD N
impossible JJ N
to TO N
obtain VB N
it PRP N
in IN N
8 CD N
of IN N
20 CD N
(40%) JJ N
19 CD N
of IN N
20 CD N
(95%) NNS N
and CC N
4 CD N
of IN N
5 CD N
(80%) NNS N
of IN N
patients NNS N
with IN N
the DT N
latter JJ N
orientation NN N
. . N

In IN N
the DT N
remaining VBG N
patients NNS N
extremely RB N
angulated VBD N
uneasy JJ N
projection NN N
was VBD N
often RB N
required VBN N
to TO N
get VB N
a DT N
correct JJ N
fluoroscopic NN N
image NN N
. . N

The DT N
Doppler NNP N
study NN N
showed VBD N
a DT N
similarly RB N
favorable JJ N
hemodynamic JJ O
performance NN O
regardless NN N
of IN N
valve JJ N
orientation NN N
. . N

Prosthesis NNP I
orientation NN N
crucially RB N
affects VBZ N
the DT N
rate NN O
of IN O
success NN O
of IN O
the DT O
fluoroscopic JJ O
evaluation NN O
. . O

The DT N
orientation NN N
perpendicular NN N
to TO N
the DT N
ventricular JJ N
septum NN N
greatly RB N
facilitates VBZ N
the DT N
postoperative JJ N
feasibility NN O
and CC O
accuracy NN O
of IN N
fluoroscopy NN N
and CC N
it PRP N
is VBZ N
not RB N
detrimental JJ N
to TO N
the DT N
valve's JJ O
hemodynamic JJ O
performance NN O
. . O

This DT N
valve JJ N
orientation NN N
may MD N
provide VB N
a DT N
better JJR N
fluoroscopic NN N
window NN N
whenever WRB N
a DT N
valve NN N
dysfunction NN N
is VBZ N
suspected VBN N
. . N

-DOCSTART- -X- O O

Economic NNP O
burden NN O
of IN N
childhood NN P
autism NN P
spectrum NN P
disorders NNS P
. . P

OBJECTIVE NNP N
To TO N
estimate VB N
the DT N
associations NNS N
between IN N
autism NN P
spectrum NN P
disorder NN P
(ASD) NN P
diagnoses NNS N
and CC N
service NN O
use NN O
caregiver NN O
time NN O
and CC O
cost NN O
outcomes NNS O
. . O

METHODS NNP N
We PRP N
used VBD N
national JJ N
data NNS N
from IN N
the DT N
Medical NNP N
Expenditure NNP N
Panel NNP N
Survey NNP N
linked VBD N
to TO N
the DT N
National NNP N
Health NNP N
Interview NNP N
Survey NNP N
and CC N
a DT N
study-specific JJ N
survey NN N
to TO N
estimate VB N
the DT N
annual JJ O
utilization NN O
and CC O
costs NNS O
for IN O
health NN O
care NN O
school NN O
ASD-related JJ O
therapy NN O
family-coordinated JJ O
services NNS O
as RB O
well RB O
as IN O
caregiver NN O
time NN O
in IN N
children NNS P
aged VBD P
3 CD P
to TO P
17 CD P
years NNS P
with IN P
and CC P
without IN P
parent-reported JJ P
ASD NNP P
. . P

Regression NNP O
analyses VBZ O
estimated VBN N
the DT N
association NN O
between IN O
ASD NNP O
diagnosis NN O
and CC O
cost NN O
controlling NN O
for IN O
child NN O
gender NN O
age NN O
race/ethnicity NN O
insurance NN O
status NN O
household VBD O
income NN O
country NN O
region NN O
and CC O
urban/rural JJ O
classification NN O
and CC O
non-ASD-related JJ O
illnesses NNS O
. . O

RESULTS NNP N
Children NNP P
with IN P
parent-reported JJ P
ASD NNP P
had VBD N
higher JJR N
levels NNS N
of IN N
health NN O
care NN O
office NN O
visits NNS O
and CC O
prescription NN O
drug NN O
use NN O
compared VBN N
with IN N
children NNS N
without IN N
ASD NNP N
(P NNP N
< NNP N
.05) NNP N
. . N

A NNP N
greater JJR N
proportion NN N
of IN N
children NNS N
in IN N
the DT N
ASD NNP N
group NN N
used VBD N
special JJ O
educational JJ O
services NNS O
(76% VBP N
vs NN N
. . N

7% CD N
in IN N
the DT N
control NN N
group NN N
P NNP N
< NNP N
.05) NNP N
. . N

After IN N
adjusting VBG N
for IN N
child JJ N
demographic JJ N
characteristics NNS N
and CC N
non-ASD-associated JJ N
illnesses NNS N
ASD NNP N
was VBD N
associated VBN N
with IN N
$3020 NNP N
(95% NNP N
confidence NN N
interval NN N
[CI]: VBD N
$1017-$4259) JJ N
higher JJR N
health NN O
care NN O
costs NNS O
and CC N
$14 $ N
061 CD N
(95% JJ N
CI: NNP N
$4390-$24 NN N
302) CD N
higher JJR N
aggregate NN N
non-health JJ O
care NN O
costs NNS O
including VBG N
$8610 JJ N
(95% JJ N
CI: NNP N
$6595-$10 NN N
421) CD N
higher JJR O
school NN O
costs NNS O
. . O

In IN N
adjusted JJ N
analyses NNS N
parents NNS N
who WP N
reported VBD N
that IN N
their PRP$ N
child NN N
had VBD N
ASD NNP N
did VBD N
not RB N
have VB N
significantly RB N
higher JJR N
out-of-pocket NN O
costs NNS O
or CC N
spend VB N
more JJR N
time NN O
on IN O
caregiving VBG O
activities NNS O
compared VBN N
with IN N
control NN N
parents NNS N
. . N

CONCLUSIONS VB N
The DT N
economic JJ O
burden NN O
associated VBN N
with IN N
ASD NNP N
is VBZ N
substantial JJ N
and CC N
can MD N
be VB N
measured VBN N
across IN N
multiple JJ N
sectors NNS N
of IN N
our PRP$ N
society NN N
. . N

Previous JJ N
analyses NNS N
that WDT N
focused VBD N
on IN N
health NN N
care NN N
underestimated VBD N
this DT N
economic JJ O
burden NN O
particularly RB N
for IN N
school NN N
systems NNS N
. . N

-DOCSTART- -X- O O

Inference-Based JJ I
Approach NNP I
versus NN N
Cognitive NNP I
Behavioral NNP I
Therapy NNP I
in IN N
the DT N
Treatment NNP N
of IN N
Obsessive-Compulsive NNP P
Disorder NNP P
with IN P
Poor NNP P
Insight: NNP P
A NNP N
24-Session JJ N
Randomized NNP N
Controlled NNP N
Trial NNP N
. . N

OBJECTIVE NNP N
Obsessive-compulsive JJ P
disorder NN P
(OCD) NN P
with IN P
poor JJ P
insight NN P
has VBZ N
severe JJ N
consequences NNS N
for IN N
patients; NN N
nonetheless RB N
no DT N
randomized NN N
controlled VBD N
trial NN N
has VBZ N
ever RB N
been VBN N
performed VBN N
to TO N
evaluate VB N
the DT N
effectiveness NN O
of IN N
any DT N
treatment NN N
specifically RB N
for IN N
poor-insight JJ P
OCD NNP P
. . P

A DT N
new JJ N
psychotherapy NN N
for IN N
OCD NNP P
the DT N
inference-based JJ I
approach NN I
(IBA) NNP I
targets NNS N
insight VBD N
in IN N
OCD NNP P
by IN N
strengthening VBG N
normal JJ N
sensory-driven JJ N
reality NN N
testing VBG N
. . N

The DT N
goal NN N
of IN N
the DT N
present JJ N
study NN N
is VBZ N
to TO N
compare VB N
the DT N
effectiveness NN O
of IN N
this DT N
new JJ N
treatment NN N
to TO N
the DT N
effectiveness NN O
of IN N
cognitive JJ I
behavior NN I
therapy NN I
(CBT) NN I
for IN N
patients NNS P
with IN P
OCD NNP P
with IN P
poor JJ P
insight NN P
. . P

METHOD NNP N
A NNP N
randomized VBD N
controlled JJ N
trial NN N
was VBD N
conducted VBN N
in IN N
which WDT N
90 CD P
patients NNS P
with IN P
OCD NNP P
with IN P
poor JJ P
insight NN P
received VBD N
either RB N
24 CD N
CBT NNP I
sessions NNS N
or CC N
24 CD N
IBA JJ I
sessions NNS N
. . N

The DT N
primary JJ N
outcome NN N
measure NN N
was VBD N
the DT N
Yale-Brown JJ O
Obsessive NNP O
Compulsive NNP O
Scale NNP O
(YBOCS) NNP O
. . O

Secondary NNP N
outcome NN N
measures NNS N
were VBD N
level NN O
of IN O
insight JJ O
anxiety NN O
and CC O
depressive JJ O
symptoms NNS O
and CC O
quality NN O
of IN O
life NN O
. . O

Mixed-effects NNS O
models NNS O
were VBD N
used VBN N
to TO N
determine VB N
the DT N
treatment NN N
effect NN N
. . N

RESULTS NN N
In IN N
both DT N
conditions NNS N
a DT N
significant JJ N
OCD NNP O
symptom NN O
reduction NN O
was VBD N
reached VBN N
but CC N
no DT N
condition NN O
effects NNS O
were VBD N
established VBN N
. . N

Post NNP N
hoc NN N
in IN N
a DT N
small JJ N
subgroup NN N
of IN N
patients NNS N
with IN N
the DT N
worst JJS N
insight JJ N
(n NN N
= VBZ N
23) CD N
it PRP N
was VBD N
found VBN N
that IN N
the DT N
patients NNS N
treated VBN N
with IN N
the DT N
IBA NNP I
reached VBD N
a DT N
significantly RB N
higher JJR N
OCD NNP O
symptom VBZ O
reduction NN O
than IN N
the DT N
patients NNS N
treated VBN N
with IN N
CBT NNP I
[estimated VBD N
marginal JJ N
mean NN N
= NNP N
-7.77 NNP N
t(219.45) NN N
= NNP N
-2.4 NNP N
p NN N
= VBD N
0.017] CD N
. . N

CONCLUSION NN N
Patients NNS P
with IN P
OCD NNP P
with IN P
poor JJ P
insight JJ P
improve VB N
significantly RB N
after IN N
psychological JJ N
treatment NN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
suggest VBP N
that IN N
both DT N
CBT NNP I
and CC N
the DT N
IBA NNP I
are VBP N
effective JJ O
treatments NNS N
for IN N
OCD NNP P
with IN P
poor JJ P
insight NN P
. . P

The DT N
IBA NNP I
might MD N
be VB N
more RBR N
promising JJ N
than IN N
CBT NNP I
for IN N
patients NNS P
with IN P
more RBR P
extreme JJ P
poor JJ P
insight NN P
. . P

-DOCSTART- -X- O O

Trial JJ N
design NN N
challenges NNS N
when WRB N
combining VBG N
medication NN I
and CC N
parent NN I
training NN I
in IN N
children NNS P
with IN P
pervasive JJ P
developmental NN P
disorders NNS P
. . P

This DT N
paper NN N
presents VBZ N
the DT N
rationale NN N
for IN N
a DT N
24-week JJ N
randomized JJ N
trial NN N
designed VBN N
to TO N
test VB N
whether IN N
risperidone NN I
plus CC N
structured JJ I
parent NN I
training NN I
would MD N
be VB N
superior JJ N
to TO N
risperidone VB I
only RB N
on IN N
measures NNS N
of IN N
noncompliance NN O
irritability NN O
and CC O
adaptive JJ O
functioning NN O
. . O

In IN N
this DT N
model NN N
medication NN N
reduces NNS N
tantrums VBP O
aggression NN O
and CC O
self-injury; JJ O
parent NN N
training NN N
promotes NNS N
improvement NN N
in IN N
noncompliance NN O
and CC O
adaptive JJ O
functioning NN O
. . O

Thus NNP N
medication NN I
and CC N
parent NN I
training NN I
target NN N
related VBN N
but CC N
separate JJ N
outcomes NNS N
. . N

At IN N
week NN N
24 CD N
the DT N
medication NN I
was VBD N
gradually RB N
withdrawn VBN N
to TO N
determine VB N
whether IN N
subjects NNS N
in IN N
the DT N
combined JJ N
treatment NN N
group NN N
could MD N
be VB N
managed VBN N
on IN N
a DT N
lower JJR N
dose NN N
or CC N
off IN N
medication NN N
without IN N
relapse NN N
. . N

Both DT N
symptom JJ O
reduction NN N
and CC N
functional JJ O
improvement NN N
are VBP N
important JJ N
clinical JJ N
treatment NN N
targets NNS N
. . N

Thus NNP N
experimental JJ N
evidence NN N
on IN N
the DT N
beneficial JJ N
effects NNS O
of IN N
combining VBG N
pharmacotherapy NN N
and CC N
exportable JJ N
behavioral JJ N
interventions NNS N
is VBZ N
needed VBN N
to TO N
guide VB N
clinical JJ N
practice NN N
. . N

-DOCSTART- -X- O O

The DT N
efficacy NN O
of IN N
prophylactic JJ N
ondansetron NN I
droperidol NN I
perphenazine NN I
and CC N
metoclopramide NN I
in IN N
the DT N
prevention NN N
of IN N
nausea NN N
and CC N
vomiting NN N
after IN N
major JJ P
gynecologic NN P
surgery NN P
. . P

The DT N
prophylactic JJ N
antiemetic JJ N
efficacy NN O
of IN N
intravenous JJ N
(i.v.) NNP N
ondansetron NN I
droperidol NN I
perphenazine NN I
and CC N
metoclopramide NN I
was VBD N
evaluated VBN N
in IN N
a DT N
prospective JJ N
double-blind NN N
study NN N
of IN N
360 CD P
ASA NNP P
physical JJ P
status NN P
I-III NNP P
patients NNS P
undergoing VBG P
total JJ P
abdominal JJ P
hysterectomy NN P
(TAH) NNP P
. . P

Subjects NNS N
were VBD N
randomized VBN N
to TO N
receive VB N
i.v NN N
. . N

one CD N
of IN N
ondansetron NN I
4 CD N
mg NN N
droperidol NN I
1.25 CD N
mg NN N
perphenazine NN I
5 CD N
mg NN N
metoclopramide RB I
10 CD N
mg NN N
or CC N
placebo NN I
prior RB N
to TO N
induction NN N
of IN N
anesthesia NN N
. . N

Hypotension NNP O
immediately RB N
after IN N
administration NN N
of IN N
metoclopramide NN I
was VBD N
observed VBN N
in IN N
two CD N
patients NNS N
and CC N
four CD N
patients NNS N
given VBN N
ondansetron RP I
developed JJ N
profound NN N
systolic JJ O
hypotension NN O
at IN N
induction NN N
of IN N
anesthesia NN N
. . N

Twenty-two JJ N
percent NN N
of IN N
patients NNS N
receiving VBG N
droperidol NN I
became VBD N
sedated JJ N
. . N

Postoperatively JJ N
patients NNS N
developing VBG N
severe JJ O
nausea NN O
retching NN O
or CC O
vomiting NN O
defined VBN O
as IN O
severe JJ O
emetic JJ O
sequelae NN O
(SES) NNS O
were VBD N
deemed VBN N
to TO N
have VB N
failed VBN N
antiemetic JJ N
prophylaxis NN N
and CC N
received VBN N
antiemetic JJ N
rescue NN N
. . N

A DT N
significantly RB N
larger JJR N
number NN N
of IN N
patients NNS N
who WP N
received VBD N
i.v NN N
. . N

ondansetron NN I
(63%) NN N
droperidol NN I
(76%) NNP N
and CC N
perphenazine JJ I
(70%) NNS N
were VBD N
free JJ N
of IN N
SES NNP N
when WRB N
compared VBN N
to TO N
placebo VB I
(43%); NNP N
P NNP N
< VBD N
0.05 CD N
. . N

Metoclopramide NNP I
was VBD N
ineffective JJ N
. . N

Although IN N
ondansetron NN I
droperidol NN I
and CC N
perphenazine NN I
were VBD N
effective JJ O
in IN N
providing VBG N
antiemetic JJ N
prophylaxis NN N
only RB N
i.v RB N
. . N

perphenazine NN I
was VBD N
free JJ N
of IN N
side JJ N
effects NNS N
. . N

Hence NNP N
we PRP N
conclude VBP N
that DT N
perphenazine NN I
is VBZ N
the DT N
best JJS N
choice NN N
for IN N
antiemetic JJ N
prophylaxis NN N
after IN N
TAH NNP P
. . P

-DOCSTART- -X- O O

A DT N
physiotherapy NN I
service NN I
to TO N
an DT N
emergency NN N
extended VBD N
care NN N
unit NN N
does VBZ N
not RB N
decrease VB N
admission NN O
rates NNS O
to TO O
hospital: VB O
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
One CD N
of IN N
the DT N
reasons NNS N
physiotherapy NN I
services NNS N
are VBP N
provided VBN N
to TO N
emergency NN N
departments NNS N
(EDs) CD N
and CC N
emergency NN N
extended VBN N
care NN N
units NNS N
(EECUs) VBP N
is VBZ N
to TO N
review VB N
patients' JJ N
mobility NN N
to TO N
ensure VB N
they PRP N
are VBP N
safe JJ N
to TO N
be VB N
discharged VBN N
home NN N
. . N

AIM NNP N
To TO N
investigate VB N
whether IN N
a DT N
physiotherapy NN I
service NN I
to TO N
an DT N
EECU NNP N
altered VBD N
the DT N
rate NN O
of IN O
hospital JJ O
admission NN O
rate NN O
of IN O
re-presentation NN O
to TO O
the DT O
ED NNP O
visits NNS O
to TO O
community NN O
healthcare NN O
practitioners NNS O
return VBP O
to TO O
usual JJ O
work/home/leisure NN O
activities NNS O
and CC O
patient JJ O
satisfaction NN O
. . O

METHODS NNP N
A DT N
randomised JJ N
trial NN N
with IN N
concealed JJ N
allocation NN N
assessor NN N
blinding NN N
and CC N
intention-to-treat JJ N
analysis NN N
was VBD N
undertaken VBN N
in IN N
an DT N
EECU NNP N
. . N

The DT P
sample NN P
comprised VBD P
186 CD P
patients NNS P
(mean JJ P
age NN P
70 CD P
years NNS P
123 CD P
(66%) JJ P
female NN P
patients NNS P
130 CD P
(70%) JJ P
trauma) NNS P
who WP P
were VBD P
referred VBN P
for IN P
physiotherapy NN P
assessment/intervention NN P
. . P

Referral JJ N
occurred VBD N
at IN N
any DT N
stage NN N
of IN N
the DT N
patients' NN N
EECU NNP N
admission NN N
. . N

All DT N
participants NNS N
received VBD N
medical/nursing VBG N
care NN N
as IN N
required VBN N
. . N

The DT N
physiotherapy NN I
group NN N
also RB N
received VBD N
physiotherapy JJ I
assessment/intervention NN I
. . I

RESULTS VB N
The DT N
physiotherapy NN I
group NN N
had VBD N
a DT N
4% CD N
(95% NN N
CI NNP N
-18% NNP N
to TO N
9%) CD N
lower JJR N
rate NN O
of IN O
admission NN O
to TO O
hospital NN O
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
4% CD N
(95% NN N
CI NNP N
-6% NNP N
to TO N
13%) CD N
higher JJR N
rate NN O
of IN O
re-presentation NN O
to TO O
the DT O
ED NNP O
which WDT N
were VBD N
statistically RB N
non-significant JJ N
(p≥0.45) NNP N
. . N

Differences NNS N
between IN N
groups NNS N
for IN O
use NN O
of IN O
community NN O
healthcare JJ O
resources NNS O
return VBP O
to TO O
usual JJ O
work/home/leisure NN O
activities NNS O
and CC O
satisfaction NN O
with IN O
their PRP$ O
EECU NNP O
care NN O
were VBD N
small JJ N
and CC N
not RB N
significant JJ N
. . N

CONCLUSION VB N
A NNP I
physiotherapy NN I
service NN I
for IN N
EECU NNP N
patients NNS N
as IN N
provided VBN N
in IN N
this DT N
study NN N
did VBD N
not RB N
reduce VB N
the DT O
rate NN O
of IN O
hospital JJ O
admission NN O
rate NN O
of IN O
re-presentation NN O
to TO O
the DT O
ED NNP O
use NN O
of IN O
community NN O
healthcare JJ O
resources NNS O
or CC N
improve VB N
the DT O
rate NN O
of IN O
return NN O
to TO O
usual JJ O
work/home/leisure NN O
activities NNS O
or CC O
patient JJ O
satisfaction NN O
. . N

Trial JJ N
registration NN N
number NN N
ANZCTRN12609000106235 NNP N
. . N

-DOCSTART- -X- O O

Effect NN N
of IN N
rosuvastatin NN I
monotherapy NN N
or CC N
in IN N
combination NN N
with IN N
fenofibrate NN I
or CC N
ω-3 JJ I
fatty JJ I
acids NNS I
on IN O
lipoprotein JJ O
subfraction NN O
profile NN O
in IN P
patients NNS P
with IN P
mixed JJ P
dyslipidaemia NN P
and CC P
metabolic JJ P
syndrome NN P
. . N

BACKGROUND NNP N
Raised VBD N
triglycerides NNS N
(TG) VBP N
decreased VBN N
high-density NN N
lipoprotein NN N
cholesterol NN N
(HDL-C) JJ N
levels NNS N
and CC N
a DT N
predominance NN N
of IN N
small JJ N
dense NN N
low JJ N
density NN N
lipoproteins VBZ N
(sdLDL) NNS N
are VBP N
characteristics NNS N
of IN N
the DT P
metabolic JJ P
syndrome NN P
(MetS) NN P
. . N

OBJECTIVE UH N
To TO N
compare VB N
the DT N
effect NN N
of IN N
high-dose JJ I
rosuvastatin NN I
monotherapy NN N
with IN N
moderate JJ N
dosing NN N
combined VBN N
with IN I
fenofibrate NN I
or CC I
ω-3 JJ I
fatty JJ I
acids NNS I
on IN N
the DT O
lipoprotein JJ O
subfraction NN O
profile NN O
in IN P
patients NNS P
with IN P
mixed JJ P
dyslipidaemia NN P
and CC P
MetS NNP P
. . N

METHODS NNP N
We PRP N
previously RB N
randomised VBD N
patients NNS N
with IN N
low-density JJ N
lipoprotein NNS N
cholesterol VBP N
(LDL-C) JJ N
> NN N
160 CD N
and CC N
TG NNP N
> VBD N
200 mg/dl CD I
to TO I
rosuvastatin VB I
monotherapy NN N
40 mg/day CD N
(R NNP N
group NN N
n VBD N
= $ N
30) CD I
or CC I
rosuvastatin VB I
10 CD N
mg/day NN N
combined VBN I
with IN I
fenofibrate JJ I
200 CD N
mg/day JJ N
(RF NNP N
group NN N
n VBD N
= $ N
30) CD I
or CC I
ω-3 JJ I
fatty JJ I
acids NNS N
2 CD N
g/day JJ N
(Rω NNP N
group NN N
n VBD N
= RB N
30) CD N
. . N

In IN N
the DT N
present JJ N
study NN P
only RB P
patients NNS P
with IN P
MetS NNP P
were VBD P
included VBN P
(24 JJ N
23 CD N
and CC N
24 CD N
in IN I
the DT I
R NNP N
RF NNP I
and CC N
Rω NNP N
groups NNS N
respectively) NN N
. . N

At IN N
baseline NN N
and CC N
after IN N
12 CD N
weeks NNS N
of IN N
treatment NN O
the DT O
lipoprotein JJ O
subfraction NN O
profile NN O
was VBD O
determined VBN O
by IN O
polyacrylamide JJ O
3% CD O
gel JJ O
electrophoresis NN O
. . N

RESULTS VB O
The DT O
mean JJ O
LDL NNP N
size NN N
was VBD N
significantly RB N
increased VBN N
in IN N
all DT N
groups NNS N
. . N

This DT N
change NN N
was VBD N
more RBR N
prominent JJ I
with IN N
RF NNP N
than IN N
with IN N
other JJ N
treatments NNS N
in IN N
parallel JJ N
with IN N
its PRP$ O
greater JJR O
hypotriglyceridemic JJ O
capacity NN N
(p NNP N
< VBD N
0.05 CD N
compared VBN I
with IN I
R NNP N
and CC N
Rω) NNP N
. . N

A DT N
decrease NN O
in IN O
insulin NN O
resistance NN I
by IN N
RF NNP N
was VBD N
also RB N
noted VBN I
. . N

Only RB N
RF NNP N
significantly RB O
raised VBD O
HDL-C NNP O
levels NNS N
(by VBP N
7.7% CD N
p NN N
< VBD N
0.05) CD N
by IN N
increasing VBG O
the DT O
cholesterol NN O
of IN O
small JJ O
HDL NNP O
particles NNS O
. . O

The DT O
cholesterol NN O
of IN O
larger JJR O
HDL NNP O
subclasses NNS O
was VBD N
significantly RB N
increased VBN I
by IN I
R NNP N
and CC N
Rω NNP N
. . N

CONCLUSIONS NNP N
All NNP N
regimens VBZ O
increased VBN O
mean JJ I
LDL NNP I
size; NN N
RF NNP N
was VBD N
the DT N
most RBS N
effective JJ N
. . N

A DT N
differential JJ N
effect NN N
of IN N
treatments NNS N
was VBD N
noted VBN O
on IN O
the DT O
HDL NNP O
subfraction NN O
profile NN N
. . N

-DOCSTART- -X- O O

Prediction NN N
of IN N
creatinine JJ O
clearance NN O
from IN O
serum JJ O
creatinine NN O
in IN N
patients NNS P
with IN P
rheumatoid JJ P
arthritis: NN P
comparison NN N
of IN N
six CD N
formulae NNS N
and CC N
one CD N
nomogram NN N
. . N

The DT N
estimation NN N
of IN N
glomerular JJ O
filtration NN O
rate NN O
is VBZ N
important JJ N
for IN N
the DT N
medical JJ N
treatment NN N
of IN N
patients NNS P
with IN P
rheumatoid JJ P
arthritis NN P
(RA) NN P
. . P

However RB N
the DT N
determination NN N
of IN N
endogenous JJ N
creatinine JJ N
clearance NN N
(Clcr) NN N
from IN N
a DT N
24-h JJ N
urine JJ N
collection NN N
is VBZ N
an DT N
unreliable JJ N
and CC N
time-consuming JJ N
procedure NN N
. . N

We PRP N
therefore RB N
tested VBD N
the DT N
accuracy NN O
of IN N
six CD N
equations NNS N
and CC N
one CD N
nomogram NN N
for IN N
the DT N
prediction NN O
of IN O
Clcr NNP O
from IN O
serum JJ O
creatinine NN O
(Scr) NN O
in IN N
38 CD P
patients NNS P
with IN P
RA NNP P
and CC P
20 CD P
controls NNS P
. . P

A DT N
positive JJ N
correlation NN O
was VBD N
found VBN N
for IN N
all DT N
methods NNS N
in IN N
the DT N
controls NNS P
(r VBP N
= JJ N
0.83-0.94) JJ N
and CC N
RA NNP P
patients NNS P
(r JJ N
= JJ N
0.51-0.69) NN N
. . N

The DT N
methods NNS N
did VBD N
not RB N
overestimate VB N
Clcr NNP N
in IN P
RA NNP P
. . P

In IN N
the DT N
RA NNP P
group NN P
the DT N
simple JJ N
formula NN N
published VBN N
by IN N
Cockcroft NNP N
[Clcr NNP N
= NNP N
((140 NNP N
- : N
age) NN N
x IN N
body NN N
weight)/(72 JJ N
x NNP N
Scr) NNP N
x VBZ N
0.85 CD N
for IN N
females] NN N
showed VBD N
the DT N
best JJS N
correlation NN O
with IN N
the DT N
measured VBN N
Clcr NNP N
. . N

In IN N
RA NNP P
the DT N
Cockroft NNP N
formula NN N
can MD N
reliably RB N
be VB N
used VBN N
to TO N
predict VB O
Clcr NNP O
from IN O
Scr NNP O
. . O

-DOCSTART- -X- O O

Plasma NNP O
AGE-peptides NNP O
and CC O
C-peptide NNP O
in IN N
early-stage JJ P
diabetic JJ P
nephropathy JJ P
patients NNS P
on IN N
thiamine NN I
and CC N
pyridoxine NN I
therapy NN N
. . N

AIM IN N
The DT N
aim NN N
of IN N
the DT N
study NN N
was VBD N
to TO N
evaluate VB N
circulatory JJ O
AGE-peptide JJ O
levels NNS O
in IN N
diabetic JJ P
nephropathy NN P
and CC N
to TO N
observe VB N
the DT N
effects NNS N
of IN N
thiamine NN I
(vitamin NNP I
B1) NNP I
and CC N
pyridoxine VB I
(vitamin NNP I
B6) NNP I
therapy NN N
. . N

METHODS NNP N
Type NNP P
2 CD P
diabetic JJ P
patients NNS P
(N.=57) WDT P
were VBD P
divided VBN P
into IN P
two CD P
groups NNS P
as IN P
"with JJ P
nephropathy" JJ P
(N.=27) NN P
and CC P
"without NN P
nephropathy" RB P
(N.=30) NNP P
. . P

Diabetic NNP P
nephropathy JJ P
patients NNS P
were VBD N
treated VBN N
with IN N
either DT N
B6 NNP I
(N.=12) NNP N
(250 NNP N
mg/day) NN N
or CC N
B1+B6 NNP I
(N.=15) NNP N
(250 NNP N
mg/day NN N
each) NN N
for IN N
five CD N
months NNS N
. . N

At IN N
the DT N
beginning NN N
and CC N
the DT N
end NN N
of IN N
the DT N
experimentation NN N
period NN N
glucose VBD O
HbA1c NNP O
triglyceride IN O
cholesterol NN O
insulin NN O
C-peptide NNP O
thiamine NN O
pyrophosphate NN O
pyridoxal NN O
phosphate NN O
and CC O
AGE- NNP O
peptides NNS O
were VBD N
measured VBN N
. . N

RESULTS JJ N
AGE-peptides NNS O
were VBD N
higher JJR N
in IN N
the DT N
diabetic JJ P
group NN N
with IN N
nephropathy JJ N
than IN N
without IN N
nephropathy JJ N
(P=0.005) NN N
. . N

Within IN N
five CD N
months NNS N
AGE-peptides NNS O
increased VBD N
in IN N
the DT N
diabetic JJ P
group NN N
without IN N
nephropathy JJ N
(P=0.042) NNS N
but CC N
not RB N
in IN N
the DT N
group NN N
with IN N
nephropathy JJ N
treated VBN N
either RB N
with IN N
B1+B6 NNP I
or CC N
B6 NNP I
. . I

In IN N
B6 NNP I
treated VBD N
group NN N
a DT N
substantial JJ N
decrease NN N
was VBD N
observed VBN N
in IN N
HbA1c NNP O
(P=0.033) NNP N
. . N

B1+B6 NNP I
or CC N
B6 NNP I
treatment NN N
both DT N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP O
(P=0.006 NNP N
P=0.004) NNP N
. . N

CONCLUSION NNP N
Among IN N
the DT N
parameters NNS N
measured VBD N
plasma JJ O
AGE-peptides NNP O
was VBD N
the DT N
only JJ N
parameter NN N
found VBD N
to TO N
be VB N
higher JJR N
in IN N
type NN P
2 CD P
diabetes NNS P
mellitus JJ P
patients NNS P
"with VBP P
nephropathy" JJ P
than IN N
"without IN N
nephropathy" NN N
. . N

However RB N
patients NNS P
with IN P
nephropathy JJ P
treated VBN N
with IN N
B1+B6 NNP I
or CC N
B6 NNP I
did VBD N
not RB N
display VB N
any DT N
further JJ N
increase NN N
in IN N
AGE-peptides NNP O
within IN N
five CD N
months NNS N
. . N

Both DT N
of IN N
the DT N
treatments NNS N
caused VBD N
an DT N
increase NN N
in IN N
C-peptide NNP O
. . O

-DOCSTART- -X- O O

[Antazoline/tetryzoline JJ I
eyedrops NNS N
in IN N
comparison NN N
with IN N
levocabastine JJ I
eyedrops NNS N
in IN N
acute JJ P
allergic JJ P
conjunctivitis] NN P
. . N

BACKGROUND NNP N
Allergic NNP P
conjunctivitis NN P
is VBZ N
one CD N
of IN N
the DT N
most RBS N
frequent JJ N
allergic JJ N
diseases NNS N
of IN N
the DT N
anterior JJ N
eye NN N
segment NN N
. . N

METHODS NNP N
This DT N
multicentre JJ N
clinical JJ N
trial NN N
was VBD N
an DT N
investigation NN N
to TO N
compare VB N
the DT N
antiallergic JJ N
efficacy NN O
local JJ O
tolerance NN O
and CC N
safety NN O
of IN N
Antazolin/Tetryzolin NNP I
eye NN N
drops NNS N
and CC N
Levocabastine NNP I
eye NN N
drops NNS N
. . N

69 CD P
patients NNS P
were VBD N
treated VBN N
over IN N
a DT N
2 CD N
weeks NNS N
course NN N
of IN N
therapy NN N
. . N

The DT N
subjective JJ O
and CC O
objective JJ O
ocular NN O
symptoms NNS O
were VBD N
documented VBN N
over IN N
the DT N
treatment NN N
period NN N
. . N

RESULTS NNP N
Both NNP N
eye NN N
drops NNS N
reduced VBD N
subjective JJ O
and CC O
objective JJ O
ocular NN O
symptoms NNS O
effective JJ N
. . N

The DT N
difference NN N
between IN N
the DT N
treatments NNS N
(p VBP N
= JJ N
0.0395) CD N
was VBD N
the DT N
faster JJ N
onset NN N
of IN N
action NN N
of IN N
Antazolin/Tetryzolin NNP I
30 CD N
minutes NNS N
after IN N
administration NN N
of IN N
the DT N
first JJ N
drop NN N
of IN N
trial NN N
medication NN N
. . N

CONCLUSION VB N
A DT N
fast JJ N
and CC N
effective JJ O
onset NN N
of IN N
action NN N
is VBZ N
of IN N
high JJ N
clinical JJ N
relevance NN N
. . N

Therefore IN N
the DT N
benefits NNS N
of IN N
using VBG N
Antazolin/Tetryzolin NNP I
eye NN N
drops NN N
was VBD N
clearly RB N
outweigh JJ N
. . N

-DOCSTART- -X- O O

Cophenylcaine NNP I
spray NN I
vs NN N
. . N

placebo NN I
in IN N
flexible JJ P
nasendoscopy: NN P
a DT N
prospective JJ N
double-blind NN N
randomised VBD N
controlled VBN N
trial NN N
. . N

Practices NNS N
vary VBP N
across IN N
the DT N
UK NNP N
on IN N
the DT N
use NN N
of IN N
topical JJ N
preparation NN N
prior RB N
to TO N
flexible JJ P
fibreoptic JJ P
nasendoscopy NN P
. . P

In IN N
this DT N
double-blind JJ N
study NN N
we PRP N
randomised VBD N
98 CD P
patients NNS P
to TO N
receive VB N
cophenylcaine NN I
or CC N
placebo NN I
nasal JJ N
spray NN N
before IN N
flexible JJ P
nasendoscopy NN P
. . P

A DT N
visual JJ O
analogue NN O
scale NN O
(1-100) NN O
was VBD O
used VBN O
to TO O
record VB O
pain NN O
unpleasantness NN O
of IN O
taste NN O
and CC O
overall JJ O
discomfort NN O
experienced VBD O
. . O

Overall VB N
the DT N
procedure NN N
was VBD N
associated VBN N
with IN N
minimal JJ N
pain NN O
and CC O
discomfort NN O
in IN N
both DT N
groups NNS N
. . N

There EX N
was VBD N
no DT N
significant JJ N
difference NN N
in IN N
pain NN O
or CC O
overall JJ O
discomfort NN O
experienced VBD N
between IN N
the DT N
two CD N
groups; NN N
however RB N
the DT N
sensation NN O
of IN O
bad JJ O
taste NN O
was VBD N
significantly RB N
worse JJR N
in IN N
the DT N
cophenylcaine NN I
group NN N
. . N

In IN N
linear JJ N
regression NN N
factors NNS N
that WDT N
predicted VBD N
the DT N
overall JJ N
unpleasantness NN O
of IN N
the DT N
experience NN N
were VBD N
primarily RB N
pain VBN O
experienced JJ N
and CC N
secondarily JJ N
unpleasantness NN O
of IN O
taste NN O
. . O

We PRP N
conclude VBP N
that IN N
the DT N
routine JJ N
use NN N
of IN N
cophenylcaine NN I
for IN N
nasal JJ N
preparation NN N
is VBZ N
not RB N
justified VBN N
before IN N
flexible JJ P
nasendoscopy NN P
. . P

-DOCSTART- -X- O O

Group NNP I
cognitive JJ I
behavior NN I
therapy NN I
for IN N
children NNS P
with IN P
high-functioning JJ P
autism NN P
spectrum NN P
disorders NNS P
and CC P
anxiety: VB P
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Children NNP P
with IN N
high-functioning JJ N
autism NN N
spectrum NN N
disorders NNS N
(ASD) VBP N
are VBP N
at IN N
high JJ N
risk NN N
for IN N
developing VBG N
significant JJ N
anxiety NN N
. . N

Anxiety NN N
can MD N
adversely RB N
impact VB N
functioning VBG N
across IN N
school NN N
home NN N
and CC N
community NN N
environments NNS N
. . N

Cognitive JJ I
behavioral JJ I
therapies NNS I
(CBT) WDT I
are VBP N
frequently RB N
used VBN N
with IN N
success NN N
for IN N
children NNS N
with IN N
anxiety NN O
symptoms NNS O
. . O

Modified NNP N
CBT NNP I
interventions NNS N
for IN N
anxiety NN P
in IN P
children NNS P
with IN P
ASD NNP P
have VBP N
also RB N
yielded VBN N
promising JJ N
results NNS N
. . N

METHODS NNP N
Fifty NNP P
children NNS P
with IN P
high-functioning JJ P
ASD NNP P
and CC P
anxiety NN P
were VBD N
randomizedto JJ N
group NN N
CBT NNP I
or CC N
treatment-as-usual JJ I
(TAU) NN I
for IN N
12 CD N
weeks NNS N
. . N

Independent NNP N
clinical JJ N
evaluators NNS N
blind VBP N
to TO N
condition NN N
completed VBN N
structured JJ O
interviews NNS O
(Anxiety NN O
Disorders NNP O
Interview NNP O
Schedule NNP O
– NNP O
Parent NNP O
Version;ADIS-P) NNP O
pre- NN N
and CC N
post-intervention NN N
condition NN N
. . N

RESULTS NNP P
Forty-seven JJ P
children NNS P
completed VBN P
either CC P
the DT P
CBT NNP P
or CC P
TAU NNP P
condition NN P
. . N

Results NNS N
indicated VBD N
markedly RB N
better RBR N
outcomes NNS N
for IN N
the DT I
CBT NNP I
group NN N
. . N

Significant JJ N
differences NNS N
by IN N
group NN N
were VBD N
noted VBN N
in IN O
Clinician JJ O
Severity NNP O
Ratings NNP O
diagnostic JJ O
status NN O
and CC O
clinician JJ O
ratings NNS O
of IN O
global JJ O
improvement NN O
. . N

In IN N
the DT N
intent-to-treat JJ N
sample NN N
10 CD N
of IN N
20 CD N
children NNS N
(50%) VBN N
in IN N
the DT I
CBT NNP I
group NN N
had VBD N
a DT N
clinically RB N
meaningful JJ N
positive JJ O
treatment NN O
response NN O
compared VBN N
to TO N
2 CD N
of IN N
23 CD N
children NNS N
(8.7%) VBN N
in IN N
the DT I
TAU NNP I
group NN N
. . N

CONCLUSIONS NNP N
Initial JJ N
results NNS N
from IN N
this DT N
randomized VBN N
designed VBN N
treatment NN N
study NN N
suggest VBP N
that IN N
agroup NN I
CBT NNP I
intervention NN N
specifically RB N
developed VBD N
for IN P
children NNS P
with IN P
ASD NNP P
may MD N
be VB N
effective JJ N
in IN N
decreasing VBG N
anxiety NN N
. . N

-DOCSTART- -X- O O

Lowering VBG N
the DT N
triglyceride/high-density NN O
lipoprotein NN O
cholesterol NN O
ratio NN O
is VBZ N
associated VBN N
with IN N
the DT N
beneficial JJ N
impact NN N
of IN N
pioglitazone NN I
on IN N
progression NN O
of IN O
coronary JJ P
atherosclerosis NN P
in IN P
diabetic JJ P
patients: NN P
insights NNS N
from IN N
the DT N
PERISCOPE NNP N
(Pioglitazone NNP I
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation) NNP N
study NN N
. . N

OBJECTIVES CC N
The DT N
purpose NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
determine VB N
the DT N
factors NNS N
associated VBN N
with IN N
the DT N
favorable JJ N
effect NN O
of IN N
pioglitazone NN I
on IN N
atheroma JJ O
progression NN O
. . O

BACKGROUND NNP N
Diabetes NNP P
mellitus NN P
is VBZ N
associated VBN N
with IN N
accelerated JJ N
coronary JJ P
atheroma NN P
progression NN O
. . O

Pioglitazone NN I
slowed VBD N
progression NN O
compared VBN N
with IN N
glimepiride NN I
in IN N
this DT N
population NN N
. . N

METHODS NNP N
In IN N
all DT N
360 CD P
diabetic JJ P
patients NNS P
with IN P
coronary JJ P
artery NN P
disease NN P
were VBD N
treated VBN N
with IN N
pioglitazone NN I
or CC N
glimepiride NN I
for IN N
18 CD N
months NNS N
in IN N
the DT N
PERISCOPE NNP N
(Pioglitazone NNP I
Effect NNP N
on IN N
Regression NNP N
of IN N
Intravascular NNP N
Sonographic NNP N
Coronary NNP N
Obstruction NNP N
Prospective NNP N
Evaluation) NNP N
study NN N
. . N

Coronary NNP O
atheroma NN O
progression NN O
was VBD O
evaluated VBN O
by IN O
serial JJ O
intravascular JJ O
ultrasound NN O
. . O

The DT N
relationship NN N
between IN N
changes NNS O
in IN O
biochemical JJ O
parameters NNS O
percent JJ O
atheroma NN O
volume NN O
and CC O
total JJ O
atheroma NN O
volume NN O
was VBD N
investigated VBN N
. . N

RESULTS JJ N
Pioglitazone-treated JJ I
patients NNS N
demonstrated VBD N
greater JJR N
increases NNS N
in IN N
high-density NN O
lipoprotein NN O
cholesterol NN O
(HDL-C) JJ O
and CC N
reductions NNS N
in IN N
glycated JJ O
hemoglobin NN O
triglycerides NNS O
and CC O
C-reactive JJ O
protein NN O
. . O

Significant JJ N
correlations NNS N
were VBD N
observed VBN N
between IN N
changes NNS N
in IN N
percent NN O
atheroma NN O
volume NN O
and CC O
triglycerides NNS O
(r VBP N
= $ N
0.15 CD N
p NN N
= VBD N
0.04) CD N
triglyceride/HDL-C JJ O
ratio NN O
(r NNP N
= VBZ N
0.16 CD N
p NN N
= NN N
0.03) CD N
and CC N
glycated VBD O
hemoglobin NN O
(r NNP N
= VBZ N
0.16 CD N
p NN N
= VBD N
0.03) CD N
with IN N
pioglitazone NN I
and CC N
changes NNS N
in IN N
low-density NN O
lipoprotein NN O
cholesterol NN O
(r NNP N
= NNP N
-0.15 NNP N
p NN N
= VBD N
0.05) CD N
apolipoprotein NN O
B NNP O
(r NNP N
= NNP N
-0.16 NNP N
p NN N
= VBD N
0.04) CD N
and CC N
apolipoprotein JJ O
A-I NNP O
(r NNP N
= NNP N
-0.20 NNP N
p NN N
= VBD N
0.01) CD N
with IN N
glimepiride NN I
. . I

Substantial JJ O
atheroma JJ O
regression NN O
compared VBN N
to TO N
progression NN O
was VBD N
associated VBN N
with IN N
greater JJR N
relative JJ N
increases NNS N
in IN N
HDL-C NNP O
(14.2% NNP N
vs NN N
. . N

7.8% CD N
p JJ N
= $ N
0.04) CD N
relative JJ N
decreases NNS N
in IN N
triglycerides NNS O
(-13.3% JJ N
vs NN N
. . N

-1.9% CC N
p JJ N
= JJ N
0.045) CD N
triglyceride/HDL-C JJ O
ratio NN O
(-22.5 JJ N
vs NN N
. . N

-9.9% CC N
p JJ N
= NN N
0.05) CD N
and CC N
decrease NN N
in IN N
glycated JJ O
hemoglobin JJ O
(-0.6% JJ N
vs NN N
. . N

-0.3% CC N
p JJ N
= NN N
0.01) CD N
. . N

Multivariable JJ N
analysis NN N
revealed VBD N
that IN N
pioglitazone-induced JJ I
effects NNS N
on IN N
triglyceride/HDL-C NN O
were VBD N
associated VBN N
with IN N
changes NNS N
in IN N
percent NN O
atheroma NN O
volume NN O
(p NNP N
= VBZ N
0.03) CD N
and CC N
total JJ O
atheroma NN O
volume NN O
(p NNP N
= VBZ N
0.02) CD N
. . N

CONCLUSIONS NNP N
Favorable JJ N
effects NNS N
of IN N
pioglitazone NN I
on IN N
the DT N
triglyceride/HDL-C JJ O
ratio NN O
correlated VBN N
with IN N
delayed JJ N
atheroma NN O
progression NN O
in IN N
diabetic JJ P
patients NNS P
. . P

This DT N
finding NN N
highlights VBZ N
the DT N
potential JJ N
importance NN N
of IN N
targeting VBG N
atherogenic JJ N
dyslipidemia NN N
in IN N
diabetic JJ P
patients NNS P
with IN P
coronary JJ P
artery NN P
disease NN P
. . P

-DOCSTART- -X- O O

Bacteremia NNP O
due JJ N
to TO N
Bacteroides NNP N
fragilis NN N
after IN P
elective JJ P
appendectomy NN P
in IN P
renal JJ P
transplant NN P
recipients NNS P
. . P

Bacteremia NNP O
caused VBN N
by IN N
Bacteroides NNP N
fragilis NN N
occurred VBD N
in IN N
four CD N
of IN N
75 CD P
children NNS P
after IN P
renal JJ P
transplantation NN P
and CC N
B NNP N
. . N

fragilis NN N
was VBD N
the DT N
most RBS N
common JJ N
cause NN N
of IN N
postoperative JJ O
bacteremia NN O
. . O

Bacteroides NNP N
bacteremia NN O
was VBD N
significantly RB N
associated VBN N
with IN N
performance NN O
of IN O
elective JJ P
appendectomy NN P
at IN N
the DT N
time NN N
of IN N
transplantation NN P
(P NNP N
less JJR N
than IN N
0.01) CD N
and CC N
with IN N
profound JJ N
lymphocytopenia NN O
(P NNP N
= VBZ N
0.01) CD N
. . N

No DT N
patient NN N
received VBD N
antibiotics NNS N
at IN N
the DT N
time NN N
of IN N
surgery NN N
or CC N
prior RB N
to TO N
the DT N
first JJ N
positive JJ N
blood NN N
culture NN N
yet RB N
B NNP N
. . N

fragilis NN N
was VBD N
the DT N
single JJ N
organism NN N
isolated VBN N
from IN N
blood NN N
and CC N
abscesses NNS N
in IN N
these DT N
patients NNS N
. . N

A DT N
role NN N
for IN N
lymphocytes NNS N
in IN N
containment NN N
of IN N
B NNP N
. . N

fragilis NN N
has VBZ N
not RB N
been VBN N
suggested VBN N
previously RB N
although IN N
unexplained JJ N
occurrence NN O
of IN O
bacteroides NNS O
bacteremia VBP O
in IN N
immunocompromised JJ N
patients NNS N
has VBZ N
occasionally RB N
been VBN N
reported VBN N
. . N

Lymphocytes VBZ N
themselves PRP N
may MD N
be VB N
important JJ N
in IN N
this DT N
host-bacterium JJ N
interaction NN N
or CC N
lymphocytopenia NN N
may MD N
be VB N
the DT N
marker NN N
for IN N
a DT N
more RBR N
generalized JJ N
deficiency NN N
in IN N
host NN N
defenses NNS N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
randomized NN N
controlled VBD N
multicenter JJR N
safety NN O
and CC N
immunogenicity NN O
study NN N
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP I
. . I

The DT N
vaccine NN N
Zostavax NNP I
has VBZ N
been VBN N
shown VBN N
to TO N
prevent VB N
herpes NNS N
zoster JJR N
(HZ) NN N
and CC N
postherpetic JJ N
neuralgia NN N
and CC N
is VBZ N
recommended VBN N
for IN N
individuals NNS N
> CD N
or CC N
=60 CD N
years NNS N
of IN N
age NN N
. . N

This DT N
study NN N
compared VBN N
the DT N
safety NN O
and CC N
the DT N
immunogenicity NN O
of IN N
a DT N
refrigerator-stable JJ N
formulation NN N
(Zostavax NNP I
refrigerated) NN N
with IN N
those DT N
of IN N
the DT N
current JJ N
formulation NN N
(Zostavax NN I
frozen) NN N
in IN N
subjects NNS P
> VBP P
or CC P
=50 CD P
years NNS P
of IN P
age NN P
. . P

Subjects VBZ P
with IN P
a DT P
negative JJ P
history NN P
for IN P
HZ NNP P
were VBD N
randomized VBN N
1:1 CD N
to TO N
receive VB N
one CD N
dose NN N
of IN N
either DT N
formulation NN N
. . N

Enrollment NN P
was VBD P
stratified VBN P
1:2 CD P
by IN P
age NN P
(50 NN P
to TO P
59 CD P
years NNS P
and CC P
> NN P
or CC P
=60 JJ P
years) NN P
. . N

Safety NNP O
was VBD N
evaluated VBN N
for IN N
28 CD N
days NNS N
postvaccination NN N
. . N

Varicella-zoster NNP O
virus NN O
(VZV) NNP O
antibody NN O
responses NNS O
were VBD N
measured VBN N
by IN N
a DT N
glycoprotein JJ O
enzyme-linked JJ O
immunosorbent NN O
assay NN O
(gpELISA) NN O
. . O

The DT N
primary JJ N
endpoints NNS N
were VBD N
the DT N
VZV NNP O
antibody NN O
geometric JJ O
mean NN O
titer NN O
(GMT; NNP O
day NN N
28) CD N
the DT N
VZV NNP O
antibody NN O
geometric JJ O
mean NN O
rise NN O
(GMR; NNP O
days NNS N
1 CD N
to TO N
28) CD N
and CC N
the DT N
incidence NN O
of IN O
vaccine-related JJ O
serious JJ O
adverse JJ O
experiences NNS O
(AEs) VBP O
over IN N
28 CD N
days NNS N
. . N

The DT N
refrigerated JJ N
(n NNP N
= NNP N
182) CD N
and CC N
frozen JJ N
(n NNP N
= NNP N
185) CD N
formulations NNS N
induced VBD N
similar JJ N
GMTs NNP O
(727.4 NNP N
and CC N
834.4 CD N
gpELISA NN O
units/ml JJ N
respectively); VBZ N
the DT N
estimated JJ N
GMT NNP O
ratio NN N
(refrigerated VBD N
formulation/frozen JJ N
formulation) NN N
was VBD N
0.87 CD N
(95% JJ N
confidence NN N
interval NN N
0.71 CD N
to TO N
1.07) CD N
. . N

The DT N
GMRs NNPS O
were VBD N
2.6- JJ N
and CC N
2.9-fold JJ N
respectively RB N
. . N

No DT N
vaccine-related JJ O
serious JJ O
AEs NNP O
were VBD N
reported VBN N
in IN N
either DT N
group NN N
and CC N
the DT N
safety NN O
profiles NNS N
of IN N
the DT N
formulations NNS N
were VBD N
generally RB N
similar JJ N
. . N

The DT N
frequencies NNS N
of IN N
injection-site JJ O
AEs NNP O
during IN N
follow-up JJ N
were VBD N
35.6% CD N
and CC N
46.4% CD N
in IN N
the DT N
refrigerated JJ N
and CC N
the DT N
frozen JJ N
formulation NN N
groups NNS N
respectively RB N
and CC N
were VBD N
generally RB N
mild VBN N
. . N

The DT N
frequencies NNS N
of IN N
systemic JJ O
AEs NNP O
were VBD N
similar JJ N
in IN N
the DT N
two CD N
groups NNS N
and CC N
those DT N
of IN N
vaccine-related JJ O
AEs NNP O
were VBD N
approximately RB N
6% CD N
in IN N
both DT N
groups NNS N
. . N

The DT N
refrigerator-stable JJ N
formulation NN N
of IN N
Zostavax NNP I
has VBZ N
an DT N
acceptable JJ N
safety NN O
profile NN N
and CC N
is VBZ N
as RB N
immunogenic JJ O
as IN N
the DT N
frozen JJ N
formulation; NN N
thus RB N
the DT N
vaccine NN N
may MD N
be VB N
used VBN N
in IN N
clinical JJ N
settings NNS N
where WRB N
freezer NN N
availability NN N
is VBZ N
limited VBN N
. . N

-DOCSTART- -X- O O

Interventions NNS N
in IN N
the DT N
initial JJ P
prodromal JJ P
states NNS P
of IN P
psychosis NN P
in IN P
Germany: NNP P
concept NN N
and CC N
recruitment NN N
. . N

BACKGROUND VB N
The DT N
Early JJ N
Detection NN N
and CC N
Intervention NNP N
Programme NNP N
of IN N
the DT N
German JJ P
Research NNP N
Network NNP N
on IN N
Schizophrenia NNP P
(GRNS) NNP N
investigates VBZ N
the DT N
initial JJ P
prodromal JJ P
phase NN P
of IN P
psychosis NN P
in IN N
a DT N
multidimensional JJ N
approach NN N
. . N

Two CD N
intervention NN N
strategies NNS N
are VBP N
being VBG N
studied VBN N
by IN N
two CD N
large-scale JJ N
multicentre JJ N
projects NNS N
. . N

AIMS NNP N
To TO N
present VB N
the DT N
concept NN N
of IN N
the DT N
intervention NN N
studies NNS N
and CC N
to TO N
provide VB N
an DT N
interim JJ N
report NN N
of IN N
the DT N
recruitment JJ N
procedure NN N
. . N

METHOD NNP N
Comprehensive NNP I
cognitive-behavioural JJ I
therapy NN I
has VBZ N
been VBN N
developed VBN N
for IN N
patients NNS P
in IN P
the DT P
"early JJ P
initial JJ P
prodromal JJ P
state" NN P
. . P

For IN N
patients NNS P
in IN P
the DT P
"late NNP P
initial JJ P
prodromal JJ P
state" NN P
the DT N
atypical JJ I
neuroleptic JJ I
amisulpride NN I
is VBZ N
explored VBN N
. . N

Both DT N
interventions NNS N
are VBP N
evaluated VBN N
in IN N
randomised JJ N
controlled VBN N
trials NNS N
using VBG N
clinical JJ N
management NN N
as IN N
the DT N
control NN N
condition NN N
. . N

RESULTS NNP N
Between NNP P
January NNP P
2001 CD P
and CC P
March NNP P
2003 CD P
1212 CD P
individuals NNS P
seeking VBG P
help NN P
for IN P
mental JJ P
health NN P
problems NNS P
were VBD N
screened VBN N
for IN N
putative JJ N
prodromal NN N
symptoms NNS N
at IN N
four CD P
university NN P
centres NNS P
. . P

More JJR P
than IN P
388 CD P
individuals NNS P
fulfilled VBD P
criteria NNS P
for IN P
both DT P
interventions NNS P
and CC P
188 CD P
(48.5%) NNS P
gave VBD P
informed VBN P
consent NN P
to TO P
participate VB P
in IN P
the DT P
trials NNS P
. . P

CONCLUSIONS VB N
The DT N
screening NN N
procedure NN N
appears VBZ N
to TO N
be VB N
feasible JJ N
and CC N
trial NN N
participation NN N
seems VBZ N
to TO N
be VB N
acceptable JJ N
to TO N
a DT N
relevant JJ N
proportion NN N
of IN N
people NNS P
at IN P
increased VBN P
risk NN P
of IN P
developing VBG P
psychosis NN P
. . P

-DOCSTART- -X- O O

Anti-emetic JJ O
efficacy NN O
of IN N
prophylactic JJ N
granisetron NNS I
compared VBN N
with IN N
perphenazine NN I
for IN N
the DT N
prevention NN O
of IN N
post-operative JJ P
vomiting NN N
in IN N
children NNS P
. . P

We PRP N
have VBP N
compared VBN N
the DT N
efficacy NN O
of IN N
granisetron NN I
with IN N
perphenazine NN I
in IN N
the DT N
prevention NN N
of IN N
vomiting VBG N
after IN N
tonsillectomy NN P
with IN P
or CC P
without IN P
adenoidectomy NN P
in IN P
children NNS P
. . P

In IN N
a DT N
prospective JJ N
randomized VBN N
double-blind NN N
study NN N
90 CD P
paediatric JJ P
patients NNS P
ASA VBP P
I PRP P
aged VBD P
4-10 JJ P
years NNS P
received VBD N
granisetron RB I
40 CD N
mg JJ N
kg-1 NN N
or CC N
perphenazine VB I
70 CD N
mg JJ N
kg-1 JJ N
(n NN N
= $ N
45 CD N
each) NN N
intravenously RB N
immediately RB N
after IN N
an DT N
inhalation NN N
induction NN N
of IN N
anaesthesia NN N
. . N

A DT N
standard JJ N
general JJ N
anaesthetic JJ N
technique NN N
was VBD N
employed VBN N
throughout IN N
. . N

A DT N
complete JJ O
response NN O
defined VBD O
as IN O
no DT O
emesis NN O
with IN O
no DT O
need NN O
for IN O
another DT O
rescue NN O
antiemetic NN O
during IN N
the DT N
first JJ N
3 CD N
h JJ N
(0-3 JJ N
h) NN N
after IN N
anesthesia NN N
was VBD N
87% CD N
with IN N
granisetron NN I
and CC N
78% CD N
with IN N
perphenazine NN I
(P NNP N
= VBZ N
0.204) CD N
. . N

The DT N
corresponding JJ O
incidence NN O
during IN N
the DT N
next JJ N
21 CD N
h JJ N
(3-24 JJ N
h) NN N
after IN N
anaesthesia NN N
was VBD N
87% CD N
and CC N
62% CD N
(P NNS N
= JJ N
0.007) CD N
. . N

No DT N
clinically RB N
serious JJ N
adverse JJ O
events NNS O
were VBD N
observed VBN N
in IN N
any DT N
of IN N
the DT N
groups NNS N
. . N

We PRP N
conclude VBP N
that DT N
granisetron NN I
is VBZ N
a DT N
better JJR N
anti-emetic JJ N
than IN N
perphenazine NN I
for IN N
the DT N
long-term JJ O
prevention NN O
of IN O
post-operative JJ P
vomiting NN O
in IN N
children NNS P
undergoing VBG P
general JJ P
anaesthesia NN P
for IN P
tonsillectomy NN P
. . P

-DOCSTART- -X- O O

Comparison NNP N
of IN N
budesonide JJ I
Turbuhaler NNP I
with IN N
budesonide JJ I
aqua NN I
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ P
allergic JJ P
rhinitis NN P
. . P

Rhinocort NNP N
Study NNP N
Group NNP N
. . N

OBJECTIVE NNP N
To TO N
compare VB N
the DT N
effect NN N
of IN N
budesonide NN I
Turbuhaler NNP I
400 CD N
microg/day NN N
with IN N
budesonide JJ I
aqua NN I
256 CD N
microg/day NN N
in IN N
the DT N
treatment NN N
of IN N
seasonal JJ P
allergic JJ P
rhinitis NN P
(SAR) NNP P
. . P

Secondarily RB N
to TO N
ascertain VB N
patients' JJ O
preferences NNS O
for IN O
the DT O
two CD O
nasal JJ O
devices NNS O
and CC N
to TO N
assess VB N
quality NN O
of IN O
life NN O
. . O

DESIGN NNP N
Randomized NNP N
multicentre VBD N
double-blind JJ N
double- JJ N
dummy NN N
parallel NN N
groups NNS N
study VBP N
. . N

SETTING NNP N
Private NNP P
practices NNS P
and CC P
hospital NN P
clinics NNS P
in IN P
Ontario NNP P
Quebec NNP P
and CC P
Manitoba NNP P
. . P

POPULATION NNP N
Two CD P
hundred VBD P
and CC P
eighty-four JJ P
out-patients NNS P
with IN P
SAR NNP P
who WP P
were VBD P
symptomatic JJ P
during IN P
the DT P
ragweed NN P
season NN P
volunteered VBD P
for IN P
enrolment NN P
(243 NNP P
randomized) NN P
. . P

RESULTS JJ N
Mean JJ O
daily JJ O
nasal NN O
symptom NN O
scores NNS O
were VBD N
significantly RB N
reduced VBN N
with IN N
treatment NN N
. . N

There EX N
were VBD N
no DT N
statistically RB N
significant JJ N
changes NNS N
from IN N
baseline NN N
for IN N
eye NN O
symptoms NNS O
. . O

Most JJS N
patients NNS N
(more RB N
than IN N
80%) CD N
achieved JJ N
substantial JJ N
control NN N
of IN N
their PRP$ N
symptoms NNS N
with IN N
budesonide NN I
. . I

The DT N
most RBS N
common JJ N
nasal NN O
and CC O
non-nasal JJ O
adverse JJ O
events NNS O
for IN N
both DT N
groups NNS N
were VBD N
epistaxis JJ O
and CC N
headache NN O
. . O

Turbuhaler NNP I
was VBD N
easier JJR N
to TO N
use VB N
and CC N
more RBR N
convenient JJ N
to TO N
carry VB N
had VBD N
less JJR N
of IN N
an DT N
unpleasant JJ O
taste NN O
and CC N
caused VBD N
less JJR N
nasal JJ O
irritation NN O
than IN N
the DT N
aqua JJ N
spray NN N
. . N

More JJR N
than IN N
twice RB N
as IN N
many JJ N
patients NNS N
preferred JJ N
Turbuhaler NNP I
to TO N
the DT N
aqua NN I
spray NN I
(69% NNP N
versus NN N
31%) CD N
. . N

Improvement NN N
in IN N
quality NN O
of IN O
life NN O
from IN N
baseline NN N
to TO N
clinic VB N
visits NNS N
was VBD N
statistically RB N
significant JJ N
in IN N
both DT N
groups NNS N
. . N

CONCLUSION NNP N
Once RB N
daily JJ N
use NN N
of IN N
256 CD N
mg NN N
of IN N
budesonide NN I
aqua NN I
and CC N
400 CD N
mg NN N
of IN N
budesonide NN I
Turbuhaler NNP I
are VBP N
equally RB N
safe JJ O
and CC N
efficacious JJ O
in IN N
the DT N
treatment NN N
of IN N
SAR NNP P
. . P

Patients NNS N
preferred VBD N
the DT N
budesonide NN I
powder NN I
formulation NN N
delivered VBD N
via IN N
Turbuhaler NNP I
two CD N
to TO N
one CD N
over IN N
the DT N
aqua JJ I
formulation NN N
. . N

-DOCSTART- -X- O O

Phase NNP N
III NNP N
study NN N
of IN N
concurrent JJ I
chemoradiotherapy NN I
versus NN N
radiotherapy NN I
alone RB N
for IN N
advanced JJ P
nasopharyngeal JJ P
carcinoma: NN P
positive JJ N
effect NN O
on IN N
overall JJ O
and CC O
progression-free JJ O
survival NN O
. . O

PURPOSE NNP N
Nasopharyngeal NNP P
carcinoma NN P
(NPC) NNP P
is VBZ N
a DT N
radiosensitive JJ N
and CC N
chemosensitive JJ N
tumor NN N
. . N

This DT N
randomized JJ N
phase NN N
III NNP N
trial NN N
compared VBN N
concurrent JJ I
chemoradiotherapy NN I
(CCRT) NNP I
versus NN N
radiotherapy NN I
(RT) NNP I
alone RB N
in IN N
patients NNS P
with IN P
advanced JJ P
NPC NNP P
. . P

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP P
December NNP P
1993 CD P
to TO P
April NNP P
1999 CD P
284 CD P
patients NNS P
with IN P
1992 CD P
American NNP P
Joint NNP P
Committee NNP P
on IN P
Cancer NNP P
stage NN P
III NNP P
to TO P
IV NNP P
(M0) NNP P
NPC NNP P
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
arms NNS N
. . N

Similar JJ N
dosage NN N
and CC N
fractionation NN N
of IN N
RT NNP I
was VBD N
administered VBN N
in IN N
both DT N
arms NNS N
. . N

The DT N
investigational JJ N
arm NN N
received VBD N
two CD N
cycles NNS N
of IN N
concurrent JJ N
chemotherapy NN I
with IN N
cisplatin NN I
20 CD N
mg/m(2)/d NN N
plus CC N
fluorouracil JJ I
400 CD N
mg/m(2)/d NN N
by IN N
96-hour CD N
continuous JJ N
infusion NN N
during IN N
the DT N
weeks NNS N
1 CD N
and CC N
5 CD N
of IN N
RT NNP I
. . I

Survival NNP O
analysis NN O
was VBD O
estimated VBN O
by IN O
the DT O
Kaplan-Meier NNP O
method NN O
and CC O
compared VBN O
by IN O
the DT O
log-rank JJ O
test NN O
. . O

RESULTS NNP N
Baseline NNP N
patient JJ N
characteristics NNS N
were VBD N
comparable JJ N
in IN N
both DT N
arms NNS N
. . N

After IN N
a DT N
median JJ N
follow-up NN N
of IN N
65 CD N
months NNS N
26.2% CD N
(37 NN N
of IN N
141) CD N
and CC N
46.2% CD N
(66 NN N
of IN N
143) CD N
of IN N
patients NNS N
developed JJ N
tumor NN O
relapse NN O
in IN N
the DT N
CCRT NNP I
and CC N
RT-alone NNP I
groups NNS N
respectively RB N
. . N

The DT N
5-year JJ O
overall JJ O
survival NN O
rates NNS O
were VBD N
72.3% CD N
for IN N
the DT N
CCRT NNP I
arm NN N
and CC N
54.2% CD N
for IN N
the DT N
RT-only JJ I
arm NN N
(P NN N
=.0022) NN N
. . N

The DT N
5-year JJ O
progression-free JJ O
survival NN O
rates NNS O
were VBD N
71.6% CD N
for IN N
the DT N
CCRT NNP I
group NN N
compared VBN N
with IN N
53.0% CD N
for IN N
the DT N
RT-only NNP I
group NN N
(P NNP N
=.0012) NNP N
. . N

Although IN N
significantly RB N
more JJR N
toxicity NN O
was VBD N
noted VBN N
in IN N
the DT N
CCRT NNP I
arm NN N
including VBG N
leukopenia NN O
and CC O
emesis NN O
compliance NN N
with IN N
the DT N
combined JJ N
treatment NN N
was VBD N
good JJ N
. . N

The DT N
second JJ N
cycle NN N
of IN N
concurrent JJ I
chemotherapy NN I
was VBD N
refused VBN N
by IN N
nine CD N
patients NNS N
and CC N
was VBD N
delayed VBN N
for IN N
> NN N
or CC N
= $ N
1 CD N
week NN N
for IN N
another DT N
nine CD N
patients NNS N
. . N

There EX N
were VBD N
no DT N
treatment-related JJ O
deaths NNS O
in IN N
either DT N
arm NN N
. . N

CONCLUSION NN N
We PRP N
conclude VBP N
that DT N
CCRT NNP I
is VBZ N
superior JJ N
to TO N
RT VB I
alone RB N
for IN N
patients NNS P
with IN P
advanced JJ P
NPC NNP P
in IN P
endemic JJ P
areas NNS P
. . P

-DOCSTART- -X- O O

Bolus NNP N
injection NN N
of IN N
contrast NN N
agents NNS N
with IN N
various JJ N
iodine JJ N
concentrations NNS N
and CC N
delivery NN N
rates NNS N
for IN N
intracranial JJ P
three-dimensional JJ P
CT NNP P
angiography: POS P
evaluation NN N
of IN N
intracranial JJ O
arteriovenous JJ O
contrast NN O
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
scanner NN N
. . N

PURPOSE NNP N
We PRP N
evaluated VBD N
the DT N
difference NN O
in IN N
computed JJ N
tomography NN N
(CT) NNP N
attenuation NN N
values NNS N
of IN N
the DT N
intracranial JJ N
arterial NN N
and CC N
venous JJ N
systems NNS N
among IN N
the DT N
various JJ N
contrast NN N
injection NN N
protocols VBZ N
(higher JJR N
iodine JJ N
delivery NN N
rate NN N
or CC N
higher JJR N
concentration NN N
of IN N
the DT N
agent) NN N
on IN N
the DT N
source NN N
images NNS N
of IN N
intracranial JJ N
three-dimensional JJ N
CT NNP N
angiography NN N
(3D-CTA) NN N
using VBG N
a DT N
multidetector-row JJ N
CT NNP N
(MDCT) NNP N
scanner NN N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
We PRP N
used VBD N
100 CD N
ml NN N
of IN N
iopamidol JJ I
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NNS N
100 CD N
ml NN N
of IN N
iopamidol JJ I
300 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.7 CD N
ml/s NNS N
and CC N
80 CD N
ml NN N
of IN N
iopamidol JJ I
370 CD N
at IN N
an DT N
injection NN N
rate NN N
of IN N
3.0 CD N
ml/s NN N
. . N

There EX N
were VBD N
10 CD P
patients NNS P
in IN P
each DT P
group NN P
. . P

Attenuation NNP O
values NNS O
of IN O
the DT O
bilateral JJ O
internal JJ O
carotid NN O
arteries NNS O
(ICAs) VBP O
basilar JJ O
artery NN O
trunk NN O
bilateral JJ O
cavernous JJ O
sinuses NNS O
(CSs) VBP O
and CC O
Galenic NNP O
vein NNS O
were VBD N
measured VBN N
quantitatively RB N
on IN N
the DT N
axial JJ N
CT NNP N
angiographic JJ N
source NN N
images NNS N
obtained VBN N
by IN N
four-channel JJ O
MDCT NNP O
. . O

RESULTS NNP N
Injection NNP N
of IN N
the DT N
high-concentration NN N
contrast NN N
with IN N
a DT N
higher JJR N
iodine-delivery JJ N
rate NN N
achieved VBN N
good JJ N
arteriovenous JJ O
contrast NN O
at IN O
the DT O
cavernous JJ O
portion NN O
. . O

With IN N
the DT N
same JJ N
rate NN N
of IN N
iodine NN N
delivery NN N
injection NN N
of IN N
the DT N
intermediate JJ N
concentrate NN N
agent NN N
increased VBD N
the DT N
CT NNP O
value NN O
of IN N
not RB N
only RB N
the DT N
ICAs NNP N
but CC N
also RB N
the DT N
CSs NNP N
. . N

CONCLUSION NNP N
High-concentration NNP N
contrast NN N
could MD N
increase VB N
ICA NNP O
attenuation NN O
without IN N
intracavernous JJ O
attenuation NN O
gain NN N
during IN N
the DT N
"first-pass" JJ N
phase NN N
. . N

-DOCSTART- -X- O O

Preschoolers NNS P
acquire VB N
general JJ O
knowledge NN O
by IN N
sharing VBG N
in IN N
pretense NN I
. . I

Children NNP P
acquire VB N
general JJ O
knowledge NN O
about IN N
many JJ N
kinds NNS N
of IN N
things NNS N
but CC N
there EX N
are VBP N
few JJ N
known VBN N
means NNS N
by IN N
which WDT N
this DT N
knowledge NN N
is VBZ N
acquired VBN N
. . N

In IN N
this DT N
article NN N
it PRP N
is VBZ N
proposed VBN N
that IN N
children NNS P
acquire VB N
generic JJ O
knowledge NN O
by IN N
sharing VBG N
in IN N
pretend JJ I
play NN I
. . I

In IN N
Experiment JJ N
1 CD N
twenty-two JJ P
3- JJ P
to TO P
4-year-olds NNS P
watched VBN N
pretense NN I
in IN N
which WDT N
a DT N
puppet NN N
represented VBD N
a DT N
"nerp" JJ N
(an NN N
unfamiliar JJ N
kind NN N
of IN N
animal) NN N
. . N

For IN N
instance NN N
in IN N
one CD N
scenario NN N
the DT N
nerp JJ N
ate NN N
and CC N
disliked VBD N
a DT N
carrot NN N
. . N

When WRB N
subsequently RB N
asked VBD N
generic JJ N
questions NNS N
about IN N
real JJ N
nerps NNS N
children's VBP P
responses NNS O
suggested VBD N
that IN N
they PRP N
had VBD N
learned VBN N
general JJ N
facts NNS N
(e.g VBP N
. . N

nerps CC N
dislike JJ N
carrots) NN N
. . N

In IN N
Experiment JJ N
2 CD N
thirty-two JJ P
4- JJ P
to TO P
5-year-olds NNS P
learned VBN N
from IN N
scenarios NNS I
lacking VBG I
pretend JJ I
speech NN I
or CC I
sound JJ I
effects NNS I
. . I

The DT N
findings NNS N
reveal VBP N
a DT N
long JJ N
overlooked JJ N
means NNS N
by IN N
which WDT N
children NNS P
can MD N
acquire VB N
generic JJ O
knowledge NN O
. . O

-DOCSTART- -X- O O

[Efficacy NN O
of IN N
paliperidone NN I
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ O
functions NNS O
in IN N
schizophrenics: NN P
a DT N
randomized VBN N
and CC N
controlled VBN N
study] NN N
. . N

OBJECTIVE UH N
To TO N
explore VB N
the DT N
efficacy NN O
of IN N
paliperidone NN I
extended-release JJ N
tablets NNS N
in IN N
the DT N
improvement NN N
of IN N
social JJ O
functions NNS O
in IN N
schizophrenics NNS P
. . P

METHODS NNP N
A NNP P
total NN P
of IN P
81 CD P
schizophrenics NNS P
were VBD N
randomly RB N
divided VBN N
into IN N
study NN N
group NN N
with IN N
paliperidone NN I
extended-release JJ N
tablets NNS N
and CC N
control NN N
group NN N
with IN N
risperidone NN I
for IN N
a DT N
12-week JJ N
treatment NN N
. . N

They PRP N
were VBD N
assessed VBN N
and CC N
analyzed VBN N
by IN N
positive JJ O
and CC O
negative JJ O
symptoms NNS O
scales NNS O
(PANSS) VBP O
social JJ O
disability NN O
screening VBG O
schedule NN O
(SDSS) NN O
and CC O
treatment NN O
emergent NN O
symptom NN O
scale NN O
(TESS) NN O
at IN N
baseline NN N
6(th) CD N
weekend NN N
and CC N
12(th) CD N
weekend NN N
. . N

RESULTS NNP N
In IN N
study NN N
group NN N
the DT N
factors NNS O
and CC O
total JJ O
scores NNS O
of IN O
PANSS NNP O
in IN N
the DT N
12(th) CD N
weekend NN N
of IN N
treatment NN N
[(12.0 NNP N
± VBZ N
2.8) CD N
(12.1 NN N
± VBD N
3.6) CD N
(26.2 NNP N
± VBD N
5.0) CD N
(50.2 NNP N
± VBD N
8.7)] CD N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline JJ N
[(24.7 NNP N
± NNP N
5.3) CD N
(23.8 NNP N
± VBD N
3.6) CD N
(45.0 NNP N
± VBD N
2.9) CD N
(93.5 NNP N
± VBD N
6.8)] CD N
(t JJ N
= JJ N
9.60-16.78 JJ N
P NNP N
< NNP N
0.05) CD N
. . N

In IN N
study NN N
group NN O
the DT O
positive JJ O
factor NN O
negative JJ O
factor NN O
and CC O
total JJ O
scores NNS O
of IN O
PANSS NNP N
in IN N
the DT N
12(th) CD N
weekend NN N
of IN N
treatment NN N
[(12.0 NNP N
± VBZ N
2.8) CD N
(12.1 NN N
± VBD N
3.6) CD N
(50.2 NNP N
± VBD N
8.7)] CD N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6(th) CD N
weekend NN N
of IN N
treatment NN N
[(14.2 NNP N
± VBZ N
1.8) CD N
(14.6 NN N
± VBD N
2.4) CD N
(56.5 NNP N
± VBD N
6.4)] CD N
(t JJ N
= JJ N
2.58-4.26 JJ N
P NNP N
< NNP N
0.05) CD N
. . N

In IN N
the DT N
12(th) CD N
weekend NN N
of IN N
treatment NN O
the DT O
factors NNS O
and CC O
total JJ O
scores NNS O
of IN N
PANSS NNP N
in IN N
study NN N
group NN N
[(12.0 NNP N
± VBZ N
2.8) CD N
(12.1 NN N
± VBD N
3.6) CD N
(26.2 NNP N
± VBD N
5.0) CD N
(50.2 NNP N
± VBD N
8.7)] CD N
were VBD N
all DT N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
[(16.9 NNP N
± VBZ N
4.9) CD N
(18.7 NN N
± VBD N
5.3) CD N
(32.5 NNP N
± VBD N
5.1) CD N
(68.1 NNP N
± VBD N
13.0)] CD N
(t NNP N
= NNP N
-4.28--5.67 NNP N
P NNP N
< VBD N
0.05) CD N
. . N

In IN N
study NN O
group NN O
the DT O
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
the DT N
12(th) CD N
weekend NN N
of IN N
treatment NN N
(5.93 NNP N
± $ N
2.78) CD N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
at IN N
baseline JJ N
(13.9 NNP N
± NNP N
3.4) CD N
(t NNP N
= VBD N
10.83 CD N
P NNP N
< VBD N
0.05) CD N
. . N

In IN O
study NN O
group NN O
the DT O
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
the DT N
12(th) CD N
weekend NN N
of IN N
treatment NN N
(5.9 NNP N
± $ N
2.8) CD N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
the DT N
6(th) CD N
weekend NN N
of IN N
treatment NN N
(7.6 NNP N
± VBZ N
2.9) CD N
(t NN N
= VBD N
5.21 CD N
P NNP N
< VBD N
0.05) CD N
. . N

But CC N
there EX N
was VBD N
no DT N
significant JJ N
improvement NN N
in IN N
control NN N
group NN N
(t NNP N
= VBZ N
1.88 CD N
P NNP N
> VBD N
0.05) CD N
. . N

In IN N
the DT N
12(th) CD N
weekend NN O
of IN O
treatment NN O
the DT N
total JJ N
scores NNS N
of IN N
SDSS NNP N
in IN N
study NN N
group NN N
(5.9 NNP N
± VBZ N
2.8) CD N
were VBD N
significantly RB N
lower JJR N
than IN N
those DT N
in IN N
control NN N
group NN N
(8.8 NNP N
± VBZ N
2.9) CD O
(t NN O
= NNP O
-4.49 NNP O
P NNP O
< VBD O
0.05) CD O
. . N

No DT N
severe JJ N
adverse JJ N
effect NN N
was VBD N
reported VBN N
in IN I
either DT I
group NN I
. . N

CONCLUSION NNP N
Paliperidone NNP N
extended-release JJ O
tablets NNS O
are VBP O
effective JJ O
to TO N
improve VB O
social JJ O
functions NNS O
and CC P
psychiatric JJ P
symptoms NNS N
of IN N
schizophrenics NNS N
. . N

-DOCSTART- -X- O O

A DT N
controlled VBN N
study NN N
of IN N
psychiatric JJ I
hospital NN I
versus NN N
community NN I
treatment NN I
- : N
the DT N
effect NN O
on IN O
relatives NNS O
. . O

One CD P
hundred CD P
and CC P
twenty JJ P
patients NNS P
presenting VBG P
at IN P
Macquarie NNP P
Hospital NNP P
for IN P
admission NN P
were VBD N
randomly RB N
allocated VBN N
into IN N
two CD N
groups NNS N
. . N

The DT N
control NN N
group NN N
patients NNS N
received VBD N
standard JJ I
hospital NN I
care NN I
and CC I
follow-up NN I
. . I

The DT N
project NN N
group NN N
patients NNS N
were VBD N
not RB N
admitted VBN N
if IN N
this DT N
could MD N
be VB N
avoided; VBN N
instead RB N
they PRP N
were VBD N
taken VBN I
back RB I
to TO I
the DT I
community NN I
by IN N
the DT N
project NN N
team NN N
who WP N
provided VBD N
them PRP N
and CC N
their PRP$ N
relatives NNS N
with IN N
comprehensive JJ N
assertive NN N
and CC N
prolonged VBD N
follow-up JJ I
treatment NN I
backed VBN N
by IN N
a DT N
24-hour JJ N
crisis NN N
service NN N
. . N

The DT N
majority NN N
(63%) NN N
of IN N
the DT N
project NN N
group NN N
had VBD N
no DT N
admission NN O
during IN N
the DT N
10 CD N
month NN N
study NN N
period NN N
. . N

Initially RB N
the DT N
burden NN O
on IN O
the DT O
relatives NNS O
of IN N
the DT N
project NN N
group NN N
was VBD N
higher JJR N
but CC N
by IN N
one CD N
month NN N
it PRP N
was VBD N
somewhat RB N
lower JJR N
and CC N
by IN N
four CD N
months NNS N
it PRP N
was VBD N
significantly RB N
lower JJR N
than IN N
the DT N
burden NN O
on IN O
the DT O
control NN O
group NN O
relatives VBZ O
. . O

Relatives NNS N
of IN N
the DT N
project NN N
group NN N
patients NNS N
were VBD N
significantly RB N
more RBR N
satisfied JJ O
with IN N
the DT N
treatment NN N
than IN N
control NN N
group NN N
relatives VBZ N
. . N

It PRP N
is VBZ N
clearly RB N
feasible JJ N
to TO N
treat VB N
most JJS N
psychiatric JJ P
patients NNS P
in IN N
the DT N
community NN N
without IN N
increasing VBG N
the DT N
burden NN O
on IN O
their PRP$ O
relatives NNS O
. . O

-DOCSTART- -X- O O

Prospective JJ N
study NN N
of IN N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
gonadotropin-releasing JJ I
hormone NN I
agonist NN I
in IN N
an DT N
in IN P
vitro JJ P
fertilization NN P
program NN N
. . N

OBJECTIVE NNP N
To TO N
assess VB N
the DT N
usefulness NN O
of IN N
the DT N
ultrashort JJ N
regimen NNS N
of IN N
gonadotropin-releasing JJ I
hormone NN I
agonist JJ I
(GnRH-a) NN I
in IN N
ovulation NN N
induction NN N
in IN N
an DT N
in IN P
vitro JJ P
fertilization NN P
(IVF) NNP P
program NN N
. . N

DESIGN VB N
A DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
short JJ N
and CC N
ultrashort JJ N
regimens NNS N
of IN N
GnRH-a NNP I
. . I

SETTING NN N
Aberdeen NNP P
Assisted NNP P
Reproduction NNP P
Unit NNP P
. . P

PATIENTS NNP N
Forty-eight JJ P
patients NNS P
having VBG P
IVF NNP P
for IN P
the DT P
first JJ P
time NN P
were VBD N
randomized VBN N
between IN N
the DT N
two CD N
protocols NNS N
. . N

MAIN NNP N
OUTCOME NNP N
MEASURES NNP N
Response NNP O
to TO O
ovarian JJ O
stimulation NN O
and CC O
occurrence NN O
of IN O
spontaneous JJ O
luteinizing VBG O
hormone NN O
(LH) NN O
surges VBZ O
. . O

RESULTS NNP N
In IN N
ovulation NN O
induction NN O
fertilization NN O
and CC O
pregnancy NN O
rates NNS O
the DT N
ultrashort JJ N
regimen NNS N
produces VBZ N
results NNS N
that WDT N
were VBD N
no DT N
different JJ N
to TO N
the DT N
short JJ N
regimen NNS N
but CC N
it PRP N
did VBD N
not RB N
always RB N
prevent VB N
an DT N
LH NNP O
surge NN O
. . O

CONCLUSION VB N
The DT N
ultrashort JJ N
regimen NNS N
can MD N
be VB N
a DT N
useful JJ N
alternative NN N
for IN N
ovarian JJ O
stimulation NN O
of IN N
patients NNS P
undergoing VBG P
IVF NNP P
. . P

-DOCSTART- -X- O O

[Neoton NN I
and CC N
thrombolytic JJ I
therapy NN I
of IN N
myocardial JJ P
infarction] NN P
. . N

AIM NNP N
To TO N
evaluate VB N
neoton JJ I
therapy NN N
effects NNS N
in IN N
acute JJ P
myocardial JJ P
infarction NN P
(MI) NN P
on IN N
systolic JJ O
function NN O
of IN O
the DT O
left JJ O
ventricle NN O
arrhythmia NN O
and CC O
clinical JJ O
symptoms NNS O
in IN N
patients NNS P
on IN P
thrombolytic JJ P
therapy NN P
(TLT) NN P
. . P

MATERIAL NNP N
AND NNP N
METHODS NNP N
106 CD P
males NNS P
with IN P
Q-MI NNP P
entered VBD P
the DT P
study NN P
. . P

47 CD N
received VBD N
treatment NN N
without IN N
TLT NNP I
and CC N
neoton $ I
30 CD N
patients NNS N
received VBD N
TLT NNP I
with IN N
streptokinase JJ I
preparations NNS N
29 CD N
patients NNS N
were VBD N
given VBN N
streptokinase JJ I
preparations NNS I
and CC N
neoton NN I
. . I

Left NNP O
ventricular JJ O
systolic JJ O
function NN O
was VBD O
measured VBN O
by IN O
echocardiography NN O
on IN N
day NN N
1 CD N
3 CD N
7 CD N
14 CD N
21 CD N
and CC N
28; CD N
arrhythmia NN O
was VBD O
analysed VBN O
at IN O
Holter NNP O
monitoring VBG O
in IN N
day NN N
1 CD N
and CC N
2 CD N
of IN N
MI NNP N
. . N

RESULTS NNP N
TLT NNP I
failed VBD N
to TO N
arrest VB N
progression NN N
of IN N
left JJ N
ventricular JJ N
dilation NN N
by IN N
the DT N
end NN N
of IN N
the DT N
hospital NN N
stay NN N
. . N

Patients NNS N
given VBN N
neoton NNS I
in IN N
acute JJ N
period NN N
of IN N
MI NNP N
had VBD N
no DT N
increase NN N
in IN N
the DT N
end NN N
systolic NN O
and CC O
diastolic JJ O
volumes NNS O
of IN N
the DT N
left JJ N
ventricle NN N
in IN N
the DT N
course NN N
of IN N
the DT N
first JJ N
months NNS N
after IN N
MI NNP N
onset NN N
. . N

Antiarrhythmic NNP N
action NN N
of IN N
neoton NN I
manifested VBN N
on IN N
MI NNP N
day NN N
2 CD N
. . N

CONCLUSION NNP N
Neoton NNP I
given VBN N
to TO N
MI NNP P
patients NNS P
receiving VBG P
TLT NNP P
prevents NNS N
progression NN N
of IN N
left JJ O
ventricular JJ O
systolic JJ O
dysfunction NN O
and CC N
establishment NN N
of IN N
predictors NNS N
of IN N
unfavourable JJ N
outcome NN N
. . N

-DOCSTART- -X- O O

Measurement NN N
of IN N
transfer NN N
factor NN N
during IN N
constant JJ N
exhalation NN N
. . N

BACKGROUND NNP N
Transfer NNP I
factor NN I
of IN I
the DT I
lung NN I
for IN I
carbon NN I
monoxide NN I
(TLCO) NNP O
was VBD N
measured VBN N
by IN N
a DT N
new JJ N
method NN N
based VBN N
on IN N
analysis NN N
of IN N
the DT N
ratio NN O
of IN O
the DT O
concentrations NNS O
of IN O
carbon NN O
monoxide NN O
to TO N
an DT N
inert NN N
gas NN N
(methane) NNP N
relative NN N
to TO N
lung NN N
volume NN N
during IN N
a DT N
constant JJ N
exhalation NN N
. . N

Since IN N
this DT N
new JJ N
technique NN N
is VBZ N
based VBN N
solely RB N
upon JJ N
exhalation NN N
anomalies NNS N
associated VBN N
with IN N
inspiration NN N
and CC N
breath NN N
holding VBG N
do VBP N
not RB N
affect VB N
results NNS N
. . N

Additionally RB N
because IN N
prolonged JJ N
breath NN N
holding NN N
is VBZ N
not RB N
required JJ N
measurements NNS N
can MD N
readily RB N
be VB N
made VBN N
in IN N
dyspnoeic JJ P
patients NNS P
. . P

METHODS NNP N
Exhalation NNP O
TLCO NNP I
(TLCO NNP I
ex) NN O
was VBD N
compared VBN N
with IN N
the DT N
standard JJ I
(Jones NNS I
and CC I
Meade) NNP I
10 CD O
second JJ O
breath NN O
holding VBG O
TLCO NNP I
(TLCO NNP I
bh) NN O
in IN N
100 CD P
consecutive JJ P
patients NNS P
. . P

Patients NNS N
did VBD N
not RB N
practise VB N
the DT N
exhalation NN N
manoeuvre NN N
prior RB N
to TO N
testing VBG N
. . N

RESULTS VB N
The DT N
comparative JJ N
results NNS N
were VBD N
very RB N
close; JJ N
mean NN N
difference NN N
(bias) NNP N
+/- JJ N
standard NN N
deviation NN N
(precision) NNP N
was VBD N
0.05 CD N
(0.84) JJ N
mmol/min/kPa NN N
. . N

The DT N
relation NN N
was VBD N
equally RB N
strong JJ N
in IN N
patients NNS P
with IN P
severe JJ P
pulmonary JJ P
disease; NN P
for IN N
patients NNS N
with IN N
FEV1 NNP N
< $ N
1.51 CD N
the DT N
mean NN N
difference NN N
was VBD N
0.21 CD N
(0.80) JJ N
mmol/min/kPa NN N
. . N

CONCLUSIONS NNP N
Since IN N
the DT N
results NNS N
were VBD N
essentially RB N
identical JJ N
between IN N
the DT N
techniques NNS N
it PRP N
seems VBZ N
that IN N
comparable JJ N
pathophysiological JJ N
factors NNS N
affect VBP N
TLCO NNP I
during IN N
breath NN N
holding NN N
and CC N
constant JJ N
exhalation NN N
. . N

Constant JJ N
exhalation NN N
may MD N
therefore RB N
be VB N
a DT N
useful JJ N
alternative NN N
to TO N
the DT N
breath NN N
holding NN N
technique NN N
for IN N
clinical JJ O
measurement NN O
of IN O
TLCO NNP I
. . I

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
four CD N
different JJ N
irrigation NN N
systems NNS N
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
. . N

OBJECTIVES CC N
The DT N
aim NN N
of IN N
this DT N
study NN N
was VBD N
to TO N
compare VB N
the DT N
efficiency NN O
of IN N
sonic JJ I
ultrasonic JJ I
and CC I
hydrodynamic JJ I
devices NNS I
in IN N
the DT N
removal NN N
of IN N
a DT N
root JJ N
canal JJ N
sealer NN N
from IN N
the DT N
surface NN N
and CC N
from IN N
simulated JJ N
irregularities NNS N
of IN N
root NN N
canals NNS N
. . N

MATERIALS NNP N
AND CC N
METHODS NNP N
Fifty-three NNP P
root NN P
canals NNS P
with IN N
two CD N
standardized JJ N
grooves NNS N
in IN N
the DT N
apical JJ N
and CC N
coronal JJ N
parts NNS N
of IN N
longitudinally RB N
split VBN N
roots NNS N
were VBD N
covered VBN N
with IN N
AH NNP N
Plus NNP N
root VBP N
canal JJ N
sealer NN N
. . N

Compared VBN N
were VBD N
the DT N
effects NNS N
of IN N
(control) JJ N
syringe NN I
irrigation NN I
(1) NNP N
CanalBrush NNP I
(2) NNP N
passive JJ I
ultrasonic JJ I
irrigation NN I
(3) NNP N
EndoActivator NNP I
and CC N
(4) NNP N
RinsEndo NNP I
on IN N
the DT N
removal NN N
of IN N
the DT N
sealer NN N
. . N

The DT N
specimens NNS N
were VBD N
divided VBN N
into IN N
four CD N
groups NNS N
(N = 12) RB N
and CC N
one CD N
control NN N
group NN N
(N = 5) NNP N
via IN N
randomization NN O
. . O

The DT O
amount NN O
of IN O
remaining VBG O
sealer NN O
in IN O
the DT O
root NN O
canal JJ O
irregularities NNS O
was VBD O
evaluated VBN O
under IN O
a DT O
microscope NN O
using VBG O
a DT O
4-grade JJ O
scoring NN O
system NN N
whereas IN O
the DT O
remaining VBG O
sealer NN O
on IN O
the DT O
root NN O
canal JJ O
surface NN O
was VBD O
evaluated VBN O
with IN O
a DT O
7-grade JJ O
scoring NN O
system NN N
. . N

RESULTS NNP I
Passive NNP I
ultrasonic JJ I
irrigation NN I
is VBZ N
more RBR N
effective JJ N
than IN N
the DT N
other JJ I
tested JJ I
irrigation NN I
systems NNS I
or CC I
syringe JJ I
irrigation NN I
in IN O
removing VBG O
sealer NN O
from IN O
root JJ O
canal JJ O
walls NNS N
(p < 0.01) VBP N
. . N

None NN N
of IN N
the DT N
techniques NNS N
had VBD N
a DT N
significant JJ O
effect NN O
on IN O
cleaning VBG O
the DT O
lateral JJ O
grooves NNS N
. . N

CONCLUSIONS NNP N
Within IN N
the DT N
limitations NNS N
of IN N
this DT N
study NN I
protocol VBZ I
ultrasonic JJ I
irrigation NN N
shows VBZ N
a DT N
superior JJ O
effect NN O
on IN O
sealer NN O
removal NN O
from IN O
the DT O
root NN O
canal JJ O
surface NN N
during IN N
endodontic JJ N
retreatment NN N
. . N

Cleaning NN N
of IN N
lateral JJ N
grooves NNS N
seems VBZ N
not RB N
to TO N
be VB N
possible JJ N
with IN N
one CD N
of IN N
the DT N
techniques NNS N
investigated VBN N
. . N

CLINICAL JJ N
RELEVANCE NNP O
Incomplete NNP O
removal NN O
of IN O
root JJ O
canal JJ O
sealer NN N
during IN N
re-treatment NN N
may MD N
cause VB N
treatment NN I
failure NN I
. . I

Passive NNP I
Ultrasonic NNP I
irrigation NN N
seems VBZ N
to TO N
be VB N
the DT N
most RBS N
effective JJ O
system NN O
to TO O
remove VB O
sealer NN O
from IN O
a DT O
root NN N
canal NN N
. . N

-DOCSTART- -X- O O

Identifying VBG O
patients NNS O
at IN O
high JJ O
risk NN O
for IN O
neutropenic JJ O
complications NNS O
during IN N
chemotherapy NN P
for IN P
metastatic JJ P
breast NN P
cancer NN P
with IN N
doxorubicin NN I
or CC N
pegylated VBN I
liposomal JJ I
doxorubicin: NN I
the DT N
development NN N
of IN N
a DT N
prediction NN N
model NN N
. . N

OBJECTIVE UH N
To TO N
develop VB N
a DT N
cycle-based JJ O
risk NN O
prediction NN O
model NN O
for IN O
neutropenic JJ O
complications NNS O
(NC) VBP O
during IN N
chemotherapy NN N
with IN N
doxorubicin JJ I
(DOX) NN I
or CC N
a DT N
pegylated JJ I
liposomal JJ I
formulation NN I
(PLD) NN I
for IN N
patients NNS P
with IN P
metastatic JJ P
breast NN P
cancer NN P
(MBC) NNP P
. . P

METHODS NNP N
Data NNP N
analyzed VBD N
was VBD N
from IN N
a DT N
phase NN N
III NNP N
randomized VBD N
clinical JJ N
trial NN N
of IN N
DOX NNP I
(60 NNP N
mg/m(2) NN N
every DT N
3 CD N
weeks) NN N
or CC N
PLD NNP I
(50 NNP N
mg/m(2) NN N
every DT N
4 CD N
weeks) NN N
for IN N
the DT N
first JJ N
line NN N
therapy NN N
for IN N
MBC NNP P
(n NNP P
= VBD P
509) CD P
(O'Brien NNP N
et FW N
al NN N
Ann NNP N
Oncol NNP N
. . N

2004;15:440-449) JJ N
. . N

NC NNP O
were VBD N
defined VBN N
as IN N
an DT N
absolute NN O
neutrophil NN O
count NN O
< NNP O
or CC O
=1.5 NNP O
x VBP O
10(9) CD O
cells/L JJ O
(ie NNP O
> NN O
or CC O
=grade VB O
II) NNP O
before IN O
the DT O
next JJ O
cycle NN O
febrile JJ O
neutropenia NN O
or CC O
neutropenia NN O
with IN O
a DT O
documented JJ O
infection NN O
. . O

Patient NNP O
and CC O
hematologic JJ O
factors NNS O
potentially RB O
associated VBN O
with IN O
NC NNP O
were VBD N
evaluated VBN N
. . N

Factors NNS N
with IN N
a DT N
P NNP N
value NN N
of IN N
< NNP N
or CC N
=0.25 NNP N
within IN N
a DT N
cycle NN N
were VBD N
included VBN N
in IN N
a DT N
generalized JJ N
estimating NN N
equations NNS N
regression NN N
model NN N
. . N

Using VBG N
backward JJ N
elimination NN N
we PRP N
derived VBD N
a DT N
risk NN O
scoring VBG O
algorithm JJ O
(range JJ N
0-63) NN N
from IN N
the DT N
final JJ N
reduced VBN N
model NN N
. . N

RESULTS NNP N
Risk NNP O
factors NNS O
retained VBD N
in IN N
the DT N
model NN N
included VBD N
poor JJ O
performance NN O
status NN O
absolute NN O
neutrophil NN O
count NN O
< NNP O
or CC O
=2.0 NNP O
x VBP O
10(9) CD O
cells/L NN O
in IN N
the DT N
previous JJ N
cycle NN N
the DT N
first JJ N
cycle NN N
of IN N
chemotherapy NN N
DOX NNP I
versus NN N
PLD NNP I
and CC N
advanced JJ N
age NN O
. . O

A DT N
precycle NN O
risk NN O
score NN O
from IN N
> NN N
or CC N
=25 NN N
to TO N
<40 VB N
for IN N
a DT N
given VBN N
patient NN N
was VBD N
identified VBN N
as IN N
being VBG N
the DT N
optimal JJ N
threshold NN N
for IN N
sensitivity NN N
(58.0%) NNP N
and CC N
specificity NN N
(78.7%) NNP N
. . N

Patients NNS N
with IN N
a DT N
score NN N
at IN N
or CC N
beyond IN N
this DT N
threshold NN N
would MD N
be VB N
considered VBN N
at IN N
high JJ N
risk NN O
for IN N
developing VBG N
NC NNP O
in IN N
later JJ N
cycles NNS N
. . N

CONCLUSION NNP N
The DT N
use NN N
of IN N
this DT N
model NN N
may MD N
enhance VB N
patient NN N
care NN N
by IN N
targeting VBG N
preventative JJ N
therapies NNS N
(eg VBP N
granulocyte JJ N
colony NN N
stimulating VBG N
factor NN N
or CC N
PLD) NNP I
to TO N
those DT N
MBC NNP P
patients NNS P
most RBS N
likely JJ N
to TO N
experience VB N
NC NNP O
during IN N
anthracycline-based JJ N
chemotherapy NN N
. . N

-DOCSTART- -X- O O

A DT N
double-blind JJ N
placebo-controlled JJ N
study NN N
of IN N
fluvoxamine NN I
in IN N
adults NNS P
with IN P
autistic JJ P
disorder NN P
. . P

BACKGROUND NNP N
Autistic NNP P
disorder NN P
is VBZ N
characterized VBN N
by IN N
a DT N
fundamental JJ N
disturbance NN N
in IN N
social JJ O
interaction NN O
impairments NNS O
in IN O
communication NN O
and CC N
a DT N
markedly RB N
restricted JJ O
repertoire NN O
of IN O
activities NNS O
and CC O
interests NNS O
. . O

Abnormalities NNS N
in IN N
the DT N
serotonin NN N
neurotransmitter NN N
system NN N
have VBP N
been VBN N
identified VBN N
in IN N
some DT N
persons NNS N
with IN N
autism NN P
. . P

No DT N
consistently RB N
effective JJ N
and CC N
safe JJ N
drugs NNS N
have VBP N
been VBN N
developed VBN N
for IN N
treating VBG N
the DT N
symptoms NNS N
of IN N
autism NN P
. . P

METHODS NNP N
Thirty NNP P
adults NNS P
with IN P
autistic JJ P
disorder NN P
completed VBD N
a DT N
12-week JJ N
double-blind JJ N
placebo-controlled JJ I
trial NN N
of IN N
the DT N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitor NN N
fluvoxamine NN I
maleate NN I
. . I

Behavioral JJ N
ratings NNS N
were VBD N
obtained VBN N
at IN N
baseline NN N
and CC N
after IN N
4 CD N
8 CD N
and CC N
12 CD N
weeks NNS N
of IN N
treatment NN N
. . N

RESULTS NNP N
Eight NNP N
(53%) NNP N
of IN N
15 CD N
patients NNS N
in IN N
the DT N
fluvoxamine-treated JJ I
group NN N
were VBD N
categorized VBN N
as IN N
responders NNS N
compared VBN N
with IN N
none NN N
of IN N
15 CD N
in IN N
the DT N
placebo NN I
group NN N
(P NNP N
= NNP N
.001) NNP N
. . N

Fluvoxamine NNP I
was VBD N
superior JJ N
to TO N
placebo VB I
in IN N
reducing VBG N
repetitive JJ O
thoughts NNS O
and CC O
behavior JJ O
(P NNP N
< NNP N
.001) NNP N
maladaptive JJ O
behavior NN O
(P NNP N
< NNP N
.001) NNP N
and CC N
aggression NN O
(P NNP N
< NNP N
.03) NNP N
and CC N
in IN N
improving VBG N
some DT N
aspects NNS N
of IN N
social JJ O
relatedness NN O
(P NNP N
< NNP N
.04) NNP N
especially RB N
language NN O
usage JJ O
(P NNP N
< NNP N
.008) NNP N
. . N

Treatment NNP O
response NN O
was VBD N
not RB N
correlated VBN N
with IN N
age NN N
level NN N
of IN N
autistic JJ N
behavior NN N
or CC N
full-scale JJ N
IQ NNP N
. . N

Other JJ N
than IN N
mild JJ O
sedation NN O
and CC N
nausea NN O
in IN N
a DT N
few JJ N
patients NNS N
fluvoxamine NN I
was VBD N
well RB N
tolerated VBN N
. . N

No DT N
dyskinesias JJ O
adverse JJ O
cardiovascular JJ O
events NNS O
or CC N
seizures NNS O
occurred VBD N
. . N

CONCLUSIONS NNP N
Fluvoxamine NNP I
is VBZ N
more RBR N
effective JJ O
than IN N
placebo NN I
in IN N
the DT N
short-term JJ N
treatment NN N
of IN N
the DT N
symptoms NNS N
of IN N
autistic JJ P
disorder NN P
in IN P
adults NNS P
. . P

Controlled JJ N
studies NNS N
of IN N
fluvoxamine NN I
and CC N
other JJ N
potent NN N
and CC N
selective JJ N
serotonin NN N
uptake JJ N
inhibitors NNS N
seem VBP N
warranted VBN N
in IN N
children NNS N
and CC N
adolescents NNS N
with IN N
autism NN N
. . N

-DOCSTART- -X- O O

Effectiveness NN O
of IN N
hygienic-dietary JJ I
recommendations NNS I
as IN N
enhancers NNS N
of IN N
antidepressant JJ N
treatment NN N
in IN N
patients NNS P
with IN P
depression: NN P
study NN N
protocol NN N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
. . N

BACKGROUND NNP N
In IN N
recent JJ N
years NNS N
some DT N
studies NNS N
have VBP N
been VBN N
published VBN N
supporting VBG N
the DT N
efficacy NN O
of IN N
light JJ N
exposure JJ N
physical JJ N
activity NN N
sleep NN N
control NN N
and CC N
a DT N
Mediterranean NNP N
diet JJ N
pattern NN N
on IN N
the DT N
improvement NN N
or CC N
prevention NN N
of IN N
depression NN P
. . P

However RB N
to TO N
our PRP$ N
knowledge NN N
there RB N
have VBP N
been VBN N
no DT N
studies NNS N
using VBG N
all PDT N
these DT N
measures NNS N
together RB N
as IN N
an DT N
adjuvant JJ N
antidepressant NN N
strategy NN N
. . N

METHODS NNP N
Multicenter NNP N
randomized VBD N
controlled VBN N
two CD N
arm-parallel JJ N
clinical JJ N
trial NN N
. . N

Eighty NNP P
depressed VBD P
patients NNS P
undergoing VBG P
standard JJ P
antidepressant JJ P
treatment NN P
will MD N
be VB N
advised VBN N
to TO N
follow VB N
four CD N
additional JJ N
hygienic-dietary JJ I
recommendations NNS I
about IN N
exercise NN N
diet JJ N
sunlight NN N
exposure NN N
and CC N
sleep NN N
. . N

Outcome NNP O
measures NNS O
will MD N
be VB N
assessed VBN N
before IN N
and CC N
after IN N
the DT N
6 CD N
month NN N
intervention NN N
period NN N
. . N

DISCUSSION NNP N
We PRP N
expect VBP N
the DT N
patients NNS N
in IN N
the DT N
active JJ N
recommendations NNS N
group NN N
to TO N
experience VB N
a DT N
greater JJR N
improvement NN N
in IN N
their PRP$ N
depressive NN O
symptoms NNS O
. . O

If IN N
so IN N
this DT N
would MD N
be VB N
a DT N
great JJ N
support NN N
for IN N
doctors NNS N
who WP N
might MD N
systematically RB N
recommend VB N
these DT N
simple JJ N
and CC N
costless JJ N
measures NNS N
especially RB N
in IN N
primary JJ N
care NN N
. . N

TRIAL NNP N
REGISTRATION NNP N
ISRCTN59506583 NNP N
. . N

-DOCSTART- -X- O O

Feasibility NN O
of IN N
two CD N
dose-dense JJ N
FEC NNP I
regimens VBZ N
with IN N
growth NN N
factor NN N
support NN N
for IN N
adjuvant JJ N
therapy NN N
in IN N
patients NNS P
with IN P
early JJ P
breast NN P
cancer: NN P
results NNS N
from IN N
a DT N
randomised JJ N
study NN N
of IN N
the DT N
Central NNP N
European NNP P
Cooperative NNP N
Oncology NNP N
Group NNP N
(CECOG) NNP N
. . N

Addition NNP N
of IN N
epirubicin NN I
to TO N
adjuvant VB N
chemotherapy NN N
can MD N
provide VB N
important JJ N
benefits NNS N
for IN N
patients NNS P
with IN P
early JJ P
breast NN P
cancer NN P
but CC N
the DT N
optimal JJ N
dose NN N
remains VBZ N
unclear JJ N
. . N

Further JJ N
improvements NNS N
can MD N
be VB N
achieved VBN N
with IN N
dose-dense JJ N
regimens NNS N
but CC N
densification NN N
of IN N
fluorouracil/epirubicin/cyclophosphamide NN I
(FEC) NNP I
has VBZ N
proved VBN N
difficult JJ N
with IN N
FEC(60) NNP I
providing VBG N
little JJ N
benefit NN N
over IN N
standard JJ N
chemotherapy NN N
and CC N
FEC(100) NNP I
associated VBD N
with IN N
toxicity NN N
. . N

We PRP N
investigated VBD N
the DT N
feasibility NN O
of IN N
two CD N
intermediate JJ N
dose-dense JJ N
FEC NNP I
regimens NNS N
. . N

Patients NNS N
were VBD N
randomised VBN N
to TO N
six CD N
cycles NNS N
of IN N
FEC(75) NNP I
or CC N
FEC(90) NNP I
with IN N
all DT N
three CD N
drugs NNS N
given VBN N
on IN N
day NN N
1 CD N
of IN N
each DT N
14-day JJ N
cycle NN N
. . N

Patients NNS N
also RB N
received VBD N
pegfilgrastim JJ I
6 CD N
mg NN N
as IN N
a DT N
single JJ N
subcutaneous JJ N
injection NN N
on IN N
day NN N
2 CD N
of IN N
each DT N
cycle NN N
. . N

The DT N
primary JJ N
efficacy NN O
endpoint NN N
was VBD N
the DT N
proportion NN O
of IN O
subjects NNS O
receiving VBG O
> NN O
or CC O
=85% JJ O
relative JJ O
dose NN O
intensity NN O
and CC N
was VBD N
achieved VBN N
by IN N
96% CD N
and CC N
88% CD N
of IN N
patients NNS N
in IN N
the DT N
FEC(75) NNP I
and CC N
FEC(90) NNP I
arms NNS N
respectively RB N
. . N

Of IN N
147 CD N
FEC(75) NNP I
infusions NNS N
4.1% CD N
were VBD N
delayed VBN N
while IN N
9.8% CD N
of IN N
143 CD N
FEC(90) NNP I
infusions NNS N
were VBD N
delayed VBN N
. . N

The DT N
most RBS N
common JJ N
reasons NNS N
for IN N
delay NN N
were VBD N
adverse JJ O
events NNS O
and CC N
personal/logistical JJ N
reasons NNS N
. . N

One CD N
dose JJ N
reduction NN N
occurred VBD N
during IN N
the DT N
study NN N
(FEC(90)) NNP I
related VBD N
to TO N
diarrhoea VB O
. . O

Grade VB N
3-4 JJ N
haematological JJ O
toxicities NNS O
were VBD N
reported VBN N
in IN N
two CD N
patients NNS N
in IN N
the DT N
FEC(90) NNP I
arm NN N
. . N

There EX N
were VBD N
no DT N
incidences NNS N
of IN N
febrile JJ O
neutropenia NN O
during IN N
the DT N
study NN N
. . N

The DT N
most RBS N
common JJ N
adverse JJ O
events NNS O
were VBD N
increases NNS O
in IN O
liver NN O
enzymes NNS O
and CC O
gastrointestinal JJ O
events; NN O
no DT N
event NN N
resulted VBD N
in IN N
discontinuation NN N
. . N

Only RB N
one CD N
patient NN N
(FEC(90)) NN I
experienced VBD N
serious JJ O
adverse JJ O
events NNS O
(vomiting VBG O
and CC O
throat NN O
oedema) NN O
. . O

In IN N
conclusion NN N
dose-dense JJ N
FEC(75 NNP I
)and NNP N
FEC(90) NNP I
are VBP N
feasible JJ O
with IN N
pegfilgrastim JJ I
support NN N
. . N

These DT N
regimens NNS N
are VBP N
associated VBN N
with IN N
a DT N
very RB N
low JJ N
risk NN N
of IN N
Grade NNP N
3-4 JJ N
toxicity NN N
. . N

-DOCSTART- -X- O O

Economic JJ O
evaluation NN O
of IN N
aquatic JJ I
exercise NN I
for IN N
persons NNS P
with IN P
osteoarthritis NN P
. . P

OBJECTIVES NNP N
To TO N
estimate VB N
cost NN O
and CC O
outcomes NNS O
of IN N
the DT N
Arthritis NNP N
Foundation NNP N
aquatic JJ I
exercise NN I
classes NNS I
from IN N
the DT N
societal JJ N
perspective NN N
. . N

DESIGN NNP N
Randomized NNP N
trial NN N
of IN N
20-week JJ N
aquatic JJ I
classes NNS I
. . I

Cost NN O
per IN O
quality-adjusted JJ O
life NN O
year NN O
(QALY) NN O
gained VBD O
was VBD N
estimated VBN N
using VBG N
trial NN N
data NNS N
. . N

Sample NNP N
size NN N
was VBD N
based VBN N
on IN N
80% CD N
power NN N
to TO N
reject VB N
the DT N
null JJ N
hypothesis NN N
that IN N
the DT N
cost/QALY NN O
gained VBD O
would MD N
not RB N
exceed VB N
$50 RB N
000 CD N
. . N

SUBJECTS NNP N
AND NNP N
METHODS NNP N
Recruited VBD P
249 CD P
adults NNS P
from IN P
Washington NNP P
State NNP P
aged VBD P
55 CD P
to TO P
75 CD P
with IN P
a DT P
doctor-confirmed JJ P
diagnosis NN P
of IN P
osteoarthritis NN P
to TO P
participate VB P
in IN P
aquatic JJ P
classes NNS P
. . P

The DT N
Quality NN O
of IN O
Well-Being NNP O
Scale NNP O
(QWB) NNP O
and CC N
Current NNP O
Health NNP O
Desirability NNP O
Rating NNP O
(CHDR) NNP O
were VBD N
used VBN N
for IN N
economic JJ O
evaluation NN O
supplemented VBN N
by IN N
the DT N
arthritis-specific JJ O
Health NNP O
Assessment NNP O
Questionnaire NNP O
(HAQ) NNP O
Center NNP O
for IN O
Epidemiologic NNP O
Studies-Depression NNP O
Scale NNP O
(CES-D) NN O
and CC N
Perceived NNP O
Quality NNP O
of IN O
Life NNP O
Scale NNP O
(PQOL) NNP O
collected VBD N
at IN N
baseline NN N
and CC N
postclass NN N
. . N

Outcome NNP N
results NNS N
applied VBD N
to TO N
life NN O
expectancy NN O
tables NNS O
were VBD N
used VBN N
to TO N
estimate VB N
QALYs NNP O
. . O

Use NNP O
of IN O
health NN O
care NN O
facilities NNS O
was VBD N
assessed VBN N
from IN N
diaries/questionnaires NNS O
and CC N
Medicare NNP O
reimbursement NN O
rates NNS O
used VBD N
to TO N
estimate VB N
costs NNS O
. . O

Nonparametric NNP O
bootstrap NN O
sampling NN O
of IN O
costs/QALY NN O
ratios NNS O
established VBD N
the DT N
95% CD N
CI NNP N
around IN N
the DT N
estimates NNS N
. . N

RESULTS NNP N
Aquatic JJ I
exercisers NNS I
reported VBD N
equal JJ N
(QWB) NN O
or CC N
better JJR N
(CHDR NN O
HAQ NNP O
PQOL) NNP O
health-related JJ N
quality NN N
of IN N
life NN N
compared VBN N
with IN N
controls NNS N
. . N

Outcomes NNS N
improved VBN N
with IN N
regular JJ N
class NN N
attendance NN N
. . N

Costs/QALY NNP O
gained VBD N
discounted VBN N
at IN N
3% CD N
were VBD N
$205 JJ N
186 CD N
using VBG N
the DT N
QWB NNP O
and CC N
$32 $ N
643 CD N
using VBG N
the DT N
CHRD NNP O
. . O

CONCLUSION NNP N
Aquatic NNP I
exercise NN I
exceeded VBD N
$50 $ N
000 CD N
per IN N
QALY NN O
gained VBN O
using VBG N
the DT N
community-weighted JJ N
outcome NN N
but CC N
fell VBD N
below IN N
this DT N
arbitrary JJ N
budget NN N
constraint NN N
when WRB N
using VBG N
the DT N
participant-weighted JJ N
measure NN N
. . N

Confidence NN N
intervals NNS N
around IN N
these DT N
ratios NNS N
suggested VBD N
wide JJ N
variability NN N
of IN N
cost NN N
effectiveness NN N
of IN N
aquatic JJ I
exercise NN I
. . I

-DOCSTART- -X- O O

Effects NNS N
of IN N
individualized JJ I
breast NN I
cancer NN I
risk NN I
counseling: VBP I
a DT N
randomized JJ N
trial NN N
. . N

BACKGROUND NNP N
Studies NNPS N
have VBP N
shown VBN N
that IN N
a DT N
majority NN N
of IN N
women NNS P
with IN P
a DT P
family NN P
history NN P
of IN P
breast NN P
cancer NN P
have VBP N
exaggerated VBN N
perceptions NNS N
of IN N
their PRP$ N
own JJ N
risk NN N
of IN N
this DT N
disease NN N
and CC N
experience NN N
excessive JJ N
anxiety NN N
. . N

In IN N
response NN N
to TO N
the DT N
need NN N
to TO N
communicate VB N
more JJR N
accurate JJ N
risk NN N
information NN N
to TO N
these DT N
women NNS P
specialized VBD N
programs NNS N
for IN N
breast NN N
cancer NN N
risk NN N
counseling VBG N
have VBP N
been VBN N
initiated VBN N
in IN N
medical JJ N
centers NNS N
across IN N
the DT P
United NNP P
States NNPS P
. . P

PURPOSE VB N
Our PRP$ N
purpose NN N
was VBD N
1) CD N
to TO N
evaluate VB N
the DT N
impact NN N
of IN N
a DT N
standardized JJ N
protocol NN N
for IN N
individualized JJ I
breast NN I
cancer NN I
risk NN I
counseling VBG I
on IN N
comprehension NN N
of IN N
personal JJ N
risk NN N
among IN N
first-degree JJ P
relatives NNS P
of IN P
index NN P
breast NN P
cancer NN P
patients NNS P
and CC N
2) CD N
to TO N
identify VB N
women NNS N
most RBS N
and CC N
least JJS N
likely JJ N
to TO N
benefit VB O
from IN N
such JJ N
counseling NN I
. . I

METHODS NNP N
This DT N
study NN N
is VBZ N
a DT N
prospective JJ N
randomized VBN N
trial NN N
comparing VBG N
individualized VBN I
breast NN I
cancer NN I
risk NN I
counseling VBG I
to TO N
general JJ I
health NN I
counseling NN I
(control) NN I
. . I

We PRP N
studied VBD N
200 CD P
women NNS P
aged VBN P
35 CD P
years NNS P
and CC P
older JJR P
who WP P
had VBD P
a DT P
family NN P
history NN P
of IN P
breast NN P
cancer NN P
in IN P
a DT P
first-degree JJ P
relative NN P
. . P

Women NNS P
with IN P
a DT P
personal JJ P
history NN P
of IN P
cancer NN P
were VBD P
excluded VBN P
. . P

Risk NNP O
comprehension NN O
was VBD N
assessed VBN N
as IN N
the DT N
concordance NN O
between IN O
perceived VBN O
"subjective" NNP O
lifetime JJ O
breast NN O
cancer NN O
risk NN O
and CC O
estimated VBN O
"objective" NNP O
lifetime NN O
risk NN O
. . O

RESULTS VB N
The DT N
results NNS N
of IN N
logistic JJ N
regression NN N
analysis NN N
showed VBD N
that IN N
women NNS N
who WP N
received VBD N
risk NN I
counseling NN I
were VBD N
significantly RB N
more RBR N
likely JJ N
to TO N
improve VB N
their PRP$ N
risk NN O
comprehension NN O
compared VBN N
with IN N
women NNS N
in IN N
the DT N
control NN N
condition NN N
(odds NNP N
ratio NN N
[OR] NNP N
= VBD N
3.5; CD N
95% CD N
confidence NN N
interval NN N
[CI] NNP N
= NNP N
1.3-9.5; JJ N
P NNP N
= NNP N
.01) NNP N
. . N

However RB N
in IN N
both DT N
groups NNS N
about IN N
two CD N
thirds NNS N
of IN N
women NNS N
continued VBN N
to TO N
overestimate VB N
their PRP$ N
lifetime NN O
risks NNS O
substantially RB N
following VBG N
counseling VBG I
. . I

Examination NN N
of IN N
subjects NNS N
by IN N
treatment NN N
interaction NN N
effects NNS N
indicated VBD N
that IN N
risk NN I
counseling VBG I
did VBD N
not RB N
produce VB N
improved JJ N
comprehension NN O
among IN N
the DT N
large JJ N
proportion NN N
of IN N
women NNS N
who WP N
had VBD N
high JJ N
levels NNS N
of IN N
anxious JJ N
preoccupation NN N
with IN N
breast NN N
cancer NN N
at IN N
base NN N
line NN N
(P NNP N
= NNP N
.02) NNP N
. . N

In IN N
addition NN N
white JJ N
women NNS N
were VBD N
less RBR N
likely JJ N
to TO N
benefit VB N
than IN N
African-American JJ N
women NNS N
(OR VBD N
= JJ N
0.34; CD N
95% CD N
CI NNP N
= NNP N
0.11-0.99; JJ N
P NNP N
= NNP N
.05) NNP N
. . N

CONCLUSION NNP N
Efforts NNPS N
to TO N
counsel NN N
women NNS N
about IN N
their PRP$ N
breast NN N
cancer NN N
risks NNS N
are VBP N
not RB N
likely JJ N
to TO N
be VB N
effective JJ N
unless IN N
their PRP$ N
breast NN N
cancer NN N
anxieties NNS N
are VBP N
also RB N
addressed VBN N
. . N

IMPLICATIONS NNP N
Attention NNP N
to TO N
the DT N
psychological JJ N
aspects NNS N
of IN N
breast NN N
cancer NN N
risk NN N
will MD N
be VB N
critical JJ N
in IN N
the DT N
development NN N
of IN N
risk-counseling JJ I
programs NNS I
that WDT N
incorporate VBP N
testing VBG N
for IN N
the DT N
recently RB N
cloned VBN N
breast NN N
cancer NN N
susceptibility NN N
gene NN N
BRCA1 NNP N
(and NNP N
BRCA2 NNP N
when WRB N
that DT N
gene NN N
has VBZ N
also RB N
been VBN N
cloned) NN N
. . N

-DOCSTART- -X- O O

Intervention NN N
to TO N
lower VB N
household NN P
wood NN P
smoke NN P
exposure NN P
in IN N
Guatemala NNP P
reduces NNS N
ST-segment NNP O
depression NN O
on IN N
electrocardiograms NNS N
. . N

BACKGROUND VB N
A DT N
large JJ N
body NN N
of IN N
evidence NN N
suggests VBZ N
that IN N
fine JJ N
particulate NN N
matter NN N
(PM) NNP N
air NN N
pollution NN N
is VBZ N
a DT N
cause NN N
of IN N
cardiovascular JJ N
disease NN N
but CC N
little JJ N
is VBZ N
known VBN N
in IN N
particular JJ N
about IN N
the DT N
cardiovascular JJ N
effects NNS N
of IN N
indoor JJ N
air NN N
pollution NN N
from IN N
household NN N
use NN N
of IN N
solid JJ N
fuels NNS N
in IN N
developing VBG N
countries NNS N
. . N

RESPIRE NNP N
(Randomized VBD N
Exposure NNP N
Study NNP N
of IN N
Pollution NNP N
Indoors NNP N
and CC N
Respiratory NNP N
Effects) NNP N
was VBD N
a DT N
randomized JJ N
trial NN N
of IN N
a DT N
chimney NN I
woodstove NN I
that WDT N
reduces VBZ N
wood NN N
smoke NN N
exposure NN N
. . N

OBJECTIVES IN N
We PRP N
tested VBD N
the DT N
hypotheses NNS N
that IN N
the DT N
stove NN I
intervention NN I
compared VBN N
with IN N
open JJ I
fire NN I
use NN N
would MD N
reduce VB N
ST-segment NNP O
depression NN O
and CC N
increase VB N
heart NN O
rate NN O
variability NN O
(HRV) NNP O
. . O

METHODS NNP N
We PRP N
used VBD N
two CD N
complementary JJ N
study NN N
designs: VBD N
a) JJ N
between-groups JJ N
comparisons NNS N
based VBN N
on IN N
randomized JJ N
stove JJ I
assignment NN N
and CC N
b) JJ N
before-and-after NN N
comparisons NNS N
within IN N
control NN N
subjects NNS N
who WP N
used VBD N
open JJ I
fires NNS I
during IN N
the DT N
trial NN N
and CC N
received VBD N
chimney NN I
stoves NNS I
after IN N
the DT N
trial NN N
. . N

Electrocardiogram NNP O
sessions NNS O
that WDT N
lasted VBD N
20 CD N
hr NNS N
were VBD N
repeated VBN N
up RP N
to TO N
three CD N
times NNS N
among IN N
49 CD P
intervention NN P
and CC P
70 CD P
control NN P
women NNS P
38-84 CD P
years NNS P
of IN P
age NN P
and CC P
55 CD P
control NN P
subjects NNS P
were VBD P
also RB P
assessed VBN P
after IN P
receiving VBG P
stoves NNS P
. . P

HRV NNP O
and CC O
ST-segment JJ O
values NNS O
were VBD N
assessed VBN N
for IN N
each DT N
30-min JJ N
period NN N
. . N

ST-segment JJ O
depression NN O
was VBD O
defined VBN O
as IN O
an DT O
average JJ O
value NN O
below IN O
-1.00 NNP O
mm NN O
. . O

Personal JJ O
fine JJ O
PM NNP O
[aerodynamic NNP O
diameter NN O
≤ VBD O
2.5 CD O
μm NNP O
(PM₂.₅] NN O
exposures NNS O
were VBD N
measured VBN N
for IN N
24 CD N
hr NN N
before IN O
each DT O
electrocardiogram NN O
. . N

RESULTS NNP O
PM₂.₅ NNP O
exposure NN N
means NNS N
were VBD N
266 CD N
and CC N
102 CD N
μg/m³ NN N
during IN N
the DT N
trial NN N
period NN N
in IN N
the DT N
control NN N
and CC N
intervention NN N
groups NNS N
respectively RB N
. . N

During IN N
the DT I
trial NN I
the DT I
stove NN I
intervention NN N
was VBD N
associated VBN N
with IN N
an DT N
odds NNS N
ratio NN N
of IN N
0.26 CD N
(95% JJ N
confidence NN N
interval JJ N
0.08-0.90) JJ O
for IN O
ST-segment JJ O
depression NN N
. . N

We PRP N
found VBD N
similar JJ N
associations NNS N
with IN N
the DT N
before-and-after JJ N
comparison NN N
. . N

The DT N
intervention NN N
was VBD N
not RB N
significantly RB N
associated VBN O
with IN N
HRV NNP N
. . N

CONCLUSIONS NNP I
The DT I
stove NN I
intervention NN N
was VBD N
associated VBN N
with IN N
reduced JJ N
occurrence NN N
of IN O
nonspecific JJ O
ST-segment JJ O
depression NN N
suggesting VBG N
that IN N
household NN N
wood NN N
smoke NN N
exposures NNS N
affect VBP N
ventricular JJ N
repolarization NN N
and CC N
potentially RB N
cardiovascular JJ N
health NN N
. . N

-DOCSTART- -X- O O

Training VBG N
referential JJ I
communicative JJ I
skills NNS I
to TO N
individuals NNS P
with IN P
autism NN P
spectrum NN P
disorder: VBZ P
a DT N
pilot NN N
study NN N
. . N

The DT N
present JJ N
study NN N
reports VBZ N
the DT N
effects NNS N
of IN N
referential JJ I
communication NN I
training NN I
in IN N
individuals NNS P
formally RB P
diagnosed VBN P
with IN P
autism NN P
spectrum NN P
disorder NN P
(ASD) NNP P
. . P

Participants NNS N
were VBD N
20 CD P
children NNS P
with IN P
ASD NNP P
(M NNP P
age NN P
= VBD P
14.3 CD P
yr NN P
. . P

SD NNP P
= VBD P
4.2; CD P
6 CD P
girls NNS P
14 CD P
boys) NN P
in IN P
the DT P
role NN P
of IN P
speakers NNS P
and CC P
20 CD P
control NN P
children NNS P
who WP P
acted VBD P
as IN P
listeners NNS P
. . P

They PRP N
were VBD N
all DT N
enrolled VBN N
in IN N
mainstream JJ N
compulsory NN N
education NN N
. . N

Inclusion/exclusion NNP P
criteria NNS P
were VBD P
defined VBN P
according VBG P
to TO P
the DT P
clinical JJ P
diagnosis NN P
of IN P
ASD NNP P
the DT P
presence NN P
or CC P
absence NN P
of IN P
additional JJ P
or CC P
associated VBN P
disability NN P
previous JJ P
training NN P
in IN P
referential JJ P
communication NN P
and CC P
any DT P
drug NN P
treatment NN P
. . P

Speakers NNS N
were VBD N
randomly RB N
assigned VBN N
to TO N
one CD N
of IN N
two CD N
groups NNS N
(trained VBD N
vs JJ N
untrained) NN N
. . N

Linguistic JJ O
age NN O
cognitive JJ O
level NN O
and CC O
autistic JJ O
symptoms NNS O
were VBD N
analyzed VBN N
respectively RB N
with IN N
the DT N
Peabody NNP O
Picture NNP O
Vocabulary NNP O
Test NNP O
(PPVT) VBD O
the DT O
Wechsler NNP O
Intelligence NNP O
Scale NNP O
(WISC-R JJ O
or CC O
WAIS-III) JJ O
and CC O
the DT O
Autistic NNP O
Behavior NNP O
Checklist NNP O
(ABC) NNP O
. . O

Communicative JJ O
abilities NNS O
were VBD N
analyzed VBN N
through IN N
two CD N
indexes NNS O
related VBN O
to TO O
message VB O
complexity NN O
and CC O
self-regulation NN O
. . O

The DT N
trained JJ N
group NN N
was VBD N
trained VBN N
in IN N
referential JJ I
communication NN I
tasks NNS I
(task VBP I
analysis NN I
role NN I
taking NN I
and CC N
task NN I
evaluation) NN I
while IN N
the DT N
untrained JJ N
group NN N
took VBD N
part NN N
in IN N
a DT N
communicative JJ I
game NN I
but CC N
without IN N
any DT N
specific JJ N
communicative JJ N
training NN N
. . N

The DT N
results NNS N
showed VBD N
that IN N
the DT N
complexity NN O
of IN O
emitted JJ O
messages NNS O
had VBD N
improved VBN N
statistically RB N
significantly RB N
in IN N
the DT N
trained JJ N
group NN N
as IN N
an DT N
effect NN N
of IN N
training NN N
. . N

Ecological JJ N
referential JJ I
communication NN I
is VBZ N
shown VBN N
to TO N
be VB N
an DT N
appropriate JJ N
paradigm NN N
for IN N
studying VBG N
the DT N
communicative JJ N
process NN N
and CC N
its PRP$ N
products NNS N
and CC N
could MD N
be VB N
used VBN N
to TO N
develop VB N
and CC N
implement VB N
a DT N
training NN N
program NN N
focused VBN N
on IN N
those DT N
skills NNS N
in IN N
which WDT N
individuals NNS P
with IN P
ASD NNP P
are VBP N
most RBS N
deficient JJ N
. . N

-DOCSTART- -X- O O

The DT N
treatment NN N
of IN N
asthma NN P
in IN P
adults NNS P
using VBG N
sodium NN I
cromoglycate NN I
pressurized VBN N
aerosol: IN N
a DT N
double-blind NN N
controlled VBN N
trial NN N
. . N

Sodium NN I
cromoglycate NN I
formulated VBN N
as IN N
a DT N
pressurized JJ N
aerosol NN N
(2 NNP N
mg VBZ N
4-times JJ N
daily) NN N
and CC N
placebo NN I
were VBD N
compared VBN N
in IN N
31 CD P
adult NN P
asthmatic JJ P
patients NNS P
in IN N
a DT N
double-blind JJ N
crossover NN N
trial NN N
lasting VBG N
12 CD N
weeks NNS N
. . N

Sodium NNP I
cromoglycate NN I
was VBD N
superior JJ N
to TO N
placebo VB I
in IN N
improving VBG N
breathlessness NN O
at IN O
rest NN O
(p NN N
less JJR N
than IN N
0.001) CD N
breathlessness NN O
on IN O
exertion NN O
(p NNP N
less JJR N
than IN N
0.05) CD N
and CC N
the DT N
quality NN O
of IN O
sleep JJ O
(p NNP N
less JJR N
than IN N
0.001) CD N
and CC N
also RB N
in IN N
improving VBG N
the DT N
morning NN O
peak NN O
expiratory NN O
flow NN O
rate NN O
value NN O
(p NNP N
less JJR N
than IN N
0.05) CD N
. . N

Both CC N
the DT N
patients' NN N
(p NNP N
less JJR N
than IN N
0.05) CD N
and CC N
the DT N
clinicians' NN N
(p NNP N
less JJR N
than IN N
0.01) CD N
treatment NN O
opinions NNS O
and CC N
their PRP$ N
treatment NN O
preferences NNS O
(p RB N
less JJR N
than IN N
0.05) CD N
favoured JJ N
sodium NN I
cromoglycate NN I
. . I

Moreover RB N
usage NN N
of IN N
bronchodilators NNS N
(theophylline NNP N
and CC N
aerosol JJ N
beta-stimulants NNS N
combined) NN N
declined VBD N
significantly RB N
(p NNP N
less JJR N
than IN N
0.001) CD N
during IN N
sodium NN I
cromoglycate NN I
treatment NN N
compared VBN N
to TO N
placebo VB I
. . I

No DT N
side-effects NNS O
were VBD N
reported VBN N
. . N

The DT N
results NNS N
of IN N
this DT N
study NN N
show NN N
that IN N
sodium NN I
cromoglycate NN I
delivered VBN N
by IN N
pressurized JJ N
aerosol NN N
was VBD N
significantly RB N
superior JJ O
to TO N
placebo VB I
not RB N
only RB N
in IN N
improving VBG N
asthmatic JJ O
symptoms NNS O
but CC N
also RB N
in IN N
reducing VBG N
the DT N
amount NN N
of IN N
concomitant JJ N
bronchodilator NN O
therapy NN O
required VBN O
. . O

-DOCSTART- -X- O O

Language NNP O
outcome NN O
in IN N
autism: JJ P
randomized JJ N
comparison NN N
of IN N
joint JJ I
attention NN I
and CC N
play NN I
interventions NNS I
. . I

This DT N
study NN N
reports VBZ N
results NNS N
of IN N
a DT N
randomized VBN N
controlled VBN N
trial NN N
aimed VBN N
at IN N
joint JJ I
attention NN I
(JA) NN I
and CC N
symbolic JJ I
play NN I
(SP) NN I
in IN N
preschool JJ P
children NNS P
with IN P
autism NN P
with IN N
prediction NN N
to TO N
language NN O
outcome RB O
12 CD N
months NNS N
later RB N
. . N

Participants NNS P
were VBD P
58 CD P
children NNS P
(46 JJ P
boys) NN P
with IN P
autism NN P
between IN P
3 CD P
and CC P
4 CD P
years NNS P
of IN P
age NN P
. . P

Children NNP N
were VBD N
randomized VBN N
to TO N
a DT N
JA NNP I
intervention NN N
an DT N
SP NNP I
intervention NN N
or CC N
control NN N
group NN N
. . N

Interventions NNS N
were VBD N
conducted VBN N
30 CD N
min JJ N
daily JJ N
for IN N
5-6 JJ N
weeks NNS N
. . N

Assessments NNS N
of IN N
JA NNP I
skills NNS O
SP NNP I
skills VBZ O
mother-child JJ O
interactions NNS O
and CC O
language NN O
development NN O
were VBD N
collected VBN N
at IN N
4 CD N
time NN N
points: JJ N
pre- JJ N
and CC N
postintervention NN N
and CC N
6 CD N
and CC N
12 CD N
months NNS N
postintervention NN N
by IN N
independent JJ N
testers NNS N
. . N

Results NNS N
indicate VBP N
that IN N
expressive JJ O
language NN O
gains NNS O
were VBD N
greater JJR N
for IN N
both DT N
treatment NN N
groups NNS N
compared VBN N
with IN N
the DT N
control NN N
group NN N
and CC N
results NNS N
could MD N
not RB N
be VB N
explained VBN N
by IN N
differences NNS N
in IN N
other JJ N
interventions NNS N
in IN N
which WDT N
children NNS N
participated VBD N
. . N

For IN N
children NNS P
beginning VBG N
treatment NN N
with IN N
the DT N
lowest JJS N
language NN N
levels NNS N
the DT N
JA NNP I
intervention NN N
improved VBD N
language NN O
outcome NN O
significantly RB N
more RBR N
than IN N
did VBD N
the DT N
SP NNP I
or CC N
control VB N
interventions NNS N
. . N

These DT N
findings NNS N
suggest VBP N
clinically RB N
significant JJ N
benefits NNS N
of IN N
actively RB N
treating VBG N
JA NNP I
and CC N
SP NNP I
skills NNS N
in IN N
young JJ P
children NNS P
with IN P
autism NN P
. . P

-DOCSTART- -X- O O

Effects NNS N
of IN N
guided JJ N
imagery NN N
with IN N
relaxation NN I
training NN I
on IN N
anxiety NN O
and CC N
quality NN O
of IN O
life NN O
among IN N
patients NNS P
with IN P
inflammatory JJ P
bowel NN P
disease NN P
. . P

BACKGROUND NNP N
Inflammatory NNP P
Bowel NNP P
Disease NNP P
(IBD) NNP P
impacts VBZ N
quality NN O
of IN O
life NN O
(QoL) NNP O
. . O

Psychological JJ N
factors NNS N
influence VBP N
the DT N
course NN N
of IN N
the DT N
disease NN N
and CC N
should MD N
be VB N
targeted VBN N
for IN N
intervention NN N
. . N

METHODS NNP N
Our PRP$ N
study NN N
was VBD N
a DT N
prospective JJ N
randomised VBN N
control NN N
trial NN N
. . N

Fifty-six JJ P
outpatients NNS P
were VBD N
randomly RB N
chosen VBN N
and CC N
allocated VBN N
to TO N
a DT N
treatment NN N
group NN N
or CC N
a DT N
waiting-list JJ N
control NN N
group NN N
. . N

Treatment NNP N
group NN N
patients NNS N
attended VBD N
three CD N
relaxation-training JJ I
sessions NNS I
and CC N
received VBD N
an DT N
audio JJ N
disc NN N
for IN N
home NN N
practice NN N
. . N

Evaluations NNS N
performed VBD N
pre JJ N
and CC N
post-treatment: JJ N
state NN O
anxiety NN O
was VBD O
assessed VBN O
with IN O
the DT O
State-Trait NNP O
Anxiety NNP O
Inventory NNP O
QoL NNP O
with IN O
the DT O
IBD NNP O
Questionnaire NNP O
. . O

The DT O
Visual NNP O
Analogue NNP O
Scale NNP O
assessed VBD O
pain NN O
depression NN O
stress NN O
and CC O
mood NN O
. . O

Patients NNS N
completed VBD N
a DT N
symptom JJ O
monitoring NN O
diary NN O
. . O

The DT N
control NN N
group's NN N
symptoms NNS N
were VBD N
monitored VBN N
without IN N
study-related JJ N
treatment NN N
. . N

RESULTS NNP N
Thirty-nine JJ P
subjects NNS P
completed VBD P
the DT P
study NN P
and CC N
were VBD N
included VBN N
in IN N
the DT N
data NN N
analysis NN N
. . N

Following VBG N
the DT N
relaxation-training JJ I
intervention NN N
the DT N
treatment NN N
group's NN N
(n = 18) NN N
measured VBD N
results NNS N
showed VBD N
a DT N
statistically RB N
significant JJ N
improvement NN N
as IN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
(n = 21) NNP N
(time NN N
by IN N
treatment NN N
interaction): JJ O
anxiety NN O
levels NNS N
decreased VBN N
(p < 0.01) NNP O
QoL NNP O
and CC N
mood NN N
improved VBN N
(p < 0.05) NNP O
while IN O
levels NNS O
of IN O
pain NN N
and CC N
stress NN N
decreased VBN N
(p < 0.01) NNP N
. . N

CONCLUSIONS NNP P
Findings NNP P
indicate VBP P
IBD NNP N
patients NNS I
may MD I
benefit VB I
from IN I
relaxation NN N
training NN N
in IN N
their PRP$ N
holistic JJ N
care NN N
. . N

New NNP N
studies NNS N
as RB N
well RB N
as IN N
further JJ N
investigation NN N
of IN N
the DT N
subject NN N
are VBP N
warranted VBN N
. . N

-DOCSTART- -X- O O

The DT N
effect NN N
of IN N
cognitive-behavioral JJ I
therapy NN I
versus NN N
treatment NN I
as IN I
usual JJ I
for IN N
anxiety NN P
in IN P
children NNS P
with IN P
autism NN P
spectrum NN P
disorders: VBZ P
a DT N
randomized JJ N
controlled JJ N
trial NN N
. . N

OBJECTIVE UH N
To TO N
examine VB N
the DT N
efficacy NN O
of IN N
a DT N
modular JJ N
cognitive-behavioral JJ I
therapy NN I
(CBT) NNP I
protocol NN N
relative NN N
to TO N
treatment NN I
as IN I
usual JJ I
(TAU) NN I
among IN N
children NNS P
with IN P
high-functioning JJ P
autism NN P
spectrum NN P
disorders NNS P
(ASD) VBP P
and CC P
clinically RB P
significant JJ P
anxiety NN P
. . P

METHOD NNP N
A NNP P
total NN P
of IN P
45 CD P
children NNS P
(7-11 CD P
years NNS P
of IN P
age) NN P
with IN P
high-functioning JJ P
ASD NNP P
and CC P
clinically RB P
significant JJ P
anxiety NN P
were VBD N
randomized VBN N
to TO N
receive VB N
16 CD N
sessions NNS N
of IN N
weekly JJ N
CBT NNP I
or CC N
TAU NNP I
for IN N
an DT N
equivalent JJ N
duration NN N
. . N

After IN N
screening VBG N
assessments NNS N
were VBD N
conducted VBN N
at IN N
baseline JJ N
post-treatment JJ N
and CC N
3-month JJ N
follow-up NN N
. . N

Raters NNPS N
were VBD N
blind RB N
to TO N
treatment NN N
condition NN N
. . N

RESULTS NNP N
Youth NNP N
receiving VBG N
CBT NNP I
showed VBD N
substantial JJ N
improvement NN N
relative NN N
to TO N
TAU VB I
on IN N
primary JJ O
anxiety NN O
outcomes NNS O
. . O

Of IN N
24 CD N
children NNS N
randomized VBN N
to TO N
the DT N
CBT NNP I
arm NN N
18 CD N
(75%) NN N
were VBD N
treatment NN O
responders NNS O
versus VBP N
only RB N
3 CD N
of IN N
21 CD N
children NNS N
(14%) VBN N
in IN N
the DT N
TAU NNP I
arm NN N
. . N

Gains NNS N
were VBD N
generally RB N
maintained VBN N
at IN N
3-month JJ N
follow-up NN N
for IN N
CBT NNP I
responders NNS N
. . N

CONCLUSIONS NNP N
Relative NNP N
to TO N
usual JJ N
care NN N
CBT NNP I
adapted VBD N
for IN N
anxious JJ P
youth NN P
with IN P
high-functioning JJ P
ASD NNP P
demonstrates VBZ N
large JJ N
effects NNS N
in IN N
reducing VBG N
anxiety NN O
symptoms NNS O
. . O

This DT N
study NN N
contributes VBZ N
to TO N
the DT N
growing VBG N
literature NN N
supporting VBG N
adapted VBN N
CBT NNP I
approaches NNS N
for IN N
treating VBG N
anxiety NN P
in IN P
youth NN P
with IN P
ASD NNP P
. . P

-DOCSTART- -X- O O

Efficacy NN O
of IN N
intramuscular JJ N
oxytetracycline NN I
as IN N
a DT N
dry JJ N
cow NN P
treatment NN N
for IN N
Staphylococcus NNP P
aureus NN P
mastitis NN P
. . P

To TO N
determine VB N
the DT N
efficacy NN O
of IN N
intramuscular JJ N
oxytetracycline NN I
as IN N
a DT N
supplemental JJ N
dry JJ N
cow NN P
treatment NN N
for IN N
Staphylococcus NNP P
aureus VBD P
mastitis $ P
37 CD P
Holstein NNP P
cows NNS P
were VBD N
randomly RB N
assigned VBN N
to TO N
two CD N
treatment NN N
groups: JJ N
intracisternal JJ N
infusion NN N
with IN N
a DT N
commercial JJ N
preparation NN N
of IN N
cephapirin JJ I
benzathine NN I
at IN N
drying VBG N
off RP N
(20 JJ N
cows) NN N
and CC N
infusion NN N
with IN N
cephapirin JJ I
benzathine NN I
at IN N
drying VBG N
off RP N
and CC N
intramuscular JJ N
oxytetracycline NN I
at IN N
11 CD N
mg/kg NNS N
once RB N
daily RB N
on IN N
d NN N
7 CD N
8 CD N
9 CD N
and CC N
10 CD N
after IN N
drying VBG N
off RP N
(17 JJ N
cows) NN N
. . N

Milk NN O
samples NNS O
collected VBD N
7 CD N
14 CD N
30 CD N
and CC N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
plated VBN N
for IN N
bacterial JJ N
isolation NN N
within IN N
24 CD N
h NN N
after IN N
collection NN N
and CC N
after IN N
24 CD N
to TO N
72 CD N
h NN N
of IN N
storage NN N
at IN N
-20 NNP N
degrees NNS N
C NNP N
. . N

Quarters NNS N
were VBD N
defined VBN N
as IN N
infected JJ O
if IN N
S NNP N
. . N

aureus NN N
was VBD N
isolated VBN N
from IN N
the DT N
fresh JJ N
and CC N
frozen JJ N
cultures NNS N
from IN N
any DT N
one CD N
sample NN N
collected VBD N
before IN N
drying VBG N
off RP N
. . N

An DT N
infected JJ N
quarter NN N
was VBD N
defined VBN N
as IN N
cured JJ N
if IN N
S NNP N
. . N

aureus NN N
was VBD N
not RB N
isolated VBN N
from IN N
the DT N
fresh JJ N
or CC N
frozen JJ N
culture NN N
from IN N
milk NN N
samples NNS N
obtained VBD N
following VBG N
calving NN N
. . N

The DT N
rate NN O
of IN O
cure NN O
by IN N
30 CD N
d NN N
after IN N
calving VBG N
for IN N
systemic JJ N
oxytetracycline NN I
(in NNP N
combination NN N
with IN N
cephapirin JJ I
treatment) NN N
was VBD N
29.4% CD N
for IN N
infected JJ N
quarters NNS N
and CC N
29.4% CD N
for IN N
infected JJ N
cows NNS N
compared VBN N
with IN N
27.5 CD N
and CC N
25.0% CD N
respectively RB N
for IN N
the DT N
cephapirin NN I
treatment NN N
only RB N
. . N

Results NNS N
including VBG N
the DT N
culture NN N
at IN N
60 CD N
d NN N
after IN N
calving VBG N
were VBD N
21.2 CD N
and CC N
22.5% CD N
respectively RB N
for IN N
combination NN N
therapy NN N
and CC N
cephapirin NN I
therapy NN N
only RB N
. . N

Systemic NNP N
oxytetracycline NN I
in IN N
combination NN N
with IN N
intramammary JJ N
dry JJ N
cow NN N
treatment NN N
did VBD N
not RB N
improve VB N
the DT N
rate NN O
of IN O
cure NN O
for IN N
S NNP P
. . P

aureus NN P
mastitis NN P
. . P

-DOCSTART- -X- O O

Compensation NN O
in IN N
intergroup NN N
relations: VBP N
an DT N
investigation NN N
of IN N
its PRP$ N
structural JJ N
and CC N
strategic JJ N
foundations NNS N
. . N

Recent JJ N
work NN N
in IN N
intergroup JJ N
relations NNS N
stresses VBZ N
the DT N
role NN N
of IN N
two CD N
fundamental JJ N
dimensions NNS N
competence NN N
and CC N
warmth NN N
which WDT N
organize VBP N
the DT N
perception NN N
of IN N
social JJ N
groups NNS N
. . N

A DT N
pattern NN N
often RB N
encountered VBN N
in IN N
people's JJ N
ratings NNS N
is VBZ N
one CD N
of IN N
compensation NN N
in IN N
that DT N
a DT N
group NN N
that WDT N
is VBZ N
evaluated VBN N
higher JJR N
than IN N
another DT N
group NN N
on IN N
one CD N
of IN N
the DT N
two CD N
fundamental JJ N
dimensions NNS N
is VBZ N
also RB N
judged VBN N
lower JJR N
on IN N
the DT N
other JJ N
fundamental JJ N
dimension NN N
. . N

Based VBN N
on IN N
Social NNP N
Identity NNP N
Theory NNP N
the DT N
present JJ N
work NN N
extends VBZ N
previous JJ N
research NN N
on IN N
compensation NN N
by IN N
examining VBG N
boundary JJ O
conditions NNS O
as RB N
well RB N
as IN N
underlying VBG O
psychological JJ O
processes NNS O
. . O

Two CD N
studies NNS N
involving VBG N
experimental JJ N
and CC N
correlational JJ N
evidence NN N
minimal NN N
and CC N
real JJ N
groups NNS N
and CC N
different JJ N
kinds NNS N
of IN N
conflict NN N
reveal NN N
that IN N
compensation NN N
is VBZ N
more RBR N
likely JJ N
when WRB N
the DT N
groups NNS N
are VBP N
in IN N
asymmetrical JJ N
relation NN N
and CC N
share NN N
a DT N
cooperative JJ N
view NN N
of IN N
the DT N
intergroup NN N
setting NN N
. . N

Our PRP$ N
data NNS N
also RB N
suggest VBP N
that IN N
among IN N
members NNS N
of IN N
low JJ N
status NN N
groups NNS N
compensation NN N
is VBZ N
associated VBN N
with IN N
social JJ O
creativity NN O
. . O

In IN N
contrast NN N
and CC N
in IN N
line NN N
with IN N
the DT N
'noblesse NNP N
oblige' MD N
effect NN N
members NNS N
of IN N
the DT N
high JJ N
status NN N
group NN N
would MD N
seem VB N
to TO N
rely VB N
on IN N
compensation NN N
as IN N
a DT N
means NN N
to TO N
appear VB N
non-discriminatory JJ N
. . N

-DOCSTART- -X- O O

[The JJ N
chemotherapy NN I
of IN N
advanced JJ P
breast NN P
cancer NN P
. . P

A DT N
report NN N
on IN N
the DT N
first JJ N
600 CD P
cases NNS P
in IN N
a DT N
cooperative JJ N
programme NN N
to TO N
carry VB N
out RP N
a DT N
systematic JJ N
study NN N
(1974-1977) JJ N
(author's NNP N
transl)] NN N
. . N

The DT N
authors NNS N
explain VBP N
the DT N
objectives NNS N
and CC N
the DT N
structure NN N
of IN N
a DT N
programme NN N
evolved VBN N
for IN N
the DT N
methodic JJ N
study NN N
of IN N
advanced JJ P
breast NN P
cancers NNS P
which WDT N
they PRP N
have VBP N
worked VBN N
out RP N
and CC N
carried VBD N
out RP N
in IN N
cooperation NN N
with IN N
the DT N
departments NNS N
of IN N
medicine NN N
in IN P
eight CD P
French JJ P
anticancer NN P
centres NNS P
. . P

They PRP N
analyse VBP N
the DT N
initial JJ N
phases NNS N
which WDT N
correspond VBP N
to TO N
the DT N
three CD N
first JJ N
years NNS N
of IN N
work NN N
. . N

They PRP N
give VBP N
the DT N
state NN N
of IN N
the DT N
results NNS N
that WDT N
have VBP N
been VBN N
obtained VBN N
in IN N
603 CD P
patients NNS P
using VBG N
three CD N
protocols NNS N
for IN N
treatment NN N
. . N

These DT N
consisted VBN N
of IN N
the DT N
administration NN N
in IN N
interrupted JJ N
doses NNS N
of IN N
chemotherapy NN I
which WDT N
consisted VBD N
of IN N
vincristine NN I
associated VBN N
for IN N
the DT N
one CD N
part NN N
with IN N
cyclophosphamide NN I
and CC N
5-fluoro-uracil JJ I
and CC N
on IN N
the DT N
other JJ N
hand NN N
with IN N
doxorubicine NN I
or/and NN N
with IN N
methotrexate NN I
. . I

From IN N
this DT N
study NN N
there RB N
emerged VBD N
the DT N
value NN N
of IN N
combined JJ N
therapy NN N
using VBG N
doxorubicine NN I
as IN N
much JJ N
because IN N
of IN N
the DT N
frequency NN N
with IN N
which WDT N
results NNS O
better JJR N
than IN N
50% CD N
were VBD N
obtained VBN N
(in RP N
a DT N
randomised JJ N
trial) NN N
as IN N
by IN N
their PRP$ N
quality NN O
which WDT N
was VBD N
made VBN N
clear JJ N
in IN N
an DT N
important JJ N
series NN N
of IN N
240 CD N
cases NNS N
. . N

They PRP N
point VBP N
out RP N
the DT N
conditions NNS N
required VBN N
to TO N
initiate VB N
the DT N
place NN N
of IN N
such PDT N
a DT N
scheme NN N
in IN N
all DT N
complex JJ N
therapy NN N
which WDT N
aims VBZ N
as RB N
much JJ N
at IN N
palliation NN N
as IN N
at IN N
cure NN N
and CC N
point NN N
out RP N
how WRB N
important JJ N
it PRP N
is VBZ N
to TO N
be VB N
methodical JJ N
in IN N
the DT N
application NN N
of IN N
chemotherapy NN I
in IN N
order NN N
to TO N
ensure VB N
its PRP$ N
development NN N
as IN N
an DT N
anticancer NN N
therapy NN N
. . N

-DOCSTART- -X- O O

Serum NNP O
biochemical JJ O
characteristics NNS O
of IN N
Beluga NNP P
Huso NNP P
huso NN P
(L.) NN P
in IN N
response NN N
to TO N
blood NN N
sampling NN N
after IN N
clove NN N
powder NN N
solution NN N
exposure NN N
. . N

In IN N
order NN N
to TO N
investigate VB N
the DT N
effect NN N
of IN N
anesthesia NN I
on IN N
serum NN O
parameters NNS O
Beluga NNP P
Huso NNP P
huso NN P
(L.) NN P
were VBD N
blood-sampled JJ N
immediately RB N
without IN N
anesthesia JJ I
(control) NN N
or CC N
subjected VBN N
to TO N
following VBG N
anesthesia JJ I
procedure: JJ N
40 CD N
120 CD N
and CC N
240 CD N
s NN N
exposure NN N
to TO N
3 CD N
000 CD N
700 CD N
and CC N
500 CD N
mg NN N
l⁻¹ NN I
clove VB I
solution NN I
respectively RB O
. . O

Blood NN O
samples NNS O
were VBD N
collected VBN N
after IN N
these DT N
periods NNS N
when WRB P
fish NN P
were VBD N
immobile JJ N
and CC N
reached VBD N
stage NN N
4 CD N
anesthesia NN N
. . N

Results NNS N
showed VBD N
that IN O
cortisol NN O
and CC O
glucose JJ O
levels NNS O
were VBD N
significantly RB N
high JJ N
in IN N
700 CD N
and CC N
500 CD N
but CC N
not RB N
3 CD N
000 CD N
mg NN N
l⁻¹ NN N
group NN N
compared VBN N
to TO N
control VB O
. . O

Serum NNP O
lactate NN O
levels NNS O
were VBD N
significantly RB N
high JJ N
in IN N
500 CD N
mg NNS N
l⁻¹ JJ N
group NN N
compared VBN N
to TO N
control VB O
group NN O
. . O

Lactate NNP O
levels NNS N
were VBD N
not RB N
significantly RB N
differed VBN N
between IN N
control NN N
3 CD N
000 CD N
and CC N
700 CD N
mg NN N
l⁻¹ NN N
groups NNS N
. . N

There EX N
were VBD N
no DT N
significant JJ N
differences NNS O
in IN O
serum NN O
levels NNS O
of IN O
cholesterol NN O
total JJ O
protein NN O
lactate NN O
dehydrogenase NN O
aspartate JJ O
aminotransferase NN O
alanine NN O
aminotransferase NN O
Na⁺ NNP O
Cl⁻ NNP O
K⁺ NNP N
and CC N
Ca²⁺ NNP N
. . N

Results NNP I
suggest VBP I
that IN I
rapid JJ N
anesthesia NN N
with IN N
higher JJR N
dose NN I
is VBZ I
better JJR I
than IN N
slow JJ N
anesthesia NN O
with IN O
lower JJR O
dose NN O
for IN P
blood NN P
sampling NN N
in IN N
Beluga NNP N
. . N

-DOCSTART- -X- O O

Data NNP N
mining NN N
the DT N
ScanBrit NNP N
study NN N
of IN N
a DT N
gluten- JJ I
and CC I
casein-free JJ I
dietary JJ I
intervention NN I
for IN N
children NNS P
with IN P
autism NN P
spectrum NN P
disorders: JJ P
behavioural JJ O
and CC O
psychometric JJ O
measures NNS O
of IN O
dietary JJ O
response NN O
. . O

We PRP N
previously RB N
reported VBD N
results NNS N
based VBN N
on IN N
the DT N
examination NN N
of IN N
a DT N
gluten- JJ I
and CC I
casein-free JJ I
diet NN I
as IN N
an DT N
intervention NN N
for IN N
children NNS P
diagnosed VBN P
with IN P
an DT P
autism NN P
spectrum NN P
disorder NN P
as IN N
part NN N
of IN N
the DT N
ScanBrit NNP N
collaboration NN N
. . N

Analysis NN N
based VBN N
on IN N
grouped JJ N
results NNS N
indicated VBD N
several JJ N
significant JJ N
differences NNS N
between IN N
dietary JJ N
and CC N
non-dietary JJ N
participants NNS N
across IN N
various JJ N
core NN N
and CC N
peripheral JJ N
areas NNS N
of IN N
functioning VBG N
. . N

Results NNP N
also RB N
indicated VBD N
some DT N
disparity NN N
in IN N
individual JJ N
responses NNS O
to TO O
dietary JJ O
modification NN O
potentially RB N
indicative JJ N
of IN N
responder NN N
and CC N
non-responder JJ N
differences NNS N
. . N

Further JJ N
examination NN N
of IN N
the DT N
behavioural JJ O
and CC O
psychometric JJ O
data NNS O
garnered VBN N
from IN N
participants NNS N
was VBD N
undertaken VBN N
with IN N
a DT N
view NN N
to TO N
determining VBG N
potential JJ N
factors NNS N
pertinent VBP N
to TO N
response NN O
to TO O
dietary JJ I
intervention NN I
. . I

Participants NNS N
with IN N
clinically RB N
significant JJ N
scores NNS N
indicative JJ N
of IN N
inattention NN O
and CC O
hyperactivity NN O
behaviours NNS O
and CC N
who WP N
had VBD N
a DT N
significant JJ N
positive JJ N
changes NNS N
to TO N
said VBD N
scores NNS N
were VBD N
defined VBN N
as IN N
responders NNS O
to TO O
the DT O
dietary JJ I
intervention NN I
. . I

Analyses NNS N
indicated VBD N
several JJ N
factors NNS N
to TO N
be VB N
potentially RB N
pertinent JJ N
to TO N
a DT N
positive JJ N
response NN O
to TO O
dietary JJ I
intervention NN I
in IN N
terms NNS N
of IN N
symptom NN O
presentation NN O
. . O

Chronological JJ O
age NN O
was VBD N
found VBN N
to TO N
be VB N
the DT N
strongest JJS N
predictor NN N
of IN N
response NN N
where WRB N
those DT N
participants NNS N
aged VBD N
between IN N
7 CD N
and CC N
9 CD N
years NNS N
seemed VBD N
to TO N
derive VB N
most JJS N
benefit NN N
from IN N
dietary JJ I
intervention NN I
. . I

Further CC N
analysis NN N
based VBN N
on IN N
the DT N
criteria NNS N
for IN N
original JJ N
study NN N
inclusion NN N
on IN N
the DT N
presence NN N
of IN N
the DT N
urine JJ O
compound NN O
trans-indolyl-3-acryloylglycine NN O
may MD N
also RB N
merit VB N
further JJ N
investigation NN N
. . N

These DT N
preliminary JJ N
observations NNS N
on IN N
potential JJ N
best JJS N
responder NN N
characteristics NNS N
to TO N
a DT N
gluten- JJ I
and CC I
casein-free JJ I
diet NN I
for IN N
children NNS P
with IN P
autism NN P
require VBP N
independent JJ N
replication NN N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
low-dose JJ N
aspirin NN I
on IN N
clinic NN O
and CC O
ambulatory JJ O
blood NN O
pressure NN O
in IN N
treated JJ P
hypertensive JJ P
patients NNS P
. . P

Collaborative NNP N
Group NNP N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
(PPP)--Hypertension NN P
study NN N
. . N

Nonsteroidal NNP N
antiinflammatory JJ N
drugs NNS N
may MD N
affect VB N
blood NN O
pressure NN O
(BP) NNP O
control NN O
in IN N
hypertensive JJ P
patients NNS P
receiving VBG P
drug NN P
treatment NN P
but CC N
data NNS N
on IN N
the DT N
effects NNS N
of IN N
low-dose JJ N
aspirin NNS I
are VBP N
scanty RB N
. . N

This DT N
study NN N
assessed VBD N
the DT N
effects NNS N
of IN N
chronic JJ N
treatment NN N
with IN N
low JJ N
doses NNS N
of IN N
aspirin JJ I
(100 NNP N
mg/day) NN N
on IN N
clinic NN O
and CC O
ambulatory JJ O
systolic JJ O
(SBP) NN O
and CC O
diastolic JJ O
(DBP) NNP O
BP NNP O
in IN N
hypertensives NNS P
on IN P
chronic JJ P
stable JJ P
antihypertensive JJ P
therapy NN P
. . P

The DT N
study NN N
was VBD N
conducted VBN N
in IN N
the DT N
framework NN N
of IN N
the DT N
Primary NNP N
Prevention NNP N
Project NNP N
(PPP) VBZ N
a DT N
randomized JJ N
controlled VBN N
factorial JJ N
trial NN N
on IN N
the DT N
preventive JJ N
effect NN N
of IN N
aspirin NN I
or CC N
vitamin NN I
E NN I
in IN N
people NNS P
with IN P
one CD P
or CC P
more JJR P
cardiovascular JJ P
risk NN P
factors NNS P
. . P

Fifteen NNP P
Italian JJ P
hypertension NN P
units NNS P
studied VBD P
142 CD P
hypertensive JJ P
patients NNS P
(76 VBP P
men NNS P
66 CD P
women; NNS P
mean JJ P
age NN P
59 CD P
+/- JJ P
5.9 CD P
years) NN P
treated VBN P
with IN P
different JJ P
antihypertensive JJ P
drugs: NN P
71 CD N
patients NNS N
were VBD N
randomized VBN N
to TO N
aspirin VB I
and CC N
71 CD N
served VBD N
as IN N
controls NNS N
. . N

All DT N
patients NNS N
underwent VBD N
a DT N
clinic JJ O
BP NNP O
evaluation NN N
with IN N
an DT N
automatic JJ N
sphygmomanometer NN N
and CC N
a DT N
24-h JJ O
ambulatory NN O
BP NNP O
monitoring NN O
at IN N
baseline NN N
and CC N
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ I
treatment NN N
. . N

At IN N
the DT N
end NN N
of IN N
the DT N
study NN N
the DT N
changes NNS N
in IN N
clinic JJ O
SBP NNP O
and CC O
DBP NNP O
were VBD N
not RB N
statistically RB N
different JJ N
in IN N
treated JJ N
and CC N
untreated JJ N
subjects NNS N
. . N

Ambulatory NNP O
SBP NNP O
and CC O
DBP NNP O
after IN N
3 CD N
months NNS N
of IN N
aspirin JJ I
treatment NN N
were VBD N
similar JJ N
to TO N
baseline: VB N
deltaSBP JJ N
-0.5 NNP N
mmHg NN N
(95% NNP N
confidence NN N
intervals NNS N
[CI] VBP N
from IN N
-1.9 NN N
to TO N
+2.9 VB N
mm JJ N
Hg) NNP N
and CC N
deltaDBP VB N
-1.1 NNP N
mm FW N
Hg NNP N
(95% NNP N
CI NNP N
from IN N
-2.5 NNP N
to TO N
+0.3 VB N
mm JJ N
Hg) NNP N
. . N

The DT N
pattern NN N
was VBD N
similar JJ N
in IN N
the DT N
control NN N
group NN N
. . N

No DT N
interaction NN N
was VBD N
found VBN N
between IN N
aspirin NN I
and CC N
the DT N
most RBS N
used JJ N
antihypertensive JJ N
drug NN N
classes NNS N
(angiotensin VBP N
converting VBG N
enzyme NN N
inhibitors NNS N
and CC N
calcium NN N
antagonists) NN N
. . N

Despite IN N
the DT N
relatively RB N
small JJ N
sample NN N
size NN N
our PRP$ N
results NNS N
seem VBP N
to TO N
exclude VB N
any DT N
significant JJ N
influence NN N
of IN N
low-dose JJ N
aspirin NN I
on IN N
BP NNP O
control NN N
in IN N
hypertensives NNS P
under IN P
treatment NN P
. . P

-DOCSTART- -X- O O

Remote NNP I
ischaemic JJ I
conditioning NN I
before IN N
hospital JJ N
admission NN N
as IN N
a DT N
complement NN N
to TO N
angioplasty VB N
and CC N
effect NN N
on IN N
myocardial JJ O
salvage NN O
in IN N
patients NNS P
with IN P
acute JJ P
myocardial JJ P
infarction: NN P
a DT N
randomised JJ N
trial NN N
. . N

BACKGROUND NNP N
Remote NNP I
ischaemic JJ I
preconditioning NN I
attenuates NNS N
cardiac JJ N
injury NN N
at IN N
elective JJ N
surgery NN N
and CC N
angioplasty NN N
. . N

We PRP N
tested VBD N
the DT N
hypothesis NN N
that WDT N
remote VBP I
ischaemic JJ I
conditioning NN I
during IN N
evolving VBG N
ST-elevation NNP P
myocardial JJ P
infarction NN P
and CC N
done VBN N
before IN N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
increases VBZ N
myocardial JJ O
salvage NN O
. . O

METHODS NNP N
333 CD P
consecutive JJ P
adult NN P
patients NNS P
with IN P
a DT P
suspected VBN P
first JJ P
acute JJ P
myocardial JJ P
infarction NN P
were VBD N
randomly RB N
assigned VBN N
in IN N
a DT N
1:1 CD N
ratio NN N
by IN N
computerised JJ N
block NN N
randomisation NN N
to TO N
receive VB N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
with IN N
(n=166 NNP N
patients) VBP N
versus NN N
without IN N
(n=167) NNP N
remote VBP I
conditioning VBG I
(intermittent NN N
arm NN N
ischaemia NN N
through IN N
four CD N
cycles NNS N
of IN N
5-min JJ N
inflation NN N
and CC N
5-min JJ N
deflation NN N
of IN N
a DT N
blood-pressure JJ N
cuff) NN N
. . N

Allocation NNP N
was VBD N
concealed VBN N
with IN N
opaque NN N
sealed VBN N
envelopes NNS N
. . N

Patients NNS N
received VBD N
remote JJ I
conditioning NN I
during IN N
transport NN N
to TO N
hospital NN N
and CC N
primary JJ N
percutaneous JJ N
coronary JJ N
intervention NN N
in IN N
hospital NN N
. . N

The DT N
primary JJ N
endpoint NN N
was VBD N
myocardial JJ O
salvage NN O
index NN O
at IN O
30 CD O
days NNS O
after IN O
primary JJ O
percutaneous JJ O
coronary JJ O
intervention NN O
measured VBN O
by IN O
myocardial JJ O
perfusion NN O
imaging NN O
as IN N
the DT N
proportion NN O
of IN O
the DT O
area NN O
at IN O
risk NN O
salvaged VBN O
by IN O
treatment; JJ O
analysis NN N
was VBD N
per IN N
protocol NN N
. . N

This DT N
study NN N
is VBZ N
registered VBN N
with IN N
ClinicalTrials.gov NNP N
number NN N
NCT00435266 NNP N
. . N

FINDINGS NNP N
82 CD P
patients NNS P
were VBD P
excluded VBN P
on IN P
arrival NN P
at IN P
hospital NN P
because IN P
they PRP P
did VBD P
not RB P
meet VB P
inclusion NN P
criteria NNS P
32 CD P
were VBD P
lost VBN P
to TO P
follow-up JJ P
and CC P
77 CD P
did VBD P
not RB P
complete VB P
the DT P
follow-up JJ P
with IN P
data NNS P
for IN P
salvage NN P
index NN P
. . P

Median JJ O
salvage NN O
index NN O
was VBD N
0.75 CD N
(IQR JJ N
0.50-0.93 JJ N
n=73) NN N
in IN N
the DT N
remote JJ I
conditioning NN I
group NN N
versus VBD N
0.55 CD N
(0.35-0.88 JJ N
n=69) NN N
in IN N
the DT N
control NN N
group NN N
with IN N
median JJ O
difference NN O
of IN N
0.10 CD N
(95% JJ N
CI NNP N
0.01-0.22; JJ N
p=0.0333); NN N
mean JJ O
salvage NN O
index NN O
was VBD N
0.69 CD N
(SD JJ N
0.27) CD N
versus NN N
0.57 CD N
(0.26) NN N
with IN N
mean JJ O
difference NN O
of IN N
0.12 CD N
(95% JJ N
CI NNP N
0.01-0.21; JJ N
p=0.0333) NN N
. . N

Major JJ O
adverse JJ O
coronary JJ O
events NNS O
were VBD N
death NN O
(n=3 NN N
per IN N
group) NN N
reinfarction NN O
(n=1 FW N
per IN N
group) NN N
and CC N
heart NN O
failure NN O
(n=3 FW N
per IN N
group) NN N
. . N

INTERPRETATION NNP N
Remote NNP I
ischaemic JJ I
conditioning NN I
before IN N
hospital JJ N
admission NN N
increases VBZ N
myocardial JJ O
salvage NN O
and CC N
has VBZ N
a DT N
favourable JJ N
safety NN O
profile NN O
. . O

Our PRP$ N
findings NNS N
merit VBP N
a DT N
larger JJR N
trial NN N
to TO N
establish VB N
the DT N
effect NN N
of IN N
remote JJ I
conditioning NN I
on IN N
clinical JJ N
outcomes NNS N
. . N

FUNDING NN N
Fondation NNP N
Leducq NNP N
. . N

-DOCSTART- -X- O O

Effects NNS N
of IN N
Saccharomyces NNP I
boulardii NN I
in IN N
children NNS P
with IN P
acute JJ P
diarrhoea NN P
. . P

AIM NNP N
Certain NNP N
probiotic JJ N
agents NNS N
e.g VBP N
. . N

Lactobacillus CC N
GG NNP N
have VBP N
shown VBN N
efficacy NN N
in IN N
clinical JJ N
trials NNS N
for IN N
the DT N
treatment NN N
of IN N
acute JJ P
childhood NN P
diarrhoea NN P
but CC N
few JJ N
studies NNS N
have VBP N
examined VBN N
the DT N
effect NN N
of IN N
Saccharomyces NNP I
boulardii NN I
. . I

We PRP N
evaluated VBD N
the DT N
effect NN O
of IN N
S NNP I
. . I

boulardii NN I
in IN N
children NNS P
with IN P
acute JJ P
diarrhoea NN P
. . P

METHODS NNP N
Two CD P
hundred VBD P
children NNS P
were VBD N
randomized VBN N
to TO N
receive VB N
S NNP I
. . I

boulardii NN I
in IN N
a DT N
granulated JJ N
form NN N
in IN N
a DT N
daily JJ N
dose NN N
of IN N
250 CD N
mg NN N
(S NN I
. . I

boulardii VB I
group) NN N
or CC N
placebo NN I
(placebo VBP I
group) NN N
for IN N
5 CD N
d NN N
. . N

Clinical JJ N
and CC N
demographic JJ N
characteristics NNS N
on IN N
admission NN N
were VBD N
similar JJ N
between IN N
the DT N
study NN N
groups NNS N
. . N

RESULTS VB N
The DT N
medians NNS N
of IN N
the DT N
average JJ O
stool NN O
frequency NN O
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
were VBD N
significantly RB N
lower JJR N
in IN N
the DT N
S NNP I
. . I

boulardii NN I
group NN N
than IN N
in IN N
the DT N
placebo NN I
group NN N
(p NNP N
= VBZ N
0.003) CD N
. . N

The DT N
duration NN O
of IN O
diarrhoea NN P
significantly RB N
reduced VBN N
in IN N
the DT N
S NNP I
. . I

boulardii NN I
group NN N
compared VBN N
with IN N
the DT N
placebo NN I
group NN N
(4.7 NNP N
vs VBZ N
5.5 CD N
d NN N
p NN N
= VBD N
0.03) CD N
. . N

The DT N
effect NN O
of IN N
S NNP I
. . I

boulardii NN I
on IN N
watery NN P
diarrhoea NN P
became VBD N
apparent JJ N
after IN N
the DT N
second JJ N
day NN N
of IN N
the DT N
treatment NN N
. . N

The DT N
duration NN O
of IN O
hospital NN O
stay NN O
was VBD N
shorter JJR N
in IN N
the DT N
S NNP I
. . I

boulardii NN I
group NN N
than IN N
in IN N
the DT N
placebo NN I
group NN N
(2.9 NNP N
vs VBZ N
3.9 CD N
d NN N
p NN N
< VBD N
0.001) CD N
. . N

Four CD N
children NNS N
from IN N
the DT N
placebo NN I
group NN N
versus VBD N
only RB N
one CD N
child NN N
from IN N
the DT N
S NNP I
. . I

boulardii NN I
group NN N
had VBD N
persisting VBG N
diarrhoea NN N
. . N

CONCLUSION VB N
The DT N
placebo-controlled JJ N
study NN N
suggested VBD N
that IN N
S NNP I
. . I

boulardii NN I
significantly RB N
reduced VBD N
the DT N
duration NN O
of IN O
acute JJ P
diarrhoea NN P
and CC O
the DT O
duration NN O
of IN O
hospital NN O
stay NN O
. . O

S NNP I
. . I

boulardii NN I
seems VBZ N
to TO N
be VB N
a DT N
promising JJ N
agent NN N
for IN N
the DT N
amelioration NN N
of IN N
the DT N
course NN N
of IN N
acute JJ P
diarrhoea NN P
in IN P
children NNS P
when WRB N
used VBN N
therapeutically RB N
. . N

-DOCSTART- -X- O O

A DT N
pilot NN N
study NN N
on IN N
the DT N
effect NN N
of IN N
progressive JJ I
muscle NN I
relaxation NN I
training NN I
of IN N
patients NNS P
after IN P
stoma NN P
surgery NN P
. . P

Eighteen JJ P
patients NNS P
who WP P
had VBD P
undergone JJ P
stoma NN P
surgery NN P
were VBD N
assessed VBN N
with IN N
respect NN N
to TO N
their PRP$ N
anxiety NN O
level NN O
and CC O
self-reported JJ O
quality NN O
of IN O
life NN O
(QoL) NN O
on IN N
three CD N
occasions; NNS N
namely RB N
immediately RB N
after IN N
surgery NN N
5 CD N
weeks NNS N
after IN N
surgery NN N
and CC N
10 CD N
weeks NNS N
after IN N
surgery NN N
. . N

The DT N
patients NNS N
were VBD N
randomised VBN N
into IN N
a DT N
control NN N
group NN N
(n NNP N
= VBZ N
10) CD N
and CC N
an DT N
experimental JJ N
group NN N
(n NNP N
= VBZ N
8) CD N
. . N

A DT N
20-min JJ N
set NN N
of IN N
audiotaped JJ N
instructions NNS N
on IN N
progressive JJ I
muscle NN I
relaxation NN I
training NN I
(PMRT) NN I
was VBD N
given VBN N
to TO N
the DT N
patients NNS N
in IN N
the DT N
experimental JJ N
group NN N
for IN N
home NN N
practice NN N
. . N

Assessment NNP N
instructions NNS N
included VBD N
the DT N
Chinese JJ O
State-Trait NNP O
Anxiety NNP O
Inventory NNP O
(C-STAI) CD O
the DT O
Quality NN O
of IN O
Life NNP O
Index NNP O
for IN O
Colostomy NNP O
(QoL-Colostomy) JJ O
and CC O
the DT O
Hong NNP O
Kong NNP O
Chinese JJ O
version NN O
of IN O
the DT O
World NNP O
Health NNP O
Organisation NNP O
Quality NNP O
of IN O
Life NNP O
Scale NNP O
(WHOQoL) NNP O
. . O

Results NNP N
indicated VBD N
that IN N
there EX N
was VBD N
a DT N
significant JJ N
decrease NN N
in IN N
both DT N
the DT N
C-STAI NNP O
score NN O
(F NNP N
= VBZ N
4.66 CD N
P NNP N
< VBD N
0.05) CD N
and CC N
the DT N
WHOQoL NNP O
score NN O
(F NNP N
= VBZ N
4.74 CD N
P NNP N
< VBD N
0.05) CD N
in IN N
the DT N
experimental JJ N
group NN N
. . N

Among IN N
the DT N
domains NNS N
of IN N
WHOQoL NNP O
a DT N
significant JJ N
difference NN N
was VBD N
shown VBN N
in IN N
physical JJ N
health/independence NN N
and CC N
general JJ N
perception NN N
of IN N
QoL NNP O
with IN N
the DT N
experimental JJ N
group NN N
demonstrating VBG N
better JJR N
functioning NN N
. . N

For IN N
the DT N
QoL-Colostomy JJ O
however RB N
there EX N
was VBD N
no DT N
significant JJ N
difference NN N
between IN N
the DT N
control NN N
and CC N
experimental JJ N
groups NNS N
. . N

The DT N
results NNS N
suggest VBP N
that IN N
the DT N
use NN N
of IN N
PMRT NNP I
could MD N
enhance VB N
quality NN O
of IN O
life NN O
and CC N
decrease NN N
state NN N
anxiety NN O
in IN N
patients NNS P
after IN P
stoma NN P
surgery NN P
. . P

-DOCSTART- -X- O O

Effects NNS N
of IN N
mild JJ I
physical JJ I
exercise NN I
on IN N
serum NN O
lipoproteins NNS O
and CC O
metabolites NNS O
of IN O
arachidonic JJ O
acid: NN O
a DT N
controlled VBN N
randomised JJ N
trial NN N
in IN N
middle JJ P
aged VBN P
men NNS P
. . P

To TO N
study VB N
the DT N
effects NNS N
of IN N
physical JJ I
exercise NN I
on IN N
biochemical JJ O
risk NN O
factors NNS O
for IN O
ischaemic JJ O
heart NN O
disease NN O
31 CD P
healthy JJ P
middle NNS P
aged VBN P
men NNS P
undertook IN N
regular JJ I
physical JJ I
exercise NN I
for IN N
two CD N
months NNS N
and CC N
29 CD N
served VBD N
as IN N
controls NNS N
in IN N
a DT N
randomised JJ N
trial NN N
. . N

In IN N
the DT N
men NNS N
taking VBG N
regular JJ I
exercise NN I
serum NN O
cholesterol NN O
concentrations NNS O
increased VBD N
26% CD N
more RBR N
in IN N
the DT N
high JJ O
density NN O
lipoprotein VBP O
subfraction NN O
two CD O
(HDL2) NN O
and CC N
decreased VBD N
31% CD N
more RBR N
in IN N
the DT N
subfraction NN O
three CD O
(HDL3) NN O
and CC N
9% CD N
more JJR N
in IN N
the DT N
low JJ O
density NN O
lipoprotein NN O
fraction NN O
than IN N
in IN N
the DT N
control NN N
group NN N
. . N

A DT N
tendency NN N
towards NNS N
increased VBD N
plasma JJ O
6-keto-prostaglandin JJ O
F1 NNP O
alpha NN O
concentration NN O
and CC N
decreased VBD N
serum NN O
thromboxane NN O
B2 NNP O
concentration NN O
was VBD N
found VBN N
during IN N
the DT N
period NN N
of IN N
regular JJ I
exercise NN I
but CC N
prostaglandin NN O
E2 NNP O
concentrations NNS O
remained VBD N
unchanged JJ N
. . N

The DT N
increase NN N
in IN N
plasma JJ O
6-keto-prostaglandin JJ O
F1 NNP O
alpha NN O
concentration NN O
was VBD N
associated VBN N
with IN N
an DT N
increase NN N
in IN N
serum JJ O
HDL2 NNP O
cholesterol NN O
concentration NN O
in IN N
the DT N
group NN N
taking VBG N
regular JJ I
exercise NN I
. . I

Our PRP$ N
data NNS N
suggest VBP N
that IN N
mild JJ I
regular JJ I
physical JJ I
exercise NN I
favourably RB N
influences VBZ N
cholesterol NN N
distribution NN N
in IN N
serum NN O
lipoproteins NNS O
in IN N
healthy JJ P
middle NN P
aged VBN P
men NNS P
and CC N
may MD N
have VB N
beneficial JJ N
effects NNS N
on IN N
circulating VBG O
metabolites NNS O
of IN O
arachidonic JJ O
acid NN O
. . O

-DOCSTART- -X- O O

Oral JJ N
ciprofloxacin NN I
vs NN N
. . N

intramuscular JJ N
ceftriaxone NN I
as IN N
empiric JJ N
treatment NN N
of IN N
acute JJ P
invasive JJ P
diarrhea NN P
in IN P
children NNS P
. . P

BACKGROUND NNP N
Acute NNP P
invasive JJ P
diarrhea NN P
is VBZ N
a DT N
potentially RB N
serious JJ N
condition NN N
in IN P
children NNS P
. . P

Because IN N
of IN N
the DT N
increasing VBG N
resistance NN N
of IN N
enteric JJ N
pathogens NNS N
to TO N
commonly RB N
used JJ N
oral JJ N
antibiotics NNS N
intramuscular JJ N
ceftriaxone NN I
has VBZ N
become VBN N
the DT N
routine JJ N
drug NN N
in IN N
the DT N
treatment NN N
of IN N
acute JJ P
invasive JJ P
diarrhea NN P
requiring VBG P
an DT P
emergency NN P
visit NN P
in IN P
southern JJ P
Israel NNP P
. . P

The DT N
inconvenience NN N
of IN N
this DT N
parenteral JJ N
regimen NNS N
created VBD N
an DT N
increased VBN N
need NN N
for IN N
oral JJ N
pediatric JJ N
formulations NNS N
for IN N
the DT N
treatment NN N
of IN N
invasive JJ P
diarrhea NN P
. . P

OBJECTIVES NNP N
To TO N
evaluate VB N
the DT N
efficacy NN O
and CC N
safety NN O
of IN N
a DT N
suspension NN N
formulation NN N
of IN N
ciprofloxacin NN I
in IN N
the DT N
treatment NN N
of IN N
acute JJ P
invasive JJ P
diarrhea NN P
in IN P
infants NNS P
and CC P
children NNS P
. . P

PATIENTS NNP N
AND CC N
METHODS NNP N
From NNP P
July NNP P
1996 CD P
through IN P
December NNP P
1997 CD P
201 CD P
evaluable JJ P
children NNS P
ages VBZ P
6 CD P
months NNS P
to TO P
10 CD P
years NNS P
(35% JJ P
<1 NNP P
year; NN P
70% CD P
<3 NN P
years) NN P
presenting VBG P
with IN P
acute JJ P
invasive JJ P
diarrhea NN P
at IN P
the DT P
Pediatric NNP P
Emergency NNP P
Room NNP P
were VBD N
randomized VBN N
to TO N
receive VB N
either DT N
ciprofloxacin JJ I
suspension NN N
(10 NNP N
mg/kg NNP N
twice RB N
a DT N
day NN N
+ NNP N
im NN N
placebo; NN N
n JJ N
= VBZ N
95) CD N
or CC N
im VB N
ceftriaxone NN I
(50 NNP N
mg/kg/day NN N
+ NNP N
placebo NN N
suspension; NN N
n JJ N
= VBZ N
106) CD N
for IN N
3 CD N
days NNS N
in IN N
a DT N
double JJ N
blind NN N
manner NN N
. . N

Stool NNP O
cultures NNS O
for IN O
Shigella NNP O
Salmonella NNP O
Campylobacter NNP O
spp NN O
. . O

and CC O
diarrheagenic JJ O
Escherichia NNP O
coli NNS O
were VBD N
obtained VBN N
on IN N
Days NNS N
1 CD N
3 CD N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
. . N

Clinical JJ O
response NN O
and CC O
safety NN O
were VBD N
assessed VBN N
on IN N
Days NNS N
1 CD N
2 CD N
3 CD N
4 CD N
to TO N
5 CD N
and CC N
21 CD N
+/- JJ N
5 CD N
. . N

RESULTS NNP N
We PRP N
isolated VBD N
127 CD N
pathogens NNS N
from IN N
121 CD N
(60%) NNS N
patients: RB N
73 CD N
(57%) JJ N
Shigella; NNP N
23 CD N
(18%) NNP N
Salmonella; NNP N
18 CD N
(14%) NNP N
E NNP N
. . N

coli; NN N
and CC N
13 CD N
(10%) JJ N
Campylobacter NNP N
. . N

Overall NNP N
bacteriologic JJ N
eradication NN N
on IN N
Day NNP N
4 CD N
to TO N
5 CD N
was VBD N
99% CD N
for IN N
Shigella NNP N
77% CD N
for IN N
Salmonella NNP N
and CC N
77% CD N
for IN N
Campylobacter NNP N
with IN N
no DT N
difference NN N
between IN N
the DT N
2 CD N
groups NNS N
. . N

Clinical JJ O
cure NN O
or CC O
improvement NN O
was VBD N
observed VBN N
in IN N
100 CD N
and CC N
99% CD N
of IN N
the DT N
ciprofloxacin NN I
and CC N
ceftriaxone NN I
groups NNS N
respectively RB N
. . N

Serum NNP N
ciprofloxacin NN I
values NNS N
determined VBN N
on IN N
Day NNP N
3 CD N
of IN N
the DT N
treatment NN N
were VBD N
higher JJR N
in IN N
the DT N
majority NN N
of IN N
patients NNS N
than IN N
were VBD N
the DT N
MIC50 NNP N
and CC N
MIC90 NNP N
values NNS N
for IN N
the DT N
Shigella NNP N
and CC N
Salmonella NNP N
spp NN N
. . N

isolated VBN N
. . N

Possible JJ N
drug-related JJ N
adverse JJ O
events NNS O
occurred VBD N
in IN N
13 CD N
patients NNS N
[ciprofloxacin JJ I
8 CD N
(8%); NNP N
ceftriaxone NN I
5 CD N
(4.7%)] NN N
and CC N
were VBD N
mild NNS N
and CC N
transient NN N
. . N

Joint JJ O
examination NN O
was VBD N
normal JJ N
during IN N
and CC N
after IN N
completion NN N
of IN N
therapy NN N
in IN N
all DT N
patients NNS N
. . N

CONCLUSION NNP N
Oral NNP N
ciprofloxacin NN I
was VBD N
as IN N
safe JJ O
and CC O
effective JJ O
as IN N
intramuscular JJ N
ceftriaxone NN I
for IN N
the DT N
empiric JJ N
treatment NN N
of IN N
acute JJ P
invasive JJ P
diarrhea NN P
in IN P
ambulatory JJ P
pediatric JJ P
patients NNS P
requiring VBG P
an DT P
emergency NN P
room NN P
visit NN P
. . P

-DOCSTART- -X- O O

Randomized VBN N
controlled VBD N
study NN N
of IN N
chemoimmunotherapy NN N
with IN N
bestatin NN I
of IN N
acute JJ P
nonlymphocytic JJ P
leukemia NN P
in IN P
adults NNS P
. . P

A DT N
new JJ N
immunomodulating NN N
agent NN N
bestatin NN I
(INN: NN N
Ubenimex NNP N
has VBZ N
low JJ N
toxicity NN N
even RB N
after IN N
long-term JJ N
oral JJ N
administration NN N
and CC N
has VBZ N
significant JJ N
modifications NNS N
in IN N
immunological JJ N
response NN N
. . N

A DT N
cooperative JJ N
randomized NN N
controlled VBD N
study NN N
of IN N
bestatin NN I
immunotherapy NN N
in IN N
combination NN N
with IN N
remission NN N
maintenance NN N
chemotherapy NN N
for IN N
adult NN P
acute JJ P
nonlymphocytic JJ P
leukemia NN P
(ANLL) NN P
was VBD N
performed VBN N
. . N

After IN N
induction NN N
of IN N
complete JJ N
remission NN N
patients NNS N
were VBD N
randomized VBN N
to TO N
the DT N
bestatin NN I
group NN N
(30 NNP N
mg/bw VBZ N
per IN N
os NN N
(po) NN N
daily) NN N
and CC N
the DT N
control NN N
group NN N
. . N

The DT P
101 CD P
eligible JJ P
cases NNS P
(bestatin: VBP P
48 CD P
control: NNS P
53) CD P
were VBD N
analyzed; VBN N
the DT N
bestatin NN I
group NN N
achieved VBD N
longer JJR O
remission NN O
than IN N
the DT N
control NN N
group NN N
and CC N
a DT N
statistically RB N
significant JJ N
longer JJR O
survival NN O
. . O

Though IN N
this DT N
prolongation NN O
of IN O
remission NN O
was VBD N
not RB N
significant JJ N
in IN N
the DT N
bestatin NN I
group NN N
compared VBN N
to TO N
the DT N
control NN N
group NN N
in IN N
the DT N
15-49 JJ N
yr NN N
age NN N
group NN N
in IN N
the DT N
50-65 JJ N
yr NN N
age NN N
group NN N
it PRP N
was VBD N
significantly RB N
longer JJR N
. . N

Bestatin NNP I
is VBZ N
shown VBN N
to TO N
be VB N
a DT N
clinically RB N
useful JJ N
drug NN N
for IN N
immunotherapy NN N
of IN N
adult NN P
ANLL NNP P
since IN N
it PRP N
has VBZ N
prolonged VBN O
survival NN O
and CC O
remission NN O
especially RB N
in IN N
elderly JJ N
patients NNS N
with IN N
few JJ N
side-effects NNS O
. . O

